0001628280-22-029903.txt : 20221114 0001628280-22-029903.hdr.sgml : 20221114 20221114170715 ACCESSION NUMBER: 0001628280-22-029903 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 99 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221114 DATE AS OF CHANGE: 20221114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Accelerate Diagnostics, Inc CENTRAL INDEX KEY: 0000727207 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 841072256 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-31822 FILM NUMBER: 221387431 BUSINESS ADDRESS: STREET 1: 3950 S. COUNTRY CLUB ROAD #470 STREET 2: BUILDING 3-307 CITY: TUCSON STATE: AZ ZIP: 85714 BUSINESS PHONE: 303-863-8088 MAIL ADDRESS: STREET 1: 3950 S. COUNTRY CLUB ROAD #470 STREET 2: BUILDING 3-307 CITY: TUCSON STATE: AZ ZIP: 85714 FORMER COMPANY: FORMER CONFORMED NAME: ACCELR8 TECHNOLOGY CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: HYDRO SEEK INC DATE OF NAME CHANGE: 19880802 10-Q 1 axdx-20220930.htm 10-Q axdx-20220930
0000727207falseDecember 31Q32022P1YP2Y0.03234280.022640.032342800007272072022-01-012022-09-3000007272072022-11-10xbrli:shares00007272072022-09-30iso4217:USD00007272072021-12-31iso4217:USDxbrli:shares00007272072022-07-012022-09-3000007272072021-07-012021-09-3000007272072021-01-012021-09-3000007272072020-12-3100007272072021-09-300000727207us-gaap:PreferredStockMember2022-06-300000727207us-gaap:PreferredStockMember2021-06-300000727207us-gaap:PreferredStockMember2021-12-310000727207us-gaap:PreferredStockMember2020-12-310000727207us-gaap:PreferredStockMember2021-07-012021-09-300000727207us-gaap:PreferredStockMember2021-01-012021-09-300000727207us-gaap:PreferredStockMember2022-09-300000727207us-gaap:PreferredStockMember2021-09-300000727207us-gaap:CommonStockMember2022-06-300000727207us-gaap:CommonStockMember2021-06-300000727207us-gaap:CommonStockMember2021-12-310000727207us-gaap:CommonStockMember2020-12-310000727207us-gaap:CommonStockMember2022-07-012022-09-300000727207us-gaap:CommonStockMember2021-07-012021-09-300000727207us-gaap:CommonStockMember2022-01-012022-09-300000727207us-gaap:CommonStockMember2021-01-012021-09-300000727207us-gaap:CommonStockMember2022-09-300000727207us-gaap:CommonStockMember2021-09-300000727207us-gaap:AdditionalPaidInCapitalMember2022-06-300000727207us-gaap:AdditionalPaidInCapitalMember2021-06-300000727207us-gaap:AdditionalPaidInCapitalMember2021-12-310000727207us-gaap:AdditionalPaidInCapitalMember2020-12-310000727207us-gaap:AdditionalPaidInCapitalMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310000727207us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000727207us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000727207us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300000727207us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300000727207us-gaap:AdditionalPaidInCapitalMember2022-09-300000727207us-gaap:AdditionalPaidInCapitalMember2021-09-300000727207us-gaap:RetainedEarningsMember2022-06-300000727207us-gaap:RetainedEarningsMember2021-06-300000727207us-gaap:RetainedEarningsMember2021-12-310000727207us-gaap:RetainedEarningsMember2020-12-310000727207us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310000727207us-gaap:RetainedEarningsMember2022-07-012022-09-300000727207us-gaap:RetainedEarningsMember2021-07-012021-09-300000727207us-gaap:RetainedEarningsMember2022-01-012022-09-300000727207us-gaap:RetainedEarningsMember2021-01-012021-09-300000727207us-gaap:RetainedEarningsMember2022-09-300000727207us-gaap:RetainedEarningsMember2021-09-300000727207us-gaap:TreasuryStockCommonMember2022-06-300000727207us-gaap:TreasuryStockCommonMember2021-06-300000727207us-gaap:TreasuryStockCommonMember2021-12-310000727207us-gaap:TreasuryStockCommonMember2020-12-310000727207us-gaap:TreasuryStockCommonMember2022-09-300000727207us-gaap:TreasuryStockCommonMember2021-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000727207us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-30axdx:instrument0000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-09-30xbrli:pure00007272072022-06-3000007272072021-06-300000727207srt:MinimumMember2022-01-012022-09-300000727207srt:MaximumMember2022-01-012022-09-300000727207axdx:InstrumentsMember2022-01-012022-09-300000727207srt:MinimumMember2022-09-300000727207srt:MaximumMember2022-09-300000727207us-gaap:EquipmentMember2022-09-300000727207srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AccountingStandardsUpdate202006Member2022-01-010000727207us-gaap:CreditConcentrationRiskMemberaxdx:FinancialInstitutionsOneMemberus-gaap:CashAndCashEquivalentsMember2022-01-012022-09-300000727207us-gaap:CreditConcentrationRiskMemberaxdx:FinancialInstitutionsTwoMemberus-gaap:CashAndCashEquivalentsMember2022-01-012022-09-300000727207us-gaap:CreditConcentrationRiskMemberaxdx:FinancialInstitutionsThreeMemberus-gaap:CashAndCashEquivalentsMember2022-01-012022-09-300000727207us-gaap:CreditConcentrationRiskMemberaxdx:FinancialInstitutionsOneMemberus-gaap:CashAndCashEquivalentsMember2021-01-012021-12-310000727207us-gaap:CreditConcentrationRiskMemberaxdx:FinancialInstitutionsTwoMemberus-gaap:CashAndCashEquivalentsMember2021-01-012021-12-310000727207us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberaxdx:OneCustomerMember2022-01-012022-09-300000727207us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberaxdx:OneCustomerMember2021-01-012021-12-310000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:MutualFundMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:MutualFundMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleDebtMember2022-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2021-12-310000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleDebtMember2021-12-310000727207us-gaap:SeniorNotesMemberaxdx:JackWSchulerLivingTrustMemberus-gaap:FairValueInputsLevel3Memberaxdx:FivePointZeroPercentSecuredPromissoryNoteMember2022-08-150000727207axdx:August2022ExchangeTransactionMemberaxdx:JackWSchulerLivingTrustMemberaxdx:EmbededWarrantMemberus-gaap:FairValueInputsLevel3Member2022-08-150000727207us-gaap:CertificatesOfDepositMember2022-09-300000727207us-gaap:USTreasuryAndGovernmentMember2022-09-300000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-09-300000727207us-gaap:CorporateDebtSecuritiesMember2022-09-300000727207us-gaap:CertificatesOfDepositMember2021-12-310000727207us-gaap:USTreasuryAndGovernmentMember2021-12-310000727207us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2021-12-310000727207us-gaap:CorporateDebtSecuritiesMember2021-12-310000727207us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-09-300000727207us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-07-012021-09-300000727207us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-09-300000727207us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-07-012022-09-300000727207us-gaap:ComputerEquipmentMember2022-09-300000727207us-gaap:ComputerEquipmentMember2021-12-310000727207us-gaap:TechnologyEquipmentMember2022-09-300000727207us-gaap:TechnologyEquipmentMember2021-12-310000727207us-gaap:LeaseholdsAndLeaseholdImprovementsMember2022-09-300000727207us-gaap:LeaseholdsAndLeaseholdImprovementsMember2021-12-310000727207axdx:InstrumentsMember2022-09-300000727207axdx:InstrumentsMember2021-12-310000727207us-gaap:ConstructionInProgressMember2022-09-300000727207us-gaap:ConstructionInProgressMember2021-12-310000727207axdx:ProductsandServicesnotYetDeliveredMember2022-09-300000727207axdx:ProductsandServicesnotYetDeliveredMember2021-12-310000727207axdx:OtherLoansMemberus-gaap:NotesPayableOtherPayablesMember2020-01-012020-12-31axdx:loan0000727207srt:MinimumMemberaxdx:OtherLoansMemberus-gaap:NotesPayableOtherPayablesMember2020-12-310000727207axdx:OtherLoansMemberus-gaap:NotesPayableOtherPayablesMembersrt:MaximumMember2020-12-310000727207axdx:OtherLoansMemberus-gaap:NotesPayableOtherPayablesMember2022-09-300000727207axdx:OtherLoansMemberus-gaap:NotesPayableOtherPayablesMember2021-12-310000727207us-gaap:UnsecuredDebtMemberaxdx:PaycheckProtectionProgramMember2020-04-140000727207us-gaap:UnsecuredDebtMemberaxdx:PaycheckProtectionProgramMember2021-07-152021-07-150000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-01-012022-09-300000727207us-gaap:DebtInstrumentRedemptionPeriodTwoMemberaxdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-01-012022-09-30axdx:day0000727207us-gaap:DebtInstrumentRedemptionPeriodOneMemberaxdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-01-012022-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-07-012022-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2021-07-012021-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000727207axdx:ConvertibleNotesExchangeAgreementMemberaxdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-07-012022-09-300000727207axdx:ConvertibleNotesExchangeAgreementMemberaxdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2021-07-012021-09-300000727207axdx:ConvertibleNotesExchangeAgreementMemberaxdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-01-012022-09-300000727207axdx:ConvertibleNotesExchangeAgreementMemberaxdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000727207axdx:PrepaidForwardMember2022-01-012022-09-300000727207axdx:PrepaidForwardMember2022-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberaxdx:A2021ExchangeTransactionMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberaxdx:A2021ExchangeTransactionMemberus-gaap:ConvertibleDebtMember2021-09-300000727207axdx:TwoPointFiveZeroConvertibleNotesDue2023Memberaxdx:A2021ExchangeTransactionMemberus-gaap:ConvertibleDebtMember2021-07-012021-09-300000727207axdx:March2022ExchangeTransactionMemberaxdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-03-212022-03-21axdx:tranche0000727207axdx:March2022ExchangeTransactionMemberaxdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-03-210000727207axdx:March2022ExchangeTransactionMemberaxdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-03-292022-05-180000727207axdx:ConvertibleNotesExchangeAgreementMemberaxdx:TwoPointFiveZeroNewConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-01-012022-09-300000727207axdx:March2022ExchangeTransactionMemberaxdx:TwoPointFiveZeroNewConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-09-300000727207axdx:March2022ExchangeTransactionMemberaxdx:TwoPointFiveZeroNewConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-01-012022-09-300000727207axdx:August2022ExchangeTransactionMemberaxdx:JackWSchulerLivingTrustMemberaxdx:TwoPointFiveZeroConvertibleNotesDue2023Memberus-gaap:ConvertibleDebtMember2022-08-152022-08-150000727207axdx:August2022ExchangeTransactionMemberus-gaap:SeniorNotesMemberaxdx:JackWSchulerLivingTrustMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMember2022-08-152022-08-150000727207axdx:August2022ExchangeTransactionMemberaxdx:JackWSchulerLivingTrustMemberus-gaap:SecuredDebtMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMember2022-08-152022-08-150000727207axdx:August2022ExchangeTransactionMemberaxdx:JackWSchulerLivingTrustMemberaxdx:EmbededWarrantMember2022-08-150000727207axdx:August2022ExchangeTransactionMemberus-gaap:SeniorNotesMemberaxdx:JackWSchulerLivingTrustMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMember2022-08-150000727207axdx:August2022ExchangeTransactionMemberus-gaap:SeniorNotesMemberaxdx:JackWSchulerLivingTrustMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMember2022-09-300000727207axdx:August2022ExchangeTransactionMemberus-gaap:SeniorNotesMemberaxdx:JackWSchulerLivingTrustMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMember2022-07-012022-09-300000727207axdx:August2022ExchangeTransactionMemberus-gaap:SeniorNotesMemberaxdx:JackWSchulerLivingTrustMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMember2021-07-012021-09-300000727207axdx:August2022ExchangeTransactionMemberus-gaap:SeniorNotesMemberaxdx:JackWSchulerLivingTrustMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMember2022-01-012022-09-300000727207axdx:August2022ExchangeTransactionMemberus-gaap:SeniorNotesMemberaxdx:JackWSchulerLivingTrustMemberaxdx:FivePointZeroPercentSecuredPromissoryNoteMember2021-01-012021-09-300000727207axdx:August2022ExchangeTransactionMemberaxdx:JackWSchulerLivingTrustMemberaxdx:EmbededWarrantMember2022-08-152022-08-150000727207us-gaap:MeasurementInputExpectedTermMemberaxdx:JackWSchulerLivingTrustMemberaxdx:EmbededWarrantMember2022-09-30axdx:year0000727207us-gaap:MeasurementInputPriceVolatilityMemberaxdx:JackWSchulerLivingTrustMemberaxdx:EmbededWarrantMember2022-09-300000727207axdx:JackWSchulerLivingTrustMemberaxdx:EmbededWarrantMemberus-gaap:MeasurementInputExpectedDividendRateMember2022-09-300000727207axdx:JackWSchulerLivingTrustMemberaxdx:EmbededWarrantMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-09-300000727207us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300000727207us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300000727207us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300000727207us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300000727207us-gaap:EmployeeStockOptionMember2022-07-012022-09-300000727207us-gaap:EmployeeStockOptionMember2021-07-012021-09-300000727207us-gaap:EmployeeStockOptionMember2022-01-012022-09-300000727207us-gaap:EmployeeStockOptionMember2021-01-012021-09-300000727207us-gaap:WarrantMember2022-07-012022-09-300000727207us-gaap:WarrantMember2021-07-012021-09-300000727207us-gaap:WarrantMember2022-01-012022-09-300000727207us-gaap:WarrantMember2021-01-012021-09-300000727207us-gaap:SeriesAPreferredStockMember2022-09-300000727207axdx:March2022SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2022-03-240000727207axdx:August2022ExchangeTransactionMemberaxdx:JackWSchulerLivingTrustMember2022-01-012022-09-300000727207axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember2021-12-310000727207axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember2022-01-012022-09-300000727207axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember2022-09-300000727207us-gaap:CostOfSalesMember2022-07-012022-09-300000727207us-gaap:CostOfSalesMember2021-07-012021-09-300000727207us-gaap:CostOfSalesMember2022-01-012022-09-300000727207us-gaap:CostOfSalesMember2021-01-012021-09-300000727207us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300000727207us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000727207us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300000727207us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000727207us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300000727207us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300000727207us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300000727207us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300000727207us-gaap:RestrictedStockUnitsRSUMember2022-09-300000727207srt:MinimumMemberus-gaap:PerformanceSharesMember2022-01-012022-09-300000727207us-gaap:PerformanceSharesMembersrt:MaximumMember2022-01-012022-09-300000727207us-gaap:PerformanceSharesMember2022-01-012022-09-300000727207us-gaap:PerformanceSharesMember2020-01-012020-12-310000727207us-gaap:PerformanceSharesMember2022-09-300000727207us-gaap:PerformanceSharesMember2021-01-012021-09-300000727207srt:MinimumMemberaxdx:PerformanceBasedRestrictedStockUnitsMember2022-01-012022-09-300000727207axdx:PerformanceBasedRestrictedStockUnitsMembersrt:MaximumMember2022-01-012022-09-300000727207axdx:PerformanceBasedRestrictedStockUnitsMember2022-01-012022-09-300000727207axdx:PerformanceBasedRestrictedStockUnitsMember2020-12-310000727207axdx:PerformanceBasedRestrictedStockUnitsMember2021-12-310000727207axdx:PerformanceBasedRestrictedStockUnitsMember2021-01-012021-09-3000007272072022-04-30axdx:segment0000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:GeographicDistributionForeignMemberus-gaap:SalesRevenueNetMember2022-07-012022-09-300000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:GeographicDistributionForeignMemberus-gaap:SalesRevenueNetMember2021-07-012021-09-300000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:GeographicDistributionForeignMemberus-gaap:SalesRevenueNetMember2022-01-012022-09-300000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:GeographicDistributionForeignMemberus-gaap:SalesRevenueNetMember2021-01-012021-09-300000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:AccountsReceivableMemberus-gaap:GeographicDistributionForeignMember2022-09-300000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:AccountsReceivableMemberus-gaap:GeographicDistributionForeignMember2021-12-310000727207us-gaap:GeographicDistributionDomesticMember2022-07-012022-09-300000727207us-gaap:GeographicDistributionDomesticMember2021-07-012021-09-300000727207us-gaap:GeographicDistributionDomesticMember2022-01-012022-09-300000727207us-gaap:GeographicDistributionDomesticMember2021-01-012021-09-300000727207us-gaap:GeographicDistributionForeignMember2022-07-012022-09-300000727207us-gaap:GeographicDistributionForeignMember2021-07-012021-09-300000727207us-gaap:GeographicDistributionForeignMember2022-01-012022-09-300000727207us-gaap:GeographicDistributionForeignMember2021-01-012021-09-300000727207axdx:AcceleratePhenoMember2022-07-012022-09-300000727207axdx:AcceleratePhenoMember2021-07-012021-09-300000727207axdx:AcceleratePhenoMember2022-01-012022-09-300000727207axdx:AcceleratePhenoMember2021-01-012021-09-300000727207axdx:OtherRevenueMember2022-07-012022-09-300000727207axdx:OtherRevenueMember2021-07-012021-09-300000727207axdx:OtherRevenueMember2022-01-012022-09-300000727207axdx:OtherRevenueMember2021-01-012021-09-300000727207us-gaap:ProductMember2022-07-012022-09-300000727207us-gaap:ProductMember2021-07-012021-09-300000727207us-gaap:ProductMember2022-01-012022-09-300000727207us-gaap:ProductMember2021-01-012021-09-300000727207us-gaap:ServiceMember2022-07-012022-09-300000727207us-gaap:ServiceMember2021-07-012021-09-300000727207us-gaap:ServiceMember2022-01-012022-09-300000727207us-gaap:ServiceMember2021-01-012021-09-300000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:PropertyPlantAndEquipmentMemberus-gaap:GeographicDistributionDomesticMember2022-09-300000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:PropertyPlantAndEquipmentMemberus-gaap:GeographicDistributionDomesticMember2021-12-310000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:GeographicDistributionForeignMemberus-gaap:PropertyPlantAndEquipmentMember2022-09-300000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:GeographicDistributionForeignMemberus-gaap:PropertyPlantAndEquipmentMember2021-12-310000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:PropertyPlantAndEquipmentMember2022-09-300000727207us-gaap:GeographicConcentrationRiskMemberus-gaap:PropertyPlantAndEquipmentMember2021-12-310000727207axdx:December2020SecuritiesPurchaseAgreementMemberaxdx:CertainDirectorsAndOfficersOrAffiliatesMembersrt:AffiliatedEntityMember2020-12-310000727207axdx:JackWSchulerLivingTrustMemberaxdx:December2020SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2020-12-310000727207axdx:December2020SecuritiesPurchaseAgreementMemberaxdx:CertainDirectorsAndOfficersOrAffiliatesMembersrt:AffiliatedEntityMember2020-12-012020-12-31axdx:entity0000727207axdx:JackWSchulerLivingTrustMemberaxdx:December2020SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2020-12-012020-12-310000727207axdx:December2020SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2020-12-310000727207axdx:December2020SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2020-12-012020-12-310000727207axdx:December2020SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2021-02-192021-04-090000727207axdx:September2021RescissionAgreementMembersrt:AffiliatedEntityMember2021-09-172021-09-170000727207axdx:December2020SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2021-09-302021-09-300000727207axdx:December2020SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2021-01-012021-09-300000727207axdx:September2021SecuritiesPurchaseAgreementMemberus-gaap:SeriesAPreferredStockMembersrt:AffiliatedEntityMember2021-09-300000727207us-gaap:SeriesAPreferredStockMemberaxdx:September2021SecuritiesPurchaseAgreementSecondTrancheRightMembersrt:AffiliatedEntityMember2021-09-300000727207axdx:September2021SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2021-09-012021-09-300000727207axdx:September2021SecuritiesPurchaseAgreementMemberus-gaap:SeriesAPreferredStockMembersrt:AffiliatedEntityMember2021-09-012021-09-300000727207axdx:September2021SecuritiesPurchaseAgreementMemberus-gaap:SeriesAPreferredStockMembersrt:AffiliatedEntityMember2021-07-012021-09-300000727207us-gaap:SeriesAPreferredStockMemberaxdx:September2021SecuritiesPurchaseAgreementSecondTrancheRightMembersrt:AffiliatedEntityMember2021-09-012021-09-3000007272072021-09-220000727207us-gaap:SeriesAPreferredStockMemberaxdx:September2021SecuritiesPurchaseAgreementSecondTrancheRightMembersrt:AffiliatedEntityMember2021-10-292021-10-290000727207axdx:August2022ExchangeTransactionMemberaxdx:JackWSchulerLivingTrustMemberus-gaap:SecuredDebtMemberaxdx:ExtinguishedNotesMember2022-07-012022-09-300000727207axdx:August2022ExchangeTransactionMemberaxdx:JackWSchulerLivingTrustMemberaxdx:EmbededWarrantMemberus-gaap:FairValueInputsLevel3Member2022-08-152022-08-150000727207us-gaap:CommonStockMemberaxdx:August2022PublicOfferingMember2022-08-222022-08-220000727207axdx:August2022PublicOfferingMember2022-08-220000727207axdx:August2022PublicOfferingMember2022-08-222022-08-220000727207axdx:SchulerFamilyFoundationMemberaxdx:ConvertibleNotePurchasesMemberaxdx:A2021ExchangeTransactionMembersrt:AffiliatedEntityMember2021-09-300000727207axdx:ConvertibleNotePurchasesMemberaxdx:A2021ExchangeTransactionMembersrt:AffiliatedEntityMember2021-09-222021-09-220000727207axdx:ConvertibleNotePurchasesMemberaxdx:A2021ExchangeTransactionMembersrt:AffiliatedEntityMember2021-07-012021-09-300000727207axdx:SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2020-12-240000727207axdx:September2021SecuritiesPurchaseAgreementMemberus-gaap:SeriesAPreferredStockMembersrt:AffiliatedEntityMember2021-01-012021-09-300000727207us-gaap:SeriesAPreferredStockMemberaxdx:March2022SecuritiesPurchaseAgreementMembersrt:AffiliatedEntityMember2022-03-240000727207axdx:August2022ExchangeTransactionMemberaxdx:JackWSchulerLivingTrustMemberus-gaap:SecuredDebtMemberaxdx:ExtinguishedNotesMember2022-01-012022-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____

Commission file number: 001-31822
ACCELERATE DIAGNOSTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware84-1072256
(State or other jurisdiction(I.R.S. Employer Identification No.)
of incorporation or organization)
3950 South Country Club Road, Suite 470
Tucson,Arizona85714
(Address of principal executive offices)(Zip Code)

(520) 365-3100
(Registrant’s telephone number, including area code)

N/A
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.001 parAXDXThe Nasdaq Stock Market LLC
value per share(The Nasdaq Capital Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☑ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐
Accelerated filer☐
Non-accelerated filer☑
Smaller reporting company☑
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☑ No

As of November 10, 2022, there were 99,099,480 shares of the registrant’s common stock outstanding.


TABLE OF CONTENTS


2

PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
BALANCE SHEETS
(in thousands, except share data)
September 30,December 31,
20222021
Unaudited
ASSETS
Current assets:
Cash and cash equivalents$38,987 $39,898 
Investments16,407 23,720 
Trade accounts receivable, net2,393 2,320 
Inventory5,392 5,067 
Prepaid expenses1,119 768 
Other current assets1,974 1,558 
Total current assets66,272 73,331 
Property and equipment, net3,621 5,389 
Finance lease assets, net2,319 — 
Operating lease right of use assets, net2,012 2,510 
Other non-current assets1,623 1,817 
Total assets$75,847 $83,047 
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable$2,819 $1,983 
Accrued liabilities4,300 2,853 
Accrued interest118 909 
Deferred revenue524 451 
Current portion of long-term debt80 80 
Finance lease, current953 — 
Operating lease, current774 669 
Total current liabilities9,568 6,945 
Finance lease, non-current 698 — 
Operating lease, non-current 1,775 2,381 
Other non-current liabilities759 808 
Accrued interest related-party220 — 
Long-term debt related-party16,299 — 
Convertible notes56,325 107,984 
Total liabilities$85,644 $118,118 
Commitments and contingencies (see Note 14)

See accompanying notes to condensed consolidated financial statements.

3

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
BALANCE SHEETS (CONTINUED)
(in thousands, except share data)
September 30,December 31,
20222021
Unaudited
Stockholders’ deficit:
Preferred shares, $0.001 par value;
5,000,000 preferred shares authorized and 3,954,546 outstanding as of September 30, 2022 and December 31, 2021
4 4 
Common stock, $0.001 par value;
200,000,000 common shares authorized with 97,240,983 shares issued and outstanding on September 30, 2022 and 100,000,000 common shares authorized with 67,649,018 shares issued and outstanding on December 31, 2021
97 68 
Contributed capital627,853 580,652 
Treasury stock(45,067)(45,067)
Accumulated deficit(592,439)(570,668)
Accumulated other comprehensive loss(245)(60)
Total stockholders’ deficit(9,797)(35,071)
Total liabilities and stockholders’ deficit$75,847 $83,047 

See accompanying notes to condensed consolidated financial statements.

4

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Unaudited
(in thousands, except per share data)
Three Months EndedNine Months Ended
September 30,September 30,September 30,September 30,
2022202120222021
Net sales$2,960 $3,122 $9,780 $8,439 
Cost of sales2,190 2,136 7,127 5,502 
Gross profit770 986 2,653 2,937 
Costs and expenses:
Research and development7,285 4,712 20,885 17,341 
Sales, general and administrative8,255 10,806 30,422 37,744 
Total costs and expenses15,540 15,518 51,307 55,085 
Loss from operations(14,770)(14,532)(48,654)(52,148)
Other (expense) income:
Interest expense(203)(4,211)(1,833)(12,477)
Interest expense related-party(495)— (495)— 
Gain on extinguishment of debt— 9,840 3,565 9,840 
Foreign currency exchange loss(261)(78)(221)(238)
Interest income73 — 151 55 
Other (expense) income, net(49)(5)(206)69 
Total other (expense) income, net(935)5,546 961 (2,751)
Net loss before income taxes(15,705)(8,986)(47,693)(54,899)
Provision for income taxes— — — — 
Net loss$(15,705)$(8,986)$(47,693)$(54,899)
Basic and diluted net loss per share$(0.18)$(0.15)$(0.62)$(0.91)
Weighted average shares outstanding87,011 61,146 77,049 60,250 
Other comprehensive loss:
Net loss$(15,705)$(8,986)$(47,693)$(54,899)
Net unrealized gain (loss) on debt securities available-for-sale48 (3)(84)(21)
Foreign currency translation adjustment139 (27)(101)(87)
Comprehensive loss$(15,518)$(9,016)$(47,878)$(55,007)

See accompanying notes to condensed consolidated financial statements.

5

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS
Unaudited
(in thousands)
Nine Months Ended
September 30,September 30,
20222021
Cash flows from operating activities:
Net loss$(47,693)$(54,899)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization2,207 1,875 
Amortization of investment discount94 153 
Equity-based compensation8,179 19,058 
Amortization of debt discount and issuance costs386 9,250 
Amortization of debt discount related-party275 — 
Loss (gain) on disposal of property and equipment74 (202)
Unrealized loss (gain) on equity investments206 (39)
Gain on extinguishment of debt(3,565)(9,840)
(Increase) decrease in assets:
Contributions to deferred compensation plan(174)(304)
Accounts receivable(73)(719)
Inventory(245)(527)
Prepaid expense and other(491)860 
Increase (decrease) in liabilities:
Accounts payable1,221 1,017 
Accrued liabilities and other962 (436)
Accrued interest(785)(1,059)
Accrued interest from related-party220 — 
Deferred revenue and income73 93 
Deferred compensation(49)343 
Net cash used in operating activities(39,178)(35,376)
Cash flows from investing activities:
Purchases of equipment(446)(202)
Purchase of marketable securities(27,506)(22,345)
Maturities of marketable securities34,527 33,601 
Net cash provided by investing activities6,575 11,054 
Cash flows from financing activities:
Proceeds from issuance of common stock32,872 22,640 
Payments on finance leases(1,109)— 
Proceeds from exercise of options7 1,456 
Proceeds from issuance of common stocks under employee purchase plan184 245 
Transaction costs related to debt exchange(192)— 
Payment of debt(6)(6)
Net cash provided by financing activities31,756 24,335 

See accompanying notes to condensed consolidated financial statements.

6

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS (CONTINUED)
Unaudited
(in thousands)
Nine Months Ended
September 30,September 30,
20222021
Effect of exchange rate on cash(64)(69)
Decrease in cash and cash equivalents(911)(56)
Cash and cash equivalents, beginning of period39,898 35,781 
Cash and cash equivalents, end of period$38,987 $35,725 
Non-cash investing activities:
Net transfer of instruments (to) from inventory to property and equipment$(78)$508 
Non-cash financing activities:
Extinguishment of convertible senior notes through issuance of common stock$10,180 $34,545 
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs$49,624 $— 
Fair value of new note from related-party issued in connection with the exchange transaction$16,024 $— 
Fair value of common stock warrant issued to related-party in connection with exchange transaction$3,753 $— 
Capital contribution from related-party in connection with the exchange transaction$29,847 $— 
Supplemental cash flow information:
Interest paid$2,214 $4,288 

See accompanying notes to condensed consolidated financial statements.

7

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF STOCKHOLDERS' DEFICIT
Unaudited
(in thousands)
Three Months EndedNine Months Ended
September 30,September 30,
2022202120222021
Preferred stock shares outstanding
Beginning3,955 — 3,955 — 
Issuance of preferred stock— 2,636 — 2,636 
Ending3,955 2,636 3,955 2,636 
Preferred stock
Beginning$4 $— $4 $— 
Proceeds from issuance of preferred stock— 3 — 3 
Ending$4 $3 $4 $3 
Common stock shares outstanding
Beginning79,701 61,489 67,649 57,608 
Issuance of common stock17,500 67 17,500 2,937 
Restricted stock awards released and exercise of options6 62 1,134 1,052 
Issuance of common stock under employee purchase plan34 16 159 37 
Rescission of common stock— (2,643)— (2,643)
Issuance of shares to retire convertible notes— 5,946 10,799 5,946 
Ending97,241 64,937 97,241 64,937 
Common stock
Beginning$80 $61 $68 $58 
Proceeds from issuance of common stock17 1 17 3 
Restricted stock awards released and exercise of options— — 1 1 
Rescission of common stock— (3)— (3)
Issuance of shares to retire convertible notes— 6 11 6 
Ending$97 $65 $97 $65 
Contributed capital
Beginning$560,185 $514,122 $580,652 $475,072 
Cumulative effect of accounting changes— — (37,438)— 
Proceeds from issuance of common stock32,855 517 32,855 22,637 
Exercise of options— 234 6 1,455 
Issuance of common stock under employee purchase plan47 84 184 245 
Issuance of shares to retire Convertible Notes— 34,539 10,169 34,539 
Capital contribution from related-party in connection with exchange transaction29,847 — 29,847 — 
Warrant issued to related-party3,753 — 3,753 — 
Equity-based compensation1,166 3,638 7,825 19,186 
Ending$627,853 $553,134 $627,853 $553,134 

See accompanying notes to condensed consolidated financial statements.

8


ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF STOCKHOLDERS' DEFICIT (CONTINUED)
Unaudited
(in thousands)
Three Months EndedNine Months Ended
September 30,September 30,
2022202120222021
Accumulated deficit
Beginning$(576,734)$(538,879)$(570,668)$(492,966)
Cumulative effect of accounting changes— — 25,922 — 
Net loss(15,705)(8,986)(47,693)(54,899)
Ending$(592,439)$(547,865)$(592,439)$(547,865)
Treasury stock
Beginning$(45,067)$(45,067)$(45,067)$(45,067)
Ending$(45,067)$(45,067)$(45,067)$(45,067)
Accumulated other comprehensive (loss) income
Beginning$(432)$13 $(60)$91 
Net unrealized gain (loss) on debt securities available-for-sale48 (3)(84)(21)
Foreign currency translation adjustment139 (27)(101)(87)
Ending$(245)$(17)$(245)$(17)
Total stockholders' deficit$(9,797)$(39,747)$(9,797)$(39,747)

See accompanying notes to condensed consolidated financial statements.

9

ACCELERATE DIAGNOSTICS, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Unaudited

NOTE 1. ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION; SIGNIFICANT ACCOUNTING POLICIES

Accelerate Diagnostics, Inc. (“we” or “us” or “our” or “Accelerate” or the “Company”) is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 14, 2022.

The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date but does not include all disclosures such as notes required by U.S. GAAP.

The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2022, or any future period.

All amounts are rounded to the nearest thousand dollars unless otherwise indicated.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.

Risk and Uncertainties

The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through multiple equity raises, one convertible debt offering, and Secured Note (as defined in Note 11). The Company is subject to a number of risks similar to other early commercial stage life science companies, including, but not limited to commercially launching the Company’s products, development and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital.

The COVID-19 pandemic, containment measures, and downstream impacts to hospital staffing and financial stability have caused business slowdowns or shutdowns in affected areas, both, as well as disruptions to global supply chains and workforce participation. These effects have significantly impacted the Company’s business and results of operations, starting in the first quarter of 2020 and continuing through the current quarter, albeit to a lesser degree. These impacts include diminished access to the Company’s customers, principally hospitals, which has severely limited the ability to sell or implement products. Furthermore, the expected rate of growth of the Company’s consumable test kit sales has been reduced because of the negative impact of the COVID-19 pandemic on Accelerate Pheno system new sales and implementations. The Company has reviewed its suppliers and quantities of key materials and believes that it has sufficient stocks and alternate sources of critical materials should the supply chains become further disrupted, although raw materials for the manufacturing of
10

reagents is in high demand, and interruptions in supply are difficult to predict. The COVID-19 pandemic also caused the Company to reassess its build plan and evaluate its inventories accordingly, which resulted in additional charges to cost of sales for excess inventories in the prior year.

The Company may seek to fund its operations through public equity, private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. The Company’s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company’s business, results of operations, financial condition and the Company’s ability to develop new products. To the extent the Company raises additional funds through the sale of equity, issue convertible debt securities or exchange convertible debt for equity, the issuance of securities will result in dilution to stockholders. Investors purchasing shares or other securities in the future could have rights superior to existing stockholders. In addition, the Company has a significant number of options and restricted stock units (“RSUs”) outstanding in addition to the Warrant (as defined in Note 11). If these options or the Warrant are exercised or such RSUs are released, or shares of the Company’s common stock are issued upon conversion of the Company’s outstanding 2.50% Senior Convertible Notes due 2023 (the “Notes”) or Series A Preferred Stock, further dilution may occur.

Liquidity

The Company continues to assess liquidity needs and manage cash flows. As a result of the steps the Company has taken to enhance its liquidity, the Company currently believes that cash on hand and cash flows from operations will enable the Company to meet its working capital, capital expenditure, debt service and other funding requirements for at least one year from the date this Quarterly Report on Form 10-Q (this “Form 10-Q”) is issued. The Company’s view regarding sufficiency of cash and liquidity is primarily based on our financial forecast for 12 months from the date these condensed consolidated financial statements are filed, which is impacted by, among other things, various assumptions regarding demand and sales prices for our products. Our financial forecasts in recent periods have proven less reliable due to conditions created by the pandemic. As a result, there is no guarantee our financial forecast, which projects sufficient cash will be available to meet planned operating expenses and other cash needs, will be accurate. In the event the Company experiences lower customer demand, lower prices for its products and services, or higher expenses than it forecasted or if the Company underperforms relative to its forecast, the Company could experience negative cash flows from operations, as has been the case in prior years, which would reduce its cash balances and liquidity.

Use of Estimates

The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, convertible notes, notes from related parties, tax valuation accounts, equity–based compensation, warrants, revenue and leases. Actual results could differ materially from those estimates.

Estimated Fair Value of Financial Instruments

The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three-tiered approach and fair value measurement be classified and disclosed in one of the following three categories:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

•Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

11

The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.

See Note 4, Fair Value of Financial Instruments, for further information and related disclosures regarding the Company’s fair value measurements.

The estimated fair value of the Notes represents a Level 2 measurement. See Note 10, Convertible Notes for further detail on the Notes.

The long-term debt with a related-party consisting of the Secured Note (as defined in Note 11) and the Warrant are instruments measured at fair value on a non-recurring basis using Level 3 inputs. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note and the Warrant.

Cash and Cash Equivalents

All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.

Investments

The Company invests in various debt and equity securities which are primarily held in the custody of major financial institutions. Debt securities consist of certificates of deposit, U.S. government and agency securities, commercial paper, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ deficit. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of condensed consolidated statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.

We perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security is considered impaired if its fair value is less than its amortized cost basis at the reporting date. If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security.

Inventory

Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.

12

We charge cost of sales for inventory provisions to write-down our inventory to the lower of cost or net realizable value or for obsolete or excess inventory. Most of our inventory provisions relate to excess quantities of products, based on our inventory levels and future product purchase commitments compared to assumptions about future demand and market conditions. Once inventory has been written-off or written-down, it creates a new cost basis for the inventory that is not subsequently written-up.

See Note 6, Inventory, for further information and related disclosures.

Accounts Receivable

Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.

We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. Our customers typically have good credit quality. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data.

The allowance for credit losses for the three and nine months ended September 30, 2022 and 2021 is comprised of the following (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Beginning balance$150 $213 140 445 
(Reversals) provisions, net
(12)78 18 114 
Write-offs
— (77)(20)(345)
$138 $214 $138 $214 

The write-offs recorded during the nine months ended September 30, 2021 were in connection with a one-time restructuring activity of the Company's Europe, Middle East and Africa (“EMEA”) business. These credit losses were incurred as part of the Company terminating agreements with select distributors in geographies it exited and did not pursue collection of these accounts receivables.

Property and Equipment

Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.

Instruments Classified as Property and Equipment

Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.
13


The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of for the three and nine months ended September 30, 2022.

See Note 7, Property and Equipment, for further information and related disclosures.

Long-lived Assets

Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.

Warranty Reserve

Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The cost incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.

Warranty reserve activity for the three and nine months ended September 30, 2022 and 2021 is as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Beginning balance$255 $169 $139 $232 
Provisions (reversals), net
(4)(31)134 (41)
Warranty cost incurred
(29)(17)(51)(70)
Ending balance$222 $121 $222 $121 

Convertible Notes

On January 1, 2022 the Company adopted Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. Gain or loss on extinguishment of Notes is calculated as the difference between the (i) fair value of the consideration transferred and (ii) the sum of the carrying value of the debt at the time of repurchase.

The Company classifies the Notes as a non-current liability as the Company has sufficient shares and non-cash alternatives to settle the Notes.

See Note 2, Recently Issued Accounting Pronouncements and Note 10, Convertible Notes, for further information and related disclosures.

14

Revenue Recognition

The Company recognizes revenue when control of the promised good or service is transferred to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.

The Company determines revenue recognition through the following steps:

•Identification of the contract with a customer
•Identification of the performance obligations in the contract
•Determination of the transaction price
•Allocation of the transaction price to the performance obligations
•Recognition of revenue as we satisfy a performance obligation

Product revenue is derived from the sale or rental of instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized. Payment terms vary by the type and location of the customer and the products or services offered. The term between invoicing and when payment is due is not significant.

Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The Company generally determines relative standalone selling prices based on the price charged to customers for each individual performance obligation.

Sales commissions earned by the Company’s sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and nine months ended September 30, 2022.

Gross Profit and Gross Margin

Gross profit consists of total revenue, net of allowances, less cost of sales. Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related costs.

The Company’s overall gross margin was 26% and 32% for the three months ended September 30, 2022 and 2021, respectively, and 27% and 35% for the nine months ended September 30, 2022 and 2021, respectively. The decreases were primarily due to increases in the costs to manufacture consumables due to supply chain inflationary factors and a decrease in our average unit sales price period over period.

Shipping and Handling

Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the consolidated statements of operations and comprehensive loss.

15

Leases

The Company accounts for leases in accordance with ASC 842, Leases. The Company determines if an arrangement is or contains a lease and the type of lease at inception. The Company classifies leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.

To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.

Leases as Lessee

Operating leases are included in right-of-use (“ROU”) assets and corresponding lease liabilities, and finance leases are included in ROU assets and corresponding lease liabilities within our condensed consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option.

Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between two and six-year terms, and typically contain penalizing, early-termination provisions. Our finance leases consist of leased equipment and have three-year terms.

Leases as Lessor

The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.

Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.

Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.

Nonqualified Cash Deferral Plan

The Company's Cash Deferral Plan (the “Deferral Plan”) provides certain key employees with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of
16

the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments’ fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet.

Equity-Based Compensation

The Company may award stock options, RSUs, performance-based awards and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.

The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.

•Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.

•Expected term: The estimated expected term for employee awards is based on a simplified method that considers an insufficient history of employee exercises. For consultant awards, the estimated expected term is the same as the life of the award.

•Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.

•Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.

The Company records the fair value of RSUs or stock grants based on the published closing market price on the day before the grant date.

The Company accounts for forfeitures as they occur rather than on an estimated basis.

The Company also has an employee stock purchase program whereby eligible employees can elect payroll deductions that are subsequently used to purchase common stock at a discounted price. There is no compensation recorded for this program as (i) the purchase discount does not exceed the issuance costs that would have been incurred to raise a significant amount of capital by a public offering, (ii) substantially all employees that meet limited employment qualifications may participate on an equitable basis, and (iii) the plan doesn't incorporate option features that would require compensation to be recorded.

See Note 13, Employee Equity-Based Compensation for further information.

Deferred Tax

Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying condensed consolidated balance sheet. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.

The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more
17

likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.

Foreign Currency Translation and Foreign Currency Transactions

Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive loss in the condensed consolidated statements of stockholders’ deficit.

The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.

Loss Per Share

Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options, unvested RSUs and the Warrant. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes and the Series A Preferred Stock outstanding at the balance sheet date were converted and shares issuable in connection with the March 2022 Securities Purchase Agreement (as defined in Note 18). Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.

See Note 12, Loss Per Share, for further information.

Comprehensive Loss

In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds debt securities as available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.

NOTE 2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Standards that were recently adopted

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). This update simplifies the accounting for convertible debt instruments by removing the beneficial conversion and cash conversion separation models for convertible instruments. Under the update, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives or that do not result in substantial premiums accounted for as paid-in capital. The update also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will no longer be available. The Company adopted the standard on January 1, 2022 through application of the modified retrospective method of transition. The Company applied the standard to the Notes outstanding as of January 1, 2022, as discussed in Note 10, Convertible Notes. As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. On January 1, 2022, the cumulative effect of adoption resulted in an increase in the net carrying amount of the Notes, of $11.5 million, a decrease in additional-paid-in-capital of $37.4 million, and a decrease in accumulated deficit of $25.9 million. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share. This change has no impact on the Company given the Company was already using the if-converted method to calculate diluted earnings per share.

18

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity’s Own Equity (Topic 815 - 40). ASU 2021-04 codifies the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This ASU was adopted January 1, 2022, and did not impact the Company's consolidated financial statements at January 1, 2022.

Standards not yet adopted

In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. ASU 2022-01 is related to the portfolio layer method of hedge accounting. The amendments in this update clarify the accounting and promote consistency in reporting for hedges where the portfolio layer method is applied. This update is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. We do not expect the update to have a material effect on our condensed consolidated financial statements.

In March 2022, the FASB issued ASU 2022-02, Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. ASU 2022-02 relates to troubled debt restructurings (“TDRs”) and vintage disclosures for financing receivables. The amendments in this update eliminate the accounting guidance for TDRs by creditors while enhancing disclosure requirements for certain loan refinancing and restructurings by creditors made to borrowers experiencing financial difficulty. The amendments also require disclosure of current-period gross write-offs by year of origination for financing receivables. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not expect the update to have a material effect on our condensed consolidated financial statements.

NOTE 3. CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable.

The Company has financial institutions for banking operations that hold 10% or more of the Company’s cash and cash equivalents. As of September 30, 2022, three of the Company's financial institutions held 74%, 12% and 13% of the Company’s cash and cash equivalents. As of December 31, 2021, two of the Company's financial institutions held 72% and 13% of the Company’s cash and cash equivalents.

The Company grants credit to domestic and international customers. Exposure to losses on accounts receivable is principally dependent on each client's financial position. The Company had one customer that accounted for 16% and 13% of the Company’s net accounts receivable balance as of September 30, 2022 and December 31, 2021, respectively.

The Company did not have any customers that represented 10% or more of the Company’s total revenue for the three and nine months ended September 30, 2022 and 2021.

19

NOTE 4. FAIR VALUE OF FINANCIAL INSTRUMENTS

The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Cash and cash equivalents:
Money market funds$5,145 $— $— $5,145 
Total cash and cash equivalents5,145 — — 5,145 
Equity investments:
Mutual funds808 — — 808 
Total equity investments808 — — 808 
Debt securities available-for-sale:
Certificates of deposit— 3,382 — 3,382 
U.S. Treasury securities5,228 — — 5,228 
Commercial paper— 2,893 — 2,893 
Corporate notes and bonds— 4,096 — 4,096 
Debt securities available-for-sale5,228 10,371 — 15,599 
Total assets measured at fair value$11,181 $10,371 $— $21,552 

December 31, 2021
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Cash and cash equivalents:
Money market funds$5,563 $— $— $5,563 
Commercial paper— 200 — 200 
Total cash and cash equivalents5,563 200 — 5,763 
Equity investments:
Mutual funds841 — — 841 
Total equity investments841 — — 841 
Debt securities available-for-sale:
Certificates of deposit— 1,351 — 1,351 
U.S. Treasury securities250 — — 250 
Commercial paper— 8,046 — 8,046 
Corporate notes and bonds— 13,232 — 13,232 
Debt securities available-for-sale250 22,629 — 22,879 
Total assets measured at fair value$6,654 $22,829 $— $29,483 

20

Highly liquid investments with an original maturity of three months or less at time of purchase are included in cash and cash equivalents on the condensed consolidated balance sheet.

Level 1 assets are priced using quoted prices in active markets for identical assets which include money market funds, U.S. Treasury securities and mutual funds as these specific assets are liquid.

Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.

At September 30, 2022, the Notes had an outstanding principal amount of $56.6 million with a fair value of $51.7 million. At December 31, 2021, the Notes had an outstanding principal amount of $120.5 million with a fair value of $89.4 million. The fair value of the Notes represents a Level 2 measurement. The fair value of the Notes is typically correlated to the Company’s stock price and as a result, significant changes to the Company’s stock price will have a significant impact on the calculated fair value. See Note 10, Convertible Notes for further detail on the Notes.

The Secured Note is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. The estimated fair value of the Secured Note on August 15, 2022 was $16.0 million. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note.

The warrant is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. The estimated fair value of the warrant on August 15, 2022 was $3.8 million. See Note 11, Long-Term Debt Related-Party for further detail on the Company’s warrant with a related-party.

NOTE 5. INVESTMENTS

The following tables summarize the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
Certificates of deposit$3,400 $— $(18)$3,382 
U.S. Treasury securities5,266 — (38)5,228 
Commercial paper2,901 — (8)2,893 
Corporate notes and bonds4,131 — (35)4,096 
Total$15,698 $— $(99)$15,599 

December 31, 2021
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
Certificates of deposit$1,351 $— $— $1,351 
U.S. Treasury securities250 — — 250 
Commercial paper8,048 — (2)8,046 
Corporate notes and bonds13,245 — (13)13,232 
Total$22,894 $— $(15)$22,879 

21

The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022December 31, 2021
Amortized
Cost		Fair ValueAmortized
Cost		Fair Value
Due in less than 1 year$15,698 $15,599 $22,663 $22,649 
Due in 1-3 years— — 231 230 
Total
$15,698 $15,599 $22,894 $22,879 

There were no proceeds from sales of debt securities available-for-sale (including principal paydowns) for the three and nine months ended September 30, 2022 and 2021. The Company determines gains and losses of marketable securities based on specific identification of the securities sold. There were no material realized gains or losses from debt securities available-for-sale for the three and nine months ended September 30, 2022 and 2021. No material balances were reclassified out of accumulated other comprehensive income (loss) for the three and nine months ended September 30, 2022 and 2021. No unrealized losses on debt securities available-for-sale have been recognized in income for the three and nine months ended September 30, 2022 and 2021, as the issuers of such securities held by us were of high credit quality.

As of September 30, 2022, there were no holdings of debt securities available-for-sale of any one issuer, other than the U.S. government, in an amount greater than 10%.

As of September 30, 2022 the Company did not carry any debt securities available-for-sale that were below the Company's minimum credit rating. All debt securities available-for-sale had a credit rating of A- or better as of September 30, 2022.

Equity securities are comprised of investments in mutual funds. The fair value of equity securities for each of the periods ended September 30, 2022 and December 31, 2021 was $0.8 million.

Unrealized losses or gains on equity securities recorded in income during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Unrealized (loss) gain on equity investments$(50)$(5)$(206)$39 

These unrealized gains or losses are recorded as a component of other income (expense), net. There were no realized gains or losses from equity securities for each of the three and nine months ended September 30, 2022 and 2021.

NOTE 6. INVENTORY

Inventories consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

September 30,December 31,
20222021
Raw materials$1,769 $1,343 
Work in process2,133 1,625 
Finished goods1,490 2,099 
$5,392 $5,067 

22

NOTE 7. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

September 30,December 31,
20222021
Computer equipment$3,866 $3,181 
Technical equipment3,259 3,285 
Facilities3,674 3,675 
Instruments3,594 5,364 
Capital projects in progress48 683 
Total property and equipment$14,441 $16,188 
Accumulated depreciation(10,820)(10,799)
Property and equipment, net$3,621 $5,389 

Depreciation expense for the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Depreciation expense$381 $487 $1,284 $1,540 

Instruments at cost and accumulated depreciation where the Company is the lessor under operating leases consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

September 30,December 31,
20222021
Instruments at cost under operating leases$2,452 $3,110 
Accumulated depreciation under operating leases(1,109)(1,165)
Net property and equipment under operating leases$1,343 $1,945 

NOTE 8. DEFERRED REVENUE AND REMAINING PERFORMANCE OBLIGATIONS

Deferred revenue consists of amounts received for products or services not yet delivered or earned. If we anticipate revenue will not be earned within the following twelve months, the amount is reported as other non-current liabilities. A summary of the balances as of September 30, 2022 and December 31, 2021 follows (in thousands):

September 30,December 31,
20222021
Products and services not yet delivered$524 $451 

We recognized $0.2 million and $0.4 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2022, respectively, and $0.1 million and $0.3 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2021, respectively. No material amount of revenue recognized during the period was from performance obligations satisfied in prior periods.

23

Transaction Price Allocated to Remaining Performance Obligations

As of September 30, 2022, $9.0 million of revenue is expected to be recognized from remaining performance obligations. This balance primarily relates to product shipments for reagents sold to customers under sales-type lease agreements. These agreements have between two and four year terms and revenue is recognized as product is shipped, typically on a straight-line basis. The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis.

The Company elects not to disclose the value of unsatisfied performance obligations for (i) contracts with an expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

NOTE 9. LONG-TERM DEBT

The Company entered into two loan agreements with one financing company in 2020. Loan proceeds were $0.2 million, with interest rates ranging from 9.8% to 12.4% and maturities becoming due through 2022.

As of September 30, 2022 and December 31, 2021, long-term debt consisted of the following (in thousands):

September 30,December 31,
20222021
Loans - various interest$80 $80 
Current portion of long-term debt80 80 
Long-term debt$— $— 

The following presents maturities of future principal obligations of long-term debt as of September 30, 2022 (in thousands):

Remainder of 2022$80 
2023— 
2024— 
2025— 
2026— 
Thereafter— 
Total$80 

Paycheck Protection Program (PPP) Loan

On April 14, 2020, the Company entered into a promissory note (the “PPP Note”) evidencing an unsecured loan in the amount of $4.8 million made to the Company under the Paycheck Protection Program (“PPP”) established under the Coronavirus Aid, Relief, and Economic Security Act.

On July 15, 2021, the Small Business Administration (“SBA”) informed the Company of its full forgiveness for the entire PPP Note amount plus accrued interest, which was $4.8 million as of the date of forgiveness. The SBA’s determination of loan forgiveness does not preclude further investigation by the SBA according to its rules and regulations. With approval of the Company's application for forgiveness the Company recorded a gain on extinguishment of the entire PPP Note amount of $4.8 million during the three and nine months ended September 30, 2021.

24

NOTE 10. CONVERTIBLE NOTES

The Notes are the Company’s senior unsecured obligations and mature on March 15, 2023 (the “Maturity Date”), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. Upon conversion of the Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of common stock, at the Company’s election. The initial conversion rate of the Notes is 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock, subject to adjustment. The Company pays interest on the Notes semi-annually in arrears on March 15 and September 15 of each year. The Company’s Notes have a fixed coupon rate of 2.5% per annum on the principal amount.

The Company incurred issuance costs related to the issuance of the Notes which is amortized over the five-year contractual term of the Notes using the effective interest method. The effective interest rate on the Notes, including accretion of the Notes to par was 3.2%.

The Notes include customary terms and covenants, including certain events of default upon which the Notes may be due and payable immediately. Holders have the option to convert the Notes in multiples of $1,000 principal amount at any time prior to December 15, 2022, but only in the following circumstances:

•if the Company’s stock price exceeds 130% of the conversion price for 20 of the last 30 trading days of any calendar quarter after June 30, 2018;

•during the 5 business day period after any 5 consecutive trading day period in which the Notes’ trading price is less than 98% of the product of the common stock price times the conversion rate; or

•the occurrence of certain corporate events, such as a change of control, merger or liquidation.

At any time on or after December 15, 2022, a holder may convert its Notes in multiples of $1,000 principal amount. Holders of the Notes who convert their Notes in connection with a make-whole fundamental change (as defined in the Indenture pursuant to which the Notes were issued) are, under certain circumstances, entitled to an increase in the conversion rate. In addition, in the event of a fundamental change or event of default prior to the Maturity Date, holders will, subject to certain conditions, have the right, at their option, to require the Company to repurchase for cash all or part of the Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest up to, but excluding, the repurchase date. As of September 30, 2022 and December 31, 2021, no Notes were convertible pursuant to their original terms.

Interest expense during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual coupon interest$79 $1,024 $1,528 $3,168 
Amortization of debt issuance costs121 185 386 539 
Amortization of the debt discount— $2,987 $— $8,711 
Total interest expense on convertible notes$200 $4,196 $1,914 $12,418 

Gain on extinguishment of exchanged Notes during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Gain on extinguishment$— $4,999 $3,565 $4,999 

25

The carrying value of the Notes at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal at par
$56,595 
Unamortized debt issuance(270)
Net carrying amount
$56,325 

In connection with the Notes issuance, the Company entered into a prepaid forward stock repurchase transaction (“Prepaid Forward”) with a financial institution (“Forward Counterparty”). Pursuant to the Prepaid Forward, the Company used approximately $45.1 million of the net proceeds from its issuance of the Notes to fund the Prepaid Forward. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The expiration date for the Prepaid Forward is March 15, 2023, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. The Company’s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.

2021 Exchange Transactions

In September 2021, the Company entered into separate exchange agreements with certain holders of the Notes. Under the terms of the exchange agreements, such holders agreed to exchange Notes held by them for shares of the Company’s common stock (the “2021 Exchange Transactions”). During the nine months ended September 30, 2021, such holders exchanged $46.0 million in aggregate principal amount of Notes held by them for 5,945,718 shares of the Company’s common stock. The net carrying value of the Notes exchanged was $40.4 million which the Company repurchased for $34.5 million of common stock. The Company also incurred $0.8 million of reacquisition costs, which was recorded as an offset to gain on extinguishment of debt. The 2021 Exchange Transaction resulted in a net gain of $5.0 million reflected in other income (expense), net for the three and nine months ended September 30, 2021. See Note 18, Stockholders' Equity for additional information.

March 2022 Exchange Transaction

On March 21, 2022, the Company entered into a privately negotiated exchange agreement (the “March 2022 Exchange Agreement”) with a holder of the Notes. Under the terms of the March 2022 Exchange Agreement, the note holder agreed to exchange with the Company $14.0 million in aggregate principal amount of Notes held by it in eight equal tranches as follows for each tranche: (a) 22.64 shares per $1,000 principal amount of Notes exchanged, plus (b) an additional number of shares of the Company’s common stock per $1,000 principal amount of Notes exchanged equal to the sum, for each of the trading days during a separate agreed upon reference period for each tranche commencing on March 21, 2022 for the first tranche, of the quotient of (i) $155.67 divided by (ii) the daily volume-weighted average price for such trading day (collectively, the “March 2022 Exchange Transaction”). The closing of the March 2022 Exchange Transaction occurred in eight tranches (“Obligation to Exchange”), with the first closing occurring on March 29, 2022 and the last closing on May 18, 2022.

On March 21, 2022 the Obligation to Exchange the $14.0 million of Notes in the March 2022 Exchange Transaction was accounted for as an extinguishment and was replaced by new notes with an embedded feature (the “New Notes”). The New Notes were elected to be carried using the fair value option. The New Notes were recorded at fair value on initial measurement and remeasured at fair value (“mark to market”) at each reporting period with changes in fair value reported in other income and expense, net. This fair value election was exclusive to the New Notes and did not extend to other Notes. The embedded feature was no longer outstanding on September 30, 2022 as the New Notes were exchanged and the Obligation to Exchange retired on May 18, 2022.

26

During the nine months ended September 30, 2022 the holder of the Notes exchanged $14.0 million in aggregate principal amount of Notes held by it for 10,798,482 shares of the Company’s common stock pursuant to the March 2022 Exchange Agreement. The net carrying value of the Notes exchanged was $14.0 million which the Company repurchased for $10.2 million of common stock. The Company also incurred $0.2 million of reacquisition costs, which was recorded as an offset to gain on extinguishment of debt. This exchange transaction resulted in a net gain of $3.6 million reflected in other income (expense), net for the nine months ended September 30, 2022. See Note 18, Stockholders' Equity for additional information.

August 2022 Exchange Transaction

On August 15, 2022, the Company entered into an exchange agreement (the “August 2022 Exchange Agreement”) with the Jack W. Schuler Living Trust (the “Schuler Trust”), as discussed in Note 11, Long-Term Debt Related-Party. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) the Secured Note in an aggregate principal amount of $34.9 million and (b) the Warrant to acquire the Company’s common stock.

Under ASC 470-50-40, the transaction qualified as an extinguishment of debt. Under extinguishment accounting, the Notes were derecognized and the new instruments, which include the Secured Note and the Warrant, were recorded at their fair values. The difference between the fair values of the new instruments and the net carrying amount of the Notes being extinguished was included in the calculation of gain. The gain from the extinguishment of the Notes was treated as a capital transaction. The Secured Note includes various features that were advantageous to the Company, including a lower interest rate compared to current market rates and a share conversion feature. There were no other negotiating parties that had similar terms or economic outcomes. As such, the exchange was considered not to be an arm’s length transaction, and therefore the resulting gain was accounted for as a capital transaction. The net carrying amount of the extinguished Notes was $49.6 million. The estimated fair value of the Secured Note and the Warrant on August 15, 2022 was $16.0 million and $3.8 million, respectively, which resulted in a net gain of $29.8 million that was recorded to contributed capital. See Note 18, Stockholders' Equity and Note 11, Long-Term Debt Related-Party for additional information.

NOTE 11. LONG-TERM DEBT RELATED-PARTY

On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust, a holder of the Notes. Jack Schuler, who serves as a member of the Company’s board of directors, is the sole trustee of the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) a secured promissory note in an aggregate principal amount of $34.9 million (the “Secured Note”) and (b) a Warrant to acquire the Company’s common stock at an exercise price of $2.12 per share (the “Warrant”).

The Secured Note has a scheduled maturity date of August 15, 2027 and will be repayable upon written demand at any time on or after such date. The Company may, at its option, repay the note in (i) cash or (ii) in the form of common stock of the Company, in a number of shares that is obtained by dividing the total amount of such payment by $2.12. The Secured Note bears interest at a rate of 5.0% per annum, payable at the option of the Company in the same form, at the earlier of (i) any prepayment of principal and (ii) maturity. The Company may prepay the Secured Note at any time without premium or penalty. The Secured Note is secured by substantially all of the assets of the Company, subject to customary exceptions and limitations, pursuant to a security agreement, dated as of August 15, 2022. The Secured Note does not restrict the incurrence of future indebtedness by the Company but shall become subordinated in right of payment and lien priority upon the request of any future senior lender.

Under ASC 470-50-40, the transaction qualified as an extinguishment of debt. Under extinguishment accounting, the Notes were derecognized and the new instruments, which include the Secured Note and the Warrant, were recorded at their fair values. See Note 10, Convertible Notes for additional information. The Secured Notes is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. To estimate the Secured Note’s fair value, the Company applied a Monte Carlo simulation which simulated the share price of the Company over the remaining term to the maturity date of the Secured Note. The simulated per-share price in a given iteration determined if the Company settled in cash or shares. The estimated fair value of the Secured Note on August 15, 2022 was $16.0 million. This valuation estimated an issuance discount of $18.9 million. The effective interest rate on the Secured Note is 24.60%.

27

The carrying value of the Secured Note at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal
$34,934 
Unamortized debt issuance discount
(18,635)
Net carrying amount
$16,299 

Interest expense in connection with the Secured Note during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual interest
$220 $— $220 $— 
Amortization of the debt discount275 — 275 — 
Total interest expense
$495 $— $495 $— 

Warrant

The Warrant may be exercised from February 15, 2023 through the earlier of (i) August 15, 2029 and (ii) the consummation of certain acquisition transactions involving the Company, as set forth in the Warrant. The Warrant is exercisable for up to 2,471,710 shares of common stock. The Warrant meets the criteria for classification in stockholders’ equity and was recorded in equity and initially measured at fair value. The Warrant was measured at fair value on a non-recurring basis using Level 3 inputs. The fair value of the warrant on August 15, 2022 was $3.8 million.

The table below summarizes the inputs used to calculate the estimated fair value of the Warrant issued during the three months ended September 30, 2022:

Contractual term (in years)
7.0
Volatility76.10 %
Expected dividends— 
Risk free interest rates2.86 %

28

NOTE 12. LOSS PER SHARE

Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share are the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive due to the Company’s losses.

The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Shares issuable upon the release of RSUs4,619 2,320 4,619 2,320 
Shares issuable upon exercise of stock options5,665 7,634 5,665 7,634 
Shares issuable upon the exercise of the Warrant2,472 — 2,472 — 
12,756 9,954 12,756 9,954 

Potentially dilutive common shares would include common shares that would be outstanding if Notes convertible at the balance sheet date were converted. As discussed in Note 10, Convertible Notes, upon conversion of the Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of common stock, at the Company’s election. The initial conversion rate of the Notes is 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock. As of September 30, 2022, no Notes were convertible pursuant to the original terms. The number of shares of common stock issuable upon conversion of the outstanding Notes based on the initial conversion rate was approximately 1,830,441 shares as of September 30, 2022. Historically the Company has engaged in privately negotiated exchanges of Notes for a substantially greater number of shares than the initial conversion rate of the Notes described above because the Company’s stock price at the time of such exchanges was significantly less than the $30.92 initial conversion price of the Notes.

In connection with the Notes, the Company entered into a prepaid forward stock repurchase transaction. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company.

Potentially dilutive common shares include common shares that would be outstanding if Series A Preferred Stock were converted into common stock. Each share of Series A Preferred Stock is convertible, at the option of the holder, at any time into one share of the Company’s common stock. Additionally, each share of Series A Preferred Stock will automatically be converted into one share of the Company’s common stock immediately upon a sale of all outstanding stock of the Company or a merger of the Company into another corporation where the pre-merger Company’s stockholders cease to be the controlling stockholders of the post-merger corporation. The number of shares of common stock issuable upon conversion of the Series A Preferred Stock is 3,954,546 as of September 30, 2022.

As discussed in Note 18, Stockholders' Equity, the Company entered into a securities purchase agreement with the Schuler Trust for the issuance and sale by the Company of an aggregate of 2,439,024 shares of the Company’s common stock. The closing of the transaction is expected to occur on December 30, 2022, subject to the satisfaction of customary closing conditions and is considered an equity forward agreement. The shares to be issued from this agreement were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses.

As discussed in Note 11, Long-Term Debt Related-Party, the Company may, at its option, repay the Secured
29

Note in (i) cash or (ii) in the form of common stock of the Company, in a number of shares that is obtained by dividing the total amount of such payment by $2.12. The number of shares of common stock issuable upon conversion of the Secured Note and accrued interest was approximately 16,478,066 and 103,834 shares respectively, as of September 30, 2022. The shares issuable in connection with a repayment of the Secured Note were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses.

NOTE 13. EMPLOYEE EQUITY-BASED COMPENSATION

The following table summarizes option activity under the Company's equity-based compensation plans for the nine months ended September 30, 2022:

Number of SharesWeighted Average Exercise Price per Share
Options outstanding January 1, 20227,192,540 $13.89 
Granted140,000 3.05 
Forfeited(204,232)12.49 
Exercised(6,105)1.04 
Expired(1,457,019)10.33 
Options outstanding September 30, 20225,665,184 $14.60 

No stock options were granted during the three months ended September 30, 2022 and 2021.

The following table shows summary information for outstanding options and options that are exercisable (vested) as of September 30, 2022:

Options
Outstanding		Options
Exercisable
Number of options5,665,184 4,422,595 
Weighted average remaining contractual term (in years)5.545.04
Weighted average exercise price$14.60 $15.32 
Weighted average fair value$9.10 $9.44 
Aggregate intrinsic value (in thousands)$— $— 

The following table summarizes RSU and restricted stock award activity for the nine months ended September 30, 2022:

Number of SharesWeighted Average Grant Date Fair Value per Share
Outstanding January 1, 20222,090,182 $10.77 
Granted4,107,083 1.55 
Forfeited(451,703)8.68 
Released(1,127,017)3.43 
Outstanding September 30, 20224,618,545 $4.57 

30

The table below summarizes equity-based compensation expense for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost of sales$167 $82 $570 $257 
Research and development151 266 1,052 4,340 
Sales, general and administrative911 3,281 6,557 14,461 
$1,229 $3,629 $8,179 $19,058 

The table below summarizes share-based compensation cost capitalized to inventory for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost capitalized to inventory
$69 $77 $186 $319 

As of September 30, 2022, unrecognized equity-based compensation expense related to unvested stock options and unvested RSUs was $2.3 million and $7.8 million, respectively. This is expected to be recognized over the years 2022 through 2027.

Included in the above-noted stock options outstanding and stock compensation expense are performance-based stock options which vest only upon the achievement of certain targets. Performance-based stock options are generally granted at-the-money, contingently vest over a period of 1 to 2 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These options were valued in the same manner as the time-based options, with the assumption that performance goals will be achieved. The inputs for expected volatility, expected dividends, and risk-free rate used in estimating those options’ fair value are the same as the time-based options issued under the Company's equity incentive plans. The expected term for performance-based stock options is 5 to 7 years. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.

During 2020, the Company granted 105,000 performance-based stock options. Of these performance-based stock options, performance obligations had been met for 90,000 options which became exercisable in a prior period. Of these performance-based stock options, 90,000 options expired during the nine months ended September 30, 2022. No performance-based stock options were outstanding as of September 30, 2022.

The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2022 and 2021 (in thousands):

Nine Months Ended September 30,
20222021
Performance-based stock option expense
$— $230 

Included in the above-noted RSU and restricted stock award outstanding amounts are performance-based RSUs which vest only upon the achievement of certain targets. Performance-based RSUs contingently vest over a period of 1 to 3 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These units were valued in the same manner as other RSUs, based on the published closing market price on the day before the grant date. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.

During 2020, the Company granted performance-based RSUs of which 165,974 were outstanding as of September 30, 2022. No changes occurred during the nine months ended September 30, 2022.

During 2021, the Company granted performance-based RSUs of which 111,806 were outstanding as of September 30, 2022. No changes occurred during the nine months ended September 30, 2022.
31


The table below summarizes share-based compensation cost in connection with performance-based RSUs for the nine months ended September 30, 2022 and 2021 (in thousands):

Nine Months Ended September 30,
20222021
Performance-based RSU expense
$— $818 

NOTE 14. INCOME TAXES

For the nine months ended September 30, 2022, the Company did not carry an income tax provision amount as the Company does not recognize tax benefits from current year tax losses in the U.S. and other foreign jurisdictions. The Company’s tax expense for the nine months ended September 30, 2022 differs from the tax expense computed by applying the U.S. statutory tax rate to its year-to-date pre-tax loss of $47.7 million, as no tax benefits were recorded for tax losses generated in the U.S. and other foreign jurisdictions due to the valuation allowance. At September 30, 2022, the Company had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards and a deferred tax liability related to amortization of the Notes. The Company provided a valuation allowance against its net deferred tax assets as future realization of such assets is not more likely than not to occur.

The Company accounts for uncertain tax positions pursuant to the recognition and measurement criteria under ASC 740, Income Taxes. For the three and nine months ended September 30, 2022, we did not note any significant changes to our uncertain tax positions. We do not anticipate significant changes to uncertain tax positions within the next 12 months.

NOTE 15. COMMITMENTS

During April 2022, the Company entered into a non-cancellable purchase obligation with a supplier to acquire raw materials for a total commitment of $11.9 million. Under the terms of this agreement the Company has until March 15, 2027 to take delivery of purchased items. This commitment was entered into to ensure proper material quantities to develop and commercialize our next generation AST platform.

As of September 30, 2022 the commitment remains $11.9 million as the Company has not taken delivery of any inventory.

32

NOTE 16. LEASES

The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cash paid for amounts included in lease liabilities:
Operating cash flows from operating leases$219 $195 $712 $502 
Operating cash flows from finance leases$684 $— $1,109 $— 
ROU assets obtained in exchange for lease obligations:
Operating leases$— $— $— $— 
Finance leases$— $— $2,760 $— 
Lease Cost:
Operating leases$254 $257 $818 $816 
Finance leases
$240 $— $462 $— 
Short-term leases$26 $40 $67 $99 

The weighted average remaining lease term on our operating leases is 2.8 years. The weighted average discount rate on those leases is 7.1%. The weighted average remaining lease term on our finance leases is 2.5 years. The weighted average discount rate on those leases is 4.6%.

The following presents maturities of lease liabilities in which we are the lessee as of September 30, 2022 (in thousands):

Operating
Finance
Remainder of 2022
$227 $180 
2023968 721 
20241,047 721 
2025584 173 
2026— — 
Thereafter— — 
Total lease payments2,826 1,795 
Less imputed interest(278)(144)
$2,548 $1,651 

33

The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of September 30, 2022, the total net investment in these leases was $3.0 million. The following presents maturities of lease receivables under sales-type leases as of September 30, 2022 (in thousands):

Remainder of 2022$351 
20231,154 
2024661 
2025206 
2026640 
Thereafter— 
Total undiscounted cash flows3,012 
Less imputed interest— 
Present value of lease payments$3,012 

NOTE 17. GEOGRAPHIC AND REVENUE DISAGGREGATION

The Company operates as one operating segment. Sales to customers outside the U.S. represented 14% and 8% for the three months ended September 30, 2022 and 2021, respectively, and 14% and 12% for the nine months ended September 30, 2022 and 2021, respectively.

As of September 30, 2022 and December 31, 2021, balances due from foreign customers, in U.S. dollars, were $0.6 million and $0.7 million, respectively.

The following presents total net sales by geographic territory for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Domestic$2,551 $2,874 $8,390 $7,406 
Foreign409 248 1,390 1,033 
$2,960 $3,122 $9,780 $8,439 

The following presents total net sales by line of business for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Accelerate Pheno revenue
$2,933 $3,084 $9,669 $8,324 
Other revenue27 38 111 115 
$2,960 $3,122 $9,780 $8,439 

The following presents total net sales by products and services for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Products$2,532 $2,773 $8,554 $7,474 
Services428 349 1,226 965 
$2,960 $3,122 $9,780 $8,439 

34

Lease revenue included in net sales was $0.2 million and $0.5 million for the three months ended September 30, 2022 and 2021, respectively, and $1.3 million for each of the nine months ended September 30, 2022 and 2021.

The following presents property and equipment, net by geographic territory (in thousands):

September 30,December 31,
20222021
Domestic$3,383 $5,014 
Foreign238 375 
$3,621 $5,389 

NOTE 18. STOCKHOLDERS' EQUITY

December 2020 Securities Purchase Agreement

During December 2020, the Company entered into a securities purchase agreement (the “December 2020 Securities Purchase Agreement”) with Jack W. Schuler, John Patience, Matthew Strobeck, Mark C. Miller, Thomas D. Brown and Jack Phillips, or entities affiliated with such persons (collectively, the “Original Purchasers”), for the issuance and sale by the Company of an aggregate of 4,166,663 shares of the Company’s common stock. Each of Jack W. Schuler, John Patience, Matthew Strobeck, Mark C. Miller, Thomas D. Brown and Jack Phillips is a member of the Company’s board of directors. Mr. Phillips also serves as the Company’s President and Chief Executive Officer.

The Schuler Trust, which was the entity affiliated with Jack W. Schuler that originally entered into the December 2020 Securities Purchase Agreement for the purchase of 3,964,843 shares for an aggregate purchase price of approximately $30.5 million, subsequently entered into an assignment and assumption agreement whereby it assigned all of its rights and obligations as an Original Purchaser to three other entities under the December 2020 Securities Purchase Agreement (collectively, the “Schuler Purchasers”). These three entities are related to Jack W. Schuler but are not affiliates of his.

Pursuant to the December 2020 Securities Purchase Agreement, the Original Purchasers agreed to purchase the shares at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the Company’s common stock) of $7.68 per share, for an aggregate purchase price of approximately $32 million.

The December 2020 Securities Purchase Agreement contemplated that the closing of the purchase and sale of the shares would occur in three tranches, with the first and second tranches having closed on February 19, 2021 and April 9, 2021, respectively, whereby the Company received total proceeds of approximately $21.3 million which were recorded to contributed capital.

On September 17, 2021, the Company entered into a rescission agreement (the “Rescission Agreement”) with the Schuler Purchasers and the Schuler Trust pursuant to which, effective as of January 29, 2021, the Company and the Schuler Purchasers agreed to rescind and unwind the December 2020 Securities Purchase Agreement for all legal, tax and financial purposes ab initio as if the related transactions, including the issuance and sale of an aggregate of 2,643,228 shares in the first two tranche closings and the third tranche (as discussed below) under the December 2020 Purchase Agreement, had never occurred with respect to the Schuler Purchasers and the Company. The 2,643,228 Shares re-acquired by the Company from the Schuler Purchasers as a result of the Rescission Agreement were treated as a reduction to contributed capital and were not outstanding for purposes of the calculation of basic and diluted earnings per share.

On September 30, 2021, the Company closed the final third tranche in connection with the December 2020 Securities Purchase Agreement and received total proceeds of approximately $0.5 million. In accordance with the Rescission Agreement, the Schuler Purchasers did not participate in the third tranche. During the nine months ended September 30, 2021, the Company issued 201,820 shares and received total proceeds of approximately $1.5 million under the December 2020 Securities Purchase Agreement, which were recorded to contributed capital, after giving effect to the Rescission Agreement.

35

September 2021 Securities Purchase Agreement

During September 2021, the Company entered into a new securities purchase agreement (the “September 2021 Securities Purchase Agreement”) with the Schuler Purchasers for the issuance and sale by the Company of an aggregate of 3,954,546 shares of the Company’s newly designated Series A Preferred Stock, par value $0.001 per share (the “Series A Preferred Shares”). Each share of Series A Preferred Stock is convertible, at the option of the holder, at any time into one share of the Company’s common stock.

Pursuant to the September 2021 Securities Purchase Agreement, the Schuler Purchasers agreed to purchase the Series A Preferred Shares at a purchase price of $7.70 per share for an aggregate purchase price of approximately $30.5 million.

The September 2021 Securities Purchase Agreement contemplated the closing of the purchase and sale of the Series A Preferred Shares would occur in two tranches. The first tranche closed on the date of the execution of the September 2021 Securities Purchase Agreement whereby an aggregate of 2,636,364 Series A Preferred Shares were issued and sold to the Schuler Purchasers. The Company received total proceeds of approximately $20.3 million, which was recorded to contributed capital during the three months ended September 30, 2021.

The second tranche (the “Tranche Right”) had not closed by September 30, 2021 and was concluded to be an obligation of the Schuler Purchasers to acquire, and the Company to sell an additional 1,318,182 Series A Preferred Shares at a purchase price of $7.70 per share for proceeds of $10.2 million, subsequent to the September 30, 2021 balance sheet date. The Company concluded the Tranche Right met the definition of a freestanding financial instrument which was recorded within stockholder’s equity. The value of this Tranche Right as September 30, 2021 was $2.5 million. The estimated fair value of the Tranche Right represented a Level 3 measurement as this financial instrument has no market activity. The estimated fair value of the Tranche Right was determined as the excess value of the forward contract when compared to the underlying asset. The fair value of this forward contract can be represented by the difference between the contractual forward price of $7.70 and the prevailing exchange-traded common stock price ($5.81 at September 22, 2021 and $5.83 at September 30, 2021), multiplied by 1,318,182 Series A Preferred Shares. On October 29, 2021, the Company closed the final second tranche in connection with the September 2021 Securities Purchase Agreement whereby the Company issued and sold an aggregate of 1,318,182 Series A Preferred Shares to the Schuler Purchasers and received total proceeds of approximately $10.2 million.

2021 Exchange Transactions

During the none months ended September 30, 2021, certain holders of the Notes exchanged $46.0 million in aggregate principal amount of Notes held by them for 5,945,718 shares of the Company’s common stock pursuant to their respective exchange agreement. Using the closing stock price on September 22, 2021 of $5.81, the 5,945,718 shares of the Company’s common stock were determined to have a value of $34.5 million, which was recorded to contributed capital during the nine months ended September 30, 2021. See Note 10, Convertible Notes, for additional information.

March 2022 Exchange Transaction

During the nine months ended September 30, 2022, a holder of the Notes exchanged $14.0 million in aggregate principal amount of Notes held by it for 10,798,482 shares of the Company's common stock pursuant to the March 2022 Exchange Agreement. The 10,798,482 shares of the Company’s common stock were determined to have a value of $10.2 million, which was recorded to contributed capital during the nine months ended September 30, 2022. See Note 10, Convertible Notes for additional information.

March 2022 Securities Purchase Agreement

On March 24, 2022, the Company entered into a securities purchase agreement (the “March 2022 Securities Purchase Agreement”) with the Schuler Trust for the issuance and sale by the Company of an aggregate of 2,439,024 shares of the Company’s common stock to the Schuler Trust in an offering (the “Private Placement”) exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder.

36

Pursuant to the March 2022 Securities Purchase Agreement, the Schuler Trust agreed to purchase the shares at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the Company’s common stock) of $1.64 per share, for an aggregate purchase price of $4.0 million.

On June 29, 2022, the Company and the Schuler Trust agreed to extend the closing date of the Private Placement (the “Closing Date”) from June 30, 2022 to September 26, 2022, subject to the satisfaction of customary closing conditions. On September 29, 2022, the parties agreed to further extend the Closing Date to December 30, 2022, effective as of September 26, 2022.

August 2022 Exchange Transaction

On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) the Secured Note in an aggregate principal amount of $34.9 million and (b) the Warrant to acquire the Company’s common stock. The gain from the extinguishment of the Notes was treated as a capital transaction. The net gain on extinguishment was $29.8 million during the three months ended months ended September 30, 2022, and was recorded to contributed capital. See Note 10, Convertible Notes and Note 11, Long-Term Debt Related-Party for additional information.

The Warrant meets the criteria for classification in stockholders’ equity and was recorded in contributed capital at fair value of $3.8 million on August 15, 2022.

August 2022 Public Offering

On August 23, 2022, the Company completed a public offering 17,500,000 shares of its common stock at a public offering price of $2.00 per share. The Company received net proceeds of approximately $32.9 million from the offering after deducting underwriting discounts and commissions and offering expenses paid by the Company.

NOTE 19. RELATED-PARTY TRANSACTIONS

2021 Exchange Transactions

As discussed in Note 10, Convertible Notes, the Company carries Notes. The Schuler Family Foundation (the “Foundation”) previously held an aggregate of $42.0 million of the Notes. Jack W. Schuler, a member of the Company’s board of directors, is the President of the Foundation.

During the three months ended September 30, 2021, the Foundation transferred by gift the $42.0 million aggregate principal amount of Notes held by the Foundation to the Schuler Initiative Supporting Charitable Trust (the “Supporting Organization”), a tax-exempt organization that is not an affiliate of Jack W. Schuler.

In connection with the 2021 Exchange Transactions the Supporting Organization exchanged $42.0 million in aggregate principal amount of Notes held by it for 5,428,699 shares of the Company's common stock. Using the closing stock price on September 22, 2021 of $5.81, the 5,428,699 shares of the Company's common stock were determined to have a value of $31.5 million which was recorded to contributed capital for the three months ended September 30, 2021. The Supporting Organization had the same or similar terms as the other counter parties. The Company determined the 2021 Exchange Transactions did not meet the criteria of a capital transaction and was recorded as a gain on extinguishment of debt. See Note 10, Convertible Notes and Note 18, Stockholders' Equity, for additional information.

December 2020 Securities Purchase Agreement

On December 24, 2020, the Company entered into the December 2020 Securities Purchase Agreement with the Original Purchasers for the issuance and sale by the Company of 4,166,663 shares of the Company’s common stock. The Original Purchasers are comprised of certain directors and officers of the Company, or entities affiliated or related to such persons. See Note 18, Stockholders' Equity, for further information.

On September 17, 2021, the Company entered into the Rescission Agreement with the Schuler Purchasers and the Schuler Trust, an entity affiliated with Jack W. Schuler, pursuant to which, effective as of January 29, 2021, the Company and the Schuler Purchasers agreed to rescind and unwind the December 2020 Securities Purchase
37

Agreement for all legal, tax and financial purposes ab initio as if the related transactions, including the issuance and sale of an aggregate of 2,643,228 Shares in the first two tranche closings and the third tranche under the December 2020 Purchase Agreement, had never occurred with respect to the Schuler Purchasers and the Company. The Schuler Purchasers are related to Jack W. Schuler but are not affiliates of his. See Note 18, Stockholders' Equity, for further information.

During the nine months ended September 30, 2021, the Company issued 201,820 shares and received total proceeds of approximately $1.5 million under the December 2020 Securities Purchase Agreement after giving effect to the Rescission Agreement.

September 2021 Securities Purchase Agreement

On September 22, 2021, the Company entered into the September 2021 Securities Purchase Agreement with the Schuler Purchasers for the issuance and sale by the Company of 3,954,546 Series A Preferred Shares. The Schuler Purchasers are related to Jack W. Schuler but are not affiliates of his.

During the nine months ended September 30, 2021, the Company issued 2,636,364 Series A Preferred Shares and received total proceeds of approximately $20.3 million under the September 2021 Securities Purchase Agreement. See Note 18, Stockholders' Equity, for further information.

March 2022 Securities Purchase Agreement

On March 24, 2022, the Company entered into the March 2022 Securities Purchase Agreement with the Schuler Trust for the issuance and sale by the Company of 2,439,024 shares of the Company’s common stock. Jack Schuler serves as a member of the Company’s board of directors and is the sole trustee of the Schuler Trust. See Note 18, Stockholders’ Equity, for further information.

August 2022 Exchange Transaction

On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for the Secured Note in an aggregate principal amount of $34.9 million and a warrant to acquire the Company’s common stock. The net gain on extinguishment was $29.8 million during the nine months ended September 30, 2022, and was recorded as contributed capital. See Note 10, Convertible Notes and Note 11, Long-Term Debt Related-Party for additional information.

38


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Introductory Note

Except as otherwise indicated by the context, references in this Quarterly Report on Form 10-Q (this “Form 10-Q”) to the “Company,” “Accelerate,” “we,” “us” or “our” are references to the combined business of Accelerate Diagnostics, Inc. The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) summarizes the significant factors affecting our results of operations, liquidity, capital resources and contractual obligations. The following discussion and analysis should be read in conjunction with the Company’s unaudited condensed consolidated financial statements and related notes included elsewhere herein.

All amounts in the MD&A have been rounded to the nearest thousand unless otherwise indicated.

Forward-Looking Statements

This Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company intends that such forward-looking statements be subject to the safe harbors created thereby. These forward-looking statements, which can be identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” or “continue,” or variations thereon or comparable terminology, include but are not limited to, statements about our future development plans and growth strategy, including plans and objectives relating to our future operations, products and performance; projections as to when certain key business milestones may be achieved; our liquidity and capital requirements; expectations regarding the potential or benefits of our products and technologies; projections of future demand for our products; our continued investment in new product development to both enhance our existing products and bring new ones to market; the anticipated impacts from the COVID-19 pandemic on the Company, including to our business, results of operations, cash flows and financial position, as well as our future responses to the COVID-19 pandemic; our expectations relating to current supply chain impacts and inflationary pressures, including our belief that we currently have sufficient inventory of Accelerate Pheno system instruments to limit the impact of cost increases on such devices; our expectations regarding our commercial partnership with Becton, Dickinson and Company (“BD”), including anticipated benefits from such collaboration; and our belief that we will obtain approval from the U.S. Food and Drug Administration (“FDA”) to market our Accelerate Arc product. In addition, all statements other than statements of historical facts that address activities, events, or developments the Company expects, believes, or anticipates will or may occur in the future, and other such matters, are forward-looking statements.

Future events and actual results could differ materially from those set forth in, contemplated or suggested by, or underlying the forward-looking statements. There can be no assurances that results described in forward-looking statements will be achieved, and actual results could differ materially from those suggested by the forward-looking statements. The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties, including the duration and severity of the ongoing COVID-19 pandemic, including any new variants that may become predominant; government and other third-party responses to it and the consequences for the global economy and the businesses of our suppliers and customers, such as the possibility of customer demand fluctuations, supply chain constraints and inflationary pressures; and its ultimate effect on our business, results of operations, cash flows and financial position, as well as our ability (or inability) to execute on our plans to respond to the COVID-19 pandemic. Other important factors that could cause our actual results to differ materially from those in our forward-looking statements include those discussed herein, and in other reports filed with the U.S. Securities and Exchange Commission (the “SEC”) including but not limited to the risks in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 10-K”), the section entitled “Risk Factors” in this Form 10-Q and in the Company's subsequent filings with the SEC. These forward-looking statements are also based on certain additional assumptions, including, but not limited to, that the Company will retain key management personnel, the Company will be successful in the commercialization of the Accelerate Pheno® system and the Accelerate Arc™ system, the Company will obtain sufficient capital to commercialize the Accelerate Pheno system and the Accelerate Arc system and continue development of complementary products, the Company will be successful in obtaining marketing authorization for its products from the FDA and other regulatory agencies and governing bodies, the Company will be able to protect its intellectual property, the Company’s ability to respond effectively to technological change, the Company will
39

accurately anticipate market demand for the Company’s products and there will be no material adverse change in the Company’s operations or business and general market and industry conditions. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements will be realized. Any forward-looking statements made by us in this Form 10-Q speak only as of the date on which they are made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Overview

Accelerate is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Microbiology laboratories need new tools to address what the U.S. Centers for Disease Control and Prevention (the “CDC”) calls one of the most serious healthcare threats of our time, antibiotic resistance. A significant contributing factor to the rise of resistance is the overuse and misuse of antibiotics, which is exacerbated by a lack of timely diagnostic results. The delay of identification and antibiotic susceptibility results is often due to the reliance by microbiology laboratories on traditional culture-based tests that often take two to three days to complete. Our technology platform is intended to address these challenges by delivering significantly faster testing of infectious pathogens in various patient sample types.

Our first system to address these challenges is the Accelerate Pheno® system. The Accelerate PhenoTest® BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. The device provides identification (“ID”) results followed by antibiotic susceptibility testing (“AST”) for certain pathogenic bacteria commonly associated with or causing bacteremia. This test kit utilizes genotypic technology to identify infectious pathogens and phenotypic technology to conduct AST, which determines whether live bacterial cells are resistant or susceptible to a particular antimicrobial. This information can be used by physicians to rapidly modify antibiotic therapy to lessen adverse events, improve clinical outcomes, and help preserve the useful life of antibiotics.

On June 30, 2015, we declared our conformity to the European In Vitro Diagnostic Directive 98/79/EC and applied a CE mark to the Accelerate Pheno system and the Accelerate PhenoTest BC Kit for in vitro diagnostic use. On February 23, 2017, the U.S. Food and Drug Administration (the “FDA”) granted our de novo classification request to market the first version of our Accelerate Pheno system and Accelerate PhenoTest BC Kit.

In 2017, we began selling the Accelerate Pheno system in hospitals in the United States, Europe, and the Middle East. Consistent with our “razor” / “razor-blade” business model, revenues to date have principally been generated from the sale or leasing of the instruments and the sale of single use consumable test kits.

In July 2021, we launched our second test for use on the Accelerate Pheno system, the Accelerate PhenoTest BC Kit, AST configuration. This test kit runs antibiotic susceptibility testing following the input of an ID result from another system or methodology. In August 2021, we announced that this new AST only configuration had been CE marked for use in Europe. We believe this new AST only configuration may be attractive to prospective customers who already have a rapid ID system but still need fast susceptibility results to support getting patients on an optimal antibiotic therapy as soon as possible.

In March and May 2022, we announced the launch and commercialization of the Accelerate ArcTM system and BC Kit (“Accelerate Arc Products”). This instrument and associated one-time-use test kit automates the clean-up and concentration of microbial cells from positive blood culture samples. In May 2022, we announced IVD registration of the Accelerate Arc system and BC Kit with the FDA as a Class I device exempt from FDA clearance requirements, and in June 2022 we received CE IVDR registration for use in Europe.

On October 21, 2022, the “Company announced it has been in recent discussions with the FDA regarding its Accelerate Arc Products. Pursuant to such discussions, the FDA has challenged the Company’s commercialization of this product in the United States as a Class I device exempt from 510(k) clearance requirements. The Company is in active dialogue with the FDA to determine the appropriate regulatory pathway.
40

While these discussions are ongoing the Company has put on hold in the United States its sales and marketing efforts of Accelerate Arc Products. The Company will continue marketing and distributing the Accelerate Arc Products in Europe pursuant to its existing CE In Vitro Diagnostic Regulation (IVDR) registration.

In August 2022, we entered into a sales and marketing agreement (the “Sales and Marketing Agreement”) with BD pursuant to which BD will perform certain sales, tactical marketing, technical service call forwarding, order preparation, research and development support and/or regulatory activities on our behalf as our exclusive sales agent for certain of our products, including the Accelerate Pheno system, Accelerate Arc Products. The Sales and Marketing Agreement also grants to BD certain other rights to certain of our future products. We entered into the Sales and Marketing Agreement in order to leverage BD’s expansive global sales team, benefit from natural synergies between BD’s existing products and those from us, and reduce our sales and marketing expenses.

We continue to invest in new product development to both enhance our existing products and bring new ones to market. Current research and development areas of focus include the potential addition, if authorized by the FDA, of new AST content to our Accelerate Pheno system, additional applications for the Accelerate Arc Products, and a next generation AST platform, which is being developed with the goal to have lower costs, higher throughput, and capability to test a broader set of sample types compared to the current Accelerate Pheno system.

COVID-19 and Supply Chain Impacts Update

In late 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in Wuhan, China, and spread globally. In March 2020, the World Health Organization declared COVID-19 a global pandemic. The COVID-19 outbreak resulted in government authorities around the world implementing numerous measures to try to reduce the spread of COVID-19, such as travel bans and restrictions, quarantines, shelter-in-place, stay-at-home or total lock-down (or similar) orders and business limitations and shutdowns. New cases and hospitalizations have risen and fallen throughout the course of this pandemic. More recently, the emergence and spread of new variants of COVID-19 that are significantly more contagious than previous strains initially led many government authorities and businesses to reimplement prior restrictions in an effort to lessen the spread of COVID-19 and its variants. While most of these restrictions have been lifted, uncertainty remains as to whether additional restrictions may be initiated or again reimplemented in response to surges in COVID-19 cases. The lingering impact of the COVID pandemic continues to create significant volatility throughout the global economy, including supply chain constraints, labor supply issues and higher inflation. Accordingly, it is unclear at this point the full impact COVID-19 and its variants will have on the global economy and on our Company.

The COVID-19 pandemic, containment measures, and downstream impacts to hospital staffing and financial stability have caused, and are continuing to cause, business slowdowns in affected areas, both regionally and worldwide, as well as disruptions to global supply chains and workforce participation. These effects have significantly impacted our business and results of operations, starting in the first quarter of 2020 and continuing through the current quarter, albeit to a lesser degree. For example, we have experienced diminished access to our customers, including hospitals, which has severely limited our ability to sell and, to a lesser degree, implement previously contracted Accelerate Pheno systems. Hospital turnover resulting from burnout and vaccine mandates have further diverted the attention of hospital decision makers. In addition, in certain months with high rates of COVID-19 hospitalization, our Accelerate PhenoTest BC Kit orders declined as many hospitals curtailed elective surgeries to respond to COVID-19.

The reduced new instrument sales and implementations caused by the COVID-19 pandemic lowered our realized and expected revenue growth for 2020 and 2021. In 2022, we began to see many of the detrimental effects of the pandemic on our business discussed above start to ease. For example, in recent quarters, we have seen bloodstream infection testing regain normalcy, which has in turn lessened the adverse impact of the COVID-19 pandemic on our recurring revenues through the sale of Accelerate PhenoTest BC Kits. However, with the emergence of COVID-19 variants, including the Omicron variant and its sub-variants, vaccine hesitancy and the prevalence of breakthrough cases of infection among fully vaccinated people, there remains uncertainty regarding our access to customers and prospects, demand for our products, and ability to implement our products.

As a medical device company, we have not experienced any disruptions to our ability to manufacture our products at our Tucson, Arizona headquarters under the various State of Arizona executive orders relating to the COVID-19 pandemic because we were classified as an essential service. We continue to expect that, should future orders be issued, we would be able to sustain our essential operations. Our third-party manufacturing supply chain for Accelerate Pheno systems and consumable test kits remains stable despite a high-degree of unpredictability in
41

the broader supply chain environment. However, like many industries experiencing inflationary pressures in raw materials, the direct costs to manufacture our products are increasing and delivery schedules elongating.

For example, we are currently experiencing unprecedented cost increases from many of our suppliers primarily as a result of the ongoing COVID-19 pandemic, labor and supply disruptions and increased inflation. The areas of cost increases include raw materials, components, and value-add supplier labor. We believe that we currently have sufficient inventory of Accelerate Pheno system instruments to limit the impact of cost increases on such devices. However, we are being impacted by cost increases to components and raw materials necessary for the production of our Accelerate Pheno kits. Our ability to pass increased material costs to many of our customers is limited because of long-term sales agreements with limits on price increases. Accordingly, we are closely monitoring the ability of all our suppliers to provide us with necessary materials and services at reasonable costs. See “Risk Factors— Risks Related to Our Business and Strategy—Disruptions in the supply of raw materials, consumable goods or other key product components, or issues associated with their quality from our single source suppliers, could result in a significant disruption in sales and profitability” in Part I, Item 1A of 2021 10-K for additional information.

We continue to monitor the evolving impacts to our business caused by the COVID-19 pandemic. We may take further actions required by governmental authorities or that we determine are prudent to support the well-being of our employees, customers, suppliers, business partners and others. The degree to which the COVID-19 pandemic ultimately impacts our business, results of operations, cash flows and financial position will depend on future developments, which are highly uncertain, continuously evolving and cannot be predicted. This includes, but is not limited to, the duration and spread of the pandemic and its severity; the emergence and severity of its variants, including the Omicron variant and its subvariants; the actions to contain the virus or treat its impact, such as the availability and efficacy of vaccines (particularly with respect to emerging strains of the virus) and potential hesitancy to use them; the financial impact of COVID-19 on hospitals, including to their budget priorities; hospital staffing issues; general economic factors, such as increased inflation; global supply chain constraints and the related increase in costs; labor supply issues; and how quickly and to what extent normal economic and operating conditions can resume.

Accordingly, our current results and financial condition discussed herein may not be indicative of future operating results and trends. Refer to the section entitled “Risk Factors” in the 2021 10-K for additional risks we face due to the COVID-19 pandemic, including risks relating to our supply chain.

Changes in Results of Operations: Three and nine months ended September 30, 2022 compared to three and nine months ended September 30, 2021

The Company has provided enhanced information in a tabular format which presents some of the captions presented on the statement of operations less non-cash equity-based compensation expense. These figures are reconciled to the statement of operations and are intended to add additional clarity on the operating performance of the business. The Company believes providing such figures less non-cash equity-based compensation expense provides helpful information for investors in understanding and evaluating our operating results in the same manner as our management and our board of directors.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Net sales$2,960 $3,122 $(162)(5)%$9,780 $8,439 $1,341 16 %

For the three months ended September 30, 2022, total revenues decreased due to lower sales of Accelerate PhenoTest instruments compared to the three months ended September 30, 2021.

For the nine months ended September 30, 2022, total revenues increased primarily due to higher sales of Accelerate PhenoTest BC Kits and service contract revenue, partially offset by a decrease in sales of Accelerate PhenoTest instruments compared to the nine months ended September 30, 2021. Accelerate PhenoTest BC Kit revenue increased as customers completed their instrument verifications and began purchasing kits. Service contract revenue increased as a higher number of customers entered into multi-year service agreements following the expiration of their warranty periods.
42


Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Cost of sales$2,190 $2,136 $54 3 %$7,127 $5,502 $1,625 30 %
Non-cash equity-based compensation as a component of cost of sales
167 82 85 104 %570 257 313 122 %
Cost of sales less non-cash equity-based compensation
$2,023 $2,054 $(31)(2)%$6,557 $5,245 $1,312 25 %

For the three months ended September 30, 2022, cost of sales increased as compared to the three months months ended September 30, 2021, primarily due to higher non-cash equity-based compensation expense, partially offset by lower sales of Accelerate PhenoTest instruments.

For the nine months ended September 30, 2022, cost of sales increased as compared to the nine months ended September 30, 2021, primarily due to higher Accelerate Pheno recurring revenues, increases to our cost of manufacturing consumables and higher non-cash equity-based compensation expense. Our cost of manufacturing has increased as we are experiencing cost increases from many of our suppliers primarily as a result of the ongoing COVID-19 pandemic, labor and supply disruptions and increased inflation. The areas of cost increases include raw materials, components, and value-add supplier labor.

Cost of sales includes non-cash equity-based compensation expense of $0.2 million and $0.1 million for the three months ended September 30, 2022 and 2021, respectively, and $0.6 million and $0.3 million for the nine months ended September 30, 2022 and 2021, respectively. Non-cash equity-based compensation expense increased for the three and nine months ended September 30, 2022 when compared to the three and nine months ended September 30, 2021. Non-cash equity-based compensation expense is a component of manufacturing overhead and service cost of sales. Manufacturing overhead is capitalized as inventory and relieved to cost of sales when products are sold to a customers, or when instruments under reagent rentals are amortized to cost of sales.

Cost of sales expenses excluding non-cash equity-based compensation expense for the three months ended September 30, 2022 decreased compared to the three months ended September 30, 2021, primarily due to lower sales of Accelerate PhenoTest instruments.

Cost of sales expenses excluding non-cash equity-based compensation expense for the nine months ended September 30, 2022 increased compared to the nine months ended September 30, 2021, primarily due to higher sales of Accelerate PhenoTest BC Kits and service contract revenue, partially offset by a decrease in sales of Accelerate PhenoTest instruments. Other factors include increases to our cost of manufacturing consumables, as described above.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Gross profit$770 $986 $(216)(22)%$2,653 $2,937 $(284)(10)%
Non-cash equity-based compensation as a component of gross profit
167 82 85 104 %570 257 313 122 %
Gross profit less non-cash equity-based compensation
$937 $1,068 $(131)(12)%$3,223 $3,194 $29 1 %

43

The Company’s overall gross margin was 26% and 32% for the three months ended September 30, 2022 and 2021, respectively, and 27% and 35% for the nine months ended September 30, 2022 and 2021, respectively.

For the three months ended September 30, 2022, gross profit decreased as compared to the three months ended September 30, 2021, primarily due to lower sales of Accelerate PhenoTest instruments and higher non-cash equity-based compensation expense.

For the nine months ended September 30, 2022, gross profit decreased as compared to the nine months ended September 30, 2021, primarily due to higher non-cash equity-based compensation expense, a decrease in our average unit sales price of test kits, and increases to our cost of manufacturing consumables, as described above.

Gross profit excluding non-cash equity-based compensation expense for the three months ended September 30, 2022 decreased compared to the three months ended September 30, 2021, as a result of lower sales of Accelerate PhenoTest instruments.

Gross profit excluding non-cash equity-based compensation expense for the nine months ended September 30, 2022 remained flat compared to the nine months ended September 30, 2021, primarily due to higher Accelerate Pheno recurring revenues, offset by a decrease in our average unit sales price, and increases to our cost of manufacturing consumables, as described above.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Research and development$7,285 $4,712 $2,573 55 %$20,885 $17,341 $3,544 20 %
Non-cash equity-based compensation as a component of research and development
151 266 (115)(43)%1,052 4,340 (3,288)(76)%
Research and development less non-cash equity-based compensation
$7,134 $4,446 $2,688 60 %$19,833 $13,001 $6,832 53 %

Research and development expenses for the three and nine months ended September 30, 2022 increased as compared to the three and nine months ended September 30, 2021 primarily due to increased expenses to develop our next generation AST platform, partially offset by decreases in non-cash equity-based compensation expense.

Research and development expenses include non-cash equity-based compensation expense of $0.2 million and $0.3 million for the three months ended September 30, 2022 and 2021, respectively, and $1.1 million and $4.3 million for the nine months ended September 30, 2022 and 2021, respectively. Non-cash equity-based compensation expense decreased for the three and nine months ended September 30, 2022 when compared to the three and nine months ended September 30, 2021, due to the reversal of non-cash equity-based compensation epense as a result of employees separating from the Company and a decrease in the fair value of new awards being granted.

Research and development expenses excluding non-cash equity-based compensation expense for the three and nine months ended September 30, 2022 increased compared to the three and nine months ended September 30, 2021, primarily due to increases in contracted service costs for the development of our next generation AST platform.

44

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Sales, general and administrative$8,255 $10,806 $(2,551)(24)%$30,422 $37,744 $(7,322)(19)%
Non-cash equity-based compensation as a component of sales, general and administrative
911 3,281 (2,370)(72)%6,557 14,461 (7,904)(55)%
Sales, general and administrative less non-cash equity-based compensation
$7,344 $7,525 $(181)(2)%$23,865 $23,283 $582 2 %

Sales, general and administrative expenses for the three and nine months ended September 30, 2022 decreased as compared to the three and nine months ended September 30, 2021 primarily due to a decrease in non-cash equity-based compensation expense.

Sales, general and administrative expenses include non-cash equity-based compensation expense of $0.9 million and $3.3 million for the three months ended September 30, 2022 and 2021, respectively, and $6.6 million and $14.5 million for the nine months ended September 30, 2022 and 2021, respectively. Non-cash equity-based compensation expense decreased for the three and nine months ended September 30, 2022 when compared to the three and nine months ended September 30, 2021, primarily due to the reversal of non-cash equity-based compensation expense as a result of employees separating from the Company and a decrease in the fair value of new awards being granted.

Sales, general and administrative expenses excluding non-cash equity-based compensation expense for the three months ended September 30, 2022 decreased compared to the three months ended September 30, 2021, primarily due to decreases in employee related expenses, including ordinary salaries and commissions, partially offset by one-time severance expenses. During the three months ended September 30, 2022, the Company restructured its commercial sales team by reducing the number of employees in consideration of the Company’s new commercial partnership with BD.

Sales, general and administrative expenses excluding non-cash equity-based compensation expense for the nine months ended September 30, 2022 increased compared to the nine months ended September 30, 2021, primarily due to increases in costs related to marketing, promotional activities and one-time severance expenses discussed above. These costs were partially offset by decreases in employee related expenses, including ordinary salaries and commissions.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Loss from operations$(14,770)$(14,532)$(238)2 %$(48,654)$(52,148)$3,494 (7)%
Non-cash equity-based compensation as a component of loss from operations
1,229 3,629 $(2,400)(66)%8,179 19,058 $(10,879)(57)%
Loss from operations less non-cash equity-based compensation
$(13,541)$(10,903)$(2,638)24 %$(40,475)$(33,090)$(7,385)22 %

For the three months ended September 30, 2022, our loss from operations increased as compared to the three months ended September 30, 2021. The increase was primarily the result of increased research and
45

development expenses to develop our next generation AST platform, partially offset by decreases in non-cash equity-based compensation expense.

For the nine months ended September 30, 2022, our loss from operations decreased as compared to the nine months ended September 30, 2021. The decrease was primarily due to a decrease in non-cash equity-based compensation which was partially offset by an increase in research and development expenses.

Loss from operations excluding non-cash equity-based compensation expense for the three and nine months ended September 30, 2022 increased compared to the three and nine months ended September 30, 2021, primarily due to increases in product development costs related to the Accelerate Arc and the next generation AST platform, as discussed above.

This loss and further losses are anticipated and was the result of our continued investments in sales and marketing, key research and development personnel, related costs associated with product development, and commercialization of the Company’s products.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Total other (expense) income, net$(935)$5,546 $(6,481)(117)%$961 $(2,751)$3,712 (135)%

For the three months ended September 30, 2022 the Company incurred other expense, net compared to other income, net for the three months ended September 30, 2021. This change was the result of certain gains on extinguishments of debt for the three months ended September 30, 2021.

For the three months ended September 30, 2021, the Company entered into a privately negotiated exchange agreements with a holders of the Company’s 2.50% Senior Convertible Notes due 2023 (the “Notes”) pursuant to which such holders exchanged $46.0 million in aggregate principal amount of Notes held by them for 5,945,718 shares of the Company's common stock. The gain on extinguishment of exchanged Notes was $5.0 million for the three months ended September 30, 2022.

For the three months ended September 30, 2021, the Small Business Administration informed the Company of its full forgiveness for the entire Paycheck Protection Program loan amount plus accrued interest, which was $4.8 million. With approval of the Company's application for forgiveness the Company recorded a gain on extinguishment of $4.8 million during the three months ended September 30, 2021.

For the nine months ended September 30, 2022 the Company recognized other income, net compared to other expense, net for the nine months ended September 30, 2021. This change was the result of higher interest expense and a gain recognized upon extinguishment of the Company’s Notes during the nine months ended September 30, 2021.

The Company adopted ASU 2020-06 on January 1, 2022. This change in accounting principle resulted in a decrease in interest expense for the three and nine months ended September 30, 2022 compared to the three and nine months ended September 30, 2021. Other factors include a decrease in aggregate principal amount of the Company’s Notes outstanding. Interest expense was $0.2 million and $4.2 million for the three months ended September 30, 2022 and 2021, respectively, and $1.8 million and $12.5 million for the nine months ended September 30, 2022 and 2021, respectively.

Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)(in thousands)
20222021$ Change% Change20222021$ Change% Change
Provision for income taxes$— $— $— NM$— $— $— NM

NM indicates percentage is not meaningful
46


For the three and nine months ended September 30, 2022 and 2021, the Company did not carry an income tax provision amount as the Company does not recognize tax benefits from current year tax losses in the U.S. and other foreign jurisdictions.

Capital Resources and Liquidity

Our primary sources of liquidity have been from sales of shares of our equity securities, the issuance of our convertible notes and cash from operations. As of September 30, 2022, the Company had $55.4 million in cash and cash equivalents and investments, a decrease of $8.2 million from $63.6 million at December 31, 2021. The primary reason for the decrease was due to cash used in operations during the period.

As of September 30, 2022, management believes current cash balances and probable future cash proceeds will be sufficient to fund our capital and liquidity needs for the next twelve months. Future cash proceeds include a contracted insider equity purchase, collection of accounts receivables and future lease payments from already contracted customers and other probable events that will be realized into cash. Management also maintains plans to continue to fund the operations of the Company and to achieve self-sustaining operations upon the realization of its sales generation and cost containment strategies beyond the next twelve months.

Our primary use of capital has been for the development and commercialization of the Accelerate Pheno system and development of complementary and next generation products. We believe our capital requirements will continue to be met with our existing cash balance and those provided by revenue, grants, partnership fees, and/or additional issuance of equity or debt securities. However, if capital requirements vary materially from those currently planned, or if our business is negatively impacted by the COVID-19 pandemic more seriously or for longer than we currently expect, we may require additional capital sooner than expected. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to us, if at all. Additional issuances of equity or convertible debt securities will result in dilution to our current common stockholders.

The Company is subject to lease agreements. The future minimum lease payments under these lease agreements are included in Part I, Item 1, Note 16, Leases.

For more information on the Company’s liquidity please see Part I, Item 1, Note 1, Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies.

47


As of September 30, 2022, our contractual material cash requirements were as follows:

Payments due by Period
(in thousands)
Material Cash RequirementsTotal20222023202420252026Thereafter
Operating lease obligations$2,826 $227 $968 $1,047 $584 $— $— 
Purchase obligation 1)
11,900 — — — — — 11,900 
Finance lease obligations1,795 180 721 721 173 — — 
Long term debt80 80 — — — — — 
Deferred compensation808 — — — 406 402 — 
Convertible notes 2)
56,595 — 56,595 — — — — 
Convertible notes interest 2)
707 — 707 — — — — 
Secured Notes with related-party 3)
34,934 — — — — — 34,934 
Secured Notes accrued interest with related-party 3)
220 — — — — — 220 
Total$109,865 $487 $58,991 $1,768 $1,163 $402 $47,054 

1) The Company entered into a non-cancellable purchase obligation with a supplier to acquire raw materials for a total commitment of $11.9 million. Under the terms of this agreement the Company has until March 15, 2027 to take delivery of purchased items. As of September 30, 2022 the commitment remains $11.9 million as the Company has not taken delivery of any inventory.

2) Our capital requirements include the maturity of convertible notes due March 2023, which can be settled in shares, cash, or a combination thereof, as negotiated with the note holders. The Company has sufficient shares to settle all outstanding convertible notes in shares and will also consider options to refinance the debt or settle in cash.

3) The Company may, at its option, repay the note and accrued interest in (i) cash or (ii) in the form of common stock of the Company.

Until such time as we can generate substantial product revenue, we expect to finance our cash requirements, beyond what is currently available or on hand, through a combination of equity offerings and debt financings, or contributed partnership fees.

Summary of Cash Flows

The following summarizes selected items in the Company’s condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021:

Cash Flow Summary
Nine Months Ended September 30,
(in thousands)
20222021$ Change
Net cash used in operating activities$(39,178)$(35,376)$(3,802)
Net cash provided by investing activities6,575 11,054 (4,479)
Net cash provided by financing activities31,756 24,335 7,421 

48

Cash flows from operating activities

During the nine months ended September 30, 2022, net cash used in operating activities was primarily the result of net losses and gain on extinguishment of debt, partially offset by equity-based compensation, and depreciation and amortization.

During the nine months ended September 30, 2021, net cash used in operating activities was primarily the result of net losses and gain on extinguishment of debt, partially offset by equity-based compensation, amortization of debt discount and issuance costs, and depreciation and amortization.

The Company adopted ASU 2020-06 on January 1, 2022. This change in accounting principle resulted in a decrease in amortization of debt discount and issuance costs for the nine months ended September 30, 2022.

Cash flows from investing activities

The net cash provided by investing activities was $6.6 million for the nine months ended September 30, 2022. The Company had maturities of marketable securities of $34.5 million which were offset in part by purchases of marketable securities of $27.5 million.

The net cash provided by investing activities was $11.1 million for the nine months ended September 30, 2021. The Company had maturities of marketable securities of $33.6 million which were offset in part by purchases of marketable securities of $22.3 million.

Cash flows from financing activities

The net cash provided by financing activities was $31.8 million for the nine months ended September 30, 2022, which was primarily from the proceeds from the issuance of common stock in connection with a public offering in August 2022.

The net cash provided by financing activities was $24.3 million for the nine months ended September 30, 2021. During the nine months ended September 30, 2021, the Company received $22.6 million in proceeds from the issuance of common stock in connection with a private placement offering and $1.5 million from the exercise of stock options.

Convertible Notes

On March 27, 2018, the Company issued $150.0 million aggregate principal amount of the Notes. In connection with the offering of the Notes, the Company granted the initial purchasers an option to purchase additional amounts. The option was partially exercised, which resulted in $21.5 million of additional proceeds, for total proceeds of $171.5 million. The Notes mature on March 15, 2023, unless earlier repurchased or converted into shares of common stock subject to certain conditions. Upon conversion of the Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of common stock, at the Company's election. The initial conversion rate of the Notes is 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock, subject to adjustment. We pay interest on the Notes semi-annually in arrears on March 15 and September 15 of each year with interest payments beginning on September 15, 2018.

During the year ended December 31, 2021, the Company entered into separate exchange agreements with certain holders of the Notes. Under the terms of the exchange agreements, such holders agreed to exchange Notes held by it for shares of the Company’s common stock. During the year ended December 31, 2021, $51.0 million in aggregate principal amount of Notes were exchanged for 6,602,974 shares of the Company's common stock in these exchange transactions.

During the nine months ended September 30, 2022, the Company entered into an exchange agreement with one holder of the Notes. Under the terms of the exchange agreement, the holder agreed to exchange Notes held by them for shares of the Company’s common stock. During the nine months ended September 30, 2022, $14.0 million in aggregate principal amount of Notes were exchanged for 10,798,482 shares of the Company's common stock in this exchange transaction.

49

On August 15, 2022, the Company entered into an exchange agreement (the “August 2022 Exchange Agreement”) with the Jack W. Schuler Living Trust (the “Schuler Trust”). Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) a secured promissory note in an aggregate principal amount of $34.9 million (the “Secured Note”) and (b) a warrant to acquire the Company’s common stock. After giving effect to the exchange transactions described above, the Notes had an outstanding principal amount of $56.6 million as of September 30, 2022. See “—Capital Resources and Liquidity—Secured Note” below for additional information regarding the Secured Note.

In connection with the Notes offering, we entered into a prepaid forward stock repurchase transaction (the “Prepaid Forward”) with a financial institution. Pursuant to the Prepaid Forward, we used approximately $45.1 million of the proceeds from the offering of the Notes to pay the prepayment amount. The aggregate number of our common stock underlying the Prepaid Forward is approximately 1,858,500 shares (based on the sale price of $24.25). The expiration date for the Prepaid Forward is March 15, 2023, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to us the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward were treated as treasury stock on the condensed consolidated balance sheet (and not outstanding for purposes of the calculation of basic and diluted earnings per share), but remain outstanding for corporate law purposes, including for purposes of any future stockholders' votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to us.

See Part I, Item 1, Note 10, Convertible Notes and Note 11, Long-Term Debt Related-Party for additional information.

At-The-Market Equity Sales Agreement

On May 28, 2021, the Company entered into an Equity Sales Agreement (the “ATM Sales Agreement”) with William Blair pursuant to which it may sell shares of the Company’s common stock having an aggregate offering price of up to $50 million, from time to time, through an “at-the-market” equity offering program under which William Blair will act as sales agent. Subject to the terms and conditions of the ATM Sales Agreement, William Blair may sell shares by any method deemed to be an “at-the-market” offering as defined in Rule 415 under the Securities Act. The Company is not obligated to sell any shares under the ATM Sales Agreement. William Blair is entitled to a commission of 3% of the aggregate gross proceeds from each sale of shares occurring pursuant to the ATM Sales Agreement. During the nine months ended September 30, 2022, the Company did not sell any shares of common stock under the ATM Sales Agreement. As of September 30, 2022, the Company had an aggregate of $39.1 million available for future sales under its at-the-market equity offering program.

Sales of Equity Securities

On March 24, 2022, the Company entered into a securities purchase agreement (the “March 2022 Securities Purchase Agreement”) with the Schuler Trust for the issuance and sale by the Company of an aggregate of 2,439,024 shares of the Company’s common stock to the Schuler Trust (the “Private Placement”). Jack Schuler, serves as a member of the Company’s board of directors and is the sole trustee of the Schuler Trust.

Pursuant to the March 2022 Securities Purchase Agreement, the Schuler Trust has agreed to purchase the Shares at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the Company’s common stock) of $1.64 per share, which is equal to the consolidated closing bid price reported by Nasdaq immediately preceding the time the Company entered into the March 2022 Securities Purchase Agreement, for an aggregate purchase price of $4.0 million. On June 29, 2022, the Company and the Schuler Trust agreed to extend the closing date of the Private Placement (the “Closing Date”) from June 30, 2022 to September 26, 2022, subject to the satisfaction of customary closing conditions. On September 29, 2022, the parties agreed to further extend the Closing Date to December 30, 2022, effective as of September 26, 2022.

On August 23, 2022, the Company completed a public offering of 17,500,000 shares of its common stock at a price of $2.00 per share. The Company received net proceeds of approximately $32.9 million from the offering after deducting underwriting discounts and commissions and offering expenses paid by the Company.

50

Secured Note

For additional information regarding other sales of equity securities completed by the Company in 2020 and 2021, see “Capital Resources and Liquidity—Other sales of equity securities” in Part II, Item 7 of the 2021 10-K.

The Secured Note has a scheduled maturity date of August 15, 2027 and will be repayable upon written demand at any time on or after such date. The Company may, at its option, repay the note in (i) cash or (ii) in the form of common stock of the Company, in a number of shares that is obtained by dividing the total amount of such payment by $2.12. The Secured Note bears interest at a rate of 5.0% per annum, payable at the option of the Company in the same form, at the earlier of (i) any prepayment of principal and (ii) maturity. The Company may prepay the Secured Note at any time without premium or penalty. The Secured Note is secured by substantially all of the assets of the Company, subject to customary exceptions and limitations, pursuant to a security agreement, dated as of August 15, 2022. The Secured Note does not restrict the incurrence of future indebtedness by the Company but shall become subordinated in right of payment and lien priority upon the request of any future senior lender.

For additional information regarding other sales of equity securities completed by the Company in 2020 and 2021, see “Capital Resources and Liquidity—Other sales of equity securities” in Part II, Item 7 of the 2021 10-K.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of September 30, 2022.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. We evaluate our estimates on an ongoing basis, including those related to accounts receivable, inventories, property and equipment, intangible assets, accruals, warranty liabilities, tax valuation accounts and stock-based compensation. We base our estimates on historical experience and on various other assumptions we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and are not readily apparent from other sources. Actual results may differ from these estimates. Our critical accounting policies and estimates are discussed in the 2021 10-K.


Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for a smaller reporting company.


Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Based on an evaluation under the supervision and with the participation of the Company’s management, the Company’s Principal Executive Officer and Principal Financial Officer have concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective as of September 30, 2022, to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

51

Changes in Internal Control Over Financial Reporting

There was no change in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2022 that materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
52

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We are from time to time subject to various claims and legal actions in the ordinary course of our business. We believe that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on our results of operations or financial condition.


Item 1A. Risk Factors

In addition to the other information set forth in this Form 10-Q, you should carefully consider the risks discussed in the section entitled “Risk Factors” in the 2021 10-K and the risk factor described below, which could materially affect our business, financial condition or future results. The risks described in the 2021 10-K and below are not the only risks facing the Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, results of operations, cash flows and financial position.

Risks Related to Our Business and Strategy

We have entered into the Sales and Marketing Agreement with BD and will substantially depend on BD for the successful commercialization of our products.

As part of our collaboration with BD pursuant to the Sales and Marketing Agreement, BD will perform certain sales, tactical marketing, technical service call forwarding, order preparation, research and development support and/or regulatory activities on our behalf as our exclusive sales agent for certain of our products, including the Accelerate Pheno system, Accelerate Arc system and related BC Kits. The successful commercialization of our products, including our ability to generate revenue from our arrangement with BD, will depend on BD’s ability to successfully perform the responsibilities assigned to it pursuant to the Sales and Marketing Agreement. While BD is largely responsible for the speed and scope of sales and marketing efforts, we cannot assure you that BD will dedicate the resources necessary to successfully perform its responsibilities pursuant to the Sales and Marketing Agreement, and our ability to cause BD to increase the speed and scope of its efforts may be limited. In addition, sales and marketing efforts could be negatively impacted by the delay or failure by us to obtain additional supportive clinical trial data for our products. We cannot predict the success of our collaboration with BD, and there can be no assurance that the efforts of BD will meet our expectations or result in any significant product sales or cost savings within the anticipated time frame or at all.

In the event that BD fails to perform under the Sales and Marketing Agreement, or if the Sales and Marketing Agreement is terminated, this could delay our product commercialization efforts, which would materially and adversely affect our business, financial condition, results of operations and cash flows. The termination of the Sales and Marketing Agreement could also require us to revise our commercialization and business strategy going forward and divert management attention and resources. In addition, the termination of the Sales and Marketing Agreement could materially impact our ability to enter into additional collaboration agreements with new partners on favorable terms, if at all.

Risks Related to Our Common Stock

Our stock price has been volatile and may continue to be volatile and traded on low volumes.

The trading price of our common stock has been, and is likely to continue to be, highly volatile. Factors that may contribute to volatility in the price of our common stock include, but are not limited to:

•low trading volume currently prevailing in the market for our shares;
•concentration of our stock with one individual large shareholder who could decide to materially reduce his position;
•the substantial current short interest in our stock;
53

•the duration and severity of the COVID-19 pandemic and its effects on our business, financial condition, results of operations and cash flows;
•adverse regulatory decisions, including failure to receive regulatory approvals for any of our product candidates;
•our success in commercializing our product candidates, if and when approved;
•the introduction of new products or product enhancements by us or others in our industry;
•announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, capital commitments or restructurings;
•disputes or other developments with respect to our or others’ intellectual property rights;
•product liability claims or other litigation;
•quarterly variations in our results of operations or those of others in our industry;
•sales of large blocks of our common stock, including sales by our executive officers and directors;
•changes in senior management or key personnel;
•changes in laws or regulations which adversely affect our industry or us;
•changes in earnings estimates or recommendations by securities analysts; and
•changes in general market, economic, and political conditions in the U.S., and global economies or financial markets, including those resulting from natural disasters, terrorist attacks, acts of war (including Russia’s invasion of Ukraine), other geopolitical uncertainties, public health concerns (including health epidemics or outbreaks of communicable diseases, such as the COVID-19 pandemic),and responses to such events.

The market value of your investment in our common stock may rise or fall sharply at any time because of this volatility and also because of significant short positions that may be taken by investors from time to time in our common stock. During the nine months ended September 30, 2022, the closing price for our common stock ranged from $0.54 to $5.15 per share, during the year ended December 31, 2021, the closing price for our common stock ranged from $4.27 to $15.00 per share, and during the year ended December 31, 2020, the closing price for our common stock ranged from $4.62 to $18.74 per share. The market prices for securities of medical technology companies like us historically have been highly volatile, and the market has experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies.

In addition, in the past, following periods of volatility in the market price of a company’s securities, securities class-action litigation has often been instituted against that company. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our product offerings or business practices. Such litigation may also cause us to incur other substantial costs to defend such claims and divert management’s attention and resources. Furthermore, negative public announcements of the results of hearings, motions or other interim proceedings or developments could have a negative effect on the market price of our common stock.


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no unregistered sales of equity securities during the quarter ended September 30, 2022 other than as reported in our Current Reports on Form 8-K filed with the SEC.


Item 3. Defaults Upon Senior Securities

Not applicable.


Item 4. Mine Safety Disclosures

Not applicable.


Item 5. Other Information

None.
54


Item 6. Exhibits

Exhibit No.DescriptionFiling Information
3.1Incorporated by reference to Appendix B to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on November 13, 2012
3.1.1Incorporated by reference to Exhibit A to the Registrant’s Definitive Information Statement on Schedule 14C filed on July 12, 2013
3.1.2Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on March 15, 2016
3.1.3Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 15, 2019
3.1.4
Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 13, 2021
3.1.5
Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on September 23, 2021
3.1.6
Incorporate by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 17, 2022
3.2Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on August 8, 2019
3.2.1
Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on February 3, 2022
10.1
Incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on August 15, 2022
10.2
Incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on August 15, 2022
10.3
Incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on August 15, 2022
10.4
Incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed on August 15, 2022
10.5+
Filed herewith
31.1Filed herewith
31.2Filed herewith
32Furnished herewith

55



101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL documentFiled herewith
101.SCH Inline XBRL Taxonomy Extension Schema DocumentFiled herewith
101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentFiled herewith
101.DEFInline XBRL Taxonomy Extension Definition Linkbase DocumentFiled herewith
101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentFiled herewith
101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentFiled herewith
104Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101)Filed herewith


+ Portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. An unredacted copy of this exhibit will be furnished supplementally to the SEC upon request.
56

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.


ACCELERATE DIAGNOSTICS, INC.

November 14, 2022/s/ Jack Phillips
Jack Phillips
President and Chief Executive Officer
(Principal Executive Officer)
November 14, 2022/s/ Steve Reichling
Steve Reichling
Chief Financial Officer
(Principal Financial and Accounting Officer)
57
 EX-10.5 2 a09302022-exh105.htm EX-10.5 Document

[***] Certain information in this document has been omitted pursuant to Regulation S-K, Item (601)(b)(10). Such omitted information is both (i) not material and (ii) the type that the Registrant customarily and actually treats as private or confidential.

SALES AND MARKETING AGREEMENT
This Sales and Marketing Agreement (this “Agreement”), effective as of August 15, 2022 (the “Effective Date”), is by and between Accelerate Diagnostics Inc. with its principal place of business at 3950 S. Country Club Road, Suite 470, 4th Floor, Tucson, Arizona 85714 (“Accelerate”) and Becton, Dickinson and Company with its principal place of business at 1 Becton Drive, Franklin Lakes, NJ 07417-1880 (“BD”). Accelerate and BD are individually referred to herein as a “Party” and collectively as the “Parties.”
RECITALS
WHEREAS, the Parties desire to collaborate with respect to the commercialization of Products (as defined below); and
WHEREAS, as part of such collaboration, BD will perform certain sales, tactical marketing, technical service call forwarding, order preparation, R&D support and/or regulatory activities on behalf of Accelerate as Accelerate’s exclusive sales agent for Products in the Territory (as defined below), in accordance with the terms and conditions of this Agreement.
AGREEMENT
NOW, THEREFORE, in consideration of the premises and the mutual promises contained herein, and intending to be legally bound, the Parties hereto agree as follows:
1.DEFINITIONS
In this Agreement, the following terms shall have the following meanings:
1.1“Accelerate” has the meaning set forth in the preamble.
1.2“Accelerate Activities” has the meaning set forth in Section 4.1.
1.3“Affiliate” means any person, corporation or other entity, which controls, is controlled by, or is under common control with a Party. A person, corporation or other entity shall be deemed to control another person, corporation or entity if it (a) owns, directly or indirectly, more than fifty percent (50%) of the voting shares or other interest, or has the power to elect more than half the directors, of such other corporation or entity or (b) has the ability, via contract or otherwise, to direct the management of such entity.
1.4“Agreement” has the meaning set forth in the preamble.
1.5“Applicable Law” means all laws, statutes, rules, regulations, orders, judgments or ordinances having the effect of law of any national, multinational, federal, state, provincial, county, city or other political subdivision, in each case, which are applicable to (a) the BD Services, (b) Accelerate Activities or (c) Accelerate’s or BD’s business in the Territory.
1.6“Arc” means Accelerate’s Arc® module as described on Exhibit A.
1



1.7“Auditee Party” has the meaning set forth in Section 12.2.
1.8“Auditing Party” has the meaning set forth in Section 12.2.
1.9“Background Intellectual Property” means all intellectual property and Confidential Information owned or controlled by one Party, either (a) in existence prior to the Effective Date or (b) subsequently developed by or on behalf of the Party independent of its performance under this Agreement and without the use of or reference to any (i) Confidential Information of Accelerate, Accelerate Materials or other proprietary information, programs, databases or applications of Accelerate in the case of BD and (ii) Confidential Information of BD, BD Materials or other proprietary information, programs, databases or applications of BD in the case of Accelerate. Without limiting the generality of the foregoing, Background Intellectual Property of a Party includes that Party’s intellectual property rights therein.
1.10“BD” has the meaning set forth in the preamble.
1.11“BD Country” has the meaning set forth in Section 6.3.
1.12“BD Materials” has the meaning set forth in Section 11.2.
1.13“BD Notice of Interest” has the meaning set forth in Section 2.5(b).
1.14“BD Services” means the services to be provided by or on behalf of BD for Accelerate, including but are not limited to sales, tactical marketing, technical service call forwarding, order preparation, R&D support and/or regulatory services, as set forth in the Commercialization Plan.

1.15“Change of Control” means the (a) consolidation or merger of Accelerate with or into any Third Party not having a significant interest in Accelerate at the time of this Agreement (“Existing Third Party”), (b) sale, transfer or other disposition of all or substantially all of Accelerate’s assets or (c) acquisition by any Third Party (other than Existing Third Parties), or group of Third Parties (other than Existing Third Parties) acting in concert, of beneficial ownership of fifty percent (50%) or more (or such lesser percentage that constitutes Control) of the outstanding voting securities or other ownership interests of Accelerate. For purposes of this definition only, “Control” means, with respect to Accelerate, the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of Accelerate, whether through the ownership of voting securities (or other ownership interest), by contract or otherwise.
1.16“Change of Control Negotiation Period” has the meaning set forth in Section 2.5(b).
1.17“Commencement Date” has the meaning set forth in Section 3.4(b).
1.18“Commercialization Plan” has the meaning set forth in Section 2.2.
1.19“Commission Schedule” has the meaning set forth in Section 7.2.
2



1.20“Confidential Information” means any and all information disclosed by or on behalf of such Party (the “Disclosing Party”) to the other Party (the “Receiving Party”), either directly or indirectly, whether in oral, written, graphic, electronic or other form, identified at the time of disclosure as confidential, or by which its context would reasonably be deemed to be confidential.
1.21“Customer” means any end user, distributor to which a Product is being marketed and sold, including but not limited to doctors, hospitals, testing and research institutions, clinical or other testing laboratories which perform diagnostic services or testing using the Product.
1.22“Debarred” has the meaning set forth in Section 8.4.
1.23“Debarred Party” has the meaning set forth in Section 8.4.
1.24“Directly Competes” means (a) [***] or (b) [***].

1.25“Disclosing Party” has the meaning set forth in Section 1.20.
1.26“Distributors” has the meaning set forth in Section 2.1.
1.27“Dollars” or “$” means the United States dollars.
1.28“Effective Date” has the meaning set forth in the preamble.
1.29“EU IVDR” means the European Union In Vitro Diagnostic Regulation.
1.30“Exclusive Commercial Arrangement Fee” has the meaning set forth in Section 7.1.
1.31“Executive Officer” shall mean (a) with respect to Accelerate, its Chief Executive Officer and (b) with respect to BD, its Vice President/General Manager for Microbiology. In the event that the position of any of the Executive Officers identified in this Section 1.31 no longer exists due to a corporate reorganization, corporate restructuring or the like that results in the elimination of the identified position, the applicable Executive Officer will be replaced with another executive officer with responsibilities and seniority comparable to the eliminated Executive Officer.
1.32“Existing Countries” has the meaning set forth in Section 6.1.
1.33“Existing Third Party” has the meaning set forth in Section 1.15.
1.34“Field” means all fields of microbiology.
3



1.35“Financing” has the meaning set forth in Section 2.9.
1.36“FDA” means the United States Food and Drug Administration and any successor thereto.
1.37“Force Majeure Event” has the meaning set forth in Section 14.1.
1.38“Governmental Body” means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or entity and any court or other tribunal; or (d) self-regulatory organization.
1.39“Infringement Claim” has the meaning set forth in Section 9.3.
1.40“Installment” has the meaning set forth in Section 7.1.
1.41“Inventions” means any and all improvements, developments, discoveries, inventions, know-how and other intellectual property (whether or not protectable under state, federal, or foreign intellectual property laws) that is conceived, created, developed or reduced to practice by either Party, alone or jointly with Third Parties as a result of, or in the course of performing the BD Services (for BD) or the Accelerate Activities (for Accelerate), respectively. For clarity, Inventions does not include any BD Materials or Work Products.
1.42“Investment” means an expenditure by BD to acquire or invest in Third Party property or assets that Directly Compete.
1.43“IVDR” means (a) the In Vitro Diagnostic Regulation (EU) 2017/746 and (b) any successor, amendment or re-enactment to or of the foregoing.
1.44“Legal Proceeding” means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Body or any arbitrator or arbitration panel.
1.45“License Transaction” has the meaning set forth in Section 2.5(a).
1.46“License Transaction Negotiation Period” has the meaning set forth in Section 2.5(b).
1.47“Negotiation Right” has the meaning set forth in Section 2.5(c).
1.48“Party” or “Parties” has the meaning set forth in the preamble.
1.49“Personnel” means, as applicable, Accelerate and/or BD’s employees, subcontractors, agents or consultants that are qualified to perform the BD Services and the Accelerate Activities, as applicable, as required for fulfillment of its obligations under this Agreement. Detailed job descriptions will be provided within the Commercialization Plan.
4



1.50“Pheno 1.0” means Accelerate’s Pheno® System as described on Exhibit A.
1.51“Pheno 2.0” means Accelerate’s next generation antibiotic susceptibility test system for the Field currently under development by Accelerate.
1.52“Products” means Accelerate’s products that are specified in Exhibit A attached hereto, which can be amended from time to time by the mutual written agreement of the Parties.
1.53“Product Forecast” has the meaning set forth in Section 5.1.
1.54“Product-Specific Inventions” means any and all Inventions that are (a) directly related to Products (or their use) or developed using Products or (b) related to Accelerate’s Confidential Information, Accelerate Materials or other proprietary information, programs, databases or applications of Accelerate (or, in each of the foregoing, its or their use) or developed using Accelerate’s Confidential Information, Accelerate Materials or other proprietary information, programs, databases or applications of Accelerate.
1.55“Receiving Party” has the meaning set forth in Section 1.20.
1.56“Records” has the meaning set forth in Section 12.1.
1.57“Regulatory Approval” means all regulatory opinions, licenses, approvals or clearances that are necessary for the commercialization of Products in the Territory.
1.58“Regulatory Authority” means a federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the testing, manufacture, use, storage, import, promotion, marketing or sale of a Product in the Territory, including the FDA and EU IVDR.
1.59“Representatives” has the meaning set forth in Section 10.1.
1.60“Sales Commissions” has the meaning set forth in Section 7.2.
1.61“Steering Committee” has the meaning set forth in Section 3.1.
1.62“Target” means the annual target specified in the Commission Schedule.
1.63“Term” has the meaning set forth in Section 13.1.
1.64“Territory” means worldwide.
1.65“Third Party” means any person or entity other than Accelerate, BD or an Affiliate of Accelerate or BD.
1.66“Trademarks” means (a) any and all trademarks that are owned or controlled by Accelerate or BD, as applicable, and are used, or intended to be used, in connection with this Agreement, including all word marks, logos, trade dress, service marks and/or indicia of origin, including applicable branding, color, palette, typeface, tagline and icon and (b) all registrations and applications, therefore.

5



1.67“Transaction Notice” has the meaning set forth in Section 2.5(a).
1.68“Work Products” has the meaning set forth in Section 11.1.
2.EXCLUSIVE AGENCY; SERVICES
2.1Exclusive Agency. As of the Effective Date, subject to BD’s first payment of the Exclusive Commercial Arrangement Fee and terms and conditions of this Agreement (including, for clarity, Accelerate’s right to wind down any pre-existing Third-Party arrangements), Accelerate hereby appoints BD as its exclusive sales agent with respect to commercialization of Products in the Territory within the Field, and BD hereby accepts such appointment. Following the Effective Date, Accelerate shall wind down any existing agreements with Third-Party sales agents and/or distributors (“Distributors”), in each case, by using reasonable efforts and in a manner consistent with the terms and conditions that are set forth in such agreements and not later than [***] from the Effective Date unless specifically set forth in Exhibit F. For those Distributors identified in Exhibit F where Accelerate will not be able to wind down an existing agreement within [***], Accelerate agrees to use commercially reasonable efforts to wind down such agreements [***] and in no event will Accelerate renew such agreements beyond the expiration date outlined in Exhibit F. Notwithstanding anything to the contrary in this Section 2.1, to the extent Exhibit F identifies a Distributor that has exclusivity in a region within the Territory and within the Field, BD will not be a sales agent in such region until such exclusivity has expired. During the Term, BD shall not enter into any new agreements with a Third Party for BD to sell, promote, distribute or otherwise commercialize any Third-Party product that Directly Competes with Products in the Territory; provided, however, that BD may continue to perform its obligations under any existing agreements, including any amendments thereto, with the Third Parties listed in Exhibit G that are already in effect as of the Effective Date. Notwithstanding the foregoing or anything else to the contrary in this Agreement, during the Term nothing herein prevents BD from (i) making an Investment, or (ii) developing, improving and/or commercializing its BD Phoenix™ automated identification and susceptibility testing system. BD represents that during the Term BD will not directly sell, promote, distribute or otherwise commercialize any products as a result of an Investment that is not an acquisition that Directly Competes with Products. In the event BD makes an Investment that is an acquisition, either Party has the right to terminate this Agreement within [***] from the first public announcement of such acquisition by providing written notice to the other Party, with such termination taking effect [***] from a Party’s receipt of such notice. In the event either Party terminates this Agreement in accordance with the foregoing sentence, Accelerate’s sole and exclusive remedy for such termination is to receive the remaining balance of the Exclusive Commercial Arrangement Fee which will be paid to Accelerate within [***] of the date of termination.
2.2Commercialization Plan. The Parties acknowledge that the purpose of this Agreement is to establish an on-going commercialization services arrangement between Accelerate and BD for the provision of the BD Services in relation to Products, and any future

6


Accelerate products, if agreed as applicable, as further described in a separate commercialization plan approved by Accelerate and BD from time to time, each of which shall be deemed incorporated into this Agreement as though fully set forth herein (each, a “Commercialization Plan”). The initial Commercialization Plan will be agreed upon [***] following the Effective Date. Each such Commercialization Plan shall contain (a) a description of the BD Services, (b) the anticipated period of performance, (c) a payment schedule and (d) any other terms and conditions agreed to by the Parties that are relevant to the BD Services. Either Party shall have the right to propose amendments or updates to any then-current Commercialization Plan by written notice to the other Party; [***]. To the extent that any terms or provisions of a Commercialization Plan conflict with the terms and provisions of this Agreement, the terms and provisions of this Agreement shall control, except to the extent such Commercialization Plan specifically states the Parties’ intent that such Commercialization Plan control with respect to a particular matter.
2.3BD Services.
(a)BD shall perform (and BD shall ensure that its Personnel perform) the BD Services in a diligent and timely manner, as an agent and representative of Accelerate, in accordance with (i) this Agreement, (ii) the Commercialization Plan, (iii) any reasonable written instructions or requests of Accelerate, (iv) BD’s code of conduct and (v) all Applicable Law.
(b)BD shall (i) perform, and shall ensure that its Personnel perform, BD Services in accordance with professional and technical standards applicable thereto, (ii) ensure that its Personnel performing the BD Services are qualified with the technical skills, training, and experience to perform such BD Services, (iii) provide any and all deliverables in conformance with this Agreement, the Commercialization Plan, and the requirements of Applicable Law, and (iv) use commercially reasonable efforts to successfully complete such BD Services within the time frame set forth in the Commercialization Plan.
(c)BD shall promptly notify Accelerate, by telephone and subsequently in written or electronic form (with such telephone number and form to be agreed by the Parties), of any events that occur that materially interrupt or affect the performance of the BD Services or the completion of the BD Services in accordance with the time frame set forth in the Commercialization Plan.
(d)BD shall not subcontract any of the BD Services without the prior written consent of Accelerate; provided, however, BD may use its existing distribution network to provide BD Services without Accelerate’s prior written consent. BD shall, at all times, be responsible and liable for the compliance of its permitted subcontractors with the terms and conditions of this Agreement.
2.4Accelerate Activities.
(a)Accelerate shall perform (and Accelerate shall ensure that its Personnel perform) Accelerate Activities in accordance with (i) this Agreement, (ii) the Commercialization Plan, (iii) any reasonable written instructions or requests of BD, (iv) Accelerate’s code of conduct,
7


and (v) all Applicable Law.

(b)Accelerate shall (i) perform, and shall ensure that its Personnel perform, Accelerate Activities in accordance with professional and technical standards applicable thereto, (ii) ensure that its Personnel performing the Accelerate Activities are qualified with the technical skills, training, and experience to perform such Accelerate Activities, (iii) provide any and all deliverables in conformance with this Agreement, the Commercialization Plan, and the requirements of Applicable Law, and (iv) use commercially reasonable efforts to successfully complete such Accelerate Activities within the time frame set forth in the Commercialization Plan.
(c)Accelerate shall promptly notify BD, by telephone and subsequently in written or electronic form (with such telephone number and form to be agreed by the Parties), of any events that occur that materially interrupt or affect Accelerate’s performance of the Accelerate Activities or completion of the Accelerate Activities in accordance with the time frame set forth in the Commercialization Plan.
(d)Accelerate shall not subcontract any of the Accelerate Activities without the prior written consent of BD. Accelerate shall, at all times, be responsible and liable for the compliance of its permitted subcontractors with the terms and conditions of this Agreement.

2.5Right of First Negotiation.
(a)In the event of [***], in each case of (i) or (ii), Accelerate shall [***] notify BD of such proposal, clinical data review or determination in writing (each, a “Transaction Notice”).
(b)Upon receipt of a Transaction Notice, BD shall provide Accelerate with written notice of its good faith interest in or its decision to decline to pursue such transaction within [***] of receiving the Transaction Notice (the "BD Notice of Interest"), in which event, Accelerate and BD shall negotiate (i) [***], and in each case of (i) and (ii), negotiate, in good faith, the potential terms and conditions for a definitive agreement for such a potential transaction for a period of (A) [***] from Accelerate’s receipt of a BD Notice of Interest in the case of a License Transaction (such period, the “License Transaction Negotiation Period”) or (B) [***] (such period, the “Change of Control Negotiation Period”), unless, in each case of (A) or (B), [***]. The

8


Parties hereby acknowledge and agree that neither Party is obligated to enter into a definitive agreement concerning a Licensed Transaction or a Change of Control.
(c)During the License Transaction Negotiation Period, the Parties will each exchange information reasonably requested in connection with its due diligence, subject to an agreed-upon confidentiality agreement, if necessary to comply with Applicable Law, including antitrust law, and [*] during such [*] period so long as BD [*] (“Negotiation Right”). [*].
(d)During the Change of Control Negotiation Period, the Parties will each exchange information reasonably requested in connection with its due diligence, subject to an agreed-upon confidentiality agreement, if necessary to comply with Applicable Law, [*].
(e)BD may, in its sole discretion, withdraw from any negotiations with respect to any License Transaction or Change of Control at any time by providing written notice to Accelerate, in which case, the License Transaction Negotiation Period or the Change of Control Negotiation Period, as applicable, shall terminate. Accelerate shall thereafter have no further obligation to BD with respect to such Licensed Transaction or Change of Control, and Accelerate shall be free to consummate such Licensed Transaction or Change of Control with a Third Party.
(f)If, during either the Licensed Transaction Negotiation Period or the Change of Control Negotiation Period, as applicable, the Parties are unable to mutually agree on a definitive agreement with respect to such Licensed Transaction or Change of Control, then (i) Accelerate shall thereafter have no further obligation to BD with respect to such Licensed Transaction or Change of Control and (ii) Accelerate shall be free to consummate such Licensed Transaction or Change of Control with a Third Party.
(g)BD's right of first negotiation under this Section 2.5 shall renew (i) with respect to any new subsequent Transaction Notice or (ii) if the transaction specified in the Transaction Notice is not consummated with BD or a Third Party within [***] after the termination or expiration of the License Transaction Negotiation Period or the Change of Control Negotiation Period, as applicable.
2.6Change of Control.

(a)If Accelerate receives an unsolicited proposal from a Third Party relating to a Change of Control and the Board of Directors of Accelerate determines to proceed with such proposal, (i) Accelerate shall provide notice to BD as promptly as practicable following the receipt of such proposal (but in no event later than [*] from Accelerate’s receipt of
9


such proposal), subject to confidentiality obligations under such proposal and (ii) the provisions of Section 2.5 shall apply with respect to such Change of Control.
(b)Upon the consummation of any Change of Control transaction by Accelerate that results in a Third Party acquiring Accelerate, either Party shall have the right to terminate this Agreement (in such Party’s sole discretion) upon [***] prior written notice to the other Party. Following termination of this Agreement pursuant to this Section 2.6(b), (i) Accelerate, or any acquiring entity, shall pay BD a residual royalty of [***] on Products revenue recognized by Accelerate, or any acquiring entity, for a time period [***], and (ii) any remaining unpaid balance of Exclusive Commercial Arrangement Fee shall be forgiven.
2.7Accelerate Innovation Meetings. BD shall have the right to have a mutually agreed number of BD’s employees (at the Director level or higher) attend Accelerate’s innovation meetings (held quarterly) to discuss mutual new product development activities within microbiology; provided that all such attendees of BD shall, [***].
2.8Products. Accelerate retains all right, title and interest in and to Products. BD shall not make any modifications, alterations or improvements to any Product. Accelerate reserves the right in its absolute and sole discretion, at any time and from time to time, to modify, alter, or improve any Product; provided, that such modification, alteration, or improvement is in compliance with Applicable Laws. Accelerate shall use reasonable efforts to give [***] prior written notice (but in any case, not less than [***] prior written notice) to BD with respect to any such modification, alteration, or improvement of manufacturing of a Product. For clarity, Accelerate may not discontinue manufacturing of a Product unless [***]. In the event Accelerate discontinues manufacturing of Product because [***], any remaining unpaid balance of the Exclusive Commercial Arrangement Fees owed by BD shall be forgiven and within [***] from Accelerate’s notice to BD that it is no longer manufacturing Product, Accelerate will return the Exclusive Commercial Arrangement Fee paid by BD for the [***].
2.9Retained Rights. Except as specifically set forth in this Agreement, BD shall have no other rights with respect to Products, and for clarity, shall not commercialize any Product except as BD is expressly authorized to do under this Agreement. Accelerate reserves and retains, for itself, its Affiliates and for any Third Party, all rights in and relating to Products not expressly granted to BD under this Agreement.
2.10Accelerate Financing. To the extent reasonably possible, Accelerate agrees that

10


in the event Accelerate or the Board of Directors for Accelerate desires to seek additional financing or funding for Accelerate ("Financing"), Accelerate agrees that BD will be afforded the opportunity to provide Accelerate with up to [***] of the amount of Financing. Accelerate shall provide notice to BD no event later than [***] from Accelerate’s determination to seek Financing. Upon receipt of such notice, BD shall promptly provide Accelerate with written notice of its intent to participate in the Financing, in which case, the Parties shall negotiate terms with respect to BD’s participation in such Financing.
3.STEERING COMMITTEE
3.1Formation and Composition. Within [***] of the Effective Date, the Parties shall establish a steering committee (the “Steering Committee”) composed of three (3) representatives of each Party, [***]. Each Party may replace its representatives on the Steering Committee upon written notice to the other Party. [***] shall be responsible for scheduling Steering Committee meetings, developing the meeting agendas, and facilitating the meetings.
3.2Meetings. Unless otherwise agreed between the Parties, the Steering Committee shall meet at least [***] in the [***] following the Effective Date and once every [***] thereafter in person, by telephone conference or video conference. Each Party shall appoint one (1) of its representatives on the Steering Committee to act as a co-chairperson. The co-chairpersons shall jointly prepare and circulate agendas to other members of the Steering Committee at least [***] before each meeting and shall direct the preparation of reasonably detailed minutes for each meeting, which shall be approved by the co-chairpersons and circulated to members of the Steering Committee within [***] of such meeting. Either Party may also call a special meeting of the Steering Committee (by videoconference, teleconference, or in person) by providing at least [***] prior written notice to the other Party if such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting. Each Party shall be solely responsible for the costs incurred by its representatives in attending any meeting. Each Party may, upon prior written notice to the other Party (a) have representative(s) from its organization attend any Steering Committee meetings as regular participants and (b) invite other subject matter experts to any Steering Committee meeting on an as needed basis; provided, that such attendees (i) [***].
3.3Responsibilities. Steering Committee shall be responsible for (a) overseeing the (1) BD Services and other commercialization activities with respect to Products in the Territory under the Commercialization Plan and (2) Accelerate Activities, (b) discussing and approving any amendments or updates to the Commercialization Plan, (c) discussing and approving any new Commercialization Plan, (d) reviewing and discussing the high-level plan and timing for the commercialization of Products in the Territory and the status of such commercialization, (e) reviewing and approving Product Forecasts as set forth in Section 5.1, (f) facilitating the exchange of regulatory information and data as well as the monitoring and coordination of all
11


regulatory actions, communications, filings and submissions and (g) performing such other functions as may be appropriate to further the purposes of this Agreement or as may be mutually agreed upon by the Parties from time to time.
3.4Decision-Making; Dispute Resolution.
(a)All decisions within the authority of Steering Committee shall be made by [***]. No action taken at any meeting shall be effective unless at least one (1) representative of each Party is present at such meeting provided that [***]. If the Steering Committee does not reach agreement as to a particular matter within [***] (or another time period to be mutually agreed to by the Parties) after such matter has been brought to the Steering Committee for resolution, such disagreement shall be referred to the Executive Officers of the Parties for resolution by good faith discussions.
(b)If the Executive Officers are not able to fully resolve such matter within [***] (or another time period to be mutually agreed to by the Parties) after such matter was first referred to them, then (i) [***] shall have the final decision-making authority with respect to the day-to-day operations and management of BD Personnel, including the practical, logistical aspects of implementing BD’s obligations under this Agreement (ii) [***] shall have the final decision-making authority with respect to matters relating to Products in the Territory, subject to the following (iii), including (A) strategic matters (e.g., use of Accelerate Trademarks, Product packaging, brand positioning, messaging, Marketing Materials and other strategic marketing strategies, ) and (B) decisions about methods and criteria for monitoring BD’s compliance with and performance under the Commercialization Plan and (iii) [***] shall [***] decide and agree on tactical marketing initiatives and the date upon which BD will start providing the BD Services (“Commencement Date”). All other matters (i.e., matters that are not subject to either Party’s final decision-making authority pursuant to the foregoing subclauses (i) and (ii)) shall be finally resolved by binding and expedited arbitration administered by JAMS pursuant to JAMS’ Comprehensive Arbitration Rules and Procedures then in effect. The arbitration shall be conducted by an arbitrator jointly appointed by the Parties; provided, that if the Parties are unable to jointly appoint such arbitrator within [***] of the arbitration after JAMS issues a commencement letter, such appointment shall be made by JAMS. The seat of arbitration shall be New York City, New York and all proceedings and communications shall be in English.
4.RIGHTS AND OBLIGATIONS OF THE PARTIES
4.1Accelerate Activities. During the Term, Accelerate will be solely responsible for (except to the extent a role for BD is specifically included in the Commercialization Plan) (a) inventory management, order fulfillment and sales training with respect to Products, (b) product support and complaint handling with respect to Products, (c) regulatory filings with respect to Products, (d) technical service, expertise, and installation management with respect to Products, (e) strategic marketing efforts for Products (including, for clarity, any Marketing Materials with respect thereto) in the Territory as described in more detail in the Commercialization Plan, (f) Products requirements documentation, (g) market research, (h) Products portfolio planning, (i) scientific advisory meetings, and (j) all commercial and other activities with respect to Products

12


that are not specified to be provided by BD under the Commercialization Plan (collectively, the “Accelerate Activities”). Accelerate Activities will be performed by Accelerate’s Personnel, the composition of which will be as set forth in Exhibit H, or as otherwise set forth in the Commercialization Plan. During the Term, BD shall not [***] without Accelerate’s prior written consent. During the Term, Accelerate shall not [***] without BD’s prior written consent.

4.2Marketing Materials and Trade Shows.
(a)Accelerate shall have the primary responsibility for the content of any and all Product brochures, manuals, and other marketing and promotional materials for Products (“Marketing Materials”), and all copyright and other intellectual property rights in the Marketing Materials shall remain vested in Accelerate.
(b)Accelerate shall provide BD with copies of all Marketing Materials as necessary for BD to perform the BD Services. Marketing Materials that are intended to be used by BD Personnel must be reviewed and approved by BD. BD may develop or create any additional marketing and promotional materials in connection with the BD Services; provided, that (i) such additional marketing and promotional materials are approved in writing in advance by Accelerate, (ii) such additional marketing and promotional materials are developed or created solely at BD’s expense and (iii) such additional marketing and promotional materials shall be deemed to be Marketing Materials and all copyright and other intellectual property rights therein shall be owned by Accelerate as related to Products but not for any content related to BD’s product portfolio. Accelerate shall provide BD with the necessary training of the Products and Marketing Materials to allow BD to effectively deliver the BD Services.
(c)In connection with the BD Services, BD shall utilize only Marketing Materials provided by Accelerate or developed by BD pursuant to Section 4.2(b). BD shall immediately cease the use of any Marketing Materials when instructed to do so in writing by Accelerate. BD shall use the Marketing Materials only for the purposes of performing its obligations under this Agreement. BD Personnel shall make no claims, statements or representations regarding Products other than those expressly stated in an approved script authorized by Accelerate.
(d)BD shall neither add, delete nor modify any claims (including, but not limited to, efficacy or safety claims), nor make any changes (including, but not limited to, underlining or adding notes) in the Marketing Materials.
(e)BD shall promptly notify Accelerate in writing of any correspondence or other report or complaint received by BD or any BD Personnel from any Regulatory Authority or any Third Party claiming that any of the Marketing Materials are inconsistent with Applicable Laws or any of the BD Personnel providing the BD Services under this Agreement is making statements or claims regarding a Product that are inconsistent with the Marketing Materials.
(f)BD intends to but is not obligated to, provide appropriate space within its trade show booths within the Field to properly display, promote, brand, and demonstrate the Products in a means at BD’s sole discretion. The provision of trade show booth space shall be part
13


of the Commercial Plan.
4.3Personnel.
(a)BD shall (i) maintain the number of Personnel as provided in the applicable Commercialization Plan and (ii) use commercially reasonable efforts to hire Accelerate’s Personnel that are specified to be hired by BD in the initial Commercialization Plan, subject to BD’s hiring policies then in effect.
(b)As the employer of the Personnel, each Party shall have responsibility for its Personnel’s direction and control. BD agrees that the BD Personnel will cooperate fully with Accelerate and its management in their performance of the BD Services. Accelerate agrees that the Accelerate Personnel will cooperate fully with BD in connection with BD’s performance of the BD Services. Each Party shall have sole responsibility for (i) disciplinary procedures or corrective actions regarding its Personnel and (ii) initiating and implementing all actions regarding hiring, promotion, discipline, discharge, compensation, processing of grievances and monitoring of the professional appearance, demeanor and conduct of its Personnel. Each Party shall not issue or provide any disciplinary documents, notices or memoranda directly to any Personnel of the other Party.
(c)Each Party shall provide management and supervisory personnel to coordinate and support the activities of its Personnel as such Party determines to be appropriate to accomplish its obligations under this Agreement. The number and type of management and supervisory Personnel may be further defined in the applicable Commercialization Plan.
(d)If, at any time during the course of the BD Services, Accelerate determines that any performance of the BD Services by any BD Personnel does not meet the mutually agreed upon responsibilities and deliverables, Accelerate may request BD to remove such BD Personnel from performing the BD Services and replace such individual, notwithstanding BD retains the sole decision on removing or replacing BD Personnel. If, at any time during the course of the Accelerate Activities, BD determines that any performance of the Accelerate Activities by any Accelerate Personnel does not meet the mutually agreed upon responsibilities and deliverables, BD may request Accelerate to remove such Accelerate Personnel from performing the Accelerate Activities and replace such individual, notwithstanding Accelerate retains the sole decision on removing or replacing Accelerate Personnel.
(e)The Parties acknowledge and agree that its Personnel are, nor are they intended to be, considered or treated as, employees of the other Party or any of its Affiliates, and that such individuals are not, and are not intended to be, eligible to participate in any benefits programs or in any “Employee Benefit Plans” provided by a Party (or its Affiliate) to its employees. All matters of compensation, benefits and other terms of employment for any Personnel shall be solely a matter between the employing Party and such individual. Each Party shall be solely responsible and liable for the payment of all compensation and benefits under any such employee benefit plan to its Personnel.
4.4R&D Support. During the Term, BD shall provide nominal consulting assistance to Accelerate, at no charge, on Product development efforts impactful for both
14


organizations, including providing access to strain collections, provided, however, that [***]; provided, further, that [***]. Such consulting assistance shall include the development of interfaces between BD’s Synapsys and Arc. BD shall undertake and/or provide Accelerate any R&D support activities that are specified in the Commercialization Plan. In the event either Party anticipates that either the (i) BD R&D support activities outlined in this Section 4.4, or (ii) information provided by BD during an innovation meeting as described in Section 2.7, will likely result in the development of intellectual property, the Steering Committee will [***].

4.5Product Support. Accelerate shall be solely responsible for providing installation, go live management, and technical support to Customers with respect to Products. Following the Effective Date, the Parties shall negotiate, in good faith, to update the initial Commercialization Plan (or enter into a new Commercialization Plan) to (a) transition certain aspects of Product support from Accelerate to BD and (b) set forth Accelerate’s obligation to provide training to BD Personnel with respect thereto. During the Term, BD shall be responsible for establishing a process in its call center to guide Customers in real time to Accelerate for technical support with respect to Products.
4.6Product Implementation. During the Term, each Party shall perform obligations with respect to Product implementation that are allocated to such Party in the Commercialization Plan.
4.7Notification of Legal Proceeding. To the extent permitted by Applicable Laws, BD shall immediately notify Accelerate of any claim, demand, communication or inquiry of any type, including, but not limited to, a subpoena, civil investigative demand, or congressional inquiry letter, from any federal, state or local governmental entity or Regulatory Authority, related in any way to Accelerate, Products or this Agreement.
4.8Notification of Complaints. Each Party shall promptly notify the other party in writing of any (a) adverse event or experience in humans associated with any Product, (b) technical complaints regarding any Product and (c) report or any other problem involving any Product.
4.9Compliance; Training. Accelerate’s Quality and Regulatory Department may, [***] and will have the right to attend and provide live training to BD Personnel if it so chooses. BD Personnel shall receive testing and certification on all policies and procedures required by BD. BD and/or Accelerate will also provide any required training should any relevant and/or new policies and procedures be implemented.
5.SALES OF PRODUCTS
5.1Product Forecasts. During the Term, through the Steering Committee,
15


the Parties shall agree upon a detailed rolling twelve (12)-month sales forecasts on a quarterly basis, with the [***] of each twelve (12)-month forecast to include order fulfillment timing (each, a “Product Forecast”). For clarity, each Product Forecast is to be prepared by BD and mutually reviewed and approved by the Steering Committee. BD shall use reasonable efforts to meet or exceed each Product Forecast. Any shortfalls in market demand against inventory builds shall be discussed by the Steering Committee. Accelerate shall use reasonable efforts to produce sufficient quantities of Products to meet each Product Forecast.
5.2Order Fulfillment. BD shall generate proposals for Products for all Customers in the Territory and BD may consult with Accelerate on such proposals, provided that sales contracts for Products shall be entered into between each Customer and Accelerate and each Customer’s orders shall be placed directly with Accelerate. Accelerate agrees to make all reasonable efforts to ship Customer orders within [***] of order receipt and ensure that an effective shipping process has been established that adheres to the expected order fulfillment requirements and timelines of the Customers. Order fulfillment requirements will be defined in the Commercialization Plan. Accelerate shall book all sales of Products in the Territory. Accelerate shall be responsible for, including any costs associated with, (a) fulfilling each Customer’s orders either directly by drop shipment to such Customer’s location or by another means to be mutually agreed upon by the Steering Committee and (b) coordinating and handling all importation, customs clearance, storage and distribution matters for Products. Upon Accelerate’s request, BD shall provide logistics guidance with respect to Accelerate’s performance of its obligations under this Section 5.2 based on BD’s existing knowledge within its supply chain.
5.3Terms of Sale; Product Pricing. Accelerate shall have the sole right and responsibility for establishing and modifying the terms and conditions of the sale of Products, including (a) pricing and contracting, (b) whether Products will be subject to any discounts, (c) whether any discount will be provided for payments on accounts receivable, (d) whether Products will be subject to rebates, returns and allowances or retroactive price reductions, (e) the channels of distribution of Products and (f) whether credit is to be granted or refused in connection with the sale of any Products. BD shall have the sole right to negotiate pricing within the pricing parameters set forth in this Agreement and shall not offer any Products to a Customer at a price discounted below the pricing schedule for Products attached hereto as Exhibit B, unless approved in writing in advance by Accelerate or otherwise set forth in the Commercial Plan. The Parties acknowledge and agree that Product pricing through distribution will be set forth in the Commercialization Plan. From time to time, Accelerate shall have the right to adjust Product pricing, at its sole discretion, by providing an amended Exhibit B to BD; provided, however, that any existing proposals for Products to a Customer with pricing in effect prior to the pricing adjustment, the pricing in effect prior to the adjust will still apply.
5.4Product Returns. BD shall not solicit the return of any Product from any Customer and shall direct Product returns to Accelerate, but if for any reason, BD should receive any returned Product, BD shall promptly notify Accelerate. Upon request by Accelerate, any Product returned to BD shall be shipped by BD to Accelerate’s (or its designee’s) designated facility at Accelerate’s expense. If Accelerate does not request that such Product be returned to Accelerate, then BD shall, in compliance with Applicable Laws, destroy the Product at Accelerate’s expense. Any Products that are returned after purchase by the Customer will not
16


be deducted from its revenue for purposes of calculating the Sales Commission.
5.5Product Recalls. Accelerate will notify BD of any Product corrective actions, withdrawals, recalls according to FDA regulations and guidelines after Accelerate first learns of the Product recall.
6.REGULATORY
6.1Regulatory Approvals in Existing Countries. Accelerate shall be responsible for obtaining and maintaining Regulatory Approvals in (a) the United States and (b) other countries where Products are marketed as of the Effective Date, [***] and are set forth in Exhibit E (“Existing Countries”). All Regulatory Approvals in the Existing Countries shall be held in the name of Accelerate. Upon Accelerate’s request and at Accelerate’s expense, BD shall reasonably cooperate with, and provide reasonable assistance to, Accelerate in connection with all regulatory matters relating to Regulatory Approvals in Existing Countries as mutually agreed upon by the Steering Committee.
6.2Regulatory Approvals in Additional Accelerate Countries. Accelerate shall be responsible for obtaining and maintaining Regulatory Approvals in additional countries until [***] (“Additional Countries”). All Regulatory Approvals in the Additional Countries shall be held in the name of Accelerate. Accelerate is responsible for delivering existing and new Arc registrations as outlined in Exhibit E.
6.3Regulatory Approvals in BD Countries. Beginning [***], BD shall lead the registration process for Regulatory Approvals in any other countries within the Territory other than the Existing Countries and Additional Accelerate Countries (each such country, a “BD Country”). Parties agree that expenses associated with obtaining Regulatory Approvals in BD Countries shall be agreed upon by the Steering Committee and then set forth in the Commercialization Plan. Accelerate shall, at BD’s request, provide BD with reasonable assistance in obtaining Regulatory Approvals in a BD Country. During the Term, Accelerate may request BD to lead the Regulatory Approvals registration in any BD Country and, if BD declines such request, (a) Accelerate shall have the right to obtain and hold Regulatory Approvals in such BD Country and (b) notwithstanding anything to the contrary provided in this Agreement, Accelerate shall have the right to sell directly into Customers in such BD Country.
6.4Launch of Products in Additional Countries and BD Countries. The Steering Committee will assess and approve specific Regulatory Approval requirements by Additional Countries and BD Countries at the appropriate time in relation to the Commercialization Plan. Once Regulator y Approvals have been obtained by Accelerate in an Additional Country or by BD in a BD Country in accordance with Section 6.2 and Section 6.3, respectively, BD shall be responsible, at BD’s sole expense, for commercial launch of Products in such Additional Country or BD Country, provided that costs associated with strategic marketing for such commercial launch of Products in such Additional Country will be borne by Accelerate. In the event the Steering Committee does not approve specific Regulatory Approval requirements within a specific region or area in the Territory, BD will lose the exclusivity granted to it in such region or area and BD will not be prohibited from directly or indirectly selling, promoting, distributing or otherwise commercializing any product that Directly Competes with Products in such region or area.
17



6.5Permits. Each Party shall, at its sole cost and expense, maintain in full force and effect all permits and other authorizations required by contract and/or by Applicable Laws to carry out its duties and obligations under this Agreement.
6.6Reasonable Best Efforts. During the Term, each Party shall each use its reasonable best efforts to (a) cooperate in all respects and consult with each other in connection with any submission in connection with any investigation or other inquiry, including allowing the other Party to have a reasonable opportunity to review in advance and comment on drafts of such submissions, (b) give the other Party prompt notice, but in no event more than [***], of the making or commencement of any request, inquiry, investigation, action or Legal Proceeding brought by a Governmental Body or brought by a Third Party before any Governmental Body, in each case, with respect to the transactions contemplated hereby, (c) keep the other Party hereto informed as to the status of any such request, inquiry, investigation, action or Legal Proceeding, (d) promptly, but in no event more than [***], inform the other Party of any communication to or from the Federal Trade Commission or Antitrust Division of the U.S. Department of Justice, or any other Governmental Body in connection with any such request, inquiry, investigation, action or Legal Proceeding, (e) promptly furnish to the other Party, to the extent not prohibited by Applicable Law, and subject to appropriate joint defense and confidentiality agreements that, among other things, to limit disclosure to outside counsel and consultants retained by such counsel, and subject to redaction regarding contractual obligations and legal privilege, copies of documents provided to or received from any Governmental Body in connection with any such request, inquiry, investigation, action or Legal Proceeding, (f) subject to appropriate joint defense and confidentiality agreements that, among other things, to limit disclosure to counsel and outside consultants retained by such counsel, and to the extent reasonably practicable, consult in advance and cooperate with the other Party and consider in good faith the views of the other Party in connection with any substantive communication, analysis, appearance, presentation, memorandum, brief, argument, opinion or proposal to be made or submitted in connection with any such request, inquiry, investigation, action or Legal Proceeding, (g) provide reasonable advance notice of and permit authorized representatives of the other Party to be present at each meeting or telephone or video conference relating to such request, inquiry, investigation, action or Legal Proceeding and to have access to and be consulted in advance in connection with any argument, opinion or proposal to be made or submitted to any Governmental Body in connection with such request, inquiry, investigation, action or Legal Proceeding, except as may be prohibited by any Governmental Body or by any Applicable Law, including antitrust law and (h) unless otherwise agreed in writing, supply as promptly as practicable such information, documentation, other material or testimony that may be reasonably requested by any Governmental Body. Notwithstanding the foregoing, in the event a Party is enjoined by the Federal Trade Commission or Antitrust Division of the U.S. Department of Justice or a Governmental Body, as applicable, from complying with this Section 6.7, such Party will not be deemed in breach of this Agreement.
7.COMPENSATION AND PAYMENT

7.1Exclusive Commercial Arrangement Fee. In consideration of Accelerate’s appointment of BD as Accelerate’s exclusive sales agent pursuant to Section 2.1 and for Accelerate’s grant to BD of the right of first negotiation pursuant to Section 2.5, BD shall pay
18


Accelerate an exclusive commercial arrangement fee of fifteen million Dollars ($15,000,000) (“Exclusive Commercial Arrangement Fee”), which shall be paid in five (5) installments of three million Dollars ($3,000,000) over five (5) years (each, an “Installment”). The first Exclusive Commercial Arrangement Fee will not come due until the Commencement Date. Following the Commencement Date, Accelerate will issue an invoice to BD, and BD shall pay the first Installment within [***] of BD’s receipt of the invoice. Thereafter, Accelerate will issue an invoice to BD for subsequent Installments every [***] thereafter and BD shall pay such Installments within [***] of BD’s receipt of the invoice. BD’s obligation to pay the Exclusive Commercial Arrangement Fee in full (i.e., all five (5) Installments) shall survive any termination of this Agreement; provided, however, that such obligation will terminate if this Agreement is (a) terminated by either Party following a Change of Control transaction by Accelerate pursuant to Section 2.6(b) (b) terminated by BD for Accelerate’s material breach pursuant to Section 13.3, (c) terminated by Accelerate pursuant to Section 13.2 in the event Accelerate discontinues to manufacture Product as outlined in Section 2.8, or (d) Accelerate ceases production of Products in accordance with Section 9.3.
7.2Sales Commissions. Starting on the Commencement Date, Accelerate shall pay to BD the sales commissions in accordance with the schedule attached hereto as Exhibit C (“Commission Schedule”) as described in more detail in the Commercialization Plan (such sales commissions, the “Sales Commissions”). For clarity, Accelerate shall not be obligated to pay any amounts in excess of the Sales Commissions that are specified in the Commercialization Plan that have not been approved in writing by Accelerate in advance. On a calendar [***] basis, within [***] from the end of the applicable calendar [***], Accelerate will provide BD with the following information so that BD can determine what to invoice Accelerate for the Sales Commissions: account name/address, products name, [***] sales revenue by month, number of units sold by month, and reagent rental instrument placements by month with contract term. Unless otherwise agreed by the Parties in writing, BD shall submit detailed invoices to Accelerate to be delivered at intervals specified in the Commercialization Plan. Accelerate shall pay all invoices within [***] after Accelerate’s receipt of the invoice. If Accelerate disputes, in good faith, any portion of such invoice, Accelerate shall pay all undisputed amounts and provide BD a written notice of the dispute within [***] after Accelerate’s receipt of the disputed invoice. Thereafter, the Parties shall negotiate in good faith to resolve such dispute within [***] after BD’s receipt of notice thereof. Once resolved, if necessary, BD will issue a corrected invoice to Accelerate and Accelerate shall pay such corrected invoice within [***] of receipt of the corrected invoice.
7.3Late Payments. In addition to all other remedies that a Party may have, all past due and undisputed payments required under this Article 7 (i.e., Exclusive Commercial Arrangement Fee and Sales Commissions) will be subject to a late charge of [***] or, if such rate is in excess of the rate permitted by Applicable Law, such lower rate as is the maximum permitted by Applicable Law.
7.4Taxes. Any sales or use taxes or other taxes, fees, duties or levies (other than taxes on BD’s or its Affiliate’s income and/or any personal property taxes) assessed as a result of the BD Services covered by this Agreement shall be the sole responsibility of Accelerate.
19



8.REPRESENTATIONS, WARRANTIES AND COVENANTS
8.1Mutual. Accelerate and BD each represents, warrants and/or covenants to the other that: (a) it is, and at all times during the Term shall remain, a corporation, duly organized, validly existing and in compliance and good standing under the laws of its jurisdiction of organization; and (b) execution and delivery of this Agreement has been duly authorized by all requisite corporate action and that this Agreement is and shall remain a valid and binding obligation of Accelerate or BD, enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors. Each Party further represents, warrants and/or covenants to the other that it has not, to its knowledge, made and it shall not make any false and misleading statements in connection with submitting or obtaining any Regulatory Approvals for Products.
8.2By BD. BD represents, warrants and/or covenants to Accelerate that: (a) all BD Services will be performed in a professional and workmanlike manner in accordance with the standards of performance in its industry, the Commercialization Plan, all Applicable Laws and all business conduct and health and safety guidelines; (b) the BD Personnel shall be qualified and professionally capable of performing the BD Services; (c) BD is under no contractual or other obligation or restriction which is inconsistent with BD’s obligations under this Agreement and, during the Term, BD will not enter into any agreement, either written or oral, in conflict with BD’s obligations under this Agreement; and (d) BD has and will maintain in effect all the licenses, permissions, authorizations, consents, permits and insurance that it needs to carry out its obligations under this Agreement.
8.3By Accelerate. Accelerate represents, warrants and/or covenants to BD that: (a) Accelerate is under no contractual or other obligation or restriction which is inconsistent with Accelerate’s obligations under this Agreement and, during the Term, Accelerate will not enter into any agreement, either written or oral, in conflict with Accelerate’s obligations under this Agreement; (b) Accelerate has and will maintain in effect all the licenses, permissions, authorizations, consents, permits and insurance that it needs to carry out its obligations under this Agreement; (c) to Accelerate’s knowledge, the Accelerate Trademarks are valid and subsisting; (d) if applicable, each of its locations that is manufacturing Products has all required local, state and federal licenses, registrations, or permits applicable to the sale and distribution of the Products and shall provide proof of required licenses to BD upon request; (e) it shall operate in accordance with all Applicable Laws, including but not limited to those relating to good manufacturing processes, good housekeeping, security, crush control, moisture control, temperature control, and proper documentation of the Products being stored and distributed, which shall be made available to BD upon request; (f) it is responsible for assuring all advertising and promotional materials, including Marketing Materials, instructions for use, labeling, technical information, or any other documentation associated with the Product are compliant with Applicable Laws; and (g) all Accelerate Activities will be performed in a professional and workmanlike manner in accordance with the standards of performance in its industry, the Commercialization Plan, all Applicable Laws and all business conduct and health and safety guidelines.

8.4No Debarment. Each Party hereby represents and warrants to the other Party that it has not been debarred under the provisions of 21 United States Code § 335a or any foreign equivalents thereof (“Debarred”). In the event that during the Term a Party becomes Debarred or receives notice of action to have such Party Debarred (the “Debarred Party”), such Debarred
20


Party agrees to notify the other Party immediately. In either such event, the other Party will have the right to terminate this Agreement immediately upon written notice to the Debarred Party. Each Party further represents and warrants to the other Party that it has not used, and covenants that it will not use, in any capacity, the services of any individual, corporation, partnership, institution or association which has been Debarred. In the event either Party becomes aware that any individual, corporation, partnership, institution or association providing services to such Party which directly or indirectly relate to such Party’s activities under this Agreement has been Debarred, or has received notice of action or threat of action to have such entity Debarred, such Party will notify the other Party immediately, in which event the other Party will have the right to terminate this Agreement immediately upon written notice.
8.5Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY TO THE OTHER PARTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
9.INDEMNIFICATION; LIMITATION OF LIABILITY
9.1By BD. BD shall indemnify, defend, and hold Accelerate, its Affiliates, agents, directors, officers, and employees (collectively, the “Accelerate Indemnitees”) harmless from and against any and all loss, liability, claim, damage, and expense, injury or alleged injury to Third Parties including reasonable attorney and litigation fees (collectively, “Losses”) that Accelerate may incur resulting from any Third-Party claim, suit or proceeding made or brought against Accelerate arising from [***] BD’s obligations under this section include payment for all expenses (including reasonable attorney’s fees and expenses) incurred by an Accelerate Indemnitee in connection with responding to any subpoena, discovery demand or other directive having the force of law or governmental inquiry, served upon the Accelerate Indemnitee or any of its Affiliates that relates to BD, its business or its industry that arises out of any litigation, proceedings or investigations involving BD.
9.2By Accelerate. Accelerate shall indemnify, defend, and hold BD, its Affiliates, agents, directors, officers, and employers (collectively, the “BD Indemnitees”) harmless from and against any and all Losses that BD may incur resulting from any Third-Party claim, demand, suit or proceeding made or brought against BD from [***].

21


Accelerate’s obligations under this section include payment for all expenses (including reasonable attorneys’ fees and expenses) incurred by an BD Indemnitee in connection with responding to any subpoena, discovery demand or other directive having the force of law or governmental inquiry, served upon the BD Indemnitee or any of its Affiliates that relates to Accelerate, its business or its industry that arises out of any litigation, proceedings or investigations involving Accelerate
9.3Infringement Claim. Without limiting Section 9.2, [***] (each, an “Infringement Claim”); provided, however, that Accelerate shall not be obligated to defend BD for any [***]. On the occurrence of any Infringement Claim, or in the event Accelerate believes an Infringement Claim is likely, Accelerate may, at its option [***]. In the event that Accelerate is unwilling or unable to accomplish any of the foregoing options [***], any remaining [***] shall be forgiven.
9.4Procedures. Each Party’s obligations as an indemnitor hereunder shall be conditioned on the indemnitee promptly (a) notifying the indemnitor of the applicable Third Party claim, (b) allowing indemnitor to control the investigation and defense of such claim, (c) not settling or compromising the claim without indemnitor’s consent and (d) reasonably coordinating in the handling thereof; provided, that each indemnitee shall have the right to participate in the defense of any claim at its own cost and expense.
9.5Limitation of Liability. EXCEPT WITH RESPECT TO (a) A PARTY’S INDEMNITY OBLIGATIONS UNDER SECTIONS 9.1 OR 9.2, (b) A BREACH OF A PARTY’S OBLIGATIONS UNDER ARTICLE 10 OR ARTICLE 11 OR (c) INSTANCES OF FRAUD, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT, (i) IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, LOSS OF PROFIT, SPECIAL, CONSEQUENTIAL, INCIDENTAL, EXEMPLARY OR PUNITIVE DAMAGES (INCLUDING LOST OF ACTUAL OR ANTICIPATED REVENUES OR PROFITS, LOSS BY REASON OF SHUTDOWN, LOSS OF USE, NON-OPERATION OR INCREASED EXPENSE OF MANUFACTURING OR OPERATING, OR DAMAGE TO OR LOSS OF OTHER PRODUCTS, PROPERTY AND/OR EQUIPMENT, OR LOSS OF REPUTATION OR OPPORTUNITIES, RELATING TO THE SAME) OF ANY KIND WHATSOEVER ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT LIABILITY), OR OTHERWISE EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES and (ii) IN NO EVENT SHALL EITHER PARTY’S LIABILITY TO THE OTHER PARTY FOR ALL CLAIMS HEREUNDER, WHETHER IN CONNECTION WITH A WARRANTY CLAIM, A RECALL OR REMOVAL, AN INDEMNITY CLAIM, A COMBINATION THEREOF, OR OTHERWISE AND WHETHER ARISING UNDER CONTRACT, WARRANTY, TORT (INCLUDING NEGLIGENCE),

22


STRICT LIABILITY, PRODUCT LIABILITY, A COMBINATION THEREOF, OR ANY OTHER THEORY OF LIABILITY OR INDEMNIFICATION SHALL NOT EXCEED, IN THE AGGREGATE, [***] USD, PROVIDED THAT THE LIMITATION SET FORTH IN THE FOREGOING SUBCLAUSE (ii) SHALL NOT APPLY TO ANY BREACH OF CONTRACT CLAIMS BY ACCELERATE AGAINST BD FOR BD’S FAILURE TO PAY THE EXCLUSIVE COMMERCIAL ARRANGEMENT FEE.
9.6Insurance. During the Term and for a period of [***] after the effective date of any expiration or termination of this Agreement, each Party shall, at its own expense, obtain, maintain and carry insurance in full force and effect that, at a minimum, meets the requirements set forth in Exhibit D. Neither the procurement, maintenance nor limits of coverage required in this Agreement relieve any Party of losses or liability. Upon request, each Party shall provide a certificate of insurance to the other Party. Accelerate understands and agrees that BD may self-insure for all or part of the insurance required hereunder. Accelerate may access BD’s Memorandum of Insurance at any time by using the following web address: [***]
10.CONFIDENTIALITY
10.1Confidentiality and Non-Use Obligations. The Receiving Party shall (a) maintain all Confidential Information of the Disclosing Party in trust and confidence, (b) not disclose such Confidential Information to any Third Party except with the prior written approval of the Disclosing Party and (c) only use such Confidential Information to exercise its rights or perform its obligations under this Agreement and for no other purpose. The Receiving Party shall use the highest degree of care that the Receiving Party uses to protect its own confidential or proprietary information to protect the Confidential Information from unauthorized use and unauthorized disclosure, but no less than a reasonable degree of care. The Receiving Party shall only permit access to the Disclosing Party’s Confidential Information to the Receiving Party’s and its Affiliates’ employees, officers, directors, consultants and agents (“Representatives”) who (i) have a need to know such information for the Receiving Party’s exercise of its rights or performance of its obligations under this Agreement, (ii) have been advised by the Receiving Party of the Receiving Party’s obligations under this Agreement and (iii) are contractually or legally bound by obligations of confidentiality and non-use at least as stringent as those contained herein. The failure of any Representative of the Receiving Party to comply with the terms and conditions of this Article 10 shall be considered a breach of this Agreement by the Receiving Party. The Receiving Party shall immediately, but in no event later than [***], notify the Disclosing Party in the event of any loss, unauthorized disclosure or unauthorized use of, or any inability to account for, any Confidential Information. For the avoidance of doubt, (A) all Work Products shall be deemed the Confidential Information of Accelerate, and BD shall be deemed the “Receiving Party” of such information, notwithstanding the fact that such information is generated and disclosed by BD to Accelerate and (B) any and all information learned or observed by BD by participating in Accelerate’s quarterly innovation meetings pursuant to Section 2.6 shall be deemed the Confidential Information of Accelerate. The Receiving Party agrees that any Confidential Information disclosed to it by the Disclosing Party (including all copies thereof) will remain the sole and exclusive property of the Disclosing Party.
23


10.2Exceptions. Confidential Information of a Disclosing Party shall not include information that the Receiving Party can demonstrate by competent written evidence: (a) was part of the public domain prior to the time of disclosure to the Receiving Party by the Disclosing Party; (b) becomes, through no breach of this Agreement by the Receiving Party or any of its Representatives, part of the public domain after disclosure to the Receiving Party by the Disclosing Party; (c) was in possession of the Receiving Party, without any confidentiality restrictions, at the time of disclosure by the Disclosing Party; (d) was obtained by the Receiving Party from a Third Party not under any confidentiality and non-use obligations; or (e) was independently developed by the Receiving Party without the use of or benefit from the Disclosing Party’s Confidential Information and without any breach of this Agreement. For clarity, (i) clause (c) of the foregoing shall not apply to any Work Products and (ii) for purposes of clauses (a) and (b) of the foregoing, (A) no combination of elements within the Confidential Information shall be deemed to be part of the public domain merely because the individual elements of such combination are part of the public domain, unless the entire combination itself, or the entire principle of use or operation of such combination (if any), is part of the public domain and (B) no element within the Confidential Information shall be deemed to be a part of the public domain merely because it is embraced by more general information or data that is part of the public domain.
10.3Authorized Disclosure. Notwithstanding the provisions of Section 10.1, the Receiving Party may disclose the Disclosing Party’s Confidential Information, without violating its obligations under this Agreement, to the extent the disclosure is required by a valid order of a court or other Governmental Body of competent jurisdiction or is otherwise required by Applicable Law; provided, that the Receiving Party shall give reasonable prior written notice to the Disclosing Party of such required disclosure and, at the Disclosing Party’s request and expense, shall cooperate with the Disclosing Party’s efforts to (a) contest such requirement, (b) obtain a protective order requiring that the Confidential Information so disclosed be used only for the purposes for which the order was issued or the Applicable Law required, and/or (c) obtain other confidential treatment of such Confidential Information. In any event, the Receiving Party shall only disclose that portion of the Confidential Information that is legally required to be disclosed. Compulsory disclosures made pursuant to this Section 10.3 shall not relieve the Receiving Party of its obligations of confidentiality and non-use with respect to non-compulsory disclosures (i.e., any Confidential Information disclosed pursuant to this Section 10.3 shall remain subject to the confidentiality and non-use obligations set forth in this Agreement, unless and until such information falls under any of the exceptions set forth in clauses (a) thorough (e) in Section 10.2).
10.4Return or Destruction of Confidential Information. Upon termination or expiration of this Agreement, or upon the Disclosing Party’s earlier written request, the Receiving Party shall return to the Disclosing Party or destroy (and certify in writing the destruction of) all Confidential Information (including all copies, records and other embodiments thereof, in any medium) in the Receiving Party’s possession; provided, however, that the Receiving Party may retain a single hard copy of the Confidential Information in the Receiving Party’s secure archives for the sole purpose of monitoring compliance with its obligations hereunder and provided, further, that such Receiving Party continues to protect and maintain such Confidential Information in accordance with this Article 10. Notwithstanding the foregoing, nothing contained in this Agreement shall be construed to require the Receiving Party
24


to alter, modify, delete or destroy any electronic copy of files created automatically in the ordinary course of business pursuant to the Receiving Party’s standard electronic back-up and archival procedures so long as such electronic files are (a) maintained only on centralized storage servers (and not on personal computers or devices) and (b) not readily accessible by the Receiving Party’s Representatives (other than its information technology specialists).
10.5Confidential Terms. Each Party shall treat the terms of this Agreement as the Confidential Information of the other Party. Notwithstanding anything to the contrary, either Party may disclose the terms of this Agreement, but not any other Confidential Information of the Disclosing Party, to its advisors, actual or potential investors, actual or potential acquisition partners and other advisors who (a) have a need to know such information, (b) have been advised of the obligations of the Party disclosing such information under this Agreement and (c) are contractually or legally bound by commercially reasonable obligations of confidentiality and non-use with respect thereto.
10.6Duration. The obligations of confidentiality and non-use set forth in this Article 10 shall survive any expiration or termination of this Agreement for a period of [***]; provided, however, that any Confidential Information that constitutes the Disclosing Party’s trade secret shall continue to be subject to the obligations of confidentiality and non-use until such Confidential Information is no longer a trade secret under Applicable Law.
11.INTELLECTUAL PROPERTY RIGHTS; PUBLICITY
11.1Work Products and Product-Specific Inventions.
(a)Subject to BD’s ownership of BD Materials pursuant to Section 11.2, as between the Parties, Accelerate shall own (a) all data, information, reports, results, materials (including Marketing Materials developed by BD pursuant to Section 4.2(b)) and writings (whether or not patentable, copyrightable, or entitled to or eligible for other forms of legal protection) made by or on behalf of BD arising from or produced as a result of the performance of the BD Services (collectively, the “Work Products”) and (b) all intellectual property rights therein. To the extent applicable, Work Products shall be deemed “works for hire.” Notwithstanding the foregoing, BD hereby assigns to Accelerate all of BD’s rights to and interest in the Work Products. In the event BD desires to own or jointly share in intellectual property rights within a Work Product, before creating such Work Product, BD will inform Accelerate of such and the Steering Committee will meet to decide intellectual property rights in such Work Product as between the Parties.
(b)Notwithstanding Section 11.4, all Product-Specific Inventions shall be solely owned by Accelerate regardless of inventorship. BD hereby assigns to Accelerate all of BD’s rights to and interest in the Product-Specific Inventions.
(c)To the extent that any of Accelerate’s ownership rights contemplated under this Section 11.1(a) or Section 11.1(b) are not perfected, fail to arise, revert or terminate by operation of law, then in lieu of such ownership rights, BD shall automatically grant to Accelerate an irrevocable, perpetual, worldwide, fully paid-up, exclusive (even as to BD), sublicensable (through multiple tiers), transferable license to all rights, title and interest in any Work Product
25


and/or Product-Specific Invention for which such ownership rights failed to arise, reverted or terminated by operation of law.
(d)BD represents and warrants to Accelerate that each BD Personnel is obligated to assign all of his/her/its right, title and interest in and to Work Products and Product Specific Inventions to BD. BD and its Personnel shall sign and deliver to Accelerate all writings and do all such things as may be reasonably necessary or appropriate to vest in Accelerate all right, title and interest in and to such Work Product and Product-Specific Invention. BD will promptly disclose to Accelerate any Work Product and Product-Specific Invention arising hereunder. Accelerate may, in its sole discretion and sole expense, file and prosecute in its own name patent applications on any Product-Specific Invention or any other patentable inventions within the Work Product. Upon the request of Accelerate and at Accelerate’s sole expense, BD will reasonably assist Accelerate in the preparation, filing, prosecution, defense and/or enforcement of such patent applications and will execute and deliver any and all instruments necessary to effectuate the ownership of such patent applications and to enable Accelerate to file and prosecute such patent applications in any country.
(e)Without Accelerate’s prior written consent, BD shall not engage in any activities, on its own or in collaboration with a Third Party, or use any Third-Party facilities or Third-Party intellectual property in performing the BD Services which could result in claims of ownership to any Work Products or Product-Specific Inventions being made by such Third Party.
11.2BD Materials. As between the Parties, BD shall own (a) BD’s Background Intellectual Property, which includes, for clarity, any proprietary business information, methods, processes, techniques, procedures, data base applications or software applications, including, without limitation documentation, flat files, object code, protected libraries, source code and development tools or (b) improvements developed by BD which are solely related to BD’s Background Intellectual Property and not related to any Confidential Information of Accelerate, Accelerate Materials or other proprietary information, programs, databases or applications of Accelerate (collectively, the “BD Materials”), including all intellectual property rights therein. BD hereby grants to Accelerate an irrevocable, perpetual, royalty-free, fully paid-up, sublicensable (through multiple tiers), worldwide, non-exclusive right and license to use and otherwise exploit the BD Materials solely to the extent necessary or useful for Accelerate to use and otherwise exploit the Work Products and exercise its full rights in such Work Products as contemplated herein.
11.3Background Intellectual Property. All Background Intellectual Property is and shall, as between the Parties, remain the sole property of such Party. Unless otherwise specifically stated herein or expressly stated in a Commercialization Plan, neither Party transfers by operation of this Agreement to the other Party any right in or license to such Background Intellectual Property. Each Party agrees that neither it nor its Affiliates will reverse engineer or otherwise attempt to discover the proprietary elements or components of the other Party’s Background Intellectual Property.
11.4Inventorship and Ownership of Inventions. Inventorship of Inventions will be determined in accordance with the principles of United States patent law. Subject to Accelerate’s ownership of Product-Specific Inventions under Section 11.1(b), any other Inventions created,
26


developed, conceived or reduced to practice under this Agreement shall be treated, with respect to ownership, licensing, filing and prosecution of patents, as being owned by the Party that made the Invention, with title to and all rights in the Inventions vesting in such Party and the other Party agrees to execute all such further documents and do all such further acts that are necessary to effect the assignment of the Inventions to such other Party pursuant to this Section 11.4.

11.5Trademarks.
(a)Subject to terms and conditions of this Agreement, Accelerate hereby grants to BD a limited, royalty-free, non-exclusive, non-transferable and non-sublicensable license to use the Accelerate Trademarks solely to the extent necessary for BD to perform the BD Services within the Territory. BD shall follow the reasonable instructions and guidelines of Accelerate in connection with the use of any Accelerate Trademarks. BD hereby acknowledges and agrees that (i) the Accelerate Trademarks are valid and exclusive property of Accelerate, (ii) BD shall not, directly or indirectly, disparage or challenge the validity of any Accelerate Trademarks and (iii) BD does not have, and shall not obtain, any proprietary interest in any Accelerate Trademarks. All goodwill generated by BD’s use of the Accelerate Trademarks shall inure to the benefit of Accelerate. Any right to the use of the Accelerate Trademarks granted hereunder and all use of the Accelerate Trademarks by BD shall cease at the end of the Term. BD (and its Affiliates) shall not register, apply to register or use (A) any Accelerate Trademarks or (B) other marks (including in connection with any domain names) that are confusingly similar to any of the Accelerate Trademarks.
(b)All Marketing Materials shall include the Accelerate Trademarks and BD Trademarks. BD shall discuss and refer to Products only under the Accelerate Trademarks and shall use such Accelerate Trademarks only on the Marketing Materials and only in accordance with the terms and conditions of this Agreement.
(c)Subject to terms and conditions of this Agreement, BD hereby grants to Accelerate a limited, royalty-free, non-exclusive, non-transferable and non-sublicensable license to use the BD Trademarks solely to the extent necessary for Accelerate to perform the Accelerate Activities within the Territory. Accelerate shall follow the reasonable instructions and guidelines of BD in connection with the use of any BD Trademarks. Accelerate hereby acknowledges and agrees that (i) the BD Trademarks are valid and exclusive property of BD, (ii) Accelerate shall not, directly or indirectly, disparage or challenge the validity of any BD Trademarks and (iii) Accelerate does not have, and shall not obtain, any proprietary interest in any BD Trademarks. All goodwill generated by Accelerate’s use of the BD Trademarks shall inure to the benefit of BD. Any right to the use of the BD Trademarks granted hereunder and all use of the BD Trademarks by Accelerate shall cease at the end of the Term. Accelerate (and its Affiliates) shall not register, apply to register or use (A) any BD Trademarks or (B) other marks (including in connection with any domain names) that are confusingly similar to any of the BD Trademarks.

11.6Infringement. Each Party shall promptly inform the other Party in writing of any infringement of, or challenge to (a) any Trademark or (b) any other intellectual property relating to Products owned or controlled by Accelerate in the Territory, in each case, whether actual or threatened, which comes to the attention of such Party. As between the Parties, Accelerate shall have the exclusive right (but not an obligation) to take any action in respect of
27


the defense or enforcement of such Trademarks and/or other intellectual property relating to Products. BD shall, at Accelerate’s request and expense, provide reasonable assistance and cooperation with such activities.
11.7Accelerate Materials. BD hereby acknowledges and agrees that, as between the Parties, Accelerate owns (a) all tangible materials relating to Products and/or the BD Services provided by Accelerate to BD, including all Marketing Materials and training materials, along with any derivatives, modifications or improvements to the foregoing materials and all materials derived from the foregoing materials (the “Accelerate Materials”) and (b) all intellectual property rights therein. BD shall not supply, transfer or sell any Accelerate Materials to any Third Party or BD Personnel not performing the BD Services hereunder, without the prior written consent of Accelerate. Accelerate Materials are to be used by BD solely for the purpose of completing the BD Services as set forth in the Commercialization Plan, and BD shall not use any Accelerate Material for any other purpose. Upon expiration or termination of this Agreement, BD shall either return to Accelerate or destroy (and certify in writing such destruction) all Accelerate Materials in BD’s possession at Accelerate’s discretion and instruction.
11.8Publicity. Neither Party will make any press release or other public announcement regarding this Agreement without the other Party’s express prior written consent, except as required under Applicable Law or by any Governmental Authority, in which case, the Party required to make the press release or public disclosure shall obtain the approval of the other Party as to the form, nature and extent of the press release or public announcement prior to issuing the press release or making the public announcement.
12.RECORDS; AUDIT
12.1Records. Each Party shall keep and maintain complete and accurate written records pertaining to the performance of its obligations hereunder (including, for clarity, records pertaining to Work Products and Sales Commissions, as applicable) (“Records”) and (b) in the case of BD, retain the Records for [***] following BD’s completion of the BD Services and in the case of Accelerate, retain the Records for [***] following Accelerate’s completion of the Accelerate Activities. The Parties agree to not destroy any Records unless and until it has obtained the other Party’s prior written permission to do so. At either Party’s written request, the other Party shall (i) continue to maintain any Records beyond the [***] period specified above, subject to payment by the other Party of reasonable storage fees or (ii) transfer such records to the Party that made the request or its designee at such Party’s expense.
12.2Audit. No more than [***] every [***] during the Term, and [***] within [***] thereafter, each Party shall have the right to have its internal audit department or the audit department of its external certified public accountants, who are contractually bound by obligations of confidentiality and non-use at least as stringent as those contained in this Agreement (the “Auditing Party”), audit the other Party’s books and records (including all Records) directly related to the performance of its obligations hereunder (the “Auditee Party”) to ensure the Auditee Party’s compliance with this Agreement and to verify the accuracy of BD’s invoices; provided, that the Auditing Party shall provide the Auditee Party
28


with a reasonable advance written notice of any audit conducted hereunder and such audit shall take place at the Auditee Party’s place of business during regular business hours. The cost of any audit conducted pursuant to this Section 12.2 shall be borne by the Auditing Party, unless such audit reveals the Auditee Party’s breach of this Agreement, in which case, the Auditee Party shall bear the cost of the audit. The cost of any audit conducted pursuant to this Section 12.2 by Accelerate shall be borne by Accelerate, unless such audit reveals a variance of more than [***] from the reported amounts in an invoice for Sales Commissions, in which case, BD shall bear the cost of the audit. If such audit by Accelerate of Sales Commissions concludes that (a) additional amounts were owed by Accelerate, Accelerate shall pay BD the additional amounts, plus interest calculated in accordance with Section 7.3, or (b) excess payments were made by Accelerate, BD shall reimburse Accelerate such excess payments, in each case of (a) or (b), within [***] of the conclusion of the audit.
13.TERM AND TERMINATION
13.1Term. This Agreement shall commence on the Effective Date and shall continue until the fifth (5th) anniversary of the Effective Date (“Initial Term”) and thereafter, this Agreement shall automatically renew by successive one (1)-year renewal terms (each, a “Renewal Term” and the Initial Term and all Renewal Terms together, the “Term”), unless (a) either Party provides a written notice of non-renewal to the other Party at least [***] prior to the expiration of the then-current Term or (b) this Agreement is terminated as set forth in this Agreement.
13.2Termination for Convenience. Following the [***] anniversary of the Effective Date, either Party shall have the right to terminate this Agreement, and the right to terminate any Commercialization Plan, at any time, without cause, upon twelve (12) months’ prior written notice to the other Party. If this Agreement is terminated in accordance with this Section 13.2, no Sales Commissions paid by Accelerate prior to the effective date of such termination shall be refundable. Further, if this Agreement is terminated by Accelerate in accordance with this Section 13.2, any remaining unpaid balance of Exclusive Commercial Arrangement Fee will be forgiven.
13.3Termination for Material Breach. Either Party may terminate this Agreement for the other Party’s material breach upon [***] prior written notice ([***] prior written notice for nonpayment) if the breaching Party fails to cure such material breach during such [***] (or, for nonpayment, [***]) cure period.
13.4Termination for Insolvency. If BD or Accelerate (a) becomes insolvent, (b) makes an assignment for the benefit of creditors, (c) files a petition for bankruptcy, (d) is the subject of a petition in bankruptcy which is not dismissed within [***] from the filing thereof, (e) becomes the subject of any receivership proceeding or (f) admits in writing its inability to pay its debts generally as they become due, in each case of (a) through (f), the other Party may immediately terminate this Agreement by written notice of termination to the other Party. In the case of termination by BD pursuant to this Section 13.4 within [***] following the Effective Date, Accelerate shall refund any amount of the Exclusive Commercial Arrangement Fee paid by BD and the remaining balance of the Exclusive Commercial
29


Arrangement Fee shall be forgiven.
13.5Termination for Failure to Meet Target. Accelerate may terminate this Agreement if BD fails to meet the applicable cumulative Target for both Arc and Pheno 1.0 (or Pheno 2.0, when applicable) in any [***] period, and [***]. Accelerate agrees that purchases exceeding the Target for one Product will count towards any deficiencies in a Target for another Product. Accelerate must provide BD with notice of such termination within [***] of BD not meeting the Target, or else Accelerate’s ability to terminate this Agreement in accordance with this Section 13.5 is waived. Additionally, BD shall have the option to cure such failure by making up the Target shortfall with a commensurate payment, minus any amount of the deficit that is attributable to Accelerate.
13.6Effects of Termination. Upon a Party’s receipt of any notice of termination (or a Party’s dispatch of any notice of termination) under this Agreement, each Party shall wind down all Services in a prudent and cost-efficient manner. Upon any termination or expiration of this Agreement, (a) all rights and licenses granted to BD by Accelerate hereunder shall immediately terminate and neither Party shall exercise thereafter any of its rights set forth in this Agreement, unless otherwise set forth herein, (b) Accelerate shall pay Sales Commissions owing to BD for [***] past the effective date of such termination, (c) each Party shall return the other Party’s Confidential Information as set forth in Section 10.4, (d) BD shall return or destroy all Accelerate Materials in BD’s possession as set forth in Section 11.7, and (e) any Regulatory Approvals held in the name of BD pursuant to Section 6.3 shall be assigned and transferred to Accelerate, at Accelerate’s costs and any ongoing obligations to maintain such Regulatory Approvals will be borne by Accelerate. Further, in the event Accelerate terminates this Agreement in accordance with Section 13.2, or by BD in accordance with Section 13.3 or Section 13.4, Accelerate will reimburse BD for any direct costs incurred by BD for Regulatory Approvals in a BD Country for the immediately preceding [***] period.
13.7Survival. Neither expiration nor termination will relieve either Party of its obligations accrued prior to such expiration or termination. The following provisions shall survive any expiration or termination of this Agreement: (a) Articles 1 9, 10, 11, 12 and 14; and (b) Sections 2.5, 7.1, 7.3 (to the extent as it relates to the Exclusive Commercial Arrangement Fee), 8.5, 13.2, 13.6, 13.7.
14.MISCELLANEOUS PROVISIONS
14.1Force Majeure. Neither Party shall be liable or deemed in default for failure to perform any duty or obligation that such Party may have under this Agreement (except payment obligations) where such failure has been occasioned by any act of God, fire, strike, inevitable accidents, war, or any other cause outside the reasonable control of that Party, and occurring without its fault or negligence (each, a “Force Majeure Event”). The Party whose performance has been so interrupted shall give the other Party prompt, but in no event later than [***], notice of the interruption and cause thereof, and shall use every reasonable means in that Party’s discretion to resume full performance of this Agreement as soon as possible. Each Party shall have the right to terminate this Agreement with written notice effective upon receipt
30


if Force Majeure continues to prevent performance by the other Party for a period of more than [***].
14.2Notices. Any notice to be given under this Agreement shall be in writing and delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier, to the Party to be notified at its address(es) given below, or at any address such Party has previously designated by prior written notice to the other Party. Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) the date of actual receipt; (b) if mailed, [***] after the date of postmark; or (c) if delivered by express courier, the next business day the courier regularly makes deliveries to the addressee’s location.
To Accelerate:    Accelerate Diagnostics Inc.
3950 S. Country Club Road, Suite 470, 4th Floor
Tucson, Arizona 85714
Attn: General Counsel
Copy to:    [***]
To BD:    Becton, Dickinson and Company
1 Becton Drive
Franklin Lakes, NJ 07417-1880
Attn: Vice President/General Manager for Microbiology
Copy to:    [***]
14.3Assignment. Neither Party may assign this Agreement without the prior written consent of the other Party; provided, however, that either Party may assign this Agreement, without the other Party’s prior written consent, to its Affiliates or in connection with the transfer or sale of all or substantially all of the business of the assigning Party to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise. Any attempted assignment of this Agreement not in compliance with this Section 14.3 shall be null and void. No assignment shall relieve either Party of the performance of any accrued obligation that such Party may then have under this Agreement. This Agreement shall inure to the benefit of and be binding upon each Party, its successors and permitted assigns, subsidiaries and Affiliates and such successor and permitted assigns, subsidiaries and Affiliates will immediately provide written notification to the other Party in the event of any assignment pursuant to this Section 14.3.
14.4Injunctive Relief. Each Party hereby acknowledges and agrees that in the event of the other Party’s actual or threatened breach of any provision of this Agreement relating to Confidential Information and intellectual property rights (including, Article 10 and Article 11), the non-breaching Party would suffer an irreparable injury such that no remedy at law would adequately protect or appropriately compensate the non-breaching Party for such injury. Accordingly, each breaching Party agrees that the non-breaching Party shall have the right to enforce this Agreement and any of such provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that the non-breaching Party may have for a breach of this Agreement.
14.5Severability. If any provision of this Agreement is found by a court of competent
31


jurisdiction to be unenforceable, then such provision shall be construed, to the extent feasible, so as to render the provision enforceable, and if no feasible interpretation would save such provision, it shall be severed from the remainder of this Agreement. The remainder of this Agreement will remain in full force and effect unless the severed provision is essential and material to the rights or benefits received by either Party. In such event, the Parties will negotiate, in good faith, and substitute a valid and enforceable provision or agreement that most nearly implements the Parties’ original intent in entering into this Agreement.
14.6Waiver. No failure or delay of a Party to insist upon strict performance of any of its rights or powers under this Agreement shall operate as a waiver thereof, nor shall any other single or partial exercise of such right or power preclude any other further exercise of any rights or remedies provided by law. No waiver by a Party of a particular provision, right or remedy shall be effective unless in writing and signed by an authorized representative of such Party.
14.7Governing Law. This Agreement, and all matters arising out of or relating to this Agreement (whether in contract, equity, tort, fraud, statutory claims or otherwise), shall be governed by, and shall be construed in accordance with, the laws of the State of New York, United States of America, without regard to the conflicts of laws provisions. Other than with respect to (a) any arbitration proceeding brought by a Party pursuant to Section 14.8 or (b) any action or proceeding seeking injunctive relief pursuant to Section 14.4 or brought to enforce an arbitration ruling issued pursuant to Section 14.8(b), the Parties hereby consent and agree that the United States Federal Courts for the Southern District of New York, and State Courts of New York, shall have the sole and exclusive jurisdiction to resolve any interpretation, construction, breach, dispute or other controversy arising out of, connected to or associated with this Agreement. The Parties hereby waive any objection to such Clause and exclusive jurisdiction.
14.8Dispute Resolution.
(a)Each Party agrees that any dispute, claim or controversy arising out of or relating to this Agreement (each, a “Dispute”) shall be resolved, in the first instance, by contacting the other Party to resolve the Dispute through good faith discussions between the Parties.
(b)If a Dispute cannot be resolved by good faith discussions between the Parties pursuant to Section 14.8(a) within [***] after commencement of such discussions, the Parties agree to submit the Dispute to be finally settled by arbitration administered by JAMS pursuant to JAMS’ Comprehensive Arbitration Rules and Procedures then in effect, which proceeding shall take place in New York City, New York and shall be conducted in English. The Parties shall jointly appoint a mutually acceptable neutral third-party arbitrator. If the Parties are unable to agree upon the appointment of such arbitrator, either Party may request JAMS to appoint an arbitrator. The costs of the arbitration will be solely borne by the losing Party. Judgment made by the Arbitrator may be entered in any court having jurisdiction. The arbitrator shall have the authority to grant injunctive relief and specific performance to enforce the terms of this Agreement, and may, in its discretion, award fees and costs as part of its award.
(c)Notwithstanding anything to the contrary provided herein, the dispute resolution procedures set forth in this Section 14.8 shall not apply to any Dispute that concerns the scope, validity, enforceability, inventorship or infringement of a patent, patent application, trademark or copyright.
32



14.9No Third-Party Beneficiaries. This Agreement is for the sole benefit of the Parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any Third Party any legal or equitable right, benefit or remedy of any nature whatsoever, under or by reason of this Agreement.
14.10Headings; Interpretation. The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. All references in this Agreement to the singular shall include the plural where applicable, and vice versa. Unless otherwise specified, references in this Agreement to any section shall include all subsections and paragraphs in such section and references in this Agreement to any subsection shall include all paragraphs in such subsection. All references to “days” in this Agreement shall mean calendar days, unless otherwise specified. All references to “months” in this Agreement shall mean calendar months. The word “including” or any variation thereof means “including, without limitation” and will not be construed to limit any general statement that such word or variation thereof follows. The word “will” shall be construed to have the same meaning and effect as the word “shall” wherever context requires. The word “or” shall be interpreted in the inclusive sense commonly associated with the word “and/or.” Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist.

14.11Entire Agreement; Amendment. This Agreement, together with all Exhibits attached hereto (each of which is incorporated herein by this reference) and all Commercialization Plans, constitutes the final, complete and exclusive agreement of the Parties with respect to the subject matter hereof and supersedes all prior understandings and agreements relating to its subject matter. This Agreement may not be changed, modified, amended or supplemented except by a written instrument signed by an authorized representative of each of Accelerate and BD.
14.12Counterparts; Electronic Signatures: This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement and any Commercialization Plan may be executed by signatures on an electronic image (such as .PDF or .JPG format), and electronic signatures, all of which shall have the same force and effect as original signatures.

[Remainder of this page left intentionally blank; signature page follows]

33



IN WITNESS WHEREOF, the Parties intending to be legally bound have caused this Agreement to be executed by their respective duly authorized representatives as of the Effective Date.
ACCELERATE DIAGNOSTICS INC.
By:    
Name:    
Title:    
Date:    
BECTON, DICKINSON AND COMPANY
By:    
Name:    
Title:    
Date:    

[Signature Page to Sales and Marketing Agreement]


Exhibit A – Products
[***]
[Exhibit A – Products]


Exhibit B – Product Customer End User Pricing Schedule

[***][***][***]
[***][***][***][***]
[***][***][***][***]
[***][***][***][***]
[***][***][***][***]
[***][***][***][***]
[***][***][***][***]
[***][***][***][***]
[***][***][***][***]
[***][***][***][***]

[***]

[Exhibit B – Product Pricing Schedule]


Exhibit C – Commission Schedule
Targets and BD Fees Table1

The Parties agree that the Targets set forth below will be reviewed and mutually agreed upon [***]. Any adjustments to the Targets [***] shall be set forth in the Commercial Plan.


[***][***][***][***][***][***][***]
[***][***][***][***][***][***][***][***]
[***][***][***][***][***][***][***][***]
[***][***][***][***][***][***][***][***]
[***][***][***][***][***][***][***][***]
[***][***][***][***][***][***][***][***]
[***][***][***][***][***][***][***][***]
[***][***][***][***][***][***][***][***]
[***][***][***][***][***][***][***][***]
[***][***][***][***][***][***][***][***]

[***]

[Exhibit C – Commission Schedule]


Exhibit D – Insurance Requirements
BD:

[***][***][***]
[***][***][***][***]
[***][***]
[***][***]
[***][***]
[***][***][***][***]
[***][***][***][***]
[***][***]
[***][***][***][***]
[***][***][***][***]
[***][***][***][***]

[Exhibit D – Insurance Requirements]


Accelerate:

Without limiting any other obligation or liability of Accelerate under this Agreement, Accelerate agrees that upon execution of this Agreement and through the Term, Accelerate shall maintain and keep in force general public liability, and property damage insurance against any insurable claim or claims, which might or could arise regarding Products. [***].



Exhibit E – Existing Countries


[***]




[***]


Exhibit F – Accelerate Distributors

[***][***][***][***][***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]
[***]



Exhibit G – BD Third Parties
[***]



Exhibit H – Accelerate Personnel
Unless modified by the Steering Committee, Accelerate Activities will be performed by Accelerate’s Personnel, the composition of which will be as follows: [***].

 EX-31.1 3 a09302022-exh311.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATION PURSUANT TO
RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jack Phillips, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Accelerate Diagnostics, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 14, 2022
/s/ Jack Phillips
 
Jack Phillips
President and Chief Executive Officer
 (Principal Executive Officer)


 EX-31.2 4 a09302022-exh312.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Steve Reichling, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Accelerate Diagnostics, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 14, 2022/s/ Steve Reichling
 Steve Reichling
Chief Financial Officer
 (Principal Financial and Accounting Officer)


 EX-32 5 a09302022-exh32.htm EX-32 Document

Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned officers of Accelerate Diagnostics, Inc. (the “Company”) hereby certifies that, to his knowledge, the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2022 to which this certification is attached (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 14, 2022/s/ Jack Phillips
Jack Phillips
President and Chief Executive Officer
(Principal Executive Officer)
 
November 14, 2022/s/ Steve Reichling
Steve Reichling
Chief Financial Officer
(Principal Financial and Accounting Officer)


 EX-101.SCH 6 axdx-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Recently Issued Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Concentration of Credit Risk link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Deferred Revenue and Remaining Performance Obligations link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Convertible Notes link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Long-Term Debt Related-Party link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Employee Equity-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Geographic and Revenue Disaggregation link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Convertible Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Long-Term Debt Related-Party (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Employee Equity-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Geographic and Revenue Disaggregation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Allowance For Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Recently Issued Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Concentration of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Investments - Schedule of Available-for-sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Investments - Schedule of Available-for-Sale Investment Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Investments - Unrealized Losses or Gains on Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Property and Equipment - Property and Equipment at Cost (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Property and Equipment - Instruments at Cost and Accumulated Depreciation, Lessor (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Long-Term Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Long-Term Debt - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Long-Term Debt - Schedule of Maturities of Future Principal Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Convertible Notes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Convertible Notes - Schedule of Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Convertible Notes - Gain on Extinguishment (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Convertible Notes - Schedule of Notes and New Notes (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Long-Term Debt Related-Party - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Long-Term Debt Related-Party - Carrying Value of the Secured Notes (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Long-Term Debt Related-Party - Interest Expense in Connection with the Secured Note (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Long-Term Debt Related-Party - Summary of Inputs Used to Calculate Estimated Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Loss Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - Loss Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - Employee Equity-Based Compensation - Option Activity under the Company's Equity-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - Employee Equity-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - Employee Equity-Based Compensation - Outstanding Options and Options that are Exercisable (Vested) (Details) link:presentationLink link:calculationLink link:definitionLink 0000071 - Disclosure - Employee Equity-Based Compensation - Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - Employee Equity-Based Compensation - Equity-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000073 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000074 - Disclosure - Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 0000075 - Disclosure - Leases - Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - Leases - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - Leases - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - Leases - Sales-type Lease Receivable Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - Leases - Sales-type Lease Receivable Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 0000078 - Disclosure - Geographic and Revenue Disaggregation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000079 - Disclosure - Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000080 - Disclosure - Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details) link:presentationLink link:calculationLink link:definitionLink 0000081 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 0000082 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 axdx-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 axdx-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 axdx-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Geographic concentration Geographic Concentration Risk [Member] Due in less than 1 year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Reclassified from out of accumulated other comprehensive income (loss) Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Total lease payments Lessee, Operating Lease, Liability, to be Paid Convertible debt offerings Number Of Convertible Debt Offerings Number Of Convertible Debt Offerings Foreign Currency Translation and Foreign Currency Transactions Foreign Currency Transactions and Translations Policy [Policy Text Block] Facilities Leaseholds and Leasehold Improvements [Member] (Reversals) provisions, net Accounts Receivable, Credit Loss Expense (Reversal) Related Party Transactions [Abstract] Related Party Transactions [Abstract] Outstanding principal at par Outstanding principal Long-Term Debt, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Tranche right value Stockholders' Equity, Tranche Right Stockholders' Equity, Tranche Right Finance lease assets, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Aggregate purchase price Preferred Stock, Value, Subscriptions Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Funded prepaid forward Payments To Fund Prepaid Forward Stock Repurchase Payments To Fund Prepaid Forward Stock Repurchase Preferred Stock, shares outstanding (in shares) Beginning Balance (in shares) Ending Balance (in shares) Preferred Stock, Shares Outstanding 2024 Long-Term Debt, Maturity, Year Two Thereafter Long-Term Debt, Maturity, after Year Four Long-Term Debt, Maturity, after Year Four Consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Debt Instrument [Axis] Debt Instrument [Axis] Finance lease obligation Finance Lease, Liability Property and equipment Property, Plant and Equipment, Gross Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Other revenue Other Revenue [Member] Other Revenue [Member] Lease income Lease Income Decrease in additional paid in capital Additional Paid in Capital Thereafter Finance Lease, Liability, to be Paid, after Year Four Finance Lease, Liability, to be Paid, after Year Four Other loans Loans - various interest Other Loans [Member] Other Loans Financial Instruments [Domain] Financial Instruments [Domain] 2026 Finance Lease, Liability, to be Paid, Year Four Statistical Measurement [Domain] Statistical Measurement [Domain] Increase (decrease) in liabilities: Increase (Decrease) in Accrued Liabilities [Abstract] Provisions (reversals), net Standard Product Warranty Accrual, Increase (Decrease) for Warranties Issued and Adjustments Standard Product Warranty Accrual, Increase (Decrease) for Warranties Issued and Adjustments Depreciation and amortization Depreciation Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Contractual coupon interest Contractual interest Interest Expense, Debt, Excluding Amortization Weighted average discount rate (%) Operating Lease, Weighted Average Discount Rate, Percent Interest rate Debt Instrument, Interest Rate, Stated Percentage Maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Net property and equipment under operating leases Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, after Accumulated Depreciation Issuance of shares to retire convertible notes Stock Issued During Period, Value, Conversion of Convertible Securities Contributed capital Additional Paid in Capital, Common Stock Payment of debt Repayments of Debt Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization 2025 Finance Lease, Liability, to be Paid, Year Three Net loss Net loss Net Income (Loss) Attributable to Parent Measurement Input Type [Domain] Measurement Input Type [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Non-affiliate related entities Related Party, Number of Related Entities Related Party, Number of Related Entities Antidilutive common stock instruments outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2021 Exchange Transaction 2021 Exchange Transaction [Member] 2021 Exchange Transaction [Member] Remainder of 2022 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Schedule of Maturities of Long-term Debt Schedule of Maturities of Long-Term Debt [Table Text Block] Operating Lessee, Operating Lease, Liability, to be Paid [Abstract] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Agreement to purchase shares (in shares) Common Stock, Shares Subscribed but Unissued Net transfer of instruments (to) from inventory to property and equipment Inventory Transferred to Fixed Assets Inventory Transferred to Fixed Assets Financial Institutions Three Financial Institutions Three [Member] Financial Institutions Three Equity Component [Domain] Equity Component [Domain] Secured Debt Secured Debt [Member] Repurchase principal balance Debt Instrument, Redemption Price, Percentage Total assets measured at fair value Assets, Fair Value Disclosure Interest income Investment Income, Interest and Dividend Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Debt and Equity Securities, FV-NI [Line Items] Debt and Equity Securities, FV-NI [Line Items] Leases Lessee, Operating Leases [Text Block] Related Party [Domain] Related Party [Domain] Estimated Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Treasury stock Treasury Stock, Common, Value Debt securities available-for-sale: Fair Value Fair Value Debt Securities, Available-for-Sale Expected dividends Measurement Input, Expected Dividend Rate [Member] Schedule of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Number of operating segments Number of Operating Segments Unrecognized equity-based compensation cost, restricted stock units Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Remainder of 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Capital contribution from related-party in connection with exchange transaction Capital contribution from related-party in connection with exchange transaction Adjustment to Additional Paid-in Capital, Convertible Debt Instrument Issued at Substantial Premium Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Common stock, $0.001 par value; 200,000,000 common shares authorized with 97,240,983 shares issued and outstanding on September 30, 2022 and 100,000,000 common shares authorized with 67,649,018 shares issued and outstanding on December 31, 2021 Common Stock, Value, Outstanding Entity Address, State or Province Entity Address, State or Province Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Issuable upon conversion of the notes (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Weighted average remaining contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Award Type [Axis] Award Type [Axis] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Deferred compensation Increase (Decrease) in Deferred Compensation Operating lease, current Operating Lease, Liability, Current Leases Lessor, Sales-type Leases [Text Block] Cash paid for amounts included in lease liabilities: Cash Flow, Operating Activities, Lessee [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Expired (in shares) Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Schedule of Maturities of Available-for-Sale Investments Debt Securities, Available-for-Sale [Table Text Block] Lease Cost: Lease, Cost [Abstract] Property and equipment Property, Plant and Equipment [Member] 2025 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Three Related Party Transaction [Domain] Related Party Transaction [Domain] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Costs and expenses: Costs and Expenses [Abstract] Lender Name [Axis] Lender Name [Axis] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Restricted stock awards released and exercise of options (in shares) Exercise Of Options And Restricted Stock Awards Issued Exercise Of Options And Restricted Stock Awards Issued Long-term debt Long-Term Debt, Excluding Current Maturities Certificates of deposit Certificates of deposit Certificates of Deposit [Member] Total liabilities Liabilities Agreement to purchase preferred shares (in shares) Preferred Stock, Shares Subscribed but Unissued Weighted average remaining lease term (years) Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Amortization of investment discount Investment Income, Net, Amortization of Discount and Premium Proceeds from issuance of stock Stock Issued During Period, Value, New Issues Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Reclassified debt securities available-for-sale balances AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Document Type Document Type Realized gain (loss) from debt securities Debt Securities, Available-for-Sale, Realized Gain (Loss) Estimated useful life of assets Property, Plant and Equipment, Useful Life Long-Term Debt Long-Term Debt [Text Block] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Warranty cost incurred Standard Product Warranty Accrual, Decrease for Payments Beginning balance (in usd per share) Ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Convertible Notes Debt Disclosure [Text Block] Stock underlying the prepaid forward (in shares) Treasury Stock Acquired, Number Of Shares Prepaid Treasury Stock Acquired, Number Of Shares Prepaid Number of loan agreements Number of Debt Instruments Number of Debt Instruments Finance Finance Lease, Liability, to be Paid [Abstract] Product and Service [Domain] Product and Service [Domain] Entity Shell Company Entity Shell Company Accrued liabilities and other Increase (Decrease) in Accrued Liabilities Concentration Risk [Table] Concentration Risk [Table] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One (Increase) decrease in assets: Increase (Decrease) in Operating Assets [Abstract] Financial Instrument [Axis] Financial Instrument [Axis] 2025 Long-Term Debt, Maturity, Year Three Affiliated Entity Affiliated Entity [Member] New Notes Two Point Five Zero New Convertible Notes Due 2023 [Member] Two Point Five Zero New Convertible Notes Due 2023 Total revenue Revenue Benchmark [Member] Schedule of Deferred Revenue and Income Summary Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Document Period End Date Document Period End Date Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Accounting Standards Update 2020-06 Accounting Standards Update 2020-06 [Member] Total assets Assets Write-offs Accounts Receivable, Allowance for Credit Loss, Writeoff Debt Disclosure [Abstract] Debt Disclosure [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Accounts Receivable Accounts Receivable [Policy Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Fair Value Measurement Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Performance-based stock options Performance-based stock option expense Performance Shares [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Equity investments: Fair value of equity securities Equity Securities, FV-NI, Current Accrued liabilities Accrued Liabilities, Current Unsecured obligations Unsecured Debt [Member] Concentration of credit risk Credit Concentration Risk [Member] Current portion of long-term debt Current portion of long-term debt Long-Term Debt, Current Maturities Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Fair value Long-Term Debt, Fair Value Accounting Policies [Abstract] Accounting Policies [Abstract] Domestic Geographic Distribution, Domestic [Member] Total interest expense on convertible notes Interest Expense, Debt August 2022 Public Offering August 2022 Public Offering [Member] August 2022 Public Offering Net loss before income taxes Pre-tax loss Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Stockholders’ deficit: Stockholders' Equity Attributable to Parent [Abstract] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Amortization of debt discount and issuance costs Amortization of Debt Issuance Costs and Discounts Loss Per Share Earnings Per Share [Text Block] Customer [Axis] Customer [Axis] Schedule of Equity-Based Compensation Expense Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Finance lease, non-current Finance Lease, Liability, Noncurrent Debt instrument, convertible, number of accrued interest Debt Instrument, Convertible, Number Of Equity Instrument, Accrued Interest Debt Instrument, Convertible, Number Of Equity Instrument, Accrued Interest Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Award Type [Domain] Award Type [Domain] Leases as Lessor Lessor, Leases [Policy Text Block] Gain on extinguishment of debt Gain on extinguishment of debt Gain (Loss) on Extinguishment of Debt Weighted average remaining contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Proceeds from issuance of common stocks under employee purchase plan Proceeds from Stock Plans Computer equipment Computer Equipment [Member] Gross profit Gross Profit Entity Registrant Name Entity Registrant Name Conversion ratio (in shares) Preferred Stock, Convertible, Conversion Ratio Financial Institutions One Financial Institutions One [Member] Financial Institutions One Issuance of stock (in shares) Stock Issued During Period, Shares, New Issues Tranche Right September 2021 Securities Purchase Agreement, Second Tranche Right [Member] September 2021 Securities Purchase Agreement, Second Tranche Right Weighted Average Exercise Price per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract] Entity Address, City or Town Entity Address, City or Town Leases [Abstract] Leases [Abstract] Contractual term (in years) Measurement Input, Expected Term [Member] Mutual funds Mutual Fund [Member] Geographic Distribution [Domain] Geographic Distribution [Domain] Principles of Consolidation Consolidation, Policy [Policy Text Block] Minimum Minimum [Member] Conversion ratio Debt Instrument, Convertible, Conversion Ratio Convertible Note Purchases Convertible Note Purchases [Member] Convertible Note Purchases [Member] Due in less than 1 year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company December 2020 Securities Purchase Agreement December 2020 Securities Purchase Agreement [Member] December 2020 Securities Purchase Agreement [Member] Common Stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Raw materials Inventory, Raw Materials, Net of Reserves Unamortized debt issuance discount Debt Issuance Costs, Net Due in 1-3 years Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year One Through Three Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year One Through Three Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Treasury stock Treasury Stock, Common [Member] Outside the U.S. Foreign Geographic Distribution, Foreign [Member] Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Share price (in usd per share) Share Price Trading Symbol Trading Symbol Entity File Number Entity File Number Research and development Research and Development Expense Equipment Equipment [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Shares issuable upon the release of RSUs RSUs Restricted Stock Units (RSUs) [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Risk free interest rates Measurement Input, Risk Free Interest Rate [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash and cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Other (expense) income: Other Nonoperating Income (Expense) [Abstract] Long-term debt related-party Due to Related Parties, Noncurrent Accounts payable Increase (Decrease) in Accounts Payable Risk concentration Concentration Risk, Percentage Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Income Taxes Income Tax Disclosure [Text Block] Finished goods Inventory, Finished Goods, Net of Reserves Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Basic net loss per share (in usd per share) Earnings Per Share, Basic 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Schedule of Gain on Extinguishment Schedule of Extinguishment of Debt [Table Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Inventory Inventory, Policy [Policy Text Block] Securities Purchase Agreement Securities Purchase Agreement [Member] Securities Purchase Agreement Concentration Risk Type [Domain] Concentration Risk Type [Domain] Fair value of common stock warrant issued to related-party in connection with exchange transaction Warrants Issued Warrants Issued Counterparty Name [Domain] Counterparty Name [Domain] Number of tranches Issuance of Common Stock, Number of Tranches Issuance of Common Stock, Number of Tranches Total stockholders’ deficit Beginning Balance, amount Ending Balance, amount Stockholders' Equity Attributable to Parent Prepaid expenses Prepaid Expense, Current Finance leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 2.50% Convertible notes due 2023 Two Point Five Zero Convertible Notes Due 2023 [Member] Two Point Five Zero Convertible Notes Due 2023 [Member] Entity Interactive Data Current Entity Interactive Data Current Sale of stock (in shares) Sale of Stock, Number of Shares Issued in Transaction Long-Term Debt Related-Party Long Term Debt Related Party [Text Block] Long Term Debt Related Party [Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] August 2022 Exchange Transaction August 2022 Exchange Transaction [Member] August 2022 Exchange With Related Party [Member] Money market funds Money Market Funds [Member] March 2022 Exchange Transaction March 2022 Exchange Transaction [Member] March 2022 Exchange Transaction [Member] Accumulated deficit Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Unrecognized equity-based compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Debt forgiveness Debt Instrument, Decrease, Forgiveness Common stock Common Stock [Member] Schedule of Lease Costs Lease, Cost [Table Text Block] Class of Stock [Axis] Class of Stock [Axis] Deferred Tax Income Tax, Policy [Policy Text Block] Statement [Table] Statement [Table] Sale or merger trigger conversion ratio (in shares) Convertible Preferred Stock, Sale or Merger Trigger, Shares Issued upon Conversion Convertible Preferred Stock, Sale or Merger Trigger, Shares Issued upon Conversion Released (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Effective interest rate Debt Instrument, Interest Rate, Effective Percentage 5.0% Secured promissory note Five Point Zero Percent Secured Promissory Note [Member] Five Point Zero Percent Secured Promissory Note Commercial paper Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Lease extension Lessee, Operating Lease, Renewal Term Trade accounts receivable, net Receivables, Net, Current Document Quarterly Report Document Quarterly Report Current assets: Assets, Current [Abstract] Operating lease, non-current Operating Lease, Liability, Noncurrent Summary of Inputs Used to Calculate Estimated Fair Value Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Statistical Measurement [Axis] Statistical Measurement [Axis] Realized gains or losses from equity securities Equity Securities, FV-NI, Realized Gain (Loss) Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] Accumulated deficit Decrease in accumulated deficit Retained Earnings (Accumulated Deficit) Original Purchasers Certain Directors And Officers Or Affiliates [Member] Certain Directors And Officers Or Affiliates [Member] U.S. Treasury securities U.S. Treasury securities US Treasury and Government [Member] Equity Components [Axis] Equity Components [Axis] Conversion numerator (in usd per share) Debt Conversion, Conversion Numerator Debt Conversion, Conversion Numerator Fair Value on a Recurring Basis Fair Value, Recurring [Member] Weighted average exercise price (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Related-Party Transactions Related Party Transactions Disclosure [Text Block] Number of tranches Debt Conversion, Number Of Tranches Debt Conversion, Number Of Tranches Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Expired (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Statement [Line Items] Statement [Line Items] Payments on finance leases Operating cash flows from finance leases Finance Lease, Principal Payments Total other (expense) income, net Nonoperating Income (Expense) Other comprehensive loss: Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Sales, general and administrative Selling, General and Administrative Expense Recently Issued Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Products Product [Member] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Operating lease right of use assets, net Operating Lease, Right-of-Use Asset Rescission of common stock Stock Repurchased During Period, Value Accumulated other comprehensive (loss) income AOCI Attributable to Parent [Member] Series A Preferred Stock Series A Preferred Stock [Member] Financial Institutions Two Financial Institutions Two [Member] Financial Institutions Two 2024 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two Purchases of equipment Payments to Acquire Productive Assets Document Transition Report Document Transition Report Local Phone Number Local Phone Number Schedule of Option Activity under the Company's Equity-Based Compensation Share-Based Payment Arrangement, Option, Activity [Table Text Block] Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs Convertible notes value Debt Conversion, Converted Instrument, Amount Loss from operations Operating Income (Loss) Inventory Increase (Decrease) in Inventories Instrument warranty term Standard Product Warranty, Instruments, Term Standard Product Warranty, Instruments, Term Standards that were recently adopted and standards not yet adopted New Accounting Pronouncements, Policy [Policy Text Block] Shares issued (in shares) Debt Conversion, Converted Instrument, Shares Issued Prepaid expense and other Increase (Decrease) in Prepaid Expense and Other Assets Common Stock, shares outstanding (in shares) Beginning Balance (in shares) Ending Balance (in shares) Common Stock, Shares, Outstanding Services Service [Member] Movement in Standard Product Warranty Accrual [Roll Forward] Movement in Standard Product Warranty Accrual [Roll Forward] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Beginning balance Ending balance Standard Product Warranty Accrual Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Schedule of Warranty Reserve Schedule of Product Warranty Liability [Table Text Block] Preferred Stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Schedule of Outstanding Options and Options that are Exercisable (Vested) Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block] Performance-based RSU expense Performance-based Restricted Stock Units [Member] Performance-based Restricted Stock Units Contact period Revenue, Performance Obligation, Description of Timing Contributed capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Extinguished Notes Extinguished Notes [Member] Extinguished Notes Cost of sales Cost of Goods and Services Sold Weighted average shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Long-lived Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Concentration of Credit Risk Concentration Risk Disclosure [Text Block] Schedule of Components of Inventories Schedule of Inventory, Current [Table Text Block] Convertible notes Convertible Debt, Noncurrent Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Schedule of Available-for-Sale Investments Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Net accounts receivable Accounts Receivable [Member] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Expected term of award Share-based Compensation Arrangement by Share-based Payment Award, Expected Term of Award Share-based Compensation Arrangement by Share-based Payment Award, Expected Term of Award Investments Investments Issuance of common stock under employee purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Ownership Plan Instruments Instruments [Member] Instruments [Member] Notes exchanged Debt Conversion, Original Debt, Amount Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Instruments at cost under operating leases Property, Plant, and Equipment, Lessor Asset under Operating Lease, before Accumulated Depreciation Preferred stock Preferred Stock [Member] Purchase price Common Stock, Value, Subscriptions Senior Notes Senior Notes [Member] Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Initial conversion price (in usd per share) Debt Instrument, Convertible, Conversion Price Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Contributions to deferred compensation plan Deferred Compensation Arrangement with Individual, Contributions by Employer Convertible notes Convertible Debt [Member] Aggregate intrinsic value (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Short-term leases Short-Term Lease, Cost Preferred Stock, shares authorized (in shares) Preferred Stock, Shares Authorized Schuler Trust Jack W. Schuler Living Trust [Member] Jack W. Schuler Living Trust Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Foreign currency translation adjustment Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Commitments Commitments and Contingencies Disclosure [Text Block] Warrant issued to related-party Adjustments to Additional Paid in Capital, Warrant Issued Warrants issued, measurement input Warrants and Rights Outstanding, Measurement Input Current liabilities: Liabilities, Current [Abstract] Proceeds from debt Proceeds from Issuance of Long-Term Debt Proceeds from exercise of options Proceeds from Stock Options Exercised Common Stock, shares issued (in shares) Common Stock, Shares, Issued Concentration Risk [Line Items] Concentration Risk [Line Items] Deferred revenue Products and services not yet delivered Contract with Customer, Liability, Current Schedule of Unrealized Losses or Gains on Equity Securities Unrealized Gain (Loss) on Investments [Table Text Block] Foreign currency exchange loss Foreign Currency Transaction Gain (Loss), before Tax Warrants fair value Warrants and Rights Outstanding Income Statement Location [Domain] Income Statement Location [Domain] Interest expense Interest Expense, Other Finance lease, current Finance Lease, Liability, Current Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Unrealized loss position of debt securities Debt Securities, Available-for-Sale, Unrealized Loss Position Amendment Flag Amendment Flag Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Operating leases Operating Lease, Cost Aggregate principal amount Debt Instrument, Face Amount Investments Investment, Policy [Policy Text Block] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Capital projects in progress Construction in Progress [Member] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status March 2022 Securities Purchase Agreement March 2022 Securities Purchase Agreement [Member] March 2022 Securities Purchase Agreement Other non-current assets Other Assets, Noncurrent Remainder of 2022 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Remainder of Fiscal Year Carrying amount of convertible notes Convertible Debt September 2021 Rescission Agreement September 2021 Rescission Agreement [Member] September 2021 Rescission Agreement Number of options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Options Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Present value of lease payments Sales-type and Direct Financing Leases, Lease Receivable 2023 Finance Lease, Liability, to be Paid, Year One Depreciation expense Depreciation, Depletion and Amortization Less imputed interest Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Lease term Lessee, Operating Lease, Term of Contract Counterparty Name [Axis] Counterparty Name [Axis] Weighted average fair value (in usd per shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Fair Value Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Number of options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Schedule of Interest Expense Schedule of Interest Expense in Connection with the Secured Note Interest Income and Interest Expense Disclosure [Table Text Block] Trading price threshold, percentage Debt Instrument, Convertible, Threshold Percentage of Notes Trading Price Trigger Debt Instrument, Convertible, Threshold Percentage of Notes Trading Price Trigger Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Technical equipment Technology Equipment [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code 2024 Finance Lease, Liability, to be Paid, Year Two Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of exchange rate on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property and equipment, net Long-lived assets (excluding intangible assets) Property, Plant and Equipment, Net Operating cash flows from operating leases Operating Lease, Payments Shares issuable upon exercise of stock options Share-Based Payment Arrangement, Option [Member] Notes payable, other payables Loans - various interest Notes Payable, Other Payables [Member] Schedule of Instruments at Cost and Accumulated Depreciation, Lessor Property, Plant, and Equipment, Lessor Asset under Operating Lease [Table Text Block] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Restricted stock awards released and exercise of options Stock Issued During Period, Value, Stock Options Exercised Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Long-term debt, Total Long-Term Debt Other (expense) income, net Other Nonoperating Income (Expense) One customer One Customer [Member] One Customer Net unrealized gain (loss) on debt securities available-for-sale Net unrealized gain (loss) on debt securities available-for-sale OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Accrued interest Interest and Dividends Payable, Current Share price (in usd per share) Sale of Stock, Price Per Share Common Stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Maximum Maximum [Member] Non-cash financing activities: Other Noncash Investing and Financing Items [Abstract] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Products and services not yet delivered Products and Services not Yet Delivered [Member] Products and Services not Yet Delivered [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Deferred revenue and income Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current Revenues recognized included in contract liabilities balances Contract with Customer, Liability, Revenue Recognized Accumulated depreciation under operating leases Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, Accumulated Depreciation Entity Small Business Entity Small Business Measurement Frequency [Domain] Measurement Frequency [Domain] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Purchase of marketable securities Payments to Acquire Debt Securities, Available-for-Sale Threshold trading days Debt Instrument, Convertible, Threshold Trading Days Weighted average fair value (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value Schedule of Maturities of Sales-type Lease Receivables Sales-type and Direct Financing Leases, Lease Receivable, Maturity [Table Text Block] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Amortization of the debt discount Amortization of the debt discount Amortization of Debt Discount (Premium) Accrued interest related-party Interest Payable, Related Party, Noncurrent Interest Payable, Related Party, Noncurrent Aggregate intrinsic value (in thousands) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Warrants issued (in shares) Debt Conversion, Converted Instrument, Warrants or Options Issued Schedule of Supplemental Lease Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security September 2021 Securities Purchase Agreement September 2021 Securities Purchase Agreement [Member] September 2021 Securities Purchase Agreement Accrued interest from related-party Increase (Decrease) Related Party Accrued Interest Increase (Decrease) Related Party Accrued Interest Accelerate Pheno revenue Accelerate Pheno [Member] Accelerate Pheno [Member] Total undiscounted cash flows Sales-Type and Direct Financing Leases, Lease Receivable, Payments to be Received ROU assets obtained in exchange for lease obligations: Lessee, Operating Lease, Description [Abstract] Repurchase of exchanged amount Debt Instrument, Repurchase Amount Total costs and expenses Costs and Expenses Number of capital asset financing companies Number of Capital Asset Financing Companies Number of Capital Asset Financing Companies Debt Instrument [Line Items] Debt Instrument [Line Items] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Class of Stock [Line Items] Class of Stock [Line Items] Lessee lease liabilities Operating Lease, Liability Geographic and Revenue Disaggregation Segment Reporting Disclosure [Text Block] Volatility Measurement Input, Price Volatility [Member] Lessor lease term Lessor, Operating Lease, Term of Contract Equity-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Total lease payments Finance Lease, Liability, to be Paid Sales, general and administrative Selling, General and Administrative Expenses [Member] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Kits and accessories warranty term Standard Product Warranty, Kits And Accessories, Term Standard Product Warranty, Kits And Accessories, Term Total commitments Unrecorded Unconditional Purchase Obligation LIABILITIES AND STOCKHOLDERS’ DEFICIT Liabilities and Equity [Abstract] Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Remainder of 2022 Long-Term Debt, Maturity, Remainder of Fiscal Year Net proceeds Sale of Stock, Consideration Received on Transaction Inventory Inventory Inventory, Net Transaction costs related to debt exchange Payments Of Debt Conversion Costs Payments Of Debt Conversion Costs Accounts payable Accounts Payable, Current Unamortized debt issuance Debt Instrument, Unamortized Discount Stock price conversion threshold, percentage Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger 2026 Long-Term Debt, Maturity, Year Four Accumulated depreciation Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization RSUs and RSAs Restricted Stock Units And Restricted Stock Awards [Member] Restricted Stock Units And Restricted Stock Awards [Member] Shares issuable upon the exercise of the Warrant Warrant [Member] Entity Filer Category Entity Filer Category Proceeds from issuance of common stock Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Weighted average shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Exchange Agreement Convertible Notes Exchange Agreement [Member] Convertible Notes Exchange Agreement 2026 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Four Equity-based compensation expense Share-Based Payment Arrangement, Expense Non-cash investing activities: Noncash Investing and Financing Items [Abstract] Commitments and contingencies (see Note 14) Commitments and Contingencies Security Exchange Name Security Exchange Name Outstanding, beginning balance (in usd per share) Outstanding, ending balance (in usd per share) Weighted average exercise price (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Loss (gain) on disposal of property and equipment Gain (Loss) on Disposition of Assets Interest expense related-party Interest Expense, Related Party Extinguishment of convertible senior notes through issuance of common stock Stock Issued Preferred shares, $0.001 par value; 5,000,000 preferred shares authorized and 3,954,546 outstanding as of September 30, 2022 and December 31, 2021 Preferred Stock, Value, Issued Accrued interest Increase (Decrease) in Interest Payable, Net Prepaid Forward Prepaid Forward [Member] Prepaid Forward Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Schedule of Carrying Value of the Notes Schedule of Carrying Value of the Secured Notes Schedule of Debt [Table Text Block] Net sales Net sales Revenue from Contract with Customer, Excluding Assessed Tax Issuance of shares to retire Convertible Senior Notes (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Cash and cash equivalents Cash and Cash Equivalents [Member] Cover page. Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Leases as Lessee Lessee, Leases [Policy Text Block] Significant Unobservable Inputs (Level 3) Level 3 Fair Value, Inputs, Level 3 [Member] Geographic Distribution [Axis] Geographic Distribution [Axis] Employee Equity-Based Compensation Share-Based Payment Arrangement [Text Block] Due in 1-3 years Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Three Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Three Beginning balance Ending balance Accounts Receivable, Allowance for Credit Loss Work in process Inventory, Work in Process, Net of Reserves Gross margin Gross Margin Percentage Gross Margin Percentage Weighted average discount rate finance leases (%) Finance Lease, Weighted Average Discount Rate, Percent Common stock issuable upon conversion of the Series A Preferred Stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock Deferred Revenue and Remaining Performance Obligations Revenue from Contract with Customer [Text Block] Segment Reporting [Abstract] Segment Reporting [Abstract] Option one to convert Debt Instrument, Redemption, Period Two [Member] Net investment in leases Net Investment in Lease, before Allowance for Credit Loss Fair value of new note from related-party issued in connection with the exchange transaction Notes Issued Total liabilities and stockholders’ deficit Liabilities and Equity Contractual term Debt Instrument, Term Amortization of debt issuance costs Amortization of Debt Issuance Costs Related Party [Axis] Related Party [Axis] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Warranty Reserve Standard Product Warranty, Policy [Policy Text Block] Paycheck Protection Program Paycheck Protection Program [Member] Paycheck Protection Program Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Significant Other Observable Inputs (Level 2) Level 2 Fair Value, Inputs, Level 2 [Member] Convertible Notes Debt, Policy [Policy Text Block] Option two to convert Debt Instrument, Redemption, Period One [Member] Current Fiscal Year End Date Current Fiscal Year End Date Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Diluted net loss per share (in usd per share) Earnings Per Share, Diluted Sale of Stock [Domain] Sale of Stock [Domain] Amortization of debt discount related-party Amortization of Debt Issuance Costs, Related Party Amortization of Debt Issuance Costs, Related Party Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Debt instrument, convertible, number of equity instruments Debt Instrument, Convertible, Number of Equity Instruments Equity-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Liabilities, Current Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Capital contribution from related-party in connection with the exchange transaction Debt Conversion, Converted Instrument, Related Party Contributed Capital Debt Conversion, Converted Instrument, Related Party Contributed Capital 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Other current assets Other Assets, Current Customer concentration Customer Concentration Risk [Member] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Revenue expected to be recognized from remaining performance obligations Revenue, Remaining Performance Obligation, Amount Contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Corporate notes and bonds Corporate notes and bonds Corporate Debt Securities [Member] Cumulative effect of accounting changes Cumulative Effect, Period of Adoption, Adjustment [Member] Schedule of Allowance For Credit Losses Accounts Receivable, Allowance for Credit Loss [Table Text Block] Proceeds from issuance of preferred stock Proceeds from Issuance of Preferred Stock and Preference Stock Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Cost capitalized to inventory Share-Based Payment Arrangement, Amount Capitalized Issuance of common stock under employee purchase plan Stock Issued During Period, Value, Employee Stock Ownership Plan Unrealized loss (gain) on equity investments Unrealized (loss) gain on equity investments Unrealized Gain (Loss) on Investments Product and Service [Axis] Product and Service [Axis] Class of Stock [Domain] Class of Stock [Domain] Weighted average remaining lease term finance leases (years) Finance Lease, Weighted Average Remaining Lease Term Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Proceeds from sales of debt securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Inventory Inventory Disclosure [Text Block] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] 2023 Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year One Schedule of Long-term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Equity [Abstract] Equity [Abstract] Released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Debt Conversion Description [Axis] Debt Conversion Description [Axis] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Options Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract] Entity Tax Identification Number Entity Tax Identification Number Schedule of Long-lived Assets by Geographic Territory Long-Lived Assets by Geographic Areas [Table Text Block] Embeded Warrant Embeded Warrant [Member] Embeded Warrant [Member] Outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract] Rescission of common stock (in shares) Stock Redeemed or Called During Period, Shares Debt Conversion, Name [Domain] Debt Conversion, Name [Domain] Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Abstract] Total property and equipment Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Commercial paper Commercial Paper [Member] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Weighted Average Grant Date Fair Value per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Nonqualified Cash Deferral Plan Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block] Measurement Input Type [Axis] Measurement Input Type [Axis] Type of Adoption [Domain] Accounting Standards Update [Domain] City Area Code City Area Code ASSETS Assets [Abstract] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Schuler Family Foundation Schuler Family Foundation [Member] Schuler Family Foundation [Member] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Finance leases Finance Lease, Cost Finance Lease, Cost Loss Per Share Earnings Per Share, Policy [Policy Text Block] 2023 Long-Term Debt, Maturity, Year One Equity-based compensation Share-Based Payment Arrangement, Noncash Expense Less imputed interest Finance Lease, Liability, Undiscounted Excess Amount Other non-current liabilities Other Liabilities, Noncurrent Fair Value Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract] Impairment charges Asset Impairment Charges Thereafter Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four Research and development Research and Development Expense [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Reacquisition costs Debt Conversion, Cost Debt Conversion, Cost Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Cost of sales Cost of Sales [Member] Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies Business Description and Basis of Presentation [Text Block] Customer [Domain] Customer [Domain] EX-101.PRE 10 axdx-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2022
Nov. 10, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 001-31822  
Entity Registrant Name ACCELERATE DIAGNOSTICS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 84-1072256  
Entity Address, Address Line One 3950 South Country Club Road,  
Entity Address, Address Line Two Suite 470  
Entity Address, City or Town Tucson,  
Entity Address, State or Province AZ  
Entity Address, Postal Zip Code 85714  
City Area Code 520  
Local Phone Number 365-3100  
Title of 12(b) Security Common Stock, $0.001 par  
Trading Symbol AXDX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   99,099,480
Entity Central Index Key 0000727207  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2022  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 38,987 $ 39,898
Investments 16,407 23,720
Trade accounts receivable, net 2,393 2,320
Inventory 5,392 5,067
Prepaid expenses 1,119 768
Other current assets 1,974 1,558
Total current assets 66,272 73,331
Property and equipment, net 3,621 5,389
Finance lease assets, net 2,319 0
Operating lease right of use assets, net 2,012 2,510
Other non-current assets 1,623 1,817
Total assets 75,847 83,047
Current liabilities:    
Accounts payable 2,819 1,983
Accrued liabilities 4,300 2,853
Accrued interest 118 909
Deferred revenue 524 451
Current portion of long-term debt 80 80
Finance lease, current 953 0
Operating lease, current 774 669
Total current liabilities 9,568 6,945
Finance lease, non-current 698 0
Operating lease, non-current 1,775 2,381
Other non-current liabilities 759 808
Accrued interest related-party 220 0
Long-term debt related-party 16,299 0
Convertible notes 56,325 107,984
Total liabilities 85,644 118,118
Commitments and contingencies (see Note 14)
Stockholders’ deficit:    
Preferred shares, $0.001 par value; 5,000,000 preferred shares authorized and 3,954,546 outstanding as of September 30, 2022 and December 31, 2021 4 4
Common stock, $0.001 par value; 200,000,000 common shares authorized with 97,240,983 shares issued and outstanding on September 30, 2022 and 100,000,000 common shares authorized with 67,649,018 shares issued and outstanding on December 31, 2021 97 68
Contributed capital 627,853 580,652
Treasury stock (45,067) (45,067)
Accumulated deficit (592,439) (570,668)
Accumulated other comprehensive loss (245) (60)
Total stockholders’ deficit (9,797) (35,071)
Total liabilities and stockholders’ deficit $ 75,847 $ 83,047
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred Stock, par value (in usd per share) $ 0.001 $ 0.001
Preferred Stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred Stock, shares outstanding (in shares) 3,954,546 3,954,546
Common Stock, par value (in usd per share) $ 0.001 $ 0.001
Common Stock, shares authorized (in shares) 200,000,000 100,000,000
Common Stock, shares issued (in shares) 97,240,983 67,649,018
Common Stock, shares outstanding (in shares) 97,240,983 67,649,018
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Net sales $ 2,960,000 $ 3,122,000 $ 9,780,000 $ 8,439,000
Cost of sales 2,190,000 2,136,000 7,127,000 5,502,000
Gross profit 770,000 986,000 2,653,000 2,937,000
Costs and expenses:        
Research and development 7,285,000 4,712,000 20,885,000 17,341,000
Sales, general and administrative 8,255,000 10,806,000 30,422,000 37,744,000
Total costs and expenses 15,540,000 15,518,000 51,307,000 55,085,000
Loss from operations (14,770,000) (14,532,000) (48,654,000) (52,148,000)
Other (expense) income:        
Interest expense (203,000) (4,211,000) (1,833,000) (12,477,000)
Interest expense related-party (495,000) 0 (495,000) 0
Gain on extinguishment of debt 0 9,840,000 3,565,000 9,840,000
Foreign currency exchange loss (261,000) (78,000) (221,000) (238,000)
Interest income 73,000 0 151,000 55,000
Other (expense) income, net (49,000) (5,000) (206,000) 69,000
Total other (expense) income, net (935,000) 5,546,000 961,000 (2,751,000)
Net loss before income taxes (15,705,000) (8,986,000) (47,693,000) (54,899,000)
Provision for income taxes 0 0 0 0
Net loss $ (15,705,000) $ (8,986,000) $ (47,693,000) $ (54,899,000)
Basic net loss per share (in usd per share) $ (0.18) $ (0.15) $ (0.62) $ (0.91)
Diluted net loss per share (in usd per share) $ (0.18) $ (0.15) $ (0.62) $ (0.91)
Weighted average shares outstanding, basic (in shares) 87,011 61,146 77,049 60,250
Weighted average shares outstanding, diluted (in shares) 87,011 61,146 77,049 60,250
Other comprehensive loss:        
Net loss $ (15,705,000) $ (8,986,000) $ (47,693,000) $ (54,899,000)
Net unrealized gain (loss) on debt securities available-for-sale 48,000 (3,000) (84,000) (21,000)
Foreign currency translation adjustment 139,000 (27,000) (101,000) (87,000)
Comprehensive loss $ (15,518,000) $ (9,016,000) $ (47,878,000) $ (55,007,000)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities:    
Net loss $ (47,693) $ (54,899)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 2,207 1,875
Amortization of investment discount 94 153
Equity-based compensation 8,179 19,058
Amortization of debt discount and issuance costs 386 9,250
Amortization of debt discount related-party 275 0
Loss (gain) on disposal of property and equipment 74 (202)
Unrealized loss (gain) on equity investments 206 (39)
Gain on extinguishment of debt (3,565) (9,840)
(Increase) decrease in assets:    
Contributions to deferred compensation plan (174) (304)
Accounts receivable (73) (719)
Inventory (245) (527)
Prepaid expense and other (491) 860
Increase (decrease) in liabilities:    
Accounts payable 1,221 1,017
Accrued liabilities and other 962 (436)
Accrued interest (785) (1,059)
Accrued interest from related-party 220 0
Deferred revenue and income 73 93
Deferred compensation (49) 343
Net cash used in operating activities (39,178) (35,376)
Cash flows from investing activities:    
Purchases of equipment (446) (202)
Purchase of marketable securities (27,506) (22,345)
Maturities of marketable securities 34,527 33,601
Net cash provided by investing activities 6,575 11,054
Cash flows from financing activities:    
Proceeds from issuance of common stock 32,872 22,640
Payments on finance leases (1,109) 0
Proceeds from exercise of options 7 1,456
Proceeds from issuance of common stocks under employee purchase plan 184 245
Transaction costs related to debt exchange (192) 0
Payment of debt (6) (6)
Net cash provided by financing activities 31,756 24,335
Effect of exchange rate on cash (64) (69)
Decrease in cash and cash equivalents (911) (56)
Cash and cash equivalents, beginning of period 39,898 35,781
Cash and cash equivalents, end of period 38,987 35,725
Non-cash investing activities:    
Net transfer of instruments (to) from inventory to property and equipment (78) 508
Non-cash financing activities:    
Extinguishment of convertible senior notes through issuance of common stock 10,180 34,545
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs 49,624 0
Fair value of new note from related-party issued in connection with the exchange transaction 16,024 0
Fair value of common stock warrant issued to related-party in connection with exchange transaction 3,753 0
Capital contribution from related-party in connection with the exchange transaction 29,847 0
Supplemental cash flow information:    
Interest paid $ 2,214 $ 4,288
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)
$ in Thousands
Total
Preferred stock
Common stock
Contributed capital
Contributed capital
Cumulative effect of accounting changes
Accumulated deficit
Accumulated deficit
Cumulative effect of accounting changes
Treasury stock
Accumulated other comprehensive (loss) income
Beginning Balance (in shares) at Dec. 31, 2020   0              
Beginning Balance (in shares) at Dec. 31, 2020     57,608,000            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of stock (in shares)   2,636,000 2,937,000            
Ending Balance (in shares) at Sep. 30, 2021   2,636,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Restricted stock awards released and exercise of options (in shares)     1,052,000            
Issuance of common stock under employee purchase plan (in shares)     37,000            
Rescission of common stock (in shares)     (2,643,000)            
Issuance of shares to retire Convertible Senior Notes (in shares)     5,946,000            
Ending Balance (in shares) at Sep. 30, 2021     64,937,000            
Beginning Balance, amount at Dec. 31, 2020   $ 0 $ 58 $ 475,072   $ (492,966)   $ (45,067) $ 91
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Proceeds from issuance of stock   3 3 22,637          
Restricted stock awards released and exercise of options     1 1,455          
Rescission of common stock     (3)            
Issuance of common stock under employee purchase plan       245          
Issuance of shares to retire convertible notes     6 34,539          
Equity-based compensation       19,186          
Net loss $ (54,899)         (54,899)      
Net unrealized gain (loss) on debt securities available-for-sale (21)               (21)
Foreign currency translation adjustment (87)               (87)
Ending Balance, amount at Sep. 30, 2021 (39,747) $ 3 $ 65 553,134   (547,865)   (45,067) (17)
Beginning Balance (in shares) at Jun. 30, 2021   0              
Beginning Balance (in shares) at Jun. 30, 2021     61,489,000            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of stock (in shares)   2,636,000 67,000            
Ending Balance (in shares) at Sep. 30, 2021   2,636,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Restricted stock awards released and exercise of options (in shares)     62,000            
Issuance of common stock under employee purchase plan (in shares)     16,000            
Rescission of common stock (in shares)     (2,643,000)            
Issuance of shares to retire Convertible Senior Notes (in shares)     5,946,000            
Ending Balance (in shares) at Sep. 30, 2021     64,937,000            
Beginning Balance, amount at Jun. 30, 2021   $ 0 $ 61 514,122   (538,879)   (45,067) 13
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Proceeds from issuance of stock   3 1 517          
Restricted stock awards released and exercise of options       234          
Rescission of common stock     (3)            
Issuance of common stock under employee purchase plan       84          
Issuance of shares to retire convertible notes     6 34,539          
Equity-based compensation       3,638          
Net loss (8,986)         (8,986)      
Net unrealized gain (loss) on debt securities available-for-sale (3)               (3)
Foreign currency translation adjustment (27)               (27)
Ending Balance, amount at Sep. 30, 2021 $ (39,747) $ 3 $ 65 553,134   (547,865)   (45,067) (17)
Beginning Balance (in shares) at Dec. 31, 2021 3,954,546 3,955,000              
Beginning Balance (in shares) at Dec. 31, 2021 67,649,018   67,649,000            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of stock (in shares)     17,500,000            
Ending Balance (in shares) at Sep. 30, 2022 3,954,546 3,955,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Restricted stock awards released and exercise of options (in shares)     1,134,000            
Issuance of common stock under employee purchase plan (in shares)     159,000            
Issuance of shares to retire Convertible Senior Notes (in shares)     10,799,000            
Ending Balance (in shares) at Sep. 30, 2022 97,240,983   97,241,000            
Beginning Balance, amount at Dec. 31, 2021 $ (35,071) $ 4 $ 68 580,652 $ (37,438) (570,668) $ 25,922 (45,067) (60)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Proceeds from issuance of stock     17 32,855          
Restricted stock awards released and exercise of options     1 6          
Issuance of common stock under employee purchase plan       184          
Issuance of shares to retire convertible notes     11 10,169          
Capital contribution from related-party in connection with exchange transaction       29,847          
Warrant issued to related-party       3,753          
Equity-based compensation       7,825          
Net loss (47,693)         (47,693)      
Net unrealized gain (loss) on debt securities available-for-sale (84)               (84)
Foreign currency translation adjustment (101)               (101)
Ending Balance, amount at Sep. 30, 2022 $ (9,797) $ 4 $ 97 627,853   (592,439)   (45,067) (245)
Beginning Balance (in shares) at Jun. 30, 2022   3,955,000              
Beginning Balance (in shares) at Jun. 30, 2022     79,701,000            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of stock (in shares)     17,500,000            
Ending Balance (in shares) at Sep. 30, 2022 3,954,546 3,955,000              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Restricted stock awards released and exercise of options (in shares)     6,000            
Issuance of common stock under employee purchase plan (in shares)     34,000            
Ending Balance (in shares) at Sep. 30, 2022 97,240,983   97,241,000            
Beginning Balance, amount at Jun. 30, 2022   $ 4 $ 80 560,185   (576,734)   (45,067) (432)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Proceeds from issuance of stock     17 32,855          
Issuance of common stock under employee purchase plan       47          
Capital contribution from related-party in connection with exchange transaction       29,847          
Warrant issued to related-party       3,753          
Equity-based compensation       1,166          
Net loss $ (15,705)         (15,705)      
Net unrealized gain (loss) on debt securities available-for-sale 48               48
Foreign currency translation adjustment 139               139
Ending Balance, amount at Sep. 30, 2022 $ (9,797) $ 4 $ 97 $ 627,853   $ (592,439)   $ (45,067) $ (245)
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies
NOTE 1. ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION; SIGNIFICANT ACCOUNTING POLICIES

Accelerate Diagnostics, Inc. (“we” or “us” or “our” or “Accelerate” or the “Company”) is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 14, 2022.

The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date but does not include all disclosures such as notes required by U.S. GAAP.

The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2022, or any future period.

All amounts are rounded to the nearest thousand dollars unless otherwise indicated.

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.

Risk and Uncertainties

The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through multiple equity raises, one convertible debt offering, and Secured Note (as defined in Note 11). The Company is subject to a number of risks similar to other early commercial stage life science companies, including, but not limited to commercially launching the Company’s products, development and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital.

The COVID-19 pandemic, containment measures, and downstream impacts to hospital staffing and financial stability have caused business slowdowns or shutdowns in affected areas, both, as well as disruptions to global supply chains and workforce participation. These effects have significantly impacted the Company’s business and results of operations, starting in the first quarter of 2020 and continuing through the current quarter, albeit to a lesser degree. These impacts include diminished access to the Company’s customers, principally hospitals, which has severely limited the ability to sell or implement products. Furthermore, the expected rate of growth of the Company’s consumable test kit sales has been reduced because of the negative impact of the COVID-19 pandemic on Accelerate Pheno system new sales and implementations. The Company has reviewed its suppliers and quantities of key materials and believes that it has sufficient stocks and alternate sources of critical materials should the supply chains become further disrupted, although raw materials for the manufacturing of
reagents is in high demand, and interruptions in supply are difficult to predict. The COVID-19 pandemic also caused the Company to reassess its build plan and evaluate its inventories accordingly, which resulted in additional charges to cost of sales for excess inventories in the prior year.

The Company may seek to fund its operations through public equity, private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. The Company’s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company’s business, results of operations, financial condition and the Company’s ability to develop new products. To the extent the Company raises additional funds through the sale of equity, issue convertible debt securities or exchange convertible debt for equity, the issuance of securities will result in dilution to stockholders. Investors purchasing shares or other securities in the future could have rights superior to existing stockholders. In addition, the Company has a significant number of options and restricted stock units (“RSUs”) outstanding in addition to the Warrant (as defined in Note 11). If these options or the Warrant are exercised or such RSUs are released, or shares of the Company’s common stock are issued upon conversion of the Company’s outstanding 2.50% Senior Convertible Notes due 2023 (the “Notes”) or Series A Preferred Stock, further dilution may occur.

Liquidity

The Company continues to assess liquidity needs and manage cash flows. As a result of the steps the Company has taken to enhance its liquidity, the Company currently believes that cash on hand and cash flows from operations will enable the Company to meet its working capital, capital expenditure, debt service and other funding requirements for at least one year from the date this Quarterly Report on Form 10-Q (this “Form 10-Q”) is issued. The Company’s view regarding sufficiency of cash and liquidity is primarily based on our financial forecast for 12 months from the date these condensed consolidated financial statements are filed, which is impacted by, among other things, various assumptions regarding demand and sales prices for our products. Our financial forecasts in recent periods have proven less reliable due to conditions created by the pandemic. As a result, there is no guarantee our financial forecast, which projects sufficient cash will be available to meet planned operating expenses and other cash needs, will be accurate. In the event the Company experiences lower customer demand, lower prices for its products and services, or higher expenses than it forecasted or if the Company underperforms relative to its forecast, the Company could experience negative cash flows from operations, as has been the case in prior years, which would reduce its cash balances and liquidity.

Use of Estimates

The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, convertible notes, notes from related parties, tax valuation accounts, equity–based compensation, warrants, revenue and leases. Actual results could differ materially from those estimates.

Estimated Fair Value of Financial Instruments

The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three-tiered approach and fair value measurement be classified and disclosed in one of the following three categories:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

•Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).
The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.

See Note 4, Fair Value of Financial Instruments, for further information and related disclosures regarding the Company’s fair value measurements.

The estimated fair value of the Notes represents a Level 2 measurement. See Note 10, Convertible Notes for further detail on the Notes.

The long-term debt with a related-party consisting of the Secured Note (as defined in Note 11) and the Warrant are instruments measured at fair value on a non-recurring basis using Level 3 inputs. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note and the Warrant.

Cash and Cash Equivalents

All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.

Investments

The Company invests in various debt and equity securities which are primarily held in the custody of major financial institutions. Debt securities consist of certificates of deposit, U.S. government and agency securities, commercial paper, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ deficit. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of condensed consolidated statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.

We perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security is considered impaired if its fair value is less than its amortized cost basis at the reporting date. If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security.

Inventory

Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.
We charge cost of sales for inventory provisions to write-down our inventory to the lower of cost or net realizable value or for obsolete or excess inventory. Most of our inventory provisions relate to excess quantities of products, based on our inventory levels and future product purchase commitments compared to assumptions about future demand and market conditions. Once inventory has been written-off or written-down, it creates a new cost basis for the inventory that is not subsequently written-up.

See Note 6, Inventory, for further information and related disclosures.

Accounts Receivable

Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.

We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. Our customers typically have good credit quality. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data.

The allowance for credit losses for the three and nine months ended September 30, 2022 and 2021 is comprised of the following (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Beginning balance$150 $213 140 445 
(Reversals) provisions, net
(12)78 18 114 
Write-offs
— (77)(20)(345)
$138 $214 $138 $214 

The write-offs recorded during the nine months ended September 30, 2021 were in connection with a one-time restructuring activity of the Company's Europe, Middle East and Africa (“EMEA”) business. These credit losses were incurred as part of the Company terminating agreements with select distributors in geographies it exited and did not pursue collection of these accounts receivables.

Property and Equipment

Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.

Instruments Classified as Property and Equipment

Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.
The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of for the three and nine months ended September 30, 2022.

See Note 7, Property and Equipment, for further information and related disclosures.

Long-lived Assets

Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.

Warranty Reserve

Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The cost incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.

Warranty reserve activity for the three and nine months ended September 30, 2022 and 2021 is as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Beginning balance$255 $169 $139 $232 
Provisions (reversals), net
(4)(31)134 (41)
Warranty cost incurred
(29)(17)(51)(70)
Ending balance$222 $121 $222 $121 

Convertible Notes

On January 1, 2022 the Company adopted Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. Gain or loss on extinguishment of Notes is calculated as the difference between the (i) fair value of the consideration transferred and (ii) the sum of the carrying value of the debt at the time of repurchase.

The Company classifies the Notes as a non-current liability as the Company has sufficient shares and non-cash alternatives to settle the Notes.

See Note 2, Recently Issued Accounting Pronouncements and Note 10, Convertible Notes, for further information and related disclosures.
Revenue Recognition

The Company recognizes revenue when control of the promised good or service is transferred to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.

The Company determines revenue recognition through the following steps:

•Identification of the contract with a customer
•Identification of the performance obligations in the contract
•Determination of the transaction price
•Allocation of the transaction price to the performance obligations
•Recognition of revenue as we satisfy a performance obligation

Product revenue is derived from the sale or rental of instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized. Payment terms vary by the type and location of the customer and the products or services offered. The term between invoicing and when payment is due is not significant.

Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The Company generally determines relative standalone selling prices based on the price charged to customers for each individual performance obligation.

Sales commissions earned by the Company’s sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and nine months ended September 30, 2022.

Gross Profit and Gross Margin

Gross profit consists of total revenue, net of allowances, less cost of sales. Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related costs.

The Company’s overall gross margin was 26% and 32% for the three months ended September 30, 2022 and 2021, respectively, and 27% and 35% for the nine months ended September 30, 2022 and 2021, respectively. The decreases were primarily due to increases in the costs to manufacture consumables due to supply chain inflationary factors and a decrease in our average unit sales price period over period.

Shipping and Handling

Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the consolidated statements of operations and comprehensive loss.
Leases

The Company accounts for leases in accordance with ASC 842, Leases. The Company determines if an arrangement is or contains a lease and the type of lease at inception. The Company classifies leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.

To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.

Leases as Lessee

Operating leases are included in right-of-use (“ROU”) assets and corresponding lease liabilities, and finance leases are included in ROU assets and corresponding lease liabilities within our condensed consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option.

Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between two and six-year terms, and typically contain penalizing, early-termination provisions. Our finance leases consist of leased equipment and have three-year terms.

Leases as Lessor

The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.

Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.

Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.

Nonqualified Cash Deferral Plan

The Company's Cash Deferral Plan (the “Deferral Plan”) provides certain key employees with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of
the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments’ fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet.

Equity-Based Compensation

The Company may award stock options, RSUs, performance-based awards and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.

The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.

•Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.

•Expected term: The estimated expected term for employee awards is based on a simplified method that considers an insufficient history of employee exercises. For consultant awards, the estimated expected term is the same as the life of the award.

•Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.

•Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.

The Company records the fair value of RSUs or stock grants based on the published closing market price on the day before the grant date.

The Company accounts for forfeitures as they occur rather than on an estimated basis.

The Company also has an employee stock purchase program whereby eligible employees can elect payroll deductions that are subsequently used to purchase common stock at a discounted price. There is no compensation recorded for this program as (i) the purchase discount does not exceed the issuance costs that would have been incurred to raise a significant amount of capital by a public offering, (ii) substantially all employees that meet limited employment qualifications may participate on an equitable basis, and (iii) the plan doesn't incorporate option features that would require compensation to be recorded.

See Note 13, Employee Equity-Based Compensation for further information.

Deferred Tax

Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying condensed consolidated balance sheet. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.

The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more
likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.

Foreign Currency Translation and Foreign Currency Transactions

Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive loss in the condensed consolidated statements of stockholders’ deficit.

The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.

Loss Per Share

Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options, unvested RSUs and the Warrant. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes and the Series A Preferred Stock outstanding at the balance sheet date were converted and shares issuable in connection with the March 2022 Securities Purchase Agreement (as defined in Note 18). Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.

See Note 12, Loss Per Share, for further information.

Comprehensive Loss

In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds debt securities as available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recently Issued Accounting Pronouncements
 9 Months Ended
Sep. 30, 2022
Accounting Changes and Error Corrections [Abstract]  
Recently Issued Accounting Pronouncements
NOTE 2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Standards that were recently adopted

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). This update simplifies the accounting for convertible debt instruments by removing the beneficial conversion and cash conversion separation models for convertible instruments. Under the update, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives or that do not result in substantial premiums accounted for as paid-in capital. The update also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will no longer be available. The Company adopted the standard on January 1, 2022 through application of the modified retrospective method of transition. The Company applied the standard to the Notes outstanding as of January 1, 2022, as discussed in Note 10, Convertible Notes. As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. On January 1, 2022, the cumulative effect of adoption resulted in an increase in the net carrying amount of the Notes, of $11.5 million, a decrease in additional-paid-in-capital of $37.4 million, and a decrease in accumulated deficit of $25.9 million. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share. This change has no impact on the Company given the Company was already using the if-converted method to calculate diluted earnings per share.
In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity’s Own Equity (Topic 815 - 40). ASU 2021-04 codifies the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This ASU was adopted January 1, 2022, and did not impact the Company's consolidated financial statements at January 1, 2022.

Standards not yet adopted

In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. ASU 2022-01 is related to the portfolio layer method of hedge accounting. The amendments in this update clarify the accounting and promote consistency in reporting for hedges where the portfolio layer method is applied. This update is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. We do not expect the update to have a material effect on our condensed consolidated financial statements.

In March 2022, the FASB issued ASU 2022-02, Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. ASU 2022-02 relates to troubled debt restructurings (“TDRs”) and vintage disclosures for financing receivables. The amendments in this update eliminate the accounting guidance for TDRs by creditors while enhancing disclosure requirements for certain loan refinancing and restructurings by creditors made to borrowers experiencing financial difficulty. The amendments also require disclosure of current-period gross write-offs by year of origination for financing receivables. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not expect the update to have a material effect on our condensed consolidated financial statements.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Concentration of Credit Risk
 9 Months Ended
Sep. 30, 2022
Risks and Uncertainties [Abstract]  
Concentration of Credit Risk
NOTE 3. CONCENTRATION OF CREDIT RISK

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable.

The Company has financial institutions for banking operations that hold 10% or more of the Company’s cash and cash equivalents. As of September 30, 2022, three of the Company's financial institutions held 74%, 12% and 13% of the Company’s cash and cash equivalents. As of December 31, 2021, two of the Company's financial institutions held 72% and 13% of the Company’s cash and cash equivalents.

The Company grants credit to domestic and international customers. Exposure to losses on accounts receivable is principally dependent on each client's financial position. The Company had one customer that accounted for 16% and 13% of the Company’s net accounts receivable balance as of September 30, 2022 and December 31, 2021, respectively.

The Company did not have any customers that represented 10% or more of the Company’s total revenue for the three and nine months ended September 30, 2022 and 2021.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments
NOTE 4. FAIR VALUE OF FINANCIAL INSTRUMENTS

The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Cash and cash equivalents:
Money market funds$5,145 $— $— $5,145 
Total cash and cash equivalents5,145 — — 5,145 
Equity investments:
Mutual funds808 — — 808 
Total equity investments808 — — 808 
Debt securities available-for-sale:
Certificates of deposit— 3,382 — 3,382 
U.S. Treasury securities5,228 — — 5,228 
Commercial paper— 2,893 — 2,893 
Corporate notes and bonds— 4,096 — 4,096 
Debt securities available-for-sale5,228 10,371 — 15,599 
Total assets measured at fair value$11,181 $10,371 $— $21,552 

December 31, 2021
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Cash and cash equivalents:
Money market funds$5,563 $— $— $5,563 
Commercial paper— 200 — 200 
Total cash and cash equivalents5,563 200 — 5,763 
Equity investments:
Mutual funds841 — — 841 
Total equity investments841 — — 841 
Debt securities available-for-sale:
Certificates of deposit— 1,351 — 1,351 
U.S. Treasury securities250 — — 250 
Commercial paper— 8,046 — 8,046 
Corporate notes and bonds— 13,232 — 13,232 
Debt securities available-for-sale250 22,629 — 22,879 
Total assets measured at fair value$6,654 $22,829 $— $29,483 
Highly liquid investments with an original maturity of three months or less at time of purchase are included in cash and cash equivalents on the condensed consolidated balance sheet.

Level 1 assets are priced using quoted prices in active markets for identical assets which include money market funds, U.S. Treasury securities and mutual funds as these specific assets are liquid.

Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.

At September 30, 2022, the Notes had an outstanding principal amount of $56.6 million with a fair value of $51.7 million. At December 31, 2021, the Notes had an outstanding principal amount of $120.5 million with a fair value of $89.4 million. The fair value of the Notes represents a Level 2 measurement. The fair value of the Notes is typically correlated to the Company’s stock price and as a result, significant changes to the Company’s stock price will have a significant impact on the calculated fair value. See Note 10, Convertible Notes for further detail on the Notes.

The Secured Note is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. The estimated fair value of the Secured Note on August 15, 2022 was $16.0 million. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note.

The warrant is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. The estimated fair value of the warrant on August 15, 2022 was $3.8 million. See Note 11, Long-Term Debt Related-Party for further detail on the Company’s warrant with a related-party.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Investments
NOTE 5. INVESTMENTS

The following tables summarize the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
Certificates of deposit$3,400 $— $(18)$3,382 
U.S. Treasury securities5,266 — (38)5,228 
Commercial paper2,901 — (8)2,893 
Corporate notes and bonds4,131 — (35)4,096 
Total$15,698 $— $(99)$15,599 

December 31, 2021
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
Certificates of deposit$1,351 $— $— $1,351 
U.S. Treasury securities250 — — 250 
Commercial paper8,048 — (2)8,046 
Corporate notes and bonds13,245 — (13)13,232 
Total$22,894 $— $(15)$22,879 
The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022December 31, 2021
Amortized
Cost		Fair ValueAmortized
Cost		Fair Value
Due in less than 1 year$15,698 $15,599 $22,663 $22,649 
Due in 1-3 years— — 231 230 
Total
$15,698 $15,599 $22,894 $22,879 

There were no proceeds from sales of debt securities available-for-sale (including principal paydowns) for the three and nine months ended September 30, 2022 and 2021. The Company determines gains and losses of marketable securities based on specific identification of the securities sold. There were no material realized gains or losses from debt securities available-for-sale for the three and nine months ended September 30, 2022 and 2021. No material balances were reclassified out of accumulated other comprehensive income (loss) for the three and nine months ended September 30, 2022 and 2021. No unrealized losses on debt securities available-for-sale have been recognized in income for the three and nine months ended September 30, 2022 and 2021, as the issuers of such securities held by us were of high credit quality.

As of September 30, 2022, there were no holdings of debt securities available-for-sale of any one issuer, other than the U.S. government, in an amount greater than 10%.

As of September 30, 2022 the Company did not carry any debt securities available-for-sale that were below the Company's minimum credit rating. All debt securities available-for-sale had a credit rating of A- or better as of September 30, 2022.

Equity securities are comprised of investments in mutual funds. The fair value of equity securities for each of the periods ended September 30, 2022 and December 31, 2021 was $0.8 million.

Unrealized losses or gains on equity securities recorded in income during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Unrealized (loss) gain on equity investments$(50)$(5)$(206)$39 

These unrealized gains or losses are recorded as a component of other income (expense), net. There were no realized gains or losses from equity securities for each of the three and nine months ended September 30, 2022 and 2021.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventory
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Inventory
NOTE 6. INVENTORY

Inventories consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

September 30,December 31,
20222021
Raw materials$1,769 $1,343 
Work in process2,133 1,625 
Finished goods1,490 2,099 
$5,392 $5,067 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment
 9 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
Property and Equipment
NOTE 7. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

September 30,December 31,
20222021
Computer equipment$3,866 $3,181 
Technical equipment3,259 3,285 
Facilities3,674 3,675 
Instruments3,594 5,364 
Capital projects in progress48 683 
Total property and equipment$14,441 $16,188 
Accumulated depreciation(10,820)(10,799)
Property and equipment, net$3,621 $5,389 

Depreciation expense for the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Depreciation expense$381 $487 $1,284 $1,540 

Instruments at cost and accumulated depreciation where the Company is the lessor under operating leases consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

September 30,December 31,
20222021
Instruments at cost under operating leases$2,452 $3,110 
Accumulated depreciation under operating leases(1,109)(1,165)
Net property and equipment under operating leases$1,343 $1,945 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Deferred Revenue and Remaining Performance Obligations
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Deferred Revenue and Remaining Performance Obligations
NOTE 8. DEFERRED REVENUE AND REMAINING PERFORMANCE OBLIGATIONS

Deferred revenue consists of amounts received for products or services not yet delivered or earned. If we anticipate revenue will not be earned within the following twelve months, the amount is reported as other non-current liabilities. A summary of the balances as of September 30, 2022 and December 31, 2021 follows (in thousands):

September 30,December 31,
20222021
Products and services not yet delivered$524 $451 

We recognized $0.2 million and $0.4 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2022, respectively, and $0.1 million and $0.3 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2021, respectively. No material amount of revenue recognized during the period was from performance obligations satisfied in prior periods.
Transaction Price Allocated to Remaining Performance Obligations

As of September 30, 2022, $9.0 million of revenue is expected to be recognized from remaining performance obligations. This balance primarily relates to product shipments for reagents sold to customers under sales-type lease agreements. These agreements have between two and four year terms and revenue is recognized as product is shipped, typically on a straight-line basis. The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis.

The Company elects not to disclose the value of unsatisfied performance obligations for (i) contracts with an expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Long-Term Debt
NOTE 9. LONG-TERM DEBT

The Company entered into two loan agreements with one financing company in 2020. Loan proceeds were $0.2 million, with interest rates ranging from 9.8% to 12.4% and maturities becoming due through 2022.

As of September 30, 2022 and December 31, 2021, long-term debt consisted of the following (in thousands):

September 30,December 31,
20222021
Loans - various interest$80 $80 
Current portion of long-term debt80 80 
Long-term debt$— $— 

The following presents maturities of future principal obligations of long-term debt as of September 30, 2022 (in thousands):

Remainder of 2022$80 
2023— 
2024— 
2025— 
2026— 
Thereafter— 
Total$80 

Paycheck Protection Program (PPP) Loan

On April 14, 2020, the Company entered into a promissory note (the “PPP Note”) evidencing an unsecured loan in the amount of $4.8 million made to the Company under the Paycheck Protection Program (“PPP”) established under the Coronavirus Aid, Relief, and Economic Security Act.

On July 15, 2021, the Small Business Administration (“SBA”) informed the Company of its full forgiveness for the entire PPP Note amount plus accrued interest, which was $4.8 million as of the date of forgiveness. The SBA’s determination of loan forgiveness does not preclude further investigation by the SBA according to its rules and regulations. With approval of the Company's application for forgiveness the Company recorded a gain on extinguishment of the entire PPP Note amount of $4.8 million during the three and nine months ended September 30, 2021.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Convertible Notes
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Convertible Notes
NOTE 10. CONVERTIBLE NOTES

The Notes are the Company’s senior unsecured obligations and mature on March 15, 2023 (the “Maturity Date”), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. Upon conversion of the Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of common stock, at the Company’s election. The initial conversion rate of the Notes is 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock, subject to adjustment. The Company pays interest on the Notes semi-annually in arrears on March 15 and September 15 of each year. The Company’s Notes have a fixed coupon rate of 2.5% per annum on the principal amount.

The Company incurred issuance costs related to the issuance of the Notes which is amortized over the five-year contractual term of the Notes using the effective interest method. The effective interest rate on the Notes, including accretion of the Notes to par was 3.2%.

The Notes include customary terms and covenants, including certain events of default upon which the Notes may be due and payable immediately. Holders have the option to convert the Notes in multiples of $1,000 principal amount at any time prior to December 15, 2022, but only in the following circumstances:

•if the Company’s stock price exceeds 130% of the conversion price for 20 of the last 30 trading days of any calendar quarter after June 30, 2018;

•during the 5 business day period after any 5 consecutive trading day period in which the Notes’ trading price is less than 98% of the product of the common stock price times the conversion rate; or

•the occurrence of certain corporate events, such as a change of control, merger or liquidation.

At any time on or after December 15, 2022, a holder may convert its Notes in multiples of $1,000 principal amount. Holders of the Notes who convert their Notes in connection with a make-whole fundamental change (as defined in the Indenture pursuant to which the Notes were issued) are, under certain circumstances, entitled to an increase in the conversion rate. In addition, in the event of a fundamental change or event of default prior to the Maturity Date, holders will, subject to certain conditions, have the right, at their option, to require the Company to repurchase for cash all or part of the Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest up to, but excluding, the repurchase date. As of September 30, 2022 and December 31, 2021, no Notes were convertible pursuant to their original terms.

Interest expense during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual coupon interest$79 $1,024 $1,528 $3,168 
Amortization of debt issuance costs121 185 386 539 
Amortization of the debt discount— $2,987 $— $8,711 
Total interest expense on convertible notes$200 $4,196 $1,914 $12,418 

Gain on extinguishment of exchanged Notes during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Gain on extinguishment$— $4,999 $3,565 $4,999 
The carrying value of the Notes at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal at par
$56,595 
Unamortized debt issuance(270)
Net carrying amount
$56,325 

In connection with the Notes issuance, the Company entered into a prepaid forward stock repurchase transaction (“Prepaid Forward”) with a financial institution (“Forward Counterparty”). Pursuant to the Prepaid Forward, the Company used approximately $45.1 million of the net proceeds from its issuance of the Notes to fund the Prepaid Forward. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The expiration date for the Prepaid Forward is March 15, 2023, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. The Company’s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.

2021 Exchange Transactions

In September 2021, the Company entered into separate exchange agreements with certain holders of the Notes. Under the terms of the exchange agreements, such holders agreed to exchange Notes held by them for shares of the Company’s common stock (the “2021 Exchange Transactions”). During the nine months ended September 30, 2021, such holders exchanged $46.0 million in aggregate principal amount of Notes held by them for 5,945,718 shares of the Company’s common stock. The net carrying value of the Notes exchanged was $40.4 million which the Company repurchased for $34.5 million of common stock. The Company also incurred $0.8 million of reacquisition costs, which was recorded as an offset to gain on extinguishment of debt. The 2021 Exchange Transaction resulted in a net gain of $5.0 million reflected in other income (expense), net for the three and nine months ended September 30, 2021. See Note 18, Stockholders' Equity for additional information.

March 2022 Exchange Transaction

On March 21, 2022, the Company entered into a privately negotiated exchange agreement (the “March 2022 Exchange Agreement”) with a holder of the Notes. Under the terms of the March 2022 Exchange Agreement, the note holder agreed to exchange with the Company $14.0 million in aggregate principal amount of Notes held by it in eight equal tranches as follows for each tranche: (a) 22.64 shares per $1,000 principal amount of Notes exchanged, plus (b) an additional number of shares of the Company’s common stock per $1,000 principal amount of Notes exchanged equal to the sum, for each of the trading days during a separate agreed upon reference period for each tranche commencing on March 21, 2022 for the first tranche, of the quotient of (i) $155.67 divided by (ii) the daily volume-weighted average price for such trading day (collectively, the “March 2022 Exchange Transaction”). The closing of the March 2022 Exchange Transaction occurred in eight tranches (“Obligation to Exchange”), with the first closing occurring on March 29, 2022 and the last closing on May 18, 2022.

On March 21, 2022 the Obligation to Exchange the $14.0 million of Notes in the March 2022 Exchange Transaction was accounted for as an extinguishment and was replaced by new notes with an embedded feature (the “New Notes”). The New Notes were elected to be carried using the fair value option. The New Notes were recorded at fair value on initial measurement and remeasured at fair value (“mark to market”) at each reporting period with changes in fair value reported in other income and expense, net. This fair value election was exclusive to the New Notes and did not extend to other Notes. The embedded feature was no longer outstanding on September 30, 2022 as the New Notes were exchanged and the Obligation to Exchange retired on May 18, 2022.
During the nine months ended September 30, 2022 the holder of the Notes exchanged $14.0 million in aggregate principal amount of Notes held by it for 10,798,482 shares of the Company’s common stock pursuant to the March 2022 Exchange Agreement. The net carrying value of the Notes exchanged was $14.0 million which the Company repurchased for $10.2 million of common stock. The Company also incurred $0.2 million of reacquisition costs, which was recorded as an offset to gain on extinguishment of debt. This exchange transaction resulted in a net gain of $3.6 million reflected in other income (expense), net for the nine months ended September 30, 2022. See Note 18, Stockholders' Equity for additional information.

August 2022 Exchange Transaction

On August 15, 2022, the Company entered into an exchange agreement (the “August 2022 Exchange Agreement”) with the Jack W. Schuler Living Trust (the “Schuler Trust”), as discussed in Note 11, Long-Term Debt Related-Party. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) the Secured Note in an aggregate principal amount of $34.9 million and (b) the Warrant to acquire the Company’s common stock.

Under ASC 470-50-40, the transaction qualified as an extinguishment of debt. Under extinguishment accounting, the Notes were derecognized and the new instruments, which include the Secured Note and the Warrant, were recorded at their fair values. The difference between the fair values of the new instruments and the net carrying amount of the Notes being extinguished was included in the calculation of gain. The gain from the extinguishment of the Notes was treated as a capital transaction. The Secured Note includes various features that were advantageous to the Company, including a lower interest rate compared to current market rates and a share conversion feature. There were no other negotiating parties that had similar terms or economic outcomes. As such, the exchange was considered not to be an arm’s length transaction, and therefore the resulting gain was accounted for as a capital transaction. The net carrying amount of the extinguished Notes was $49.6 million. The estimated fair value of the Secured Note and the Warrant on August 15, 2022 was $16.0 million and $3.8 million, respectively, which resulted in a net gain of $29.8 million that was recorded to contributed capital. See Note 18, Stockholders' Equity and Note 11, Long-Term Debt Related-Party for additional information.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt Related-Party
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Long-Term Debt Related-Party
NOTE 11. LONG-TERM DEBT RELATED-PARTY

On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust, a holder of the Notes. Jack Schuler, who serves as a member of the Company’s board of directors, is the sole trustee of the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) a secured promissory note in an aggregate principal amount of $34.9 million (the “Secured Note”) and (b) a Warrant to acquire the Company’s common stock at an exercise price of $2.12 per share (the “Warrant”).

The Secured Note has a scheduled maturity date of August 15, 2027 and will be repayable upon written demand at any time on or after such date. The Company may, at its option, repay the note in (i) cash or (ii) in the form of common stock of the Company, in a number of shares that is obtained by dividing the total amount of such payment by $2.12. The Secured Note bears interest at a rate of 5.0% per annum, payable at the option of the Company in the same form, at the earlier of (i) any prepayment of principal and (ii) maturity. The Company may prepay the Secured Note at any time without premium or penalty. The Secured Note is secured by substantially all of the assets of the Company, subject to customary exceptions and limitations, pursuant to a security agreement, dated as of August 15, 2022. The Secured Note does not restrict the incurrence of future indebtedness by the Company but shall become subordinated in right of payment and lien priority upon the request of any future senior lender.

Under ASC 470-50-40, the transaction qualified as an extinguishment of debt. Under extinguishment accounting, the Notes were derecognized and the new instruments, which include the Secured Note and the Warrant, were recorded at their fair values. See Note 10, Convertible Notes for additional information. The Secured Notes is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. To estimate the Secured Note’s fair value, the Company applied a Monte Carlo simulation which simulated the share price of the Company over the remaining term to the maturity date of the Secured Note. The simulated per-share price in a given iteration determined if the Company settled in cash or shares. The estimated fair value of the Secured Note on August 15, 2022 was $16.0 million. This valuation estimated an issuance discount of $18.9 million. The effective interest rate on the Secured Note is 24.60%.
The carrying value of the Secured Note at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal
$34,934 
Unamortized debt issuance discount
(18,635)
Net carrying amount
$16,299 

Interest expense in connection with the Secured Note during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual interest
$220 $— $220 $— 
Amortization of the debt discount275 — 275 — 
Total interest expense
$495 $— $495 $— 

Warrant

The Warrant may be exercised from February 15, 2023 through the earlier of (i) August 15, 2029 and (ii) the consummation of certain acquisition transactions involving the Company, as set forth in the Warrant. The Warrant is exercisable for up to 2,471,710 shares of common stock. The Warrant meets the criteria for classification in stockholders’ equity and was recorded in equity and initially measured at fair value. The Warrant was measured at fair value on a non-recurring basis using Level 3 inputs. The fair value of the warrant on August 15, 2022 was $3.8 million.

The table below summarizes the inputs used to calculate the estimated fair value of the Warrant issued during the three months ended September 30, 2022:

Contractual term (in years)
7.0
Volatility76.10 %
Expected dividends— 
Risk free interest rates2.86 %
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Loss Per Share
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Loss Per Share
NOTE 12. LOSS PER SHARE

Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share are the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive due to the Company’s losses.

The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Shares issuable upon the release of RSUs4,619 2,320 4,619 2,320 
Shares issuable upon exercise of stock options5,665 7,634 5,665 7,634 
Shares issuable upon the exercise of the Warrant2,472 — 2,472 — 
12,756 9,954 12,756 9,954 

Potentially dilutive common shares would include common shares that would be outstanding if Notes convertible at the balance sheet date were converted. As discussed in Note 10, Convertible Notes, upon conversion of the Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of common stock, at the Company’s election. The initial conversion rate of the Notes is 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock. As of September 30, 2022, no Notes were convertible pursuant to the original terms. The number of shares of common stock issuable upon conversion of the outstanding Notes based on the initial conversion rate was approximately 1,830,441 shares as of September 30, 2022. Historically the Company has engaged in privately negotiated exchanges of Notes for a substantially greater number of shares than the initial conversion rate of the Notes described above because the Company’s stock price at the time of such exchanges was significantly less than the $30.92 initial conversion price of the Notes.

In connection with the Notes, the Company entered into a prepaid forward stock repurchase transaction. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company.

Potentially dilutive common shares include common shares that would be outstanding if Series A Preferred Stock were converted into common stock. Each share of Series A Preferred Stock is convertible, at the option of the holder, at any time into one share of the Company’s common stock. Additionally, each share of Series A Preferred Stock will automatically be converted into one share of the Company’s common stock immediately upon a sale of all outstanding stock of the Company or a merger of the Company into another corporation where the pre-merger Company’s stockholders cease to be the controlling stockholders of the post-merger corporation. The number of shares of common stock issuable upon conversion of the Series A Preferred Stock is 3,954,546 as of September 30, 2022.

As discussed in Note 18, Stockholders' Equity, the Company entered into a securities purchase agreement with the Schuler Trust for the issuance and sale by the Company of an aggregate of 2,439,024 shares of the Company’s common stock. The closing of the transaction is expected to occur on December 30, 2022, subject to the satisfaction of customary closing conditions and is considered an equity forward agreement. The shares to be issued from this agreement were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses.

As discussed in Note 11, Long-Term Debt Related-Party, the Company may, at its option, repay the Secured
Note in (i) cash or (ii) in the form of common stock of the Company, in a number of shares that is obtained by dividing the total amount of such payment by $2.12. The number of shares of common stock issuable upon conversion of the Secured Note and accrued interest was approximately 16,478,066 and 103,834 shares respectively, as of September 30, 2022. The shares issuable in connection with a repayment of the Secured Note were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Employee Equity-Based Compensation
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Employee Equity-Based Compensation
NOTE 13. EMPLOYEE EQUITY-BASED COMPENSATION

The following table summarizes option activity under the Company's equity-based compensation plans for the nine months ended September 30, 2022:

Number of SharesWeighted Average Exercise Price per Share
Options outstanding January 1, 20227,192,540 $13.89 
Granted140,000 3.05 
Forfeited(204,232)12.49 
Exercised(6,105)1.04 
Expired(1,457,019)10.33 
Options outstanding September 30, 20225,665,184 $14.60 

No stock options were granted during the three months ended September 30, 2022 and 2021.

The following table shows summary information for outstanding options and options that are exercisable (vested) as of September 30, 2022:

Options
Outstanding		Options
Exercisable
Number of options5,665,184 4,422,595 
Weighted average remaining contractual term (in years)5.545.04
Weighted average exercise price$14.60 $15.32 
Weighted average fair value$9.10 $9.44 
Aggregate intrinsic value (in thousands)$— $— 

The following table summarizes RSU and restricted stock award activity for the nine months ended September 30, 2022:

Number of SharesWeighted Average Grant Date Fair Value per Share
Outstanding January 1, 20222,090,182 $10.77 
Granted4,107,083 1.55 
Forfeited(451,703)8.68 
Released(1,127,017)3.43 
Outstanding September 30, 20224,618,545 $4.57 
The table below summarizes equity-based compensation expense for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost of sales$167 $82 $570 $257 
Research and development151 266 1,052 4,340 
Sales, general and administrative911 3,281 6,557 14,461 
$1,229 $3,629 $8,179 $19,058 

The table below summarizes share-based compensation cost capitalized to inventory for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost capitalized to inventory
$69 $77 $186 $319 

As of September 30, 2022, unrecognized equity-based compensation expense related to unvested stock options and unvested RSUs was $2.3 million and $7.8 million, respectively. This is expected to be recognized over the years 2022 through 2027.

Included in the above-noted stock options outstanding and stock compensation expense are performance-based stock options which vest only upon the achievement of certain targets. Performance-based stock options are generally granted at-the-money, contingently vest over a period of 1 to 2 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These options were valued in the same manner as the time-based options, with the assumption that performance goals will be achieved. The inputs for expected volatility, expected dividends, and risk-free rate used in estimating those options’ fair value are the same as the time-based options issued under the Company's equity incentive plans. The expected term for performance-based stock options is 5 to 7 years. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.

During 2020, the Company granted 105,000 performance-based stock options. Of these performance-based stock options, performance obligations had been met for 90,000 options which became exercisable in a prior period. Of these performance-based stock options, 90,000 options expired during the nine months ended September 30, 2022. No performance-based stock options were outstanding as of September 30, 2022.

The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2022 and 2021 (in thousands):

Nine Months Ended September 30,
20222021
Performance-based stock option expense
$— $230 

Included in the above-noted RSU and restricted stock award outstanding amounts are performance-based RSUs which vest only upon the achievement of certain targets. Performance-based RSUs contingently vest over a period of 1 to 3 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These units were valued in the same manner as other RSUs, based on the published closing market price on the day before the grant date. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.

During 2020, the Company granted performance-based RSUs of which 165,974 were outstanding as of September 30, 2022. No changes occurred during the nine months ended September 30, 2022.

During 2021, the Company granted performance-based RSUs of which 111,806 were outstanding as of September 30, 2022. No changes occurred during the nine months ended September 30, 2022.
The table below summarizes share-based compensation cost in connection with performance-based RSUs for the nine months ended September 30, 2022 and 2021 (in thousands):

Nine Months Ended September 30,
20222021
Performance-based RSU expense
$— $818 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes
NOTE 14. INCOME TAXES

For the nine months ended September 30, 2022, the Company did not carry an income tax provision amount as the Company does not recognize tax benefits from current year tax losses in the U.S. and other foreign jurisdictions. The Company’s tax expense for the nine months ended September 30, 2022 differs from the tax expense computed by applying the U.S. statutory tax rate to its year-to-date pre-tax loss of $47.7 million, as no tax benefits were recorded for tax losses generated in the U.S. and other foreign jurisdictions due to the valuation allowance. At September 30, 2022, the Company had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards and a deferred tax liability related to amortization of the Notes. The Company provided a valuation allowance against its net deferred tax assets as future realization of such assets is not more likely than not to occur.

The Company accounts for uncertain tax positions pursuant to the recognition and measurement criteria under ASC 740, Income Taxes. For the three and nine months ended September 30, 2022, we did not note any significant changes to our uncertain tax positions. We do not anticipate significant changes to uncertain tax positions within the next 12 months.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments
NOTE 15. COMMITMENTS

During April 2022, the Company entered into a non-cancellable purchase obligation with a supplier to acquire raw materials for a total commitment of $11.9 million. Under the terms of this agreement the Company has until March 15, 2027 to take delivery of purchased items. This commitment was entered into to ensure proper material quantities to develop and commercialize our next generation AST platform.

As of September 30, 2022 the commitment remains $11.9 million as the Company has not taken delivery of any inventory.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases
 9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Leases
NOTE 16. LEASES

The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cash paid for amounts included in lease liabilities:
Operating cash flows from operating leases$219 $195 $712 $502 
Operating cash flows from finance leases$684 $— $1,109 $— 
ROU assets obtained in exchange for lease obligations:
Operating leases$— $— $— $— 
Finance leases$— $— $2,760 $— 
Lease Cost:
Operating leases$254 $257 $818 $816 
Finance leases
$240 $— $462 $— 
Short-term leases$26 $40 $67 $99 

The weighted average remaining lease term on our operating leases is 2.8 years. The weighted average discount rate on those leases is 7.1%. The weighted average remaining lease term on our finance leases is 2.5 years. The weighted average discount rate on those leases is 4.6%.

The following presents maturities of lease liabilities in which we are the lessee as of September 30, 2022 (in thousands):

Operating
Finance
Remainder of 2022
$227 $180 
2023968 721 
20241,047 721 
2025584 173 
2026— — 
Thereafter— — 
Total lease payments2,826 1,795 
Less imputed interest(278)(144)
$2,548 $1,651 
The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of September 30, 2022, the total net investment in these leases was $3.0 million. The following presents maturities of lease receivables under sales-type leases as of September 30, 2022 (in thousands):

Remainder of 2022$351 
20231,154 
2024661 
2025206 
2026640 
Thereafter— 
Total undiscounted cash flows3,012 
Less imputed interest— 
Present value of lease payments$3,012 
Leases
NOTE 16. LEASES

The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cash paid for amounts included in lease liabilities:
Operating cash flows from operating leases$219 $195 $712 $502 
Operating cash flows from finance leases$684 $— $1,109 $— 
ROU assets obtained in exchange for lease obligations:
Operating leases$— $— $— $— 
Finance leases$— $— $2,760 $— 
Lease Cost:
Operating leases$254 $257 $818 $816 
Finance leases
$240 $— $462 $— 
Short-term leases$26 $40 $67 $99 

The weighted average remaining lease term on our operating leases is 2.8 years. The weighted average discount rate on those leases is 7.1%. The weighted average remaining lease term on our finance leases is 2.5 years. The weighted average discount rate on those leases is 4.6%.

The following presents maturities of lease liabilities in which we are the lessee as of September 30, 2022 (in thousands):

Operating
Finance
Remainder of 2022
$227 $180 
2023968 721 
20241,047 721 
2025584 173 
2026— — 
Thereafter— — 
Total lease payments2,826 1,795 
Less imputed interest(278)(144)
$2,548 $1,651 
The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of September 30, 2022, the total net investment in these leases was $3.0 million. The following presents maturities of lease receivables under sales-type leases as of September 30, 2022 (in thousands):

Remainder of 2022$351 
20231,154 
2024661 
2025206 
2026640 
Thereafter— 
Total undiscounted cash flows3,012 
Less imputed interest— 
Present value of lease payments$3,012 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Geographic and Revenue Disaggregation
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Geographic and Revenue Disaggregation
NOTE 17. GEOGRAPHIC AND REVENUE DISAGGREGATION

The Company operates as one operating segment. Sales to customers outside the U.S. represented 14% and 8% for the three months ended September 30, 2022 and 2021, respectively, and 14% and 12% for the nine months ended September 30, 2022 and 2021, respectively.

As of September 30, 2022 and December 31, 2021, balances due from foreign customers, in U.S. dollars, were $0.6 million and $0.7 million, respectively.

The following presents total net sales by geographic territory for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Domestic$2,551 $2,874 $8,390 $7,406 
Foreign409 248 1,390 1,033 
$2,960 $3,122 $9,780 $8,439 

The following presents total net sales by line of business for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Accelerate Pheno revenue
$2,933 $3,084 $9,669 $8,324 
Other revenue27 38 111 115 
$2,960 $3,122 $9,780 $8,439 

The following presents total net sales by products and services for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Products$2,532 $2,773 $8,554 $7,474 
Services428 349 1,226 965 
$2,960 $3,122 $9,780 $8,439 
Lease revenue included in net sales was $0.2 million and $0.5 million for the three months ended September 30, 2022 and 2021, respectively, and $1.3 million for each of the nine months ended September 30, 2022 and 2021.

The following presents property and equipment, net by geographic territory (in thousands):

September 30,December 31,
20222021
Domestic$3,383 $5,014 
Foreign238 375 
$3,621 $5,389 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Stockholders' Equity
NOTE 18. STOCKHOLDERS' EQUITY

December 2020 Securities Purchase Agreement

During December 2020, the Company entered into a securities purchase agreement (the “December 2020 Securities Purchase Agreement”) with Jack W. Schuler, John Patience, Matthew Strobeck, Mark C. Miller, Thomas D. Brown and Jack Phillips, or entities affiliated with such persons (collectively, the “Original Purchasers”), for the issuance and sale by the Company of an aggregate of 4,166,663 shares of the Company’s common stock. Each of Jack W. Schuler, John Patience, Matthew Strobeck, Mark C. Miller, Thomas D. Brown and Jack Phillips is a member of the Company’s board of directors. Mr. Phillips also serves as the Company’s President and Chief Executive Officer.

The Schuler Trust, which was the entity affiliated with Jack W. Schuler that originally entered into the December 2020 Securities Purchase Agreement for the purchase of 3,964,843 shares for an aggregate purchase price of approximately $30.5 million, subsequently entered into an assignment and assumption agreement whereby it assigned all of its rights and obligations as an Original Purchaser to three other entities under the December 2020 Securities Purchase Agreement (collectively, the “Schuler Purchasers”). These three entities are related to Jack W. Schuler but are not affiliates of his.

Pursuant to the December 2020 Securities Purchase Agreement, the Original Purchasers agreed to purchase the shares at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the Company’s common stock) of $7.68 per share, for an aggregate purchase price of approximately $32 million.

The December 2020 Securities Purchase Agreement contemplated that the closing of the purchase and sale of the shares would occur in three tranches, with the first and second tranches having closed on February 19, 2021 and April 9, 2021, respectively, whereby the Company received total proceeds of approximately $21.3 million which were recorded to contributed capital.

On September 17, 2021, the Company entered into a rescission agreement (the “Rescission Agreement”) with the Schuler Purchasers and the Schuler Trust pursuant to which, effective as of January 29, 2021, the Company and the Schuler Purchasers agreed to rescind and unwind the December 2020 Securities Purchase Agreement for all legal, tax and financial purposes ab initio as if the related transactions, including the issuance and sale of an aggregate of 2,643,228 shares in the first two tranche closings and the third tranche (as discussed below) under the December 2020 Purchase Agreement, had never occurred with respect to the Schuler Purchasers and the Company. The 2,643,228 Shares re-acquired by the Company from the Schuler Purchasers as a result of the Rescission Agreement were treated as a reduction to contributed capital and were not outstanding for purposes of the calculation of basic and diluted earnings per share.

On September 30, 2021, the Company closed the final third tranche in connection with the December 2020 Securities Purchase Agreement and received total proceeds of approximately $0.5 million. In accordance with the Rescission Agreement, the Schuler Purchasers did not participate in the third tranche. During the nine months ended September 30, 2021, the Company issued 201,820 shares and received total proceeds of approximately $1.5 million under the December 2020 Securities Purchase Agreement, which were recorded to contributed capital, after giving effect to the Rescission Agreement.
September 2021 Securities Purchase Agreement

During September 2021, the Company entered into a new securities purchase agreement (the “September 2021 Securities Purchase Agreement”) with the Schuler Purchasers for the issuance and sale by the Company of an aggregate of 3,954,546 shares of the Company’s newly designated Series A Preferred Stock, par value $0.001 per share (the “Series A Preferred Shares”). Each share of Series A Preferred Stock is convertible, at the option of the holder, at any time into one share of the Company’s common stock.

Pursuant to the September 2021 Securities Purchase Agreement, the Schuler Purchasers agreed to purchase the Series A Preferred Shares at a purchase price of $7.70 per share for an aggregate purchase price of approximately $30.5 million.

The September 2021 Securities Purchase Agreement contemplated the closing of the purchase and sale of the Series A Preferred Shares would occur in two tranches. The first tranche closed on the date of the execution of the September 2021 Securities Purchase Agreement whereby an aggregate of 2,636,364 Series A Preferred Shares were issued and sold to the Schuler Purchasers. The Company received total proceeds of approximately $20.3 million, which was recorded to contributed capital during the three months ended September 30, 2021.

The second tranche (the “Tranche Right”) had not closed by September 30, 2021 and was concluded to be an obligation of the Schuler Purchasers to acquire, and the Company to sell an additional 1,318,182 Series A Preferred Shares at a purchase price of $7.70 per share for proceeds of $10.2 million, subsequent to the September 30, 2021 balance sheet date. The Company concluded the Tranche Right met the definition of a freestanding financial instrument which was recorded within stockholder’s equity. The value of this Tranche Right as September 30, 2021 was $2.5 million. The estimated fair value of the Tranche Right represented a Level 3 measurement as this financial instrument has no market activity. The estimated fair value of the Tranche Right was determined as the excess value of the forward contract when compared to the underlying asset. The fair value of this forward contract can be represented by the difference between the contractual forward price of $7.70 and the prevailing exchange-traded common stock price ($5.81 at September 22, 2021 and $5.83 at September 30, 2021), multiplied by 1,318,182 Series A Preferred Shares. On October 29, 2021, the Company closed the final second tranche in connection with the September 2021 Securities Purchase Agreement whereby the Company issued and sold an aggregate of 1,318,182 Series A Preferred Shares to the Schuler Purchasers and received total proceeds of approximately $10.2 million.

2021 Exchange Transactions

During the none months ended September 30, 2021, certain holders of the Notes exchanged $46.0 million in aggregate principal amount of Notes held by them for 5,945,718 shares of the Company’s common stock pursuant to their respective exchange agreement. Using the closing stock price on September 22, 2021 of $5.81, the 5,945,718 shares of the Company’s common stock were determined to have a value of $34.5 million, which was recorded to contributed capital during the nine months ended September 30, 2021. See Note 10, Convertible Notes, for additional information.

March 2022 Exchange Transaction

During the nine months ended September 30, 2022, a holder of the Notes exchanged $14.0 million in aggregate principal amount of Notes held by it for 10,798,482 shares of the Company's common stock pursuant to the March 2022 Exchange Agreement. The 10,798,482 shares of the Company’s common stock were determined to have a value of $10.2 million, which was recorded to contributed capital during the nine months ended September 30, 2022. See Note 10, Convertible Notes for additional information.

March 2022 Securities Purchase Agreement

On March 24, 2022, the Company entered into a securities purchase agreement (the “March 2022 Securities Purchase Agreement”) with the Schuler Trust for the issuance and sale by the Company of an aggregate of 2,439,024 shares of the Company’s common stock to the Schuler Trust in an offering (the “Private Placement”) exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder.
Pursuant to the March 2022 Securities Purchase Agreement, the Schuler Trust agreed to purchase the shares at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the Company’s common stock) of $1.64 per share, for an aggregate purchase price of $4.0 million.

On June 29, 2022, the Company and the Schuler Trust agreed to extend the closing date of the Private Placement (the “Closing Date”) from June 30, 2022 to September 26, 2022, subject to the satisfaction of customary closing conditions. On September 29, 2022, the parties agreed to further extend the Closing Date to December 30, 2022, effective as of September 26, 2022.

August 2022 Exchange Transaction

On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) the Secured Note in an aggregate principal amount of $34.9 million and (b) the Warrant to acquire the Company’s common stock. The gain from the extinguishment of the Notes was treated as a capital transaction. The net gain on extinguishment was $29.8 million during the three months ended months ended September 30, 2022, and was recorded to contributed capital. See Note 10, Convertible Notes and Note 11, Long-Term Debt Related-Party for additional information.

The Warrant meets the criteria for classification in stockholders’ equity and was recorded in contributed capital at fair value of $3.8 million on August 15, 2022.

August 2022 Public Offering

On August 23, 2022, the Company completed a public offering 17,500,000 shares of its common stock at a public offering price of $2.00 per share. The Company received net proceeds of approximately $32.9 million from the offering after deducting underwriting discounts and commissions and offering expenses paid by the Company.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related-Party Transactions
 9 Months Ended
Sep. 30, 2022
Related Party Transactions [Abstract]  
Related-Party Transactions
NOTE 19. RELATED-PARTY TRANSACTIONS

2021 Exchange Transactions

As discussed in Note 10, Convertible Notes, the Company carries Notes. The Schuler Family Foundation (the “Foundation”) previously held an aggregate of $42.0 million of the Notes. Jack W. Schuler, a member of the Company’s board of directors, is the President of the Foundation.

During the three months ended September 30, 2021, the Foundation transferred by gift the $42.0 million aggregate principal amount of Notes held by the Foundation to the Schuler Initiative Supporting Charitable Trust (the “Supporting Organization”), a tax-exempt organization that is not an affiliate of Jack W. Schuler.

In connection with the 2021 Exchange Transactions the Supporting Organization exchanged $42.0 million in aggregate principal amount of Notes held by it for 5,428,699 shares of the Company's common stock. Using the closing stock price on September 22, 2021 of $5.81, the 5,428,699 shares of the Company's common stock were determined to have a value of $31.5 million which was recorded to contributed capital for the three months ended September 30, 2021. The Supporting Organization had the same or similar terms as the other counter parties. The Company determined the 2021 Exchange Transactions did not meet the criteria of a capital transaction and was recorded as a gain on extinguishment of debt. See Note 10, Convertible Notes and Note 18, Stockholders' Equity, for additional information.

December 2020 Securities Purchase Agreement

On December 24, 2020, the Company entered into the December 2020 Securities Purchase Agreement with the Original Purchasers for the issuance and sale by the Company of 4,166,663 shares of the Company’s common stock. The Original Purchasers are comprised of certain directors and officers of the Company, or entities affiliated or related to such persons. See Note 18, Stockholders' Equity, for further information.

On September 17, 2021, the Company entered into the Rescission Agreement with the Schuler Purchasers and the Schuler Trust, an entity affiliated with Jack W. Schuler, pursuant to which, effective as of January 29, 2021, the Company and the Schuler Purchasers agreed to rescind and unwind the December 2020 Securities Purchase
Agreement for all legal, tax and financial purposes ab initio as if the related transactions, including the issuance and sale of an aggregate of 2,643,228 Shares in the first two tranche closings and the third tranche under the December 2020 Purchase Agreement, had never occurred with respect to the Schuler Purchasers and the Company. The Schuler Purchasers are related to Jack W. Schuler but are not affiliates of his. See Note 18, Stockholders' Equity, for further information.

During the nine months ended September 30, 2021, the Company issued 201,820 shares and received total proceeds of approximately $1.5 million under the December 2020 Securities Purchase Agreement after giving effect to the Rescission Agreement.

September 2021 Securities Purchase Agreement

On September 22, 2021, the Company entered into the September 2021 Securities Purchase Agreement with the Schuler Purchasers for the issuance and sale by the Company of 3,954,546 Series A Preferred Shares. The Schuler Purchasers are related to Jack W. Schuler but are not affiliates of his.

During the nine months ended September 30, 2021, the Company issued 2,636,364 Series A Preferred Shares and received total proceeds of approximately $20.3 million under the September 2021 Securities Purchase Agreement. See Note 18, Stockholders' Equity, for further information.

March 2022 Securities Purchase Agreement

On March 24, 2022, the Company entered into the March 2022 Securities Purchase Agreement with the Schuler Trust for the issuance and sale by the Company of 2,439,024 shares of the Company’s common stock. Jack Schuler serves as a member of the Company’s board of directors and is the sole trustee of the Schuler Trust. See Note 18, Stockholders’ Equity, for further information.

August 2022 Exchange Transaction

On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for the Secured Note in an aggregate principal amount of $34.9 million and a warrant to acquire the Company’s common stock. The net gain on extinguishment was $29.8 million during the nine months ended September 30, 2022, and was recorded as contributed capital. See Note 10, Convertible Notes and Note 11, Long-Term Debt Related-Party for additional information.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 14, 2022.

The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date but does not include all disclosures such as notes required by U.S. GAAP.

The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2022, or any future period.

All amounts are rounded to the nearest thousand dollars unless otherwise indicated.
Principles of Consolidation
Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.
Use of Estimates
Use of Estimates

The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, convertible notes, notes from related parties, tax valuation accounts, equity–based compensation, warrants, revenue and leases. Actual results could differ materially from those estimates.
Estimated Fair Value of Financial Instruments
Estimated Fair Value of Financial Instruments

The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three-tiered approach and fair value measurement be classified and disclosed in one of the following three categories:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

•Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).
The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.

See Note 4, Fair Value of Financial Instruments, for further information and related disclosures regarding the Company’s fair value measurements.

The estimated fair value of the Notes represents a Level 2 measurement. See Note 10, Convertible Notes for further detail on the Notes.
The long-term debt with a related-party consisting of the Secured Note (as defined in Note 11) and the Warrant are instruments measured at fair value on a non-recurring basis using Level 3 inputs. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note and the Warrant.
Cash and Cash Equivalents
Cash and Cash Equivalents

All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.
Investments
Investments

The Company invests in various debt and equity securities which are primarily held in the custody of major financial institutions. Debt securities consist of certificates of deposit, U.S. government and agency securities, commercial paper, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ deficit. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of condensed consolidated statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.

We perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security is considered impaired if its fair value is less than its amortized cost basis at the reporting date. If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security.
Inventory
Inventory

Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.
We charge cost of sales for inventory provisions to write-down our inventory to the lower of cost or net realizable value or for obsolete or excess inventory. Most of our inventory provisions relate to excess quantities of products, based on our inventory levels and future product purchase commitments compared to assumptions about future demand and market conditions. Once inventory has been written-off or written-down, it creates a new cost basis for the inventory that is not subsequently written-up.
Accounts Receivable
Accounts Receivable

Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.

We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. Our customers typically have good credit quality. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data.
Property and Equipment
Property and Equipment

Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.

Instruments Classified as Property and Equipment

Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.
The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of for the three and nine months ended September 30, 2022.
Long-lived Assets
Long-lived Assets

Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.
Warranty Reserve
Warranty Reserve

Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The cost incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.
Convertible Notes
Convertible Notes

On January 1, 2022 the Company adopted Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. Gain or loss on extinguishment of Notes is calculated as the difference between the (i) fair value of the consideration transferred and (ii) the sum of the carrying value of the debt at the time of repurchase.

The Company classifies the Notes as a non-current liability as the Company has sufficient shares and non-cash alternatives to settle the Notes.
Revenue Recognition
Revenue Recognition

The Company recognizes revenue when control of the promised good or service is transferred to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.

The Company determines revenue recognition through the following steps:

•Identification of the contract with a customer
•Identification of the performance obligations in the contract
•Determination of the transaction price
•Allocation of the transaction price to the performance obligations
•Recognition of revenue as we satisfy a performance obligation

Product revenue is derived from the sale or rental of instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized. Payment terms vary by the type and location of the customer and the products or services offered. The term between invoicing and when payment is due is not significant.

Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.

The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The Company generally determines relative standalone selling prices based on the price charged to customers for each individual performance obligation.

Sales commissions earned by the Company’s sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and nine months ended September 30, 2022.

Gross Profit and Gross Margin

Gross profit consists of total revenue, net of allowances, less cost of sales. Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related costs.

The Company’s overall gross margin was 26% and 32% for the three months ended September 30, 2022 and 2021, respectively, and 27% and 35% for the nine months ended September 30, 2022 and 2021, respectively. The decreases were primarily due to increases in the costs to manufacture consumables due to supply chain inflationary factors and a decrease in our average unit sales price period over period.

Shipping and Handling

Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the consolidated statements of operations and comprehensive loss.
Leases as Lessee
Leases

The Company accounts for leases in accordance with ASC 842, Leases. The Company determines if an arrangement is or contains a lease and the type of lease at inception. The Company classifies leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.

To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.

Leases as Lessee

Operating leases are included in right-of-use (“ROU”) assets and corresponding lease liabilities, and finance leases are included in ROU assets and corresponding lease liabilities within our condensed consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option.

Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between two and six-year terms, and typically contain penalizing, early-termination provisions. Our finance leases consist of leased equipment and have three-year terms.
Leases as Lessor
Leases

The Company accounts for leases in accordance with ASC 842, Leases. The Company determines if an arrangement is or contains a lease and the type of lease at inception. The Company classifies leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.

To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.
Leases as Lessor

The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.

Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.

Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.
Nonqualified Cash Deferral Plan
Nonqualified Cash Deferral Plan

The Company's Cash Deferral Plan (the “Deferral Plan”) provides certain key employees with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of
the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments’ fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet.
Equity-Based Compensation
Equity-Based Compensation

The Company may award stock options, RSUs, performance-based awards and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.

The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.

•Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.

•Expected term: The estimated expected term for employee awards is based on a simplified method that considers an insufficient history of employee exercises. For consultant awards, the estimated expected term is the same as the life of the award.

•Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.

•Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.

The Company records the fair value of RSUs or stock grants based on the published closing market price on the day before the grant date.

The Company accounts for forfeitures as they occur rather than on an estimated basis.

The Company also has an employee stock purchase program whereby eligible employees can elect payroll deductions that are subsequently used to purchase common stock at a discounted price. There is no compensation recorded for this program as (i) the purchase discount does not exceed the issuance costs that would have been incurred to raise a significant amount of capital by a public offering, (ii) substantially all employees that meet limited employment qualifications may participate on an equitable basis, and (iii) the plan doesn't incorporate option features that would require compensation to be recorded.
Deferred Tax
Deferred Tax

Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying condensed consolidated balance sheet. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.

The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more
likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.
Foreign Currency Translation and Foreign Currency Transactions
Foreign Currency Translation and Foreign Currency Transactions

Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive loss in the condensed consolidated statements of stockholders’ deficit.

The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.
Loss Per Share
Loss Per Share

Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options, unvested RSUs and the Warrant. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes and the Series A Preferred Stock outstanding at the balance sheet date were converted and shares issuable in connection with the March 2022 Securities Purchase Agreement (as defined in Note 18). Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.
Comprehensive Loss
Comprehensive Loss

In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds debt securities as available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.
Standards that were recently adopted and standards not yet adopted
Standards that were recently adopted

In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). This update simplifies the accounting for convertible debt instruments by removing the beneficial conversion and cash conversion separation models for convertible instruments. Under the update, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives or that do not result in substantial premiums accounted for as paid-in capital. The update also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will no longer be available. The Company adopted the standard on January 1, 2022 through application of the modified retrospective method of transition. The Company applied the standard to the Notes outstanding as of January 1, 2022, as discussed in Note 10, Convertible Notes. As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. On January 1, 2022, the cumulative effect of adoption resulted in an increase in the net carrying amount of the Notes, of $11.5 million, a decrease in additional-paid-in-capital of $37.4 million, and a decrease in accumulated deficit of $25.9 million. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share. This change has no impact on the Company given the Company was already using the if-converted method to calculate diluted earnings per share.
In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity’s Own Equity (Topic 815 - 40). ASU 2021-04 codifies the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This ASU was adopted January 1, 2022, and did not impact the Company's consolidated financial statements at January 1, 2022.

Standards not yet adopted

In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. ASU 2022-01 is related to the portfolio layer method of hedge accounting. The amendments in this update clarify the accounting and promote consistency in reporting for hedges where the portfolio layer method is applied. This update is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. We do not expect the update to have a material effect on our condensed consolidated financial statements.

In March 2022, the FASB issued ASU 2022-02, Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. ASU 2022-02 relates to troubled debt restructurings (“TDRs”) and vintage disclosures for financing receivables. The amendments in this update eliminate the accounting guidance for TDRs by creditors while enhancing disclosure requirements for certain loan refinancing and restructurings by creditors made to borrowers experiencing financial difficulty. The amendments also require disclosure of current-period gross write-offs by year of origination for financing receivables. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not expect the update to have a material effect on our condensed consolidated financial statements.
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Schedule of Allowance For Credit Losses
The allowance for credit losses for the three and nine months ended September 30, 2022 and 2021 is comprised of the following (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Beginning balance$150 $213 140 445 
(Reversals) provisions, net
(12)78 18 114 
Write-offs
— (77)(20)(345)
$138 $214 $138 $214 
Schedule of Warranty Reserve
Warranty reserve activity for the three and nine months ended September 30, 2022 and 2021 is as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Beginning balance$255 $169 $139 $232 
Provisions (reversals), net
(4)(31)134 (41)
Warranty cost incurred
(29)(17)(51)(70)
Ending balance$222 $121 $222 $121 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Measurement
The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Cash and cash equivalents:
Money market funds$5,145 $— $— $5,145 
Total cash and cash equivalents5,145 — — 5,145 
Equity investments:
Mutual funds808 — — 808 
Total equity investments808 — — 808 
Debt securities available-for-sale:
Certificates of deposit— 3,382 — 3,382 
U.S. Treasury securities5,228 — — 5,228 
Commercial paper— 2,893 — 2,893 
Corporate notes and bonds— 4,096 — 4,096 
Debt securities available-for-sale5,228 10,371 — 15,599 
Total assets measured at fair value$11,181 $10,371 $— $21,552 

December 31, 2021
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)		Significant
Other
Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Total
Assets:
Cash and cash equivalents:
Money market funds$5,563 $— $— $5,563 
Commercial paper— 200 — 200 
Total cash and cash equivalents5,563 200 — 5,763 
Equity investments:
Mutual funds841 — — 841 
Total equity investments841 — — 841 
Debt securities available-for-sale:
Certificates of deposit— 1,351 — 1,351 
U.S. Treasury securities250 — — 250 
Commercial paper— 8,046 — 8,046 
Corporate notes and bonds— 13,232 — 13,232 
Debt securities available-for-sale250 22,629 — 22,879 
Total assets measured at fair value$6,654 $22,829 $— $29,483 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments (Tables)
 9 Months Ended
Sep. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Schedule of Available-for-Sale Investments
The following tables summarize the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
Certificates of deposit$3,400 $— $(18)$3,382 
U.S. Treasury securities5,266 — (38)5,228 
Commercial paper2,901 — (8)2,893 
Corporate notes and bonds4,131 — (35)4,096 
Total$15,698 $— $(99)$15,599 

December 31, 2021
Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair Value
Certificates of deposit$1,351 $— $— $1,351 
U.S. Treasury securities250 — — 250 
Commercial paper8,048 — (2)8,046 
Corporate notes and bonds13,245 — (13)13,232 
Total$22,894 $— $(15)$22,879 
Schedule of Maturities of Available-for-Sale Investments
The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):

September 30, 2022December 31, 2021
Amortized
Cost		Fair ValueAmortized
Cost		Fair Value
Due in less than 1 year$15,698 $15,599 $22,663 $22,649 
Due in 1-3 years— — 231 230 
Total
$15,698 $15,599 $22,894 $22,879 
Schedule of Unrealized Losses or Gains on Equity Securities
Unrealized losses or gains on equity securities recorded in income during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Unrealized (loss) gain on equity investments$(50)$(5)$(206)$39 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventory (Tables)
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Schedule of Components of Inventories
Inventories consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

September 30,December 31,
20222021
Raw materials$1,769 $1,343 
Work in process2,133 1,625 
Finished goods1,490 2,099 
$5,392 $5,067 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment (Tables)
 9 Months Ended
Sep. 30, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

September 30,December 31,
20222021
Computer equipment$3,866 $3,181 
Technical equipment3,259 3,285 
Facilities3,674 3,675 
Instruments3,594 5,364 
Capital projects in progress48 683 
Total property and equipment$14,441 $16,188 
Accumulated depreciation(10,820)(10,799)
Property and equipment, net$3,621 $5,389 

Depreciation expense for the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Depreciation expense$381 $487 $1,284 $1,540 
Schedule of Instruments at Cost and Accumulated Depreciation, Lessor
Instruments at cost and accumulated depreciation where the Company is the lessor under operating leases consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):

September 30,December 31,
20222021
Instruments at cost under operating leases$2,452 $3,110 
Accumulated depreciation under operating leases(1,109)(1,165)
Net property and equipment under operating leases$1,343 $1,945 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Deferred Revenue and Remaining Performance Obligations (Tables)
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Deferred Revenue and Income Summary A summary of the balances as of September 30, 2022 and December 31, 2021 follows (in thousands):
September 30,December 31,
20222021
Products and services not yet delivered$524 $451 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt (Tables)
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
As of September 30, 2022 and December 31, 2021, long-term debt consisted of the following (in thousands):

September 30,December 31,
20222021
Loans - various interest$80 $80 
Current portion of long-term debt80 80 
Long-term debt$— $— 
Schedule of Maturities of Long-term Debt
The following presents maturities of future principal obligations of long-term debt as of September 30, 2022 (in thousands):

Remainder of 2022$80 
2023— 
2024— 
2025— 
2026— 
Thereafter— 
Total$80 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Convertible Notes (Tables)
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Interest Expense
Interest expense during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual coupon interest$79 $1,024 $1,528 $3,168 
Amortization of debt issuance costs121 185 386 539 
Amortization of the debt discount— $2,987 $— $8,711 
Total interest expense on convertible notes$200 $4,196 $1,914 $12,418 
Interest expense in connection with the Secured Note during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual interest
$220 $— $220 $— 
Amortization of the debt discount275 — 275 — 
Total interest expense
$495 $— $495 $— 
Schedule of Gain on Extinguishment
Gain on extinguishment of exchanged Notes during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Gain on extinguishment$— $4,999 $3,565 $4,999 
Schedule of Carrying Value of the Notes
The carrying value of the Notes at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal at par
$56,595 
Unamortized debt issuance(270)
Net carrying amount
$56,325 
The carrying value of the Secured Note at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal
$34,934 
Unamortized debt issuance discount
(18,635)
Net carrying amount
$16,299 
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt Related-Party (Tables)
 9 Months Ended
Sep. 30, 2022
Debt Disclosure [Abstract]  
Schedule of Carrying Value of the Secured Notes
The carrying value of the Notes at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal at par
$56,595 
Unamortized debt issuance(270)
Net carrying amount
$56,325 
The carrying value of the Secured Note at September 30, 2022 consisted of the following (in thousands):

September 30,
2022
Outstanding principal
$34,934 
Unamortized debt issuance discount
(18,635)
Net carrying amount
$16,299 
Schedule of Interest Expense in Connection with the Secured Note
Interest expense during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual coupon interest$79 $1,024 $1,528 $3,168 
Amortization of debt issuance costs121 185 386 539 
Amortization of the debt discount— $2,987 $— $8,711 
Total interest expense on convertible notes$200 $4,196 $1,914 $12,418 
Interest expense in connection with the Secured Note during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Contractual interest
$220 $— $220 $— 
Amortization of the debt discount275 — 275 — 
Total interest expense
$495 $— $495 $— 
Summary of Inputs Used to Calculate Estimated Fair Value
The table below summarizes the inputs used to calculate the estimated fair value of the Warrant issued during the three months ended September 30, 2022:

Contractual term (in years)
7.0
Volatility76.10 %
Expected dividends— 
Risk free interest rates2.86 %
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Loss Per Share (Tables)
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share
The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Shares issuable upon the release of RSUs4,619 2,320 4,619 2,320 
Shares issuable upon exercise of stock options5,665 7,634 5,665 7,634 
Shares issuable upon the exercise of the Warrant2,472 — 2,472 — 
12,756 9,954 12,756 9,954 
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Employee Equity-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Option Activity under the Company's Equity-Based Compensation
The following table summarizes option activity under the Company's equity-based compensation plans for the nine months ended September 30, 2022:

Number of SharesWeighted Average Exercise Price per Share
Options outstanding January 1, 20227,192,540 $13.89 
Granted140,000 3.05 
Forfeited(204,232)12.49 
Exercised(6,105)1.04 
Expired(1,457,019)10.33 
Options outstanding September 30, 20225,665,184 $14.60 
Schedule of Outstanding Options and Options that are Exercisable (Vested)
The following table shows summary information for outstanding options and options that are exercisable (vested) as of September 30, 2022:

Options
Outstanding		Options
Exercisable
Number of options5,665,184 4,422,595 
Weighted average remaining contractual term (in years)5.545.04
Weighted average exercise price$14.60 $15.32 
Weighted average fair value$9.10 $9.44 
Aggregate intrinsic value (in thousands)$— $— 
Schedule of Restricted Stock Activity
The following table summarizes RSU and restricted stock award activity for the nine months ended September 30, 2022:

Number of SharesWeighted Average Grant Date Fair Value per Share
Outstanding January 1, 20222,090,182 $10.77 
Granted4,107,083 1.55 
Forfeited(451,703)8.68 
Released(1,127,017)3.43 
Outstanding September 30, 20224,618,545 $4.57 
Schedule of Equity-Based Compensation Expense
The table below summarizes equity-based compensation expense for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost of sales$167 $82 $570 $257 
Research and development151 266 1,052 4,340 
Sales, general and administrative911 3,281 6,557 14,461 
$1,229 $3,629 $8,179 $19,058 

The table below summarizes share-based compensation cost capitalized to inventory for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost capitalized to inventory
$69 $77 $186 $319 
The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2022 and 2021 (in thousands):

Nine Months Ended September 30,
20222021
Performance-based stock option expense
$— $230 
The table below summarizes share-based compensation cost in connection with performance-based RSUs for the nine months ended September 30, 2022 and 2021 (in thousands):

Nine Months Ended September 30,
20222021
Performance-based RSU expense
$— $818 
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases (Tables)
 9 Months Ended
Sep. 30, 2022
Leases [Abstract]  
Schedule of Supplemental Lease Information
The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cash paid for amounts included in lease liabilities:
Operating cash flows from operating leases$219 $195 $712 $502 
Operating cash flows from finance leases$684 $— $1,109 $— 
ROU assets obtained in exchange for lease obligations:
Operating leases$— $— $— $— 
Finance leases$— $— $2,760 $— 
Lease Cost:
Operating leases$254 $257 $818 $816 
Finance leases
$240 $— $462 $— 
Short-term leases$26 $40 $67 $99 
Schedule of Lease Costs
The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cash paid for amounts included in lease liabilities:
Operating cash flows from operating leases$219 $195 $712 $502 
Operating cash flows from finance leases$684 $— $1,109 $— 
ROU assets obtained in exchange for lease obligations:
Operating leases$— $— $— $— 
Finance leases$— $— $2,760 $— 
Lease Cost:
Operating leases$254 $257 $818 $816 
Finance leases
$240 $— $462 $— 
Short-term leases$26 $40 $67 $99 
Schedule of Maturities of Operating Lease Liabilities
The following presents maturities of lease liabilities in which we are the lessee as of September 30, 2022 (in thousands):

Operating
Finance
Remainder of 2022
$227 $180 
2023968 721 
20241,047 721 
2025584 173 
2026— — 
Thereafter— — 
Total lease payments2,826 1,795 
Less imputed interest(278)(144)
$2,548 $1,651 
Schedule of Maturities of Sales-type Lease Receivables The following presents maturities of lease receivables under sales-type leases as of September 30, 2022 (in thousands):
Remainder of 2022$351 
20231,154 
2024661 
2025206 
2026640 
Thereafter— 
Total undiscounted cash flows3,012 
Less imputed interest— 
Present value of lease payments$3,012 
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Geographic and Revenue Disaggregation (Tables)
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Schedule of Disaggregation of Revenue
The following presents total net sales by geographic territory for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Domestic$2,551 $2,874 $8,390 $7,406 
Foreign409 248 1,390 1,033 
$2,960 $3,122 $9,780 $8,439 

The following presents total net sales by line of business for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Accelerate Pheno revenue
$2,933 $3,084 $9,669 $8,324 
Other revenue27 38 111 115 
$2,960 $3,122 $9,780 $8,439 

The following presents total net sales by products and services for the three and nine months ended September 30, 2022 and 2021 (in thousands):

Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Products$2,532 $2,773 $8,554 $7,474 
Services428 349 1,226 965 
$2,960 $3,122 $9,780 $8,439 
Schedule of Long-lived Assets by Geographic Territory
The following presents property and equipment, net by geographic territory (in thousands):

September 30,December 31,
20222021
Domestic$3,383 $5,014 
Foreign238 375 
$3,621 $5,389 
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2021
Sep. 30, 2022
USD ($)
instrument
Sep. 30, 2021
Accounting Policies [Abstract]        
Convertible debt offerings | instrument     1  
Property, Plant and Equipment [Line Items]        
Impairment charges | $ $ 0   $ 0  
Instrument warranty term     1 year  
Kits and accessories warranty term     60 days  
Gross margin 0.26 0.32 0.27 0.35
Lease extension 1 year   1 year  
Lessor lease term 5 years   5 years  
Instruments        
Property, Plant and Equipment [Line Items]        
Estimated useful life of assets     5 years  
Equipment        
Property, Plant and Equipment [Line Items]        
Lease term 3 years   3 years  
Minimum        
Property, Plant and Equipment [Line Items]        
Estimated useful life of assets     1 year  
Lease term 2 years   2 years  
Maximum        
Property, Plant and Equipment [Line Items]        
Estimated useful life of assets     7 years  
Lease term 6 years   6 years  
2.50% Convertible notes due 2023 | Convertible notes        
Property, Plant and Equipment [Line Items]        
Interest rate 2.50%   2.50%  
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Allowance For Doubtful Accounts (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Accounts Receivable, Allowance for Credit Loss [Roll Forward]        
Beginning balance $ 150 $ 213 $ 140 $ 445
(Reversals) provisions, net (12) 78 18 114
Write-offs 0 (77) (20) (345)
Ending balance $ 138 $ 214 $ 138 $ 214
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Movement in Standard Product Warranty Accrual [Roll Forward]        
Beginning balance $ 255 $ 169 $ 139 $ 232
Provisions (reversals), net (4) (31) 134 (41)
Warranty cost incurred (29) (17) (51) (70)
Ending balance $ 222 $ 121 $ 222 $ 121
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Recently Issued Accounting Pronouncements (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Jan. 01, 2022
Dec. 31, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Decrease in accumulated deficit $ (592,439)   $ (570,668)
Cumulative effect of accounting changes | Accounting Standards Update 2020-06      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Carrying amount of convertible notes   $ 11,500  
Decrease in additional paid in capital   (37,400)  
Decrease in accumulated deficit   $ 25,900  
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Concentration of Credit Risk (Details)
 9 Months Ended 12 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Cash and cash equivalents | Concentration of credit risk | Financial Institutions One    
Concentration Risk [Line Items]    
Risk concentration 74.00% 72.00%
Cash and cash equivalents | Concentration of credit risk | Financial Institutions Two    
Concentration Risk [Line Items]    
Risk concentration 12.00% 13.00%
Cash and cash equivalents | Concentration of credit risk | Financial Institutions Three    
Concentration Risk [Line Items]    
Risk concentration 13.00%  
Net accounts receivable | Customer concentration | One customer    
Concentration Risk [Line Items]    
Risk concentration 16.00% 13.00%
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity investments: $ 800 $ 800
Debt securities available-for-sale: 15,599 22,879
Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 3,382 1,351
U.S. Treasury securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 5,228 250
Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 2,893 8,046
Corporate notes and bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 4,096 13,232
Fair Value on a Recurring Basis    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: 5,145 5,763
Equity investments: 808 841
Debt securities available-for-sale: 15,599 22,879
Total assets measured at fair value 21,552 29,483
Fair Value on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: 5,145 5,563
Equity investments: 808 841
Debt securities available-for-sale: 5,228 250
Total assets measured at fair value 11,181 6,654
Fair Value on a Recurring Basis | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: 0 200
Equity investments: 0 0
Debt securities available-for-sale: 10,371 22,629
Total assets measured at fair value 10,371 22,829
Fair Value on a Recurring Basis | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: 0 0
Equity investments: 0 0
Debt securities available-for-sale: 0 0
Total assets measured at fair value 0 0
Fair Value on a Recurring Basis | Mutual funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity investments: 808 841
Fair Value on a Recurring Basis | Mutual funds | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity investments: 808 841
Fair Value on a Recurring Basis | Mutual funds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity investments: 0 0
Fair Value on a Recurring Basis | Mutual funds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Equity investments: 0 0
Fair Value on a Recurring Basis | Certificates of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 3,382 1,351
Fair Value on a Recurring Basis | Certificates of deposit | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | Certificates of deposit | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 3,382 1,351
Fair Value on a Recurring Basis | Certificates of deposit | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | U.S. Treasury securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 5,228 250
Fair Value on a Recurring Basis | U.S. Treasury securities | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 5,228 250
Fair Value on a Recurring Basis | U.S. Treasury securities | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | U.S. Treasury securities | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 2,893 8,046
Fair Value on a Recurring Basis | Commercial paper | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | Commercial paper | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 2,893 8,046
Fair Value on a Recurring Basis | Commercial paper | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | Corporate notes and bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 4,096 13,232
Fair Value on a Recurring Basis | Corporate notes and bonds | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | Corporate notes and bonds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 4,096 13,232
Fair Value on a Recurring Basis | Corporate notes and bonds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt securities available-for-sale: 0 0
Fair Value on a Recurring Basis | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: 5,145 5,563
Fair Value on a Recurring Basis | Money market funds | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: 5,145 5,563
Fair Value on a Recurring Basis | Money market funds | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: 0 0
Fair Value on a Recurring Basis | Money market funds | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents: $ 0 0
Fair Value on a Recurring Basis | Commercial paper    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents:   200
Fair Value on a Recurring Basis | Commercial paper | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents:   0
Fair Value on a Recurring Basis | Commercial paper | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents:   200
Fair Value on a Recurring Basis | Commercial paper | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents:   $ 0
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value of Financial Instruments - Narrative (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Aug. 15, 2022
Dec. 31, 2021
August 2022 Exchange Transaction | Schuler Trust | Embeded Warrant      
Debt Instrument [Line Items]      
Warrants fair value   $ 3,800  
Level 3 | August 2022 Exchange Transaction | Schuler Trust | Embeded Warrant      
Debt Instrument [Line Items]      
Warrants fair value   3,800  
Convertible notes | 2.50% Convertible notes due 2023      
Debt Instrument [Line Items]      
Outstanding principal at par $ 56,595   $ 120,500
Convertible notes | 2.50% Convertible notes due 2023 | Level 2      
Debt Instrument [Line Items]      
Fair value 51,700   $ 89,400
Senior Notes | 5.0% Secured promissory note | August 2022 Exchange Transaction | Schuler Trust      
Debt Instrument [Line Items]      
Outstanding principal at par $ 34,934    
Senior Notes | 5.0% Secured promissory note | Level 3 | Schuler Trust      
Debt Instrument [Line Items]      
Fair value   $ 16,000  
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments - Schedule of Available-for-sale Securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost $ 15,698 $ 22,894
Gross Unrealized Gains 0 0
Gross Unrealized Losses (99) (15)
Fair Value 15,599 22,879
Certificates of deposit    
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost 3,400 1,351
Gross Unrealized Gains 0 0
Gross Unrealized Losses (18) 0
Fair Value 3,382 1,351
U.S. Treasury securities    
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost 5,266 250
Gross Unrealized Gains 0 0
Gross Unrealized Losses (38) 0
Fair Value 5,228 250
Commercial paper    
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost 2,901 8,048
Gross Unrealized Gains 0 0
Gross Unrealized Losses (8) (2)
Fair Value 2,893 8,046
Corporate notes and bonds    
Debt and Equity Securities, FV-NI [Line Items]    
Amortized Cost 4,131 13,245
Gross Unrealized Gains 0 0
Gross Unrealized Losses (35) (13)
Fair Value $ 4,096 $ 13,232
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments - Schedule of Available-for-Sale Investment Maturities (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Amortized Cost    
Due in less than 1 year $ 15,698 $ 22,663
Due in 1-3 years 0 231
Amortized Cost 15,698 22,894
Fair Value    
Due in less than 1 year 15,599 22,649
Due in 1-3 years 0 230
Fair Value $ 15,599 $ 22,879
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments - Narrative (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]          
Proceeds from sales of debt securities $ 0 $ 0 $ 0 $ 0  
Realized gain (loss) from debt securities 0 0 0 0  
Unrealized loss position of debt securities 0 0 0 0  
Fair value of equity securities 800,000   800,000   $ 800,000
Realized gains or losses from equity securities 0 0 0 0  
Reclassified debt securities available-for-sale balances          
Debt Securities, Available-for-sale [Line Items]          
Reclassified from out of accumulated other comprehensive income (loss) $ 0 $ 0 $ 0 $ 0  
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investments - Unrealized Losses or Gains on Equity Securities (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]        
Unrealized (loss) gain on equity investments $ (50) $ (5) $ (206) $ 39
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventory (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Raw materials $ 1,769 $ 1,343
Work in process 2,133 1,625
Finished goods 1,490 2,099
Inventory $ 5,392 $ 5,067
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment - Property and Equipment at Cost (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Property, Plant and Equipment [Line Items]          
Total property and equipment $ 14,441   $ 14,441   $ 16,188
Accumulated depreciation (10,820)   (10,820)   (10,799)
Property and equipment, net 3,621   3,621   5,389
Depreciation expense 381 $ 487 1,284 $ 1,540  
Computer equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment 3,866   3,866   3,181
Technical equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment 3,259   3,259   3,285
Facilities          
Property, Plant and Equipment [Line Items]          
Property and equipment 3,674   3,674   3,675
Instruments          
Property, Plant and Equipment [Line Items]          
Property and equipment 3,594   3,594   5,364
Capital projects in progress          
Property, Plant and Equipment [Line Items]          
Property and equipment $ 48   $ 48   $ 683
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment - Instruments at Cost and Accumulated Depreciation, Lessor (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Property, Plant and Equipment [Abstract]    
Instruments at cost under operating leases $ 2,452 $ 3,110
Accumulated depreciation under operating leases (1,109) (1,165)
Net property and equipment under operating leases $ 1,343 $ 1,945
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Deferred Revenue and Remaining Performance Obligations (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Disaggregation of Revenue [Line Items]          
Products and services not yet delivered $ 524   $ 524   $ 451
Revenues recognized included in contract liabilities balances 200 $ 100 400 $ 300  
Revenue expected to be recognized from remaining performance obligations 9,000   $ 9,000    
Contact period     These agreements have between two and four year terms and revenue is recognized as product is shipped, typically on a straight-line basis. The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis.    
Products and services not yet delivered          
Disaggregation of Revenue [Line Items]          
Products and services not yet delivered $ 524   $ 524   $ 451
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 15, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
loan
Apr. 14, 2020
USD ($)
Debt Instrument [Line Items]              
Gain on extinguishment of debt   $ 0 $ 9,840 $ 3,565 $ 9,840    
Other loans | Notes payable, other payables              
Debt Instrument [Line Items]              
Number of loan agreements | loan           2  
Number of capital asset financing companies | loan           1  
Proceeds from debt           $ 200  
Other loans | Notes payable, other payables | Minimum              
Debt Instrument [Line Items]              
Interest rate           9.80%  
Other loans | Notes payable, other payables | Maximum              
Debt Instrument [Line Items]              
Interest rate           12.40%  
Paycheck Protection Program | Unsecured obligations              
Debt Instrument [Line Items]              
Aggregate principal amount             $ 4,800
Debt forgiveness $ 4,800            
Gain on extinguishment of debt $ 4,800            
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt - Schedule of Long-term Debt (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Long-term debt, Total $ 80  
Current portion of long-term debt 80 $ 80
Long-term debt 0 0
Loans - various interest | Loans - various interest    
Debt Instrument [Line Items]    
Long-term debt, Total $ 80 $ 80
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt - Schedule of Maturities of Future Principal Obligations (Details)
$ in Thousands
Sep. 30, 2022
USD ($)
Debt Disclosure [Abstract]  
Remainder of 2022 $ 80
2023 0
2024 0
2025 0
2026 0
Thereafter 0
Long-term debt, Total $ 80
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Convertible Notes - Narrative (Details)
 2 Months Ended 3 Months Ended 9 Months Ended
Aug. 15, 2022
USD ($)
$ / shares
Mar. 21, 2022
USD ($)
tranche
May 18, 2022
tranche
Sep. 30, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
day
$ / shares
shares
Sep. 30, 2021
USD ($)
shares
Debt Instrument [Line Items]              
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs           $ 49,624,000 $ 0
Gain on extinguishment of debt       $ 0 $ 9,840,000 3,565,000 9,840,000
Convertible notes value           49,624,000 0
August 2022 Exchange Transaction | Schuler Trust | Embeded Warrant              
Debt Instrument [Line Items]              
Warrants fair value $ 3,800,000            
August 2022 Exchange Transaction | Schuler Trust | Embeded Warrant | Level 3              
Debt Instrument [Line Items]              
Warrants fair value 3,800,000            
Prepaid Forward              
Debt Instrument [Line Items]              
Funded prepaid forward           $ 45,100,000  
Stock underlying the prepaid forward (in shares) | shares       1,858,500   1,858,500  
Convertible notes | 2.50% Convertible notes due 2023              
Debt Instrument [Line Items]              
Conversion ratio           0.0323428  
Initial conversion price (in usd per share) | $ / shares       $ 30.92   $ 30.92  
Interest rate       2.50%   2.50%  
Contractual term           5 years  
Effective interest rate       3.20%   3.20%  
Repurchase principal balance           100.00%  
Convertible notes | 2.50% Convertible notes due 2023 | 2021 Exchange Transaction              
Debt Instrument [Line Items]              
Notes exchanged             $ 46,000,000
Shares issued (in shares) | shares             5,945,718
Repurchase of exchanged amount         40,400,000   $ 40,400,000
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs             34,500,000
Reacquisition costs             800,000
Gain on extinguishment of debt         5,000,000   5,000,000
Convertible notes value             34,500,000
Convertible notes | 2.50% Convertible notes due 2023 | March 2022 Exchange Transaction              
Debt Instrument [Line Items]              
Conversion ratio   0.02264          
Notes exchanged   $ 14,000,000          
Number of tranches | tranche   8 8        
Conversion numerator (in usd per share)   $ 155.67          
Convertible notes | 2.50% Convertible notes due 2023 | August 2022 Exchange Transaction | Schuler Trust              
Debt Instrument [Line Items]              
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs 49,900,000            
Convertible notes value 49,900,000            
Convertible notes | 2.50% Convertible notes due 2023 | Exchange Agreement              
Debt Instrument [Line Items]              
Gain on extinguishment of debt       $ 0 $ 4,999,000 $ 3,565,000 $ 4,999,000
Convertible notes | 2.50% Convertible notes due 2023 | Option one to convert              
Debt Instrument [Line Items]              
Stock price conversion threshold, percentage           130.00%  
Consecutive trading days | day           20  
Threshold trading days | day           30  
Convertible notes | 2.50% Convertible notes due 2023 | Option two to convert              
Debt Instrument [Line Items]              
Consecutive trading days | day           5  
Threshold trading days | day           5  
Trading price threshold, percentage           98.00%  
Convertible notes | New Notes | March 2022 Exchange Transaction              
Debt Instrument [Line Items]              
Notes exchanged           $ 14,000,000  
Shares issued (in shares) | shares           10,798,482  
Repurchase of exchanged amount       $ 14,000,000   $ 14,000,000  
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs           10,200,000  
Reacquisition costs           200,000  
Gain on extinguishment of debt           3,600,000  
Convertible notes value           10,200,000  
Convertible notes | New Notes | Exchange Agreement              
Debt Instrument [Line Items]              
Notes exchanged           $ 14,000,000  
Shares issued (in shares) | shares           10,798,482  
Senior Notes | 5.0% Secured promissory note | Schuler Trust | Level 3              
Debt Instrument [Line Items]              
Fair value $ 16,000,000            
Senior Notes | 5.0% Secured promissory note | August 2022 Exchange Transaction | Schuler Trust              
Debt Instrument [Line Items]              
Initial conversion price (in usd per share) | $ / shares $ 2.12            
Interest rate 5.00%            
Effective interest rate       24.60%   24.60%  
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs $ 34,900,000            
Convertible notes value 34,900,000            
Secured Debt | 5.0% Secured promissory note | August 2022 Exchange Transaction | Schuler Trust              
Debt Instrument [Line Items]              
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs 49,600,000            
Convertible notes value 49,600,000            
Capital contribution from related-party in connection with exchange transaction $ 29,800,000            
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
Convertible Notes - Schedule of Interest Expense (Details) - 2.50% Convertible notes due 2023 - Convertible notes - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Debt Instrument [Line Items]        
Contractual coupon interest $ 79 $ 1,024 $ 1,528 $ 3,168
Amortization of debt issuance costs 121 185 386 539
Amortization of the debt discount 0 2,987 0 8,711
Total interest expense on convertible notes $ 200 $ 4,196 $ 1,914 $ 12,418
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
Convertible Notes - Gain on Extinguishment (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Debt Instrument [Line Items]        
Gain on extinguishment of debt $ 0 $ 9,840 $ 3,565 $ 9,840
Exchange Agreement | 2.50% Convertible notes due 2023 | Convertible notes        
Debt Instrument [Line Items]        
Gain on extinguishment of debt $ 0 $ 4,999 $ 3,565 $ 4,999
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.22.2.2
Convertible Notes - Schedule of Notes and New Notes (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Long-term debt, Total $ 80  
Convertible notes | 2.50% Convertible notes due 2023    
Debt Instrument [Line Items]    
Outstanding principal at par 56,595 $ 120,500
Unamortized debt issuance discount (270)  
Long-term debt, Total $ 56,325  
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt Related-Party - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended
Aug. 15, 2022
Sep. 30, 2022
Sep. 30, 2021
Debt Instrument [Line Items]      
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs   $ 49,624 $ 0
2.50% Convertible notes due 2023 | Convertible notes      
Debt Instrument [Line Items]      
Initial conversion price (in usd per share)   $ 30.92  
Interest rate   2.50%  
Effective interest rate   3.20%  
5.0% Secured promissory note | Senior Notes | Schuler Trust | Level 3      
Debt Instrument [Line Items]      
Fair value $ 16,000    
August 2022 Exchange Transaction | Schuler Trust | Embeded Warrant      
Debt Instrument [Line Items]      
Warrants issued (in shares) 2,471,710    
Warrants fair value $ 3,800    
August 2022 Exchange Transaction | Schuler Trust | Embeded Warrant | Level 3      
Debt Instrument [Line Items]      
Warrants fair value 3,800    
August 2022 Exchange Transaction | 2.50% Convertible notes due 2023 | Convertible notes | Schuler Trust      
Debt Instrument [Line Items]      
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs 49,900    
August 2022 Exchange Transaction | 5.0% Secured promissory note | Senior Notes | Schuler Trust      
Debt Instrument [Line Items]      
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs $ 34,900    
Initial conversion price (in usd per share) $ 2.12    
Interest rate 5.00%    
Unamortized debt issuance   $ 18,900  
Effective interest rate   24.60%  
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt Related-Party - Carrying Value of the Secured Notes (Details)
$ in Thousands
Sep. 30, 2022
USD ($)
Debt Instrument [Line Items]  
Long-term debt, Total $ 80
5.0% Secured promissory note | Senior Notes | August 2022 Exchange Transaction | Schuler Trust  
Debt Instrument [Line Items]  
Outstanding principal 34,934
Unamortized debt issuance discount (18,635)
Long-term debt, Total $ 16,299
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt Related-Party - Interest Expense in Connection with the Secured Note (Details) - Schuler Trust - August 2022 Exchange Transaction - 5.0% Secured promissory note - Senior Notes - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Debt Instrument [Line Items]        
Contractual interest $ 220 $ 0 $ 220 $ 0
Amortization of the debt discount 275 0 275 0
Total interest expense on convertible notes $ 495 $ 0 $ 495 $ 0
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.22.2.2
Long-Term Debt Related-Party - Summary of Inputs Used to Calculate Estimated Fair Value (Details) - Embeded Warrant - Schuler Trust
Sep. 30, 2022
year
Contractual term (in years)  
Class of Warrant or Right [Line Items]  
Warrants issued, measurement input 7.0
Volatility  
Class of Warrant or Right [Line Items]  
Warrants issued, measurement input 0.7610
Expected dividends  
Class of Warrant or Right [Line Items]  
Warrants issued, measurement input 0
Risk free interest rates  
Class of Warrant or Right [Line Items]  
Warrants issued, measurement input 0.0286
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.22.2.2
Loss Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details) - shares
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive common stock instruments outstanding (in shares) 12,756 9,954 12,756 9,954
Shares issuable upon the release of RSUs        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive common stock instruments outstanding (in shares) 4,619 2,320 4,619 2,320
Shares issuable upon exercise of stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive common stock instruments outstanding (in shares) 5,665 7,634 5,665 7,634
Shares issuable upon the exercise of the Warrant        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive common stock instruments outstanding (in shares) 2,472 0 2,472 0
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.22.2.2
Loss Per Share - Narrative (Details)
 9 Months Ended
Sep. 30, 2022
instrument
$ / shares
shares
Aug. 15, 2022
$ / shares
Mar. 24, 2022
shares
Debt Instrument [Line Items]      
Common stock issuable upon conversion of the Series A Preferred Stock (in shares) 3,954,546    
Schuler Trust | August 2022 Exchange Transaction      
Debt Instrument [Line Items]      
Debt instrument, convertible, number of accrued interest | instrument 103,834    
March 2022 Securities Purchase Agreement | Affiliated Entity      
Debt Instrument [Line Items]      
Agreement to purchase shares (in shares)     2,439,024
Series A Preferred Stock      
Debt Instrument [Line Items]      
Conversion ratio (in shares) 0.01    
Sale or merger trigger conversion ratio (in shares) 0.01    
Series A Preferred Stock | March 2022 Securities Purchase Agreement | Affiliated Entity      
Debt Instrument [Line Items]      
Agreement to purchase shares (in shares)     2,439,024
Prepaid Forward      
Debt Instrument [Line Items]      
Stock underlying the prepaid forward (in shares) 1,858,500    
Convertible notes | 2.50% Convertible notes due 2023      
Debt Instrument [Line Items]      
Conversion ratio 0.0323428    
Initial conversion price (in usd per share) | $ / shares $ 30.92    
Issuable upon conversion of the notes (in shares) 1,830,441    
Senior Notes | 5.0% Secured promissory note | Schuler Trust | August 2022 Exchange Transaction      
Debt Instrument [Line Items]      
Initial conversion price (in usd per share) | $ / shares   $ 2.12  
Debt instrument, convertible, number of equity instruments | instrument 16,478,066    
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.22.2.2
Employee Equity-Based Compensation - Option Activity under the Company's Equity-Based Compensation (Details) - $ / shares
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Number of Shares      
Outstanding, beginning balance (in shares)     7,192,540
Granted (in shares) 0 0 140,000
Forfeited (in shares)     (204,232)
Exercised (in shares)     (6,105)
Expired (in shares)     (1,457,019)
Outstanding, ending balance (in shares) 5,665,184   5,665,184
Weighted Average Exercise Price per Share      
Outstanding, beginning balance (in usd per share)     $ 13.89
Granted (in usd per share)     3.05
Forfeited (in usd per share)     12.49
Exercised (in usd per share)     1.04
Expired (in usd per share)     10.33
Outstanding, ending balance (in usd per share) $ 14.60   $ 14.60
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.22.2.2
Employee Equity-Based Compensation - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Dec. 31, 2020
Dec. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Granted (in shares) 0 0 140,000    
Unrecognized equity-based compensation cost $ 2.3   $ 2.3    
Expired (in shares)     1,457,019    
Number of options (in shares) 5,665,184   5,665,184   7,192,540
RSUs          
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Unrecognized equity-based compensation cost, restricted stock units $ 7.8   $ 7.8    
Performance-based stock options          
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Granted (in shares)       105,000  
Contractual life     10 years    
Exercisable (in shares)       90,000  
Expired (in shares)     90,000    
Number of options (in shares) 0   0    
Performance-based stock options | Minimum          
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Vesting period     1 year    
Expected term of award     5 years    
Performance-based stock options | Maximum          
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Vesting period     2 years    
Expected term of award     7 years    
Performance-based RSU expense          
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Contractual life     10 years    
Outstanding (in shares)       165,974 111,806
Performance-based RSU expense | Minimum          
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Vesting period     1 year    
Performance-based RSU expense | Maximum          
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]          
Vesting period     3 years    
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.22.2.2
Employee Equity-Based Compensation - Outstanding Options and Options that are Exercisable (Vested) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Options Outstanding    
Number of options (in shares) 5,665,184 7,192,540
Weighted average remaining contractual term (in years) 5 years 6 months 14 days  
Weighted average exercise price (in usd per share) $ 14.60 $ 13.89
Weighted average fair value (in usd per shares) $ 9.10  
Aggregate intrinsic value (in thousands) $ 0  
Options Exercisable    
Number of options (in shares) 4,422,595  
Weighted average remaining contractual term (in years) 5 years 14 days  
Weighted average exercise price (in usd per share) $ 15.32  
Weighted average fair value (in usd per share) $ 9.44  
Aggregate intrinsic value (in thousands) $ 0  
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.22.2.2
Employee Equity-Based Compensation - Restricted Stock Activity (Details) - RSUs and RSAs
 9 Months Ended
Sep. 30, 2022
$ / shares
shares
Number of Shares  
Beginning balance (in shares) | shares 2,090,182
Granted (in shares) | shares 4,107,083
Forfeited (in shares) | shares (451,703)
Released (in shares) | shares (1,127,017)
Ending balance (in shares) | shares 4,618,545
Weighted Average Grant Date Fair Value per Share  
Beginning balance (in usd per share) | $ / shares $ 10.77
Granted (in usd per share) | $ / shares 1.55
Forfeited (in usd per share) | $ / shares 8.68
Released (in usd per share) | $ / shares 3.43
Ending balance (in usd per share) | $ / shares $ 4.57
XML 82 R72.htm IDEA: XBRL DOCUMENT v3.22.2.2
Employee Equity-Based Compensation - Equity-Based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense $ 1,229 $ 3,629 $ 8,179 $ 19,058
Cost capitalized to inventory 69 77 186 319
Performance-based stock option expense        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense     0 230
Performance-based RSU expense        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense     0 818
Cost of sales        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense 167 82 570 257
Research and development        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense 151 266 1,052 4,340
Sales, general and administrative        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Equity-based compensation expense $ 911 $ 3,281 $ 6,557 $ 14,461
XML 83 R73.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Tax Disclosure [Abstract]        
Provision for income taxes $ 0 $ 0 $ 0 $ 0
Pre-tax loss $ (15,705,000) $ (8,986,000) $ (47,693,000) $ (54,899,000)
XML 84 R74.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Apr. 30, 2022
Commitments and Contingencies Disclosure [Abstract]    
Total commitments $ 11.9 $ 11.9
XML 85 R75.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Assets and Liabilities (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Cash paid for amounts included in lease liabilities:        
Operating cash flows from operating leases $ 219 $ 195 $ 712 $ 502
Operating cash flows from finance leases 684 0 1,109 0
ROU assets obtained in exchange for lease obligations:        
Operating leases 0 0 0 0
Finance leases 0 0 2,760 0
Lease Cost:        
Operating leases 254 257 818 816
Finance leases 240 0 462 0
Short-term leases $ 26 $ 40 $ 67 $ 99
Weighted average remaining lease term (years) 2 years 9 months 18 days   2 years 9 months 18 days  
Weighted average discount rate (%) 7.10%   7.10%  
Weighted average remaining lease term finance leases (years) 2 years 6 months   2 years 6 months  
Weighted average discount rate finance leases (%) 4.60%   4.60%  
XML 86 R76.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Maturities of Lease Liabilities (Details)
$ in Thousands
Sep. 30, 2022
USD ($)
Operating  
Remainder of 2022 $ 227
2023 968
2024 1,047
2025 584
2026 0
Thereafter 0
Total lease payments 2,826
Less imputed interest (278)
Lessee lease liabilities 2,548
Finance  
Remainder of 2022 180
2023 721
2024 721
2025 173
2026 0
Thereafter 0
Total lease payments 1,795
Less imputed interest (144)
Finance lease obligation $ 1,651
XML 87 R77.htm IDEA: XBRL DOCUMENT v3.22.2.2
Leases - Sales-type Lease Receivable Maturity (Details)
$ in Thousands
Sep. 30, 2022
USD ($)
Leases [Abstract]  
Net investment in leases $ 3,000
Remainder of 2022 351
2023 1,154
2024 661
2025 206
2026 640
Thereafter 0
Total undiscounted cash flows 3,012
Less imputed interest 0
Present value of lease payments $ 3,012
XML 88 R78.htm IDEA: XBRL DOCUMENT v3.22.2.2
Geographic and Revenue Disaggregation - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Segment Reporting [Abstract]          
Number of operating segments | segment     1    
Segment Reporting Information [Line Items]          
Trade accounts receivable, net $ 2,393   $ 2,393   $ 2,320
Lease income $ 200 $ 500 $ 1,300 $ 1,300  
Geographic concentration | Outside the U.S. | Total revenue          
Segment Reporting Information [Line Items]          
Risk concentration 14.00% 8.00% 14.00% 12.00%  
Geographic concentration | Outside the U.S. | Net accounts receivable          
Segment Reporting Information [Line Items]          
Trade accounts receivable, net $ 600   $ 600   $ 700
XML 89 R79.htm IDEA: XBRL DOCUMENT v3.22.2.2
Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Disaggregation of Revenue [Line Items]        
Net sales $ 2,960 $ 3,122 $ 9,780 $ 8,439
Accelerate Pheno revenue        
Disaggregation of Revenue [Line Items]        
Net sales 2,933 3,084 9,669 8,324
Other revenue        
Disaggregation of Revenue [Line Items]        
Net sales 27 38 111 115
Products        
Disaggregation of Revenue [Line Items]        
Net sales 2,532 2,773 8,554 7,474
Services        
Disaggregation of Revenue [Line Items]        
Net sales 428 349 1,226 965
Domestic        
Disaggregation of Revenue [Line Items]        
Net sales 2,551 2,874 8,390 7,406
Foreign        
Disaggregation of Revenue [Line Items]        
Net sales $ 409 $ 248 $ 1,390 $ 1,033
XML 90 R80.htm IDEA: XBRL DOCUMENT v3.22.2.2
Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Segment Reporting Information [Line Items]    
Long-lived assets (excluding intangible assets) $ 3,621 $ 5,389
Property and equipment | Geographic concentration    
Segment Reporting Information [Line Items]    
Long-lived assets (excluding intangible assets) 3,621 5,389
Property and equipment | Geographic concentration | Domestic    
Segment Reporting Information [Line Items]    
Long-lived assets (excluding intangible assets) 3,383 5,014
Property and equipment | Geographic concentration | Foreign    
Segment Reporting Information [Line Items]    
Long-lived assets (excluding intangible assets) $ 238 $ 375
XML 91 R81.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended
Aug. 22, 2022
USD ($)
$ / shares
shares
Aug. 15, 2022
USD ($)
Mar. 21, 2022
USD ($)
Oct. 29, 2021
USD ($)
shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Sep. 17, 2021
tranche
shares
Sep. 30, 2021
USD ($)
tranche
$ / shares
shares
Dec. 31, 2020
USD ($)
entity
tranche
$ / shares
shares
Apr. 09, 2021
USD ($)
Sep. 30, 2022
USD ($)
$ / shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Sep. 30, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Mar. 24, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
$ / shares
Sep. 22, 2021
$ / shares
Class of Stock [Line Items]                                
Share price (in usd per share) | $ / shares         $ 5.83   $ 5.83       $ 5.83   $ 5.83     $ 5.81
Proceeds from issuance of common stock                       $ 32,872 $ 22,640      
Preferred Stock, par value (in usd per share) | $ / shares                   $ 0.001   $ 0.001     $ 0.001  
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs                       $ 49,624 0      
August 2022 Public Offering                                
Class of Stock [Line Items]                                
Share price (in usd per share) | $ / shares $ 2.00                              
Net proceeds $ 32,900                              
Series A Preferred Stock                                
Class of Stock [Line Items]                                
Conversion ratio (in shares)                   0.01   0.01        
Common stock | August 2022 Public Offering                                
Class of Stock [Line Items]                                
Sale of stock (in shares) | shares 17,500,000                              
2.50% Convertible notes due 2023 | Convertible notes | 2021 Exchange Transaction                                
Class of Stock [Line Items]                                
Notes exchanged                         $ 46,000      
Shares issued (in shares) | shares                         5,945,718      
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs                         $ 34,500      
2.50% Convertible notes due 2023 | Convertible notes | March 2022 Exchange Transaction                                
Class of Stock [Line Items]                                
Notes exchanged     $ 14,000                          
New Notes | Convertible notes | March 2022 Exchange Transaction                                
Class of Stock [Line Items]                                
Notes exchanged                       $ 14,000        
Shares issued (in shares) | shares                       10,798,482        
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs                       $ 10,200        
Schuler Trust | August 2022 Exchange Transaction | Embeded Warrant                                
Class of Stock [Line Items]                                
Warrants fair value   $ 3,800                            
Schuler Trust | August 2022 Exchange Transaction | Embeded Warrant | Level 3                                
Class of Stock [Line Items]                                
Warrants fair value   3,800                            
Warrant issued to related-party   3,800                            
Schuler Trust | 2.50% Convertible notes due 2023 | Convertible notes | August 2022 Exchange Transaction                                
Class of Stock [Line Items]                                
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs   49,900                            
Schuler Trust | 5.0% Secured promissory note | Senior Notes | August 2022 Exchange Transaction                                
Class of Stock [Line Items]                                
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs   34,900                            
Schuler Trust | 5.0% Secured promissory note | Secured Debt | August 2022 Exchange Transaction                                
Class of Stock [Line Items]                                
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs   49,600                            
Capital contribution from related-party in connection with exchange transaction   $ 29,800                            
Schuler Trust | Extinguished Notes | Secured Debt | August 2022 Exchange Transaction                                
Class of Stock [Line Items]                                
Capital contribution from related-party in connection with exchange transaction                   $ 29,800   $ 29,800        
December 2020 Securities Purchase Agreement | Affiliated Entity                                
Class of Stock [Line Items]                                
Purchase price               $ 32,000                
Share price (in usd per share) | $ / shares               $ 7.68                
Number of tranches | tranche               3                
Proceeds from issuance of common stock         $ 500       $ 21,300       $ 1,500      
Sale of stock (in shares) | shares                         201,820      
December 2020 Securities Purchase Agreement | Affiliated Entity | Original Purchasers                                
Class of Stock [Line Items]                                
Agreement to purchase shares (in shares) | shares               4,166,663                
Non-affiliate related entities | entity               3                
December 2020 Securities Purchase Agreement | Affiliated Entity | Schuler Trust                                
Class of Stock [Line Items]                                
Agreement to purchase shares (in shares) | shares               3,964,843                
Purchase price               $ 30,500                
Non-affiliate related entities | entity               3                
September 2021 Rescission Agreement | Affiliated Entity                                
Class of Stock [Line Items]                                
Number of tranches | tranche           2                    
Sale of stock (in shares) | shares           2,643,228                    
September 2021 Securities Purchase Agreement | Affiliated Entity                                
Class of Stock [Line Items]                                
Number of tranches | tranche             2                  
September 2021 Securities Purchase Agreement | Affiliated Entity | Series A Preferred Stock                                
Class of Stock [Line Items]                                
Sale of stock (in shares) | shares             2,636,364           2,636,364      
Agreement to purchase preferred shares (in shares) | shares         3,954,546   3,954,546       3,954,546   3,954,546      
Preferred Stock, par value (in usd per share) | $ / shares         $ 0.001   $ 0.001       $ 0.001   $ 0.001      
Conversion ratio (in shares)         1   1       1   1      
Aggregate purchase price         $ 30,500   $ 30,500       $ 30,500   $ 30,500      
Proceeds from issuance of preferred stock                     $ 20,300          
Tranche Right | Affiliated Entity | Series A Preferred Stock                                
Class of Stock [Line Items]                                
Sale of stock (in shares) | shares       1,318,182                        
Agreement to purchase preferred shares (in shares) | shares         1,318,182   1,318,182       1,318,182   1,318,182      
Share price (in usd per share) | $ / shares         $ 7.70   $ 7.70       $ 7.70   $ 7.70      
Proceeds from issuance of preferred stock       $ 10,200     $ 10,200                  
Tranche right value         $ 2,500   $ 2,500       $ 2,500   $ 2,500      
March 2022 Securities Purchase Agreement | Affiliated Entity                                
Class of Stock [Line Items]                                
Agreement to purchase shares (in shares) | shares                           2,439,024    
Purchase price                           $ 4,000    
Share price (in usd per share) | $ / shares                           $ 1.64    
March 2022 Securities Purchase Agreement | Affiliated Entity | Series A Preferred Stock                                
Class of Stock [Line Items]                                
Agreement to purchase shares (in shares) | shares                           2,439,024    
XML 92 R82.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related-Party Transactions (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 2 Months Ended 3 Months Ended 9 Months Ended
Aug. 15, 2022
Sep. 30, 2021
Sep. 22, 2021
Sep. 17, 2021
Sep. 30, 2021
Apr. 09, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Mar. 24, 2022
Dec. 31, 2020
Dec. 24, 2020
Related Party Transaction [Line Items]                          
Share price (in usd per share)   $ 5.83 $ 5.81   $ 5.83     $ 5.83   $ 5.83      
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs                 $ 49,624 $ 0      
Proceeds from issuance of common stock                 32,872 $ 22,640      
Affiliated Entity | Convertible Note Purchases | 2021 Exchange Transaction                          
Related Party Transaction [Line Items]                          
Shares issued (in shares)     5,428,699                    
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs               $ 31,500          
Affiliated Entity | September 2021 Rescission Agreement                          
Related Party Transaction [Line Items]                          
Sale of stock (in shares)       2,643,228                  
Affiliated Entity | December 2020 Securities Purchase Agreement                          
Related Party Transaction [Line Items]                          
Share price (in usd per share)                       $ 7.68  
Sale of stock (in shares)                   201,820      
Proceeds from issuance of common stock   $ 500       $ 21,300       $ 1,500      
Affiliated Entity | September 2021 Securities Purchase Agreement | Series A Preferred Stock                          
Related Party Transaction [Line Items]                          
Sale of stock (in shares)         2,636,364         2,636,364      
Agreement to purchase preferred shares (in shares)   3,954,546     3,954,546     3,954,546   3,954,546      
Proceeds from issuance of preferred stock               $ 20,300          
Affiliated Entity | Securities Purchase Agreement                          
Related Party Transaction [Line Items]                          
Agreement to purchase shares (in shares)                         4,166,663
Affiliated Entity | March 2022 Securities Purchase Agreement                          
Related Party Transaction [Line Items]                          
Share price (in usd per share)                     $ 1.64    
Agreement to purchase shares (in shares)                     2,439,024    
Affiliated Entity | March 2022 Securities Purchase Agreement | Series A Preferred Stock                          
Related Party Transaction [Line Items]                          
Agreement to purchase shares (in shares)                     2,439,024    
Affiliated Entity | Schuler Family Foundation | Convertible Note Purchases | 2021 Exchange Transaction                          
Related Party Transaction [Line Items]                          
Aggregate principal amount   $ 42,000     $ 42,000     $ 42,000   $ 42,000      
Convertible notes | 2.50% Convertible notes due 2023 | 2021 Exchange Transaction                          
Related Party Transaction [Line Items]                          
Shares issued (in shares)                   5,945,718      
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs                   $ 34,500      
Convertible notes | 2.50% Convertible notes due 2023 | Schuler Trust | August 2022 Exchange Transaction                          
Related Party Transaction [Line Items]                          
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs $ 49,900                        
Senior Notes | 5.0% Secured promissory note | Schuler Trust | August 2022 Exchange Transaction                          
Related Party Transaction [Line Items]                          
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs 34,900                        
Secured Debt | 5.0% Secured promissory note | Schuler Trust | August 2022 Exchange Transaction                          
Related Party Transaction [Line Items]                          
Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs 49,600                        
Capital contribution from related-party in connection with exchange transaction $ (29,800)                        
Secured Debt | Extinguished Notes | Schuler Trust | August 2022 Exchange Transaction                          
Related Party Transaction [Line Items]                          
Capital contribution from related-party in connection with exchange transaction             $ (29,800)   $ (29,800)        
XML 93 axdx-20220930_htm.xml IDEA: XBRL DOCUMENT 0000727207 2022-01-01 2022-09-30 0000727207 2022-11-10 0000727207 2022-09-30 0000727207 2021-12-31 0000727207 2022-07-01 2022-09-30 0000727207 2021-07-01 2021-09-30 0000727207 2021-01-01 2021-09-30 0000727207 2020-12-31 0000727207 2021-09-30 0000727207 us-gaap:PreferredStockMember 2022-06-30 0000727207 us-gaap:PreferredStockMember 2021-06-30 0000727207 us-gaap:PreferredStockMember 2021-12-31 0000727207 us-gaap:PreferredStockMember 2020-12-31 0000727207 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0000727207 us-gaap:PreferredStockMember 2021-01-01 2021-09-30 0000727207 us-gaap:PreferredStockMember 2022-09-30 0000727207 us-gaap:PreferredStockMember 2021-09-30 0000727207 us-gaap:CommonStockMember 2022-06-30 0000727207 us-gaap:CommonStockMember 2021-06-30 0000727207 us-gaap:CommonStockMember 2021-12-31 0000727207 us-gaap:CommonStockMember 2020-12-31 0000727207 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000727207 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000727207 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0000727207 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000727207 us-gaap:CommonStockMember 2022-09-30 0000727207 us-gaap:CommonStockMember 2021-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000727207 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000727207 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000727207 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000727207 us-gaap:RetainedEarningsMember 2022-06-30 0000727207 us-gaap:RetainedEarningsMember 2021-06-30 0000727207 us-gaap:RetainedEarningsMember 2021-12-31 0000727207 us-gaap:RetainedEarningsMember 2020-12-31 0000727207 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2021-12-31 0000727207 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000727207 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000727207 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0000727207 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000727207 us-gaap:RetainedEarningsMember 2022-09-30 0000727207 us-gaap:RetainedEarningsMember 2021-09-30 0000727207 us-gaap:TreasuryStockCommonMember 2022-06-30 0000727207 us-gaap:TreasuryStockCommonMember 2021-06-30 0000727207 us-gaap:TreasuryStockCommonMember 2021-12-31 0000727207 us-gaap:TreasuryStockCommonMember 2020-12-31 0000727207 us-gaap:TreasuryStockCommonMember 2022-09-30 0000727207 us-gaap:TreasuryStockCommonMember 2021-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-09-30 0000727207 2022-06-30 0000727207 2021-06-30 0000727207 srt:MinimumMember 2022-01-01 2022-09-30 0000727207 srt:MaximumMember 2022-01-01 2022-09-30 0000727207 axdx:InstrumentsMember 2022-01-01 2022-09-30 0000727207 srt:MinimumMember 2022-09-30 0000727207 srt:MaximumMember 2022-09-30 0000727207 us-gaap:EquipmentMember 2022-09-30 0000727207 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate202006Member 2022-01-01 0000727207 us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember axdx:FinancialInstitutionsOneMember 2022-01-01 2022-09-30 0000727207 us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember axdx:FinancialInstitutionsTwoMember 2022-01-01 2022-09-30 0000727207 us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember axdx:FinancialInstitutionsThreeMember 2022-01-01 2022-09-30 0000727207 us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember axdx:FinancialInstitutionsOneMember 2021-01-01 2021-12-31 0000727207 us-gaap:CashAndCashEquivalentsMember us-gaap:CreditConcentrationRiskMember axdx:FinancialInstitutionsTwoMember 2021-01-01 2021-12-31 0000727207 axdx:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0000727207 axdx:OneCustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2022-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2021-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2021-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2022-09-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-12-31 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2021-12-31 0000727207 axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:FairValueInputsLevel3Member us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2022-08-15 0000727207 axdx:EmbededWarrantMember axdx:August2022ExchangeTransactionMember us-gaap:FairValueInputsLevel3Member axdx:JackWSchulerLivingTrustMember 2022-08-15 0000727207 us-gaap:CertificatesOfDepositMember 2022-09-30 0000727207 us-gaap:USTreasuryAndGovernmentMember 2022-09-30 0000727207 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-09-30 0000727207 us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000727207 us-gaap:CertificatesOfDepositMember 2021-12-31 0000727207 us-gaap:USTreasuryAndGovernmentMember 2021-12-31 0000727207 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2021-12-31 0000727207 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000727207 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-09-30 0000727207 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-07-01 2021-09-30 0000727207 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-09-30 0000727207 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-07-01 2022-09-30 0000727207 us-gaap:ComputerEquipmentMember 2022-09-30 0000727207 us-gaap:ComputerEquipmentMember 2021-12-31 0000727207 us-gaap:TechnologyEquipmentMember 2022-09-30 0000727207 us-gaap:TechnologyEquipmentMember 2021-12-31 0000727207 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2022-09-30 0000727207 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2021-12-31 0000727207 axdx:InstrumentsMember 2022-09-30 0000727207 axdx:InstrumentsMember 2021-12-31 0000727207 us-gaap:ConstructionInProgressMember 2022-09-30 0000727207 us-gaap:ConstructionInProgressMember 2021-12-31 0000727207 axdx:ProductsandServicesnotYetDeliveredMember 2022-09-30 0000727207 axdx:ProductsandServicesnotYetDeliveredMember 2021-12-31 0000727207 axdx:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2020-01-01 2020-12-31 0000727207 srt:MinimumMember axdx:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2020-12-31 0000727207 srt:MaximumMember axdx:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2020-12-31 0000727207 axdx:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2022-09-30 0000727207 axdx:OtherLoansMember us-gaap:NotesPayableOtherPayablesMember 2021-12-31 0000727207 axdx:PaycheckProtectionProgramMember us-gaap:UnsecuredDebtMember 2020-04-14 0000727207 axdx:PaycheckProtectionProgramMember us-gaap:UnsecuredDebtMember 2021-07-15 2021-07-15 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000727207 axdx:ConvertibleNotesExchangeAgreementMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-30 0000727207 axdx:ConvertibleNotesExchangeAgreementMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0000727207 axdx:ConvertibleNotesExchangeAgreementMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0000727207 axdx:ConvertibleNotesExchangeAgreementMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000727207 axdx:PrepaidForwardMember 2022-01-01 2022-09-30 0000727207 axdx:PrepaidForwardMember 2022-09-30 0000727207 axdx:A2021ExchangeTransactionMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-01-01 2021-09-30 0000727207 axdx:A2021ExchangeTransactionMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-09-30 0000727207 axdx:A2021ExchangeTransactionMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2021-07-01 2021-09-30 0000727207 axdx:March2022ExchangeTransactionMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-03-21 2022-03-21 0000727207 axdx:March2022ExchangeTransactionMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-03-21 0000727207 axdx:March2022ExchangeTransactionMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-03-29 2022-05-18 0000727207 axdx:ConvertibleNotesExchangeAgreementMember axdx:TwoPointFiveZeroNewConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0000727207 axdx:March2022ExchangeTransactionMember axdx:TwoPointFiveZeroNewConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-09-30 0000727207 axdx:March2022ExchangeTransactionMember axdx:TwoPointFiveZeroNewConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0000727207 axdx:August2022ExchangeTransactionMember axdx:TwoPointFiveZeroConvertibleNotesDue2023Member us-gaap:ConvertibleDebtMember axdx:JackWSchulerLivingTrustMember 2022-08-15 2022-08-15 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2022-08-15 2022-08-15 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SecuredDebtMember axdx:JackWSchulerLivingTrustMember 2022-08-15 2022-08-15 0000727207 axdx:EmbededWarrantMember axdx:August2022ExchangeTransactionMember axdx:JackWSchulerLivingTrustMember 2022-08-15 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2022-08-15 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2022-09-30 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2022-07-01 2022-09-30 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2021-07-01 2021-09-30 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2022-01-01 2022-09-30 0000727207 axdx:August2022ExchangeTransactionMember axdx:FivePointZeroPercentSecuredPromissoryNoteMember us-gaap:SeniorNotesMember axdx:JackWSchulerLivingTrustMember 2021-01-01 2021-09-30 0000727207 axdx:EmbededWarrantMember axdx:August2022ExchangeTransactionMember axdx:JackWSchulerLivingTrustMember 2022-08-15 2022-08-15 0000727207 axdx:EmbededWarrantMember us-gaap:MeasurementInputExpectedTermMember axdx:JackWSchulerLivingTrustMember 2022-09-30 0000727207 axdx:EmbededWarrantMember us-gaap:MeasurementInputPriceVolatilityMember axdx:JackWSchulerLivingTrustMember 2022-09-30 0000727207 axdx:EmbededWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember axdx:JackWSchulerLivingTrustMember 2022-09-30 0000727207 axdx:EmbededWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember axdx:JackWSchulerLivingTrustMember 2022-09-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0000727207 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0000727207 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0000727207 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0000727207 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0000727207 us-gaap:WarrantMember 2022-07-01 2022-09-30 0000727207 us-gaap:WarrantMember 2021-07-01 2021-09-30 0000727207 us-gaap:WarrantMember 2022-01-01 2022-09-30 0000727207 us-gaap:WarrantMember 2021-01-01 2021-09-30 0000727207 us-gaap:SeriesAPreferredStockMember 2022-09-30 0000727207 axdx:March2022SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2022-03-24 0000727207 axdx:August2022ExchangeTransactionMember axdx:JackWSchulerLivingTrustMember 2022-01-01 2022-09-30 0000727207 axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember 2021-12-31 0000727207 axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember 2022-01-01 2022-09-30 0000727207 axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember 2022-09-30 0000727207 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000727207 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0000727207 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0000727207 us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0000727207 srt:MinimumMember us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0000727207 srt:MaximumMember us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0000727207 us-gaap:PerformanceSharesMember 2022-01-01 2022-09-30 0000727207 us-gaap:PerformanceSharesMember 2020-01-01 2020-12-31 0000727207 us-gaap:PerformanceSharesMember 2022-09-30 0000727207 us-gaap:PerformanceSharesMember 2021-01-01 2021-09-30 0000727207 srt:MinimumMember axdx:PerformanceBasedRestrictedStockUnitsMember 2022-01-01 2022-09-30 0000727207 srt:MaximumMember axdx:PerformanceBasedRestrictedStockUnitsMember 2022-01-01 2022-09-30 0000727207 axdx:PerformanceBasedRestrictedStockUnitsMember 2022-01-01 2022-09-30 0000727207 axdx:PerformanceBasedRestrictedStockUnitsMember 2020-12-31 0000727207 axdx:PerformanceBasedRestrictedStockUnitsMember 2021-12-31 0000727207 axdx:PerformanceBasedRestrictedStockUnitsMember 2021-01-01 2021-09-30 0000727207 2022-04-30 0000727207 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2022-07-01 2022-09-30 0000727207 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2021-07-01 2021-09-30 0000727207 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2022-01-01 2022-09-30 0000727207 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2021-01-01 2021-09-30 0000727207 us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2022-09-30 0000727207 us-gaap:AccountsReceivableMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2021-12-31 0000727207 us-gaap:GeographicDistributionDomesticMember 2022-07-01 2022-09-30 0000727207 us-gaap:GeographicDistributionDomesticMember 2021-07-01 2021-09-30 0000727207 us-gaap:GeographicDistributionDomesticMember 2022-01-01 2022-09-30 0000727207 us-gaap:GeographicDistributionDomesticMember 2021-01-01 2021-09-30 0000727207 us-gaap:GeographicDistributionForeignMember 2022-07-01 2022-09-30 0000727207 us-gaap:GeographicDistributionForeignMember 2021-07-01 2021-09-30 0000727207 us-gaap:GeographicDistributionForeignMember 2022-01-01 2022-09-30 0000727207 us-gaap:GeographicDistributionForeignMember 2021-01-01 2021-09-30 0000727207 axdx:AcceleratePhenoMember 2022-07-01 2022-09-30 0000727207 axdx:AcceleratePhenoMember 2021-07-01 2021-09-30 0000727207 axdx:AcceleratePhenoMember 2022-01-01 2022-09-30 0000727207 axdx:AcceleratePhenoMember 2021-01-01 2021-09-30 0000727207 axdx:OtherRevenueMember 2022-07-01 2022-09-30 0000727207 axdx:OtherRevenueMember 2021-07-01 2021-09-30 0000727207 axdx:OtherRevenueMember 2022-01-01 2022-09-30 0000727207 axdx:OtherRevenueMember 2021-01-01 2021-09-30 0000727207 us-gaap:ProductMember 2022-07-01 2022-09-30 0000727207 us-gaap:ProductMember 2021-07-01 2021-09-30 0000727207 us-gaap:ProductMember 2022-01-01 2022-09-30 0000727207 us-gaap:ProductMember 2021-01-01 2021-09-30 0000727207 us-gaap:ServiceMember 2022-07-01 2022-09-30 0000727207 us-gaap:ServiceMember 2021-07-01 2021-09-30 0000727207 us-gaap:ServiceMember 2022-01-01 2022-09-30 0000727207 us-gaap:ServiceMember 2021-01-01 2021-09-30 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionDomesticMember 2022-09-30 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionDomesticMember 2021-12-31 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2022-09-30 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2021-12-31 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember 2022-09-30 0000727207 us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicConcentrationRiskMember 2021-12-31 0000727207 axdx:CertainDirectorsAndOfficersOrAffiliatesMember axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2020-12-31 0000727207 axdx:JackWSchulerLivingTrustMember axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2020-12-31 0000727207 axdx:CertainDirectorsAndOfficersOrAffiliatesMember axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2020-12-01 2020-12-31 0000727207 axdx:JackWSchulerLivingTrustMember axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2020-12-01 2020-12-31 0000727207 axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2020-12-31 0000727207 axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2020-12-01 2020-12-31 0000727207 axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2021-02-19 2021-04-09 0000727207 axdx:September2021RescissionAgreementMember srt:AffiliatedEntityMember 2021-09-17 2021-09-17 0000727207 axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2021-09-30 2021-09-30 0000727207 axdx:December2020SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2021-01-01 2021-09-30 0000727207 axdx:September2021SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0000727207 axdx:September2021SecuritiesPurchaseAgreementSecondTrancheRightMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2021-09-30 0000727207 axdx:September2021SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2021-09-01 2021-09-30 0000727207 axdx:September2021SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2021-09-01 2021-09-30 0000727207 axdx:September2021SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2021-07-01 2021-09-30 0000727207 axdx:September2021SecuritiesPurchaseAgreementSecondTrancheRightMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2021-09-01 2021-09-30 0000727207 2021-09-22 0000727207 axdx:September2021SecuritiesPurchaseAgreementSecondTrancheRightMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2021-10-29 2021-10-29 0000727207 axdx:August2022ExchangeTransactionMember axdx:ExtinguishedNotesMember us-gaap:SecuredDebtMember axdx:JackWSchulerLivingTrustMember 2022-07-01 2022-09-30 0000727207 axdx:EmbededWarrantMember axdx:August2022ExchangeTransactionMember us-gaap:FairValueInputsLevel3Member axdx:JackWSchulerLivingTrustMember 2022-08-15 2022-08-15 0000727207 us-gaap:CommonStockMember axdx:August2022PublicOfferingMember 2022-08-22 2022-08-22 0000727207 axdx:August2022PublicOfferingMember 2022-08-22 0000727207 axdx:August2022PublicOfferingMember 2022-08-22 2022-08-22 0000727207 axdx:SchulerFamilyFoundationMember axdx:A2021ExchangeTransactionMember axdx:ConvertibleNotePurchasesMember srt:AffiliatedEntityMember 2021-09-30 0000727207 axdx:A2021ExchangeTransactionMember axdx:ConvertibleNotePurchasesMember srt:AffiliatedEntityMember 2021-09-22 2021-09-22 0000727207 axdx:A2021ExchangeTransactionMember axdx:ConvertibleNotePurchasesMember srt:AffiliatedEntityMember 2021-07-01 2021-09-30 0000727207 axdx:SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember 2020-12-24 0000727207 axdx:September2021SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2021-01-01 2021-09-30 0000727207 axdx:March2022SecuritiesPurchaseAgreementMember srt:AffiliatedEntityMember us-gaap:SeriesAPreferredStockMember 2022-03-24 0000727207 axdx:August2022ExchangeTransactionMember axdx:ExtinguishedNotesMember us-gaap:SecuredDebtMember axdx:JackWSchulerLivingTrustMember 2022-01-01 2022-09-30 shares iso4217:USD iso4217:USD shares axdx:instrument pure axdx:loan axdx:day axdx:tranche axdx:year axdx:segment axdx:entity 0000727207 false --12-31 Q3 2022 P1Y P2Y 0.0323428 0.02264 0.0323428 10-Q true 2022-09-30 false 001-31822 ACCELERATE DIAGNOSTICS, INC. DE 84-1072256 3950 South Country Club Road, Suite 470 Tucson, AZ 85714 520 365-3100 Common Stock, $0.001 par AXDX NASDAQ Yes Yes Non-accelerated Filer true false false 99099480 38987000 39898000 16407000 23720000 2393000 2320000 5392000 5067000 1119000 768000 1974000 1558000 66272000 73331000 3621000 5389000 2319000 0 2012000 2510000 1623000 1817000 75847000 83047000 2819000 1983000 4300000 2853000 118000 909000 524000 451000 80000 80000 953000 0 774000 669000 9568000 6945000 698000 0 1775000 2381000 759000 808000 220000 0 16299000 0 56325000 107984000 85644000 118118000 0.001 0.001 5000000 5000000 3954546 3954546 4000 4000 0.001 0.001 200000000 97240983 97240983 100000000 67649018 67649018 97000 68000 627853000 580652000 45067000 45067000 -592439000 -570668000 -245000 -60000 -9797000 -35071000 75847000 83047000 2960000 3122000 9780000 8439000 2190000 2136000 7127000 5502000 770000 986000 2653000 2937000 7285000 4712000 20885000 17341000 8255000 10806000 30422000 37744000 15540000 15518000 51307000 55085000 -14770000 -14532000 -48654000 -52148000 203000 4211000 1833000 12477000 495000 0 495000 0 0 9840000 3565000 9840000 -261000 -78000 -221000 -238000 73000 0 151000 55000 -49000 -5000 -206000 69000 -935000 5546000 961000 -2751000 -15705000 -8986000 -47693000 -54899000 0 0 0 0 -15705000 -8986000 -47693000 -54899000 -0.18 -0.18 -0.15 -0.15 -0.62 -0.62 -0.91 -0.91 87011000 87011000 61146000 61146000 77049000 77049000 60250000 60250000 -15705000 -8986000 -47693000 -54899000 48000 -3000 -84000 -21000 139000 -27000 -101000 -87000 -15518000 -9016000 -47878000 -55007000 -47693000 -54899000 2207000 1875000 -94000 -153000 8179000 19058000 386000 9250000 275000 0 -74000 202000 -206000 39000 3565000 9840000 174000 304000 73000 719000 245000 527000 491000 -860000 1221000 1017000 962000 -436000 -785000 -1059000 220000 0 73000 93000 -49000 343000 -39178000 -35376000 446000 202000 27506000 22345000 34527000 33601000 6575000 11054000 32872000 22640000 1109000 0 7000 1456000 184000 245000 192000 0 6000 6000 31756000 24335000 -64000 -69000 -911000 -56000 39898000 35781000 38987000 35725000 -78000 508000 10180000 34545000 49624000 0 16024000 0 3753000 0 29847000 0 2214000 4288000 3955000 0 3955000 0 2636000 2636000 3955000 2636000 3955000 2636000 4000 0 4000 0 3000 3000 4000 3000 4000 3000 79701000 61489000 67649000 57608000 17500000 67000 17500000 2937000 6000 62000 1134000 1052000 34000 16000 159000 37000 2643000 2643000 5946000 10799000 5946000 97241000 64937000 97241000 64937000 80000 61000 68000 58000 17000 1000 17000 3000 1000 1000 3000 3000 6000 11000 6000 97000 65000 97000 65000 560185000 514122000 580652000 475072000 -37438000 32855000 517000 32855000 22637000 234000 6000 1455000 47000 84000 184000 245000 34539000 10169000 34539000 29847000 29847000 3753000 3753000 1166000 3638000 7825000 19186000 627853000 553134000 627853000 553134000 -576734000 -538879000 -570668000 -492966000 25922000 -15705000 -8986000 -47693000 -54899000 -592439000 -547865000 -592439000 -547865000 -45067000 -45067000 -45067000 -45067000 -45067000 -45067000 -45067000 -45067000 -432000 13000 -60000 91000 48000 -3000 -84000 -21000 139000 -27000 -101000 -87000 -245000 -17000 -245000 -17000 -9797000 -39747000 -9797000 -39747000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION; SIGNIFICANT ACCOUNTING POLICIES</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerate Diagnostics, Inc. (“we” or “us” or “our” or “Accelerate” or the “Company”) is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 14, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date but does not include all disclosures such as notes required by U.S. GAAP.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2022, or any future period.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All amounts are rounded to the nearest thousand dollars unless otherwise indicated.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk and Uncertainties</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through multiple equity raises, one convertible debt offering, and Secured Note (as defined in Note 11). The Company is subject to a number of risks similar to other early commercial stage life science companies, including, but not limited to commercially launching the Company’s products, development and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The COVID-19 pandemic, containment measures, and downstream impacts to hospital staffing and financial stability have caused business slowdowns or shutdowns in affected areas, both, as well as disruptions to global supply chains and workforce participation. These effects have significantly impacted the Company’s business and results of operations, starting in the first quarter of 2020 and continuing through the current quarter, albeit to a lesser degree. These impacts include diminished access to the Company’s customers, principally hospitals, which has severely limited the ability to sell or implement products. Furthermore, the expected rate of growth of the Company’s consumable test kit sales has been reduced because of the negative impact of the COVID-19 pandemic on Accelerate Pheno system new sales and implementations. The Company has reviewed its suppliers and quantities of key materials and believes that it has sufficient stocks and alternate sources of critical materials should the supply chains become further disrupted, although raw materials for the manufacturing of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">reagents is in high demand, and interruptions in supply are difficult to predict. The COVID-19 pandemic also caused the Company to reassess its build plan and evaluate its inventories accordingly, which resulted in additional charges to cost of sales for excess inventories in the prior year.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company may seek to fund its operations through public equity, private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. The Company’s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company’s business, results of operations, financial condition and the Company’s ability to develop new products. To the extent the Company raises additional funds through the sale of equity, issue convertible debt securities or exchange convertible debt for equity, the issuance of securities will result in dilution to stockholders. Investors purchasing shares or other securities in the future could have rights superior to existing stockholders. In addition, the Company has a significant number of options and restricted stock units (“RSUs”) outstanding in addition to the Warrant (as defined in Note 11). If these options or the Warrant are exercised or such RSUs are released, or shares of the Company’s common stock are issued upon conversion of the Company’s outstanding 2.50% Senior Convertible Notes due 2023 (the “Notes”) or Series A Preferred Stock, further dilution may occur.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to assess liquidity needs and manage cash flows. As a result of the steps the Company has taken to enhance its liquidity, the Company currently believes that cash on hand and cash flows from operations will enable the Company to meet its working capital, capital expenditure, debt service and other funding requirements for at least one year from the date this Quarterly Report on Form 10-Q (this “Form 10-Q”) is issued. The Company’s view regarding sufficiency of cash and liquidity is primarily based on our financial forecast for 12 months from the date these condensed consolidated financial statements are filed, which is impacted by, among other things, various assumptions regarding demand and sales prices for our products. Our financial forecasts in recent periods have proven less reliable due to conditions created by the pandemic. As a result, there is no guarantee our financial forecast, which projects sufficient cash will be available to meet planned operating expenses and other cash needs, will be accurate. In the event the Company experiences lower customer demand, lower prices for its products and services, or higher expenses than it forecasted or if the Company underperforms relative to its forecast, the Company could experience negative cash flows from operations, as has been the case in prior years, which would reduce its cash balances and liquidity.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, convertible notes, notes from related parties, tax valuation accounts, equity–based compensation, warrants, revenue and leases. Actual results could differ materially from those estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimated Fair Value of Financial Instruments</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three-tiered approach and fair value measurement be classified and disclosed in one of the following three categories:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4, Fair Value of Financial Instruments, for further information and related disclosures regarding the Company’s fair value measurements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Notes represents a Level 2 measurement. See Note 10, Convertible Notes for further detail on the Notes.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The long-term debt with a related-party consisting of the Secured Note (as defined in Note 11) and the Warrant are instruments measured at fair value on a non-recurring basis using Level 3 inputs. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note and the Warrant. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in various debt and equity securities which are primarily held in the custody of major financial institutions. Debt securities consist of certificates of deposit, U.S. government and agency securities, commercial paper, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ deficit. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of condensed consolidated statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security is considered impaired if its fair value is less than its amortized cost basis at the reporting date. If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We charge cost of sales for inventory provisions to write-down our inventory to the lower of cost or net realizable value or for obsolete or excess inventory. Most of our inventory provisions relate to excess quantities of products, based on our inventory levels and future product purchase commitments compared to assumptions about future demand and market conditions. Once inventory has been written-off or written-down, it creates a new cost basis for the inventory that is not subsequently written-up.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6, Inventory, for further information and related disclosures.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. Our customers typically have good credit quality. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for credit losses for the three and nine months ended September 30, 2022 and 2021 is comprised of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">445 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Reversals) provisions, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-offs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The write-offs recorded during the nine months ended September 30, 2021 were in connection with a one-time restructuring activity of the Company's Europe, Middle East and Africa (“EMEA”) business. These credit losses were incurred as part of the Company terminating agreements with select distributors in geographies it exited and did not pursue collection of these accounts receivables.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkxM2E3ZDQwZWQxZjQxMWE4OGNlZjBmMjdhOTQwMGE2L3NlYzo5MTNhN2Q0MGVkMWY0MTFhODhjZWYwZjI3YTk0MDBhNl8zMS9mcmFnOjc3NTc5ZThlMjczZDRjZDhhMmI5ZTA0MGVmNTdkYjU3L3RleHRyZWdpb246Nzc1NzllOGUyNzNkNGNkOGEyYjllMDQwZWY1N2RiNTdfMTU2MjQ_9239f206-4045-4db4-b78c-b726f35da994">one</span> to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Instruments Classified as Property and Equipment</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of for the three and nine months ended September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 7, Property and Equipment, for further information and related disclosures.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty Reserve</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The cost incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty reserve activity for the three and nine months ended September 30, 2022 and 2021 is as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions (reversals), net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty cost incurred</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022 the Company adopted Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. Gain or loss on extinguishment of Notes is calculated as the difference between the (i) fair value of the consideration transferred and (ii) the sum of the carrying value of the debt at the time of repurchase.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies the Notes as a non-current liability as the Company has sufficient shares and non-cash alternatives to settle the Notes.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2, Recently Issued Accounting Pronouncements and Note 10, Convertible Notes, for further information and related disclosures.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the promised good or service is transferred to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines revenue recognition through the following steps:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract with a customer</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue as we satisfy a performance obligation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is derived from the sale or rental of instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized. Payment terms vary by the type and location of the customer and the products or services offered. The term between invoicing and when payment is due is not significant.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The Company generally determines relative standalone selling prices based on the price charged to customers for each individual performance obligation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions earned by the Company’s sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and nine months ended September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit and Gross Margin</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit consists of total revenue, net of allowances, less cost of sales. Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related costs.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s overall gross margin was 26% and 32% for the three months ended September 30, 2022 and 2021, respectively, and 27% and 35% for the nine months ended September 30, 2022 and 2021, respectively. The decreases were primarily due to increases in the costs to manufacture consumables due to supply chain inflationary factors and a decrease in our average unit sales price period over period.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the consolidated statements of operations and comprehensive loss.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases in accordance with ASC 842, Leases. The Company determines if an arrangement is or contains a lease and the type of lease at inception. The Company classifies leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases as Lessee</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are included in right-of-use (“ROU”) assets and corresponding lease liabilities, and finance leases are included in ROU assets and corresponding lease liabilities within our condensed consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkxM2E3ZDQwZWQxZjQxMWE4OGNlZjBmMjdhOTQwMGE2L3NlYzo5MTNhN2Q0MGVkMWY0MTFhODhjZWYwZjI3YTk0MDBhNl8zMS9mcmFnOjc3NTc5ZThlMjczZDRjZDhhMmI5ZTA0MGVmNTdkYjU3L3RleHRyZWdpb246Nzc1NzllOGUyNzNkNGNkOGEyYjllMDQwZWY1N2RiNTdfMjYyNDc_11995f99-420f-4481-b3ec-71c7dafbfaf7">two</span> and six-year terms, and typically contain penalizing, early-termination provisions. Our finance leases consist of leased equipment and have three-year terms.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases as Lessor</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Deferral Plan</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Cash Deferral Plan (the “Deferral Plan”) provides certain key employees with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments’ fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-Based Compensation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may award stock options, RSUs, performance-based awards and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term: The estimated expected term for employee awards is based on a simplified method that considers an insufficient history of employee exercises. For consultant awards, the estimated expected term is the same as the life of the award.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the fair value of RSUs or stock grants based on the published closing market price on the day before the grant date.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for forfeitures as they occur rather than on an estimated basis.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an employee stock purchase program whereby eligible employees can elect payroll deductions that are subsequently used to purchase common stock at a discounted price. There is no compensation recorded for this program as (i) the purchase discount does not exceed the issuance costs that would have been incurred to raise a significant amount of capital by a public offering, (ii) substantially all employees that meet limited employment qualifications may participate on an equitable basis, and (iii) the plan doesn't incorporate option features that would require compensation to be recorded.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 13, Employee Equity-Based Compensation for further information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying condensed consolidated balance sheet. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Foreign Currency Transactions</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive loss in the condensed consolidated statements of stockholders’ deficit.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options, unvested RSUs and the Warrant. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes and the Series A Preferred Stock outstanding at the balance sheet date were converted and shares issuable in connection with the March 2022 Securities Purchase Agreement (as defined in Note 18). Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 12, Loss Per Share, for further information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds debt securities as available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC on March 14, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date but does not include all disclosures such as notes required by U.S. GAAP.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2022, or any future period.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All amounts are rounded to the nearest thousand dollars unless otherwise indicated.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.</span></div> 1 0.0250 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, convertible notes, notes from related parties, tax valuation accounts, equity–based compensation, warrants, revenue and leases. Actual results could differ materially from those estimates.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimated Fair Value of Financial Instruments</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three-tiered approach and fair value measurement be classified and disclosed in one of the following three categories:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 4, Fair Value of Financial Instruments, for further information and related disclosures regarding the Company’s fair value measurements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Notes represents a Level 2 measurement. See Note 10, Convertible Notes for further detail on the Notes.</span></div>The long-term debt with a related-party consisting of the Secured Note (as defined in Note 11) and the Warrant are instruments measured at fair value on a non-recurring basis using Level 3 inputs. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note and the Warrant. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in various debt and equity securities which are primarily held in the custody of major financial institutions. Debt securities consist of certificates of deposit, U.S. government and agency securities, commercial paper, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ deficit. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of condensed consolidated statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security is considered impaired if its fair value is less than its amortized cost basis at the reporting date. If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first-out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.</span></div>We charge cost of sales for inventory provisions to write-down our inventory to the lower of cost or net realizable value or for obsolete or excess inventory. Most of our inventory provisions relate to excess quantities of products, based on our inventory levels and future product purchase commitments compared to assumptions about future demand and market conditions. Once inventory has been written-off or written-down, it creates a new cost basis for the inventory that is not subsequently written-up. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. Our customers typically have good credit quality. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for credit losses for the three and nine months ended September 30, 2022 and 2021 is comprised of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">445 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Reversals) provisions, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-offs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 150000 213000 140000 445000 -12000 78000 18000 114000 0 77000 20000 345000 138000 214000 138000 214000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkxM2E3ZDQwZWQxZjQxMWE4OGNlZjBmMjdhOTQwMGE2L3NlYzo5MTNhN2Q0MGVkMWY0MTFhODhjZWYwZjI3YTk0MDBhNl8zMS9mcmFnOjc3NTc5ZThlMjczZDRjZDhhMmI5ZTA0MGVmNTdkYjU3L3RleHRyZWdpb246Nzc1NzllOGUyNzNkNGNkOGEyYjllMDQwZWY1N2RiNTdfMTU2MjQ_9239f206-4045-4db4-b78c-b726f35da994">one</span> to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Instruments Classified as Property and Equipment</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.</span></div>The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of for the three and nine months ended September 30, 2022. P7Y P5Y 0 0 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warranty Reserve</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The cost incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.</span></div> P1Y P60D <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty reserve activity for the three and nine months ended September 30, 2022 and 2021 is as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">232 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions (reversals), net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warranty cost incurred</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 255000 169000 139000 232000 -4000 -31000 134000 -41000 29000 17000 51000 70000 222000 121000 222000 121000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022 the Company adopted Accounting Standards Update (“ASU”) 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. Gain or loss on extinguishment of Notes is calculated as the difference between the (i) fair value of the consideration transferred and (ii) the sum of the carrying value of the debt at the time of repurchase.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies the Notes as a non-current liability as the Company has sufficient shares and non-cash alternatives to settle the Notes.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the promised good or service is transferred to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines revenue recognition through the following steps:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract with a customer</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue as we satisfy a performance obligation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is derived from the sale or rental of instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized. Payment terms vary by the type and location of the customer and the products or services offered. The term between invoicing and when payment is due is not significant.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s contracts with customers may include multiple performance obligations. For such arrangements, the Company allocates revenue to each performance obligation based on its relative standalone selling price. The Company generally determines relative standalone selling prices based on the price charged to customers for each individual performance obligation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions earned by the Company’s sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and nine months ended September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit and Gross Margin</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit consists of total revenue, net of allowances, less cost of sales. Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related costs.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s overall gross margin was 26% and 32% for the three months ended September 30, 2022 and 2021, respectively, and 27% and 35% for the nine months ended September 30, 2022 and 2021, respectively. The decreases were primarily due to increases in the costs to manufacture consumables due to supply chain inflationary factors and a decrease in our average unit sales price period over period.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping and Handling</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the consolidated statements of operations and comprehensive loss.</span></div> 0.26 0.32 0.27 0.35 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases in accordance with ASC 842, Leases. The Company determines if an arrangement is or contains a lease and the type of lease at inception. The Company classifies leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases as Lessee</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are included in right-of-use (“ROU”) assets and corresponding lease liabilities, and finance leases are included in ROU assets and corresponding lease liabilities within our condensed consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkxM2E3ZDQwZWQxZjQxMWE4OGNlZjBmMjdhOTQwMGE2L3NlYzo5MTNhN2Q0MGVkMWY0MTFhODhjZWYwZjI3YTk0MDBhNl8zMS9mcmFnOjc3NTc5ZThlMjczZDRjZDhhMmI5ZTA0MGVmNTdkYjU3L3RleHRyZWdpb246Nzc1NzllOGUyNzNkNGNkOGEyYjllMDQwZWY1N2RiNTdfMjYyNDc_11995f99-420f-4481-b3ec-71c7dafbfaf7">two</span> and six-year terms, and typically contain penalizing, early-termination provisions. Our finance leases consist of leased equipment and have three-year terms.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases in accordance with ASC 842, Leases. The Company determines if an arrangement is or contains a lease and the type of lease at inception. The Company classifies leases as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases as Lessor</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.</span></div> P1Y P6Y P3Y P5Y <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Cash Deferral Plan</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Cash Deferral Plan (the “Deferral Plan”) provides certain key employees with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of </span></div>the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments’ fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-Based Compensation</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may award stock options, RSUs, performance-based awards and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expected term: The estimated expected term for employee awards is based on a simplified method that considers an insufficient history of employee exercises. For consultant awards, the estimated expected term is the same as the life of the award.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the fair value of RSUs or stock grants based on the published closing market price on the day before the grant date.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for forfeitures as they occur rather than on an estimated basis.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an employee stock purchase program whereby eligible employees can elect payroll deductions that are subsequently used to purchase common stock at a discounted price. There is no compensation recorded for this program as (i) the purchase discount does not exceed the issuance costs that would have been incurred to raise a significant amount of capital by a public offering, (ii) substantially all employees that meet limited employment qualifications may participate on an equitable basis, and (iii) the plan doesn't incorporate option features that would require compensation to be recorded.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying condensed consolidated balance sheet. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more </span></div>likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Foreign Currency Transactions</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive loss in the condensed consolidated statements of stockholders’ deficit.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options, unvested RSUs and the Warrant. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes and the Series A Preferred Stock outstanding at the balance sheet date were converted and shares issuable in connection with the March 2022 Securities Purchase Agreement (as defined in Note 18). Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds debt securities as available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.</span></div> <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standards that were recently adopted</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). This update simplifies the accounting for convertible debt instruments by removing the beneficial conversion and cash conversion separation models for convertible instruments. Under the update, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives or that do not result in substantial premiums accounted for as paid-in capital. The update also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will no longer be available. The Company adopted the standard on January 1, 2022 through application of the modified retrospective method of transition. The Company applied the standard to the Notes outstanding as of January 1, 2022, as discussed in Note 10, Convertible Notes. As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. On January 1, 2022, the cumulative effect of adoption resulted in an increase in the net carrying amount of the Notes, of $11.5 million, a decrease in additional-paid-in-capital of $37.4 million, and a decrease in accumulated deficit of $25.9 million. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share. This change has no impact on the Company given the Company was already using the if-converted method to calculate diluted earnings per share.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity’s Own Equity (Topic 815 - 40). ASU 2021-04 codifies the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This ASU was adopted January 1, 2022, and did not impact the Company's consolidated financial statements at January 1, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standards not yet adopted</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. ASU 2022-01 is related to the portfolio layer method of hedge accounting. The amendments in this update clarify the accounting and promote consistency in reporting for hedges where the portfolio layer method is applied. This update is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. We do not expect the update to have a material effect on our condensed consolidated financial statements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASU 2022-02, Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. ASU 2022-02 relates to troubled debt restructurings (“TDRs”) and vintage disclosures for financing receivables. The amendments in this update eliminate the accounting guidance for TDRs by creditors while enhancing disclosure requirements for certain loan refinancing and restructurings by creditors made to borrowers experiencing financial difficulty. The amendments also require disclosure of current-period gross write-offs by year of origination for financing receivables. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not expect the update to have a material effect on our condensed consolidated financial statements.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standards that were recently adopted</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40). This update simplifies the accounting for convertible debt instruments by removing the beneficial conversion and cash conversion separation models for convertible instruments. Under the update, the embedded conversion features are no longer separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives or that do not result in substantial premiums accounted for as paid-in capital. The update also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will no longer be available. The Company adopted the standard on January 1, 2022 through application of the modified retrospective method of transition. The Company applied the standard to the Notes outstanding as of January 1, 2022, as discussed in Note 10, Convertible Notes. As a result, the Notes are now accounted for as a single liability measured at their amortized cost. The Notes are no longer bifurcated between debt and equity and are instead accounted for entirely as debt at face value net of any discount or premium and issuance costs. Interest expense is comprised of (1) cash interest payments, (2) amortization of any debt discounts or premiums based on the original offering, and (3) amortization of any debt issuance costs. On January 1, 2022, the cumulative effect of adoption resulted in an increase in the net carrying amount of the Notes, of $11.5 million, a decrease in additional-paid-in-capital of $37.4 million, and a decrease in accumulated deficit of $25.9 million. ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share. This change has no impact on the Company given the Company was already using the if-converted method to calculate diluted earnings per share.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity’s Own Equity (Topic 815 - 40). ASU 2021-04 codifies the final consensus reached by the Emerging Issues Task Force (EITF) on how an issuer should account for modifications made to equity-classified written call options (hereafter referred to as a warrant to purchase the issuer’s common stock). The guidance in the ASU requires the issuer to treat a modification of an equity-classified warrant that does not cause the warrant to become liability-classified as an exchange of the original warrant for a new warrant. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the warrant or as termination of the original warrant and issuance of a new warrant. This ASU was adopted January 1, 2022, and did not impact the Company's consolidated financial statements at January 1, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standards not yet adopted</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging (Topic 815): Fair Value Hedging - Portfolio Layer Method. ASU 2022-01 is related to the portfolio layer method of hedge accounting. The amendments in this update clarify the accounting and promote consistency in reporting for hedges where the portfolio layer method is applied. This update is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. We do not expect the update to have a material effect on our condensed consolidated financial statements.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the FASB issued ASU 2022-02, Financial Instruments-Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures. ASU 2022-02 relates to troubled debt restructurings (“TDRs”) and vintage disclosures for financing receivables. The amendments in this update eliminate the accounting guidance for TDRs by creditors while enhancing disclosure requirements for certain loan refinancing and restructurings by creditors made to borrowers experiencing financial difficulty. The amendments also require disclosure of current-period gross write-offs by year of origination for financing receivables. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not expect the update to have a material effect on our condensed consolidated financial statements.</span></div> 11500000 -37400000 25900000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. CONCENTRATION OF CREDIT RISK</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has financial institutions for banking operations that hold 10% or more of the Company’s cash and cash equivalents. As of September 30, 2022, three of the Company's financial institutions held 74%, 12% and 13% of the Company’s cash and cash equivalents. As of December 31, 2021, two of the Company's financial institutions held 72% and 13% of the Company’s cash and cash equivalents.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants credit to domestic and international customers. Exposure to losses on accounts receivable is principally dependent on each client's financial position. The Company had one customer that accounted for 16% and 13% of the Company’s net accounts receivable balance as of September 30, 2022 and December 31, 2021, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any customers that represented 10% or more of the Company’s total revenue for the three and nine months ended September 30, 2022 and 2021.</span></div> 0.74 0.12 0.13 0.72 0.13 0.16 0.13 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. FAIR VALUE OF FINANCIAL INSTRUMENTS </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total equity investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,181 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,552 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,563 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,763 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total equity investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,629 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,879 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,654 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,829 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,483 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highly liquid investments with an original maturity of three months or less at time of purchase are included in cash and cash equivalents on the condensed consolidated balance sheet.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets are priced using quoted prices in active markets for identical assets which include money market funds, U.S. Treasury securities and mutual funds as these specific assets are liquid.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the Notes had an outstanding principal amount of $56.6 million with a fair value of $51.7 million. At December 31, 2021, the Notes had an outstanding principal amount of $120.5 million with a fair value of $89.4 million. The fair value of the Notes represents a Level 2 measurement. The fair value of the Notes is typically correlated to the Company’s stock price and as a result, significant changes to the Company’s stock price will have a significant impact on the calculated fair value. See Note 10, Convertible Notes for further detail on the Notes.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Secured Note is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. The estimated fair value of the Secured Note on August 15, 2022 was $16.0 million. See Note 11, Long-Term Debt Related-Party for further detail on the Secured Note.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrant is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. The estimated fair value of the warrant on August 15, 2022 was $3.8 million. See Note 11, Long-Term Debt Related-Party for further detail on the Company’s warrant with a related-party.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mutual funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total equity investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,382 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,181 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,552 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical<br/>Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Other<br/>Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,563 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,763 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mutual funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total equity investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">841 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,046 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,232 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,629 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,879 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,654 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,829 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,483 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5145000 0 0 5145000 5145000 0 0 5145000 808000 0 0 808000 808000 0 0 808000 0 3382000 0 3382000 5228000 0 0 5228000 0 2893000 0 2893000 0 4096000 0 4096000 5228000 10371000 0 15599000 11181000 10371000 0 21552000 5563000 0 0 5563000 0 200000 0 200000 5563000 200000 0 5763000 841000 0 0 841000 841000 0 0 841000 0 1351000 0 1351000 250000 0 0 250000 0 8046000 0 8046000 0 13232000 0 13232000 250000 22629000 0 22879000 6654000 22829000 0 29483000 56600000 51700000 120500000 89400000 16000000 3800000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. INVESTMENTS</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,698 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(99)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,046 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,894 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,879 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in less than 1 year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,698 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,649 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in 1-3 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,698 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,894 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,879 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no proceeds from sales of debt securities available-for-sale (including principal paydowns) for the three and nine months ended September 30, 2022 and 2021. The Company determines gains and losses of marketable securities based on specific identification of the securities sold. There were no material realized gains or losses from debt securities available-for-sale for the three and nine months ended September 30, 2022 and 2021. No material balances were reclassified out of accumulated other comprehensive income (loss) for the three and nine months ended September 30, 2022 and 2021. No unrealized losses on debt securities available-for-sale have been recognized in income for the three and nine months ended September 30, 2022 and 2021, as the issuers of such securities held by us were of high credit quality.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, there were no holdings of debt securities available-for-sale of any one issuer, other than the U.S. government, in an amount greater than 10%.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 the Company did not carry any debt securities available-for-sale that were below the Company's minimum credit rating. All debt securities available-for-sale had a credit rating of A- or better as of September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are comprised of investments in mutual funds. The fair value of equity securities for each of the periods ended September 30, 2022 and December 31, 2021 was $0.8 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses or gains on equity securities recorded in income during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized (loss) gain on equity investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(50)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(206)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unrealized gains or losses are recorded as a component of other income (expense), net. There were no realized gains or losses from equity securities for each of the three and nine months ended September 30, 2022 and 2021.</span></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,400 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,382 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,901 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,698 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(99)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,046 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,245 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,894 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,879 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3400000 0 18000 3382000 5266000 0 38000 5228000 2901000 0 8000 2893000 4131000 0 35000 4096000 15698000 0 99000 15599000 1351000 0 0 1351000 250000 0 0 250000 8048000 0 2000 8046000 13245000 0 13000 13232000 22894000 0 15000 22879000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2022</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in less than 1 year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,698 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,663 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,649 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in 1-3 years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,698 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,894 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,879 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 15698000 15599000 22663000 22649000 0 0 231000 230000 15698000 15599000 22894000 22879000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800000 800000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses or gains on equity securities recorded in income during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized (loss) gain on equity investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(50)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(206)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -50000 -5000 -206000 39000 0 0 0 0 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. INVENTORY</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,769 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,392 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,067 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,769 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,490 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,099 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,392 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,067 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1769000 1343000 2133000 1625000 1490000 2099000 5392000 5067000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. PROPERTY AND EQUIPMENT</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,866 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital projects in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">683 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,441 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,188 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,389 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">487 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments at cost and accumulated depreciation where the Company is the lessor under operating leases consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments at cost under operating leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation under operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net property and equipment under operating leases</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,343 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,945 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,866 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,674 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital projects in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">683 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,441 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,188 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,621 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,389 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">487 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3866000 3181000 3259000 3285000 3674000 3675000 3594000 5364000 48000 683000 14441000 16188000 10820000 10799000 3621000 5389000 381000 487000 1284000 1540000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments at cost and accumulated depreciation where the Company is the lessor under operating leases consisted of the following at September 30, 2022 and December 31, 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Instruments at cost under operating leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,110 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation under operating leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net property and equipment under operating leases</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,343 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,945 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2452000 3110000 1109000 1165000 1343000 1945000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. DEFERRED REVENUE AND REMAINING PERFORMANCE OBLIGATIONS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue consists of amounts received for products or services not yet delivered or earned. If we anticipate revenue will not be earned within the following twelve months, the amount is reported as other non-current liabilities. A summary of the balances as of September 30, 2022 and December 31, 2021 follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products and services not yet delivered</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">524 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $0.2 million and $0.4 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2022, respectively, and $0.1 million and $0.3 million of revenues that were included in the beginning contract liabilities balances during the three and nine months ended September 30, 2021, respectively. No material amount of revenue recognized during the period was from performance obligations satisfied in prior periods.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transaction Price Allocated to Remaining Performance Obligations</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, $9.0 million of revenue is expected to be recognized from remaining performance obligations. This balance primarily relates to product shipments for reagents sold to customers under sales-type lease agreements. These agreements have between two and four year terms and revenue is recognized as product is shipped, typically on a straight-line basis. The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elects not to disclose the value of unsatisfied performance obligations for (i) contracts with an expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</span></div> A summary of the balances as of September 30, 2022 and December 31, 2021 follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products and services not yet delivered</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">524 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">451 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 524000 451000 200000 400000 100000 300000 9000000 These agreements have between two and four year terms and revenue is recognized as product is shipped, typically on a straight-line basis. The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. LONG-TERM DEBT</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into two loan agreements with one financing company in 2020. Loan proceeds were $0.2 million, with interest rates ranging from 9.8% to 12.4% and maturities becoming due through 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, long-term debt consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans - various interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents maturities of future principal obligations of long-term debt as of September 30, 2022 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program (PPP) Loan</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 14, 2020, the Company entered into a promissory note (the “PPP Note”) evidencing an unsecured loan in the amount of $4.8 million made to the Company under the Paycheck Protection Program (“PPP”) established under the Coronavirus Aid, Relief, and Economic Security Act.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2021, the Small Business Administration (“SBA”) informed the Company of its full forgiveness for the entire PPP Note amount plus accrued interest, which was $4.8 million as of the date of forgiveness. The SBA’s determination of loan forgiveness does not preclude further investigation by the SBA according to its rules and regulations. With approval of the Company's application for forgiveness the Company recorded a gain on extinguishment of the entire PPP Note amount of $4.8 million during the three and nine months ended September 30, 2021.</span></div> 2 1 200000 0.098 0.124 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, long-term debt consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans - various interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 80000 80000 80000 80000 0 0 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents maturities of future principal obligations of long-term debt as of September 30, 2022 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 80000 0 0 0 0 0 80000 4800000 4800000 4800000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. CONVERTIBLE NOTES</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are the Company’s senior unsecured obligations and mature on March 15, 2023 (the “Maturity Date”), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. Upon conversion of the Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of common stock, at the Company’s election. The initial conversion rate of the Notes is 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock, subject to adjustment. The Company pays interest on the Notes semi-annually in arrears on March 15 and September 15 of each year. The Company’s Notes have a fixed coupon rate of 2.5% per annum on the principal amount.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred issuance costs related to the issuance of the Notes which is amortized over the five-year contractual term of the Notes using the effective interest method. The effective interest rate on the Notes, including accretion of the Notes to par was 3.2%.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes include customary terms and covenants, including certain events of default upon which the Notes may be due and payable immediately. Holders have the option to convert the Notes in multiples of $1,000 principal amount at any time prior to December 15, 2022, but only in the following circumstances:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if the Company’s stock price exceeds 130% of the conversion price for 20 of the last 30 trading days of any calendar quarter after June 30, 2018;</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">during the 5 business day period after any 5 consecutive trading day period in which the Notes’ trading price is less than 98% of the product of the common stock price times the conversion rate; or</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the occurrence of certain corporate events, such as a change of control, merger or liquidation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time on or after December 15, 2022, a holder may convert its Notes in multiples of $1,000 principal amount. Holders of the Notes who convert their Notes in connection with a make-whole fundamental change (as defined in the Indenture pursuant to which the Notes were issued) are, under certain circumstances, entitled to an increase in the conversion rate. In addition, in the event of a fundamental change or event of default prior to the Maturity Date, holders will, subject to certain conditions, have the right, at their option, to require the Company to repurchase for cash all or part of the Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest up to, but excluding, the repurchase date. As of September 30, 2022 and December 31, 2021, no Notes were convertible pursuant to their original terms.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,024 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,528 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,168 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,711 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense on convertible notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,196 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,914 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,418 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on extinguishment of exchanged Notes during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on extinguishment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,565 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Notes at September 30, 2022 consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding principal at par</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amount</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,325 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Notes issuance, the Company entered into a prepaid forward stock repurchase transaction (“Prepaid Forward”) with a financial institution (“Forward Counterparty”). Pursuant to the Prepaid Forward, the Company used approximately $45.1 million of the net proceeds from its issuance of the Notes to fund the Prepaid Forward. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The expiration date for the Prepaid Forward is March 15, 2023, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. The Company’s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Exchange Transactions</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company entered into separate exchange agreements with certain holders of the Notes. Under the terms of the exchange agreements, such holders agreed to exchange Notes held by them for shares of the Company’s common stock (the “2021 Exchange Transactions”). During the nine months ended September 30, 2021, such holders exchanged $46.0 million in aggregate principal amount of Notes held by them for 5,945,718 shares of the Company’s common stock. The net carrying value of the Notes exchanged was $40.4 million which the Company repurchased for $34.5 million of common stock. The Company also incurred $0.8 million of reacquisition costs, which was recorded as an offset to gain on extinguishment of debt. The 2021 Exchange Transaction resulted in a net gain of $5.0 million reflected in other income (expense), net for the three and nine months ended September 30, 2021. See Note 18, Stockholders' Equity for additional information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">March 2022 Exchange Transaction</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2022, the Company entered into a privately negotiated exchange agreement (the “March 2022 Exchange Agreement”) with a holder of the Notes. Under the terms of the March 2022 Exchange Agreement, the note holder agreed to exchange with the Company $14.0 million in aggregate principal amount of Notes held by it in eight equal tranches as follows for each tranche: (a) 22.64 shares per $1,000 principal amount of Notes exchanged, plus (b) an additional number of shares of the Company’s common stock per $1,000 principal amount of Notes exchanged equal to the sum, for each of the trading days during a separate agreed upon reference period for each tranche commencing on March 21, 2022 for the first tranche, of the quotient of (i) $155.67 divided by (ii) the daily volume-weighted average price for such trading day (collectively, the “March 2022 Exchange Transaction”). The closing of the March 2022 Exchange Transaction occurred in eight tranches (“Obligation to Exchange”), with the first closing occurring on March 29, 2022 and the last closing on May 18, 2022. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 21, 2022 the Obligation to Exchange the $14.0 million of Notes in the March 2022 Exchange Transaction was accounted for as an extinguishment and was replaced by new notes with an embedded feature (the “New Notes”). The New Notes were elected to be carried using the fair value option. The New Notes were recorded at fair value on initial measurement and remeasured at fair value (“mark to market”) at each reporting period with changes in fair value reported in other income and expense, net. This fair value election was exclusive to the New Notes and did not extend to other Notes. The embedded feature was no longer outstanding on September 30, 2022 as the New Notes were exchanged and the Obligation to Exchange retired on May 18, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022 the holder of the Notes exchanged $14.0 million in aggregate principal amount of Notes held by it for 10,798,482 shares of the Company’s common stock pursuant to the March 2022 Exchange Agreement. The net carrying value of the Notes exchanged was $14.0 million which the Company repurchased for $10.2 million of common stock. The Company also incurred $0.2 million of reacquisition costs, which was recorded as an offset to gain on extinguishment of debt. This exchange transaction resulted in a net gain of $3.6 million reflected in other income (expense), net for the nine months ended September 30, 2022. See Note 18, Stockholders' Equity for additional information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">August 2022 Exchange Transaction</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company entered into an exchange agreement (the “August 2022 Exchange Agreement”) with the Jack W. Schuler Living Trust (the “Schuler Trust”), as discussed in Note 11, Long-Term Debt Related-Party. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) the Secured Note in an aggregate principal amount of $34.9 million and (b) the Warrant to acquire the Company’s common stock.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 470-50-40, the transaction qualified as an extinguishment of debt. Under extinguishment accounting, the Notes were derecognized and the new instruments, which include the Secured Note and the Warrant, were recorded at their fair values. The difference between the fair values of the new instruments and the net carrying amount of the Notes being extinguished was included in the calculation of gain. The gain from the extinguishment of the Notes was treated as a capital transaction. The Secured Note includes various features that were advantageous to the Company, including a lower interest rate compared to current market rates and a share conversion feature. There were no other negotiating parties that had similar terms or economic outcomes. As such, the exchange was considered not to be an arm’s length transaction, and therefore the resulting gain was accounted for as a capital transaction. The net carrying amount of the extinguished Notes was $49.6 million. The estimated fair value of the Secured Note and the Warrant on August 15, 2022 was $16.0 million and $3.8 million, respectively, which resulted in a net gain of $29.8 million that was recorded to contributed capital. See Note 18, Stockholders' Equity and Note 11, Long-Term Debt Related-Party for additional information.</span></div> 30.92 0.025 P5Y 0.032 1.30 20 30 5 5 0.98 1 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense during the three and nine months ended September 30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual coupon interest</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,024 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,528 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,168 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,987 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,711 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense on convertible notes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,196 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,914 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,418 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense in connection with the Secured Note during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual interest</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 79000 1024000 1528000 3168000 121000 185000 386000 539000 0 2987000 0 8711000 200000 4196000 1914000 12418000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on extinguishment of exchanged Notes during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on extinguishment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,565 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 4999000 3565000 4999000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Notes at September 30, 2022 consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding principal at par</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amount</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,325 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Secured Note at September 30, 2022 consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding principal</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,934 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance discount</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,635)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amount</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,299 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 56595000 270000 56325000 45100000 1858500 46000000 5945718 40400000 34500000 800000 5000000 5000000 14000000 8 155.67 8 14000000 14000000 10798482 14000000 10200000 200000 3600000 49900000 34900000 49600000 16000000 3800000 29800000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. LONG-TERM DEBT RELATED-PARTY</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust, a holder of the Notes. Jack Schuler, who serves as a member of the Company’s board of directors, is the sole trustee of the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) a secured promissory note in an aggregate principal amount of $34.9 million (the “Secured Note”) and (b) a Warrant to acquire the Company’s common stock at an exercise price of $2.12 per share (the “Warrant”).</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Secured Note has a scheduled maturity date of August 15, 2027 and will be repayable upon written demand at any time on or after such date. The Company may, at its option, repay the note in (i) cash or (ii) in the form of common stock of the Company, in a number of shares that is obtained by dividing the total amount of such payment by $2.12. The Secured Note bears interest at a rate of 5.0% per annum, payable at the option of the Company in the same form, at the earlier of (i) any prepayment of principal and (ii) maturity. The Company may prepay the Secured Note at any time without premium or penalty. The Secured Note is secured by substantially all of the assets of the Company, subject to customary exceptions and limitations, pursuant to a security agreement, dated as of August 15, 2022. The Secured Note does not restrict the incurrence of future indebtedness by the Company but shall become subordinated in right of payment and lien priority upon the request of any future senior lender.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 470-50-40, the transaction qualified as an extinguishment of debt. Under extinguishment accounting, the Notes were derecognized and the new instruments, which include the Secured Note and the Warrant, were recorded at their fair values. See Note 10, Convertible Notes for additional information. The Secured Notes is an instrument measured at fair value on a non-recurring basis using Level 3 inputs. To estimate the Secured Note’s fair value, the Company applied a Monte Carlo simulation which simulated the share price of the Company over the remaining term to the maturity date of the Secured Note. The simulated per-share price in a given iteration determined if the Company settled in cash or shares. The estimated fair value of the Secured Note on August 15, 2022 was $16.0 million. This valuation estimated an issuance discount of $18.9 million. The effective interest rate on the Secured Note is 24.60%.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Secured Note at September 30, 2022 consisted of the following (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding principal</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,934 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance discount</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,635)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amount</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,299 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense in connection with the Secured Note during the three and nine months ended September 30, 2022 and 2021 was as follows (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual interest</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of the debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total interest expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">495 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Warrant may be exercised from February 15, 2023 through the earlier of (i) August 15, 2029 and (ii) the consummation of certain acquisition transactions involving the Company, as set forth in the Warrant. The Warrant is exercisable for up to 2,471,710 shares of common stock. The Warrant meets the criteria for classification in stockholders’ equity and was recorded in equity and initially measured at fair value. The Warrant was measured at fair value on a non-recurring basis using Level 3 inputs. The fair value of the warrant on August 15, 2022 was $3.8 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the inputs used to calculate the estimated fair value of the Warrant issued during the three months ended September 30, 2022:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:84.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 49900000 34900000 2.12 2.12 0.050 16000000 18900000 0.2460 34934000 18635000 16299000 220000 0 220000 0 275000 0 275000 0 495000 0 495000 0 2471710 3800000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the inputs used to calculate the estimated fair value of the Warrant issued during the three months ended September 30, 2022:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:84.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 7.0 0.7610 0 0.0286 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. LOSS PER SHARE</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share are the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive due to the Company’s losses.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon the release of RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon the exercise of the Warrant</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,756 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,954 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,756 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,954 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares would include common shares that would be outstanding if Notes convertible at the balance sheet date were converted. As discussed in Note 10, Convertible Notes, upon conversion of the Notes, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock, or a combination of cash and shares of common stock, at the Company’s election. The initial conversion rate of the Notes is 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock. As of September 30, 2022, no Notes were convertible pursuant to the original terms. The number of shares of common stock issuable upon conversion of the outstanding Notes based on the initial conversion rate was approximately 1,830,441 shares as of September 30, 2022. Historically the Company has engaged in privately negotiated exchanges of Notes for a substantially greater number of shares than the initial conversion rate of the Notes described above because the Company’s stock price at the time of such exchanges was significantly less than the $30.92 initial conversion price of the Notes.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Notes, the Company entered into a prepaid forward stock repurchase transaction. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares include common shares that would be outstanding if Series A Preferred Stock were converted into common stock. Each share of Series A Preferred Stock is convertible, at the option of the holder, at any time into one share of the Company’s common stock. Additionally, each share of Series A Preferred Stock will automatically be converted into one share of the Company’s common stock immediately upon a sale of all outstanding stock of the Company or a merger of the Company into another corporation where the pre-merger Company’s stockholders cease to be the controlling stockholders of the post-merger corporation. The number of shares of common stock issuable upon conversion of the Series A Preferred Stock is 3,954,546 as of September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 18, Stockholders' Equity, the Company entered into a securities purchase agreement with the Schuler Trust for the issuance and sale by the Company of an aggregate of 2,439,024 shares of the Company’s common stock. The closing of the transaction is expected to occur on December 30, 2022, subject to the satisfaction of customary closing conditions and is considered an equity forward agreement. The shares to be issued from this agreement were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 11, Long-Term Debt Related-Party, the Company may, at its option, repay the Secured </span></div>Note in (i) cash or (ii) in the form of common stock of the Company, in a number of shares that is obtained by dividing the total amount of such payment by $2.12. The number of shares of common stock issuable upon conversion of the Secured Note and accrued interest was approximately 16,478,066 and 103,834 shares respectively, as of September 30, 2022. The shares issuable in connection with a repayment of the Secured Note were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses. <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon the release of RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares issuable upon the exercise of the Warrant</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,472 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,756 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,954 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,756 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,954 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4619000 2320000 4619000 2320000 5665000 7634000 5665000 7634000 2472000 0 2472000 0 12756000 9954000 12756000 9954000 30.92 1830441 30.92 1858500 0.01 0.01 3954546 2439024 2.12 16478066 103834 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. EMPLOYEE EQUITY-BASED COMPENSATION</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the Company's equity-based compensation plans for the nine months ended September 30, 2022:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Exercise Price per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,192,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(204,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.04 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,457,019)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665,184 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.60 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock options were granted during the three months ended September 30, 2022 and 2021.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows summary information for outstanding options and options that are exercisable (vested) as of September 30, 2022:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,422,595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining contractual term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.54</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.04</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value (in thousands)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU and restricted stock award activity for the nine months ended September 30, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,090,182 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,107,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(451,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,127,017)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,618,545 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.57 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes equity-based compensation expense for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,052 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">911 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,557 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,461 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,229 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,629 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,179 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,058 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost capitalized to inventory for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost capitalized to inventory</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">319 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, unrecognized equity-based compensation expense related to unvested stock options and unvested RSUs was $2.3 million and $7.8 million, respectively. This is expected to be recognized over the years 2022 through 2027.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the above-noted stock options outstanding and stock compensation expense are performance-based stock options which vest only upon the achievement of certain targets. Performance-based stock options are generally granted at-the-money, contingently vest over a period of 1 to 2 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These options were valued in the same manner as the time-based options, with the assumption that performance goals will be achieved. The inputs for expected volatility, expected dividends, and risk-free rate used in estimating those options’ fair value are the same as the time-based options issued under the Company's equity incentive plans. The expected term for performance-based stock options is 5 to 7 years. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company granted 105,000 performance-based stock options. Of these performance-based stock options, performance obligations had been met for 90,000 options which became exercisable in a prior period. Of these performance-based stock options, 90,000 options expired during the nine months ended September 30, 2022. No performance-based stock options were outstanding as of September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based stock option expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the above-noted RSU and restricted stock award outstanding amounts are performance-based RSUs which vest only upon the achievement of certain targets. Performance-based RSUs contingently vest over a period of 1 to 3 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These units were valued in the same manner as other RSUs, based on the published closing market price on the day before the grant date. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company granted performance-based RSUs of which 165,974 were outstanding as of September 30, 2022. No changes occurred during the nine months ended September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company granted performance-based RSUs of which 111,806 were outstanding as of September 30, 2022. No changes occurred during the nine months ended September 30, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost in connection with performance-based RSUs for the nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based RSU expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the Company's equity-based compensation plans for the nine months ended September 30, 2022:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Exercise Price per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,192,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(204,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.04 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,457,019)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665,184 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.60 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7192540 13.89 140000 3.05 204232 12.49 6105 1.04 1457019 10.33 5665184 14.60 0 0 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows summary information for outstanding options and options that are exercisable (vested) as of September 30, 2022:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options<br/>Exercisable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,665,184 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,422,595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining contractual term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.54</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.04</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate intrinsic value (in thousands)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5665184 4422595 P5Y6M14D P5Y14D 14.60 15.32 9.10 9.44 0 0 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU and restricted stock award activity for the nine months ended September 30, 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,090,182 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,107,083 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(451,703)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,127,017)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,618,545 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.57 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2090182 10.77 4107083 1.55 451703 8.68 1127017 3.43 4618545 4.57 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes equity-based compensation expense for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">266 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,052 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,340 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">911 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,557 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,461 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,229 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,629 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,179 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,058 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost capitalized to inventory for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost capitalized to inventory</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">319 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost in connection with performance-based stock options for the nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based stock option expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes share-based compensation cost in connection with performance-based RSUs for the nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance-based RSU expense</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 167000 82000 570000 257000 151000 266000 1052000 4340000 911000 3281000 6557000 14461000 1229000 3629000 8179000 19058000 69000 77000 186000 319000 2300000 7800000 P1Y P2Y P10Y P5Y P7Y 105000 90000 90000 0 0 230000 P1Y P3Y P10Y 165974 111806 0 818000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14. INCOME TAXES</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, the Company did not carry an income tax provision amount as the Company does not recognize tax benefits from current year tax losses in the U.S. and other foreign jurisdictions. The Company’s tax expense for the nine months ended September 30, 2022 differs from the tax expense computed by applying the U.S. statutory tax rate to its year-to-date pre-tax loss of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$47.7 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as no tax benefits were recorded for tax losses generated in the U.S. and other foreign jurisdictions due to the valuation allowance. At September 30, 2022, the Company had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards and a deferred tax liability related to amortization of the Notes. The Company provided a valuation allowance against its net deferred tax assets as future realization of such assets is not more likely than not to occur.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions pursuant to the recognition and measurement criteria under ASC 740, Income Taxes. For the three and nine months ended September 30, 2022, we did not note any significant changes to our uncertain tax positions. We do not anticipate significant changes to uncertain tax positions within the next 12 months.</span></div> 0 -47700000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15. COMMITMENTS</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During April 2022, the Company entered into a non-cancellable purchase obligation with a supplier to acquire raw materials for a total commitment of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.9 million. Under the terms of this agreement the Company has until March 15, 2027 to take delivery of purchased items. This commitment was entered into to ensure proper material quantities to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">develop and commercialize our next generation AST platform.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 the commitment remains </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.9 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as the Company has not taken delivery of any inventory.</span></div> 11900000 11900000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 16. LEASES</span></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:39.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,760 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease Cost:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term on our operating leases is 2.8 years. The weighted average discount rate on those leases is 7.1%. The weighted average remaining lease term on our finance leases is 2.5 years. The weighted average discount rate on those leases is 4.6%. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents maturities of lease liabilities in which we are the lessee as of September 30, 2022 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,826 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,795 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(278)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,548 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of September 30, 2022, the total net investment in these leases was $3.0 million. The following presents maturities of lease receivables under sales-type leases as of September 30, 2022 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted cash flows</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,012 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 16. LEASES</span></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:39.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,760 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease Cost:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term on our operating leases is 2.8 years. The weighted average discount rate on those leases is 7.1%. The weighted average remaining lease term on our finance leases is 2.5 years. The weighted average discount rate on those leases is 4.6%. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents maturities of lease liabilities in which we are the lessee as of September 30, 2022 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,826 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,795 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(278)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,548 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of September 30, 2022, the total net investment in these leases was $3.0 million. The following presents maturities of lease receivables under sales-type leases as of September 30, 2022 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted cash flows</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,012 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:39.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,760 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease Cost:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents supplemental information related to our leases in which we are the lessee for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:39.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">195 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for lease obligations:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,760 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease Cost:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">816 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 219000 195000 712000 502000 684000 0 1109000 0 0 0 0 0 0 0 2760000 0 254000 257000 818000 816000 240000 0 462000 0 26000 40000 67000 99000 P2Y9M18D 0.071 P2Y6M 0.046 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents maturities of lease liabilities in which we are the lessee as of September 30, 2022 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">968 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">721 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,047 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">584 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,826 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,795 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(278)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,548 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,651 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 227000 180000 968000 721000 1047000 721000 584000 173000 0 0 0 0 2826000 1795000 278000 144000 2548000 1651000 3000000 The following presents maturities of lease receivables under sales-type leases as of September 30, 2022 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted cash flows</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,012 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,012 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 351000 1154000 661000 206000 640000 0 3012000 0 3012000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 17. GEOGRAPHIC AND REVENUE DISAGGREGATION</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one operating segment. Sales to customers outside the U.S. represented 14% and 8% for the three months ended September 30, 2022 and 2021, respectively, and 14% and 12% for the nine months ended September 30, 2022 and 2021, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, balances due from foreign customers, in U.S. dollars, were $0.6 million and $0.7 million, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by geographic territory for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,390 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,033 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,960 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,780 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by line of business for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerate Pheno revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,933 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,084 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,669 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,960 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,780 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by products and services for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,532 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,773 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,960 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,780 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease revenue included in net sales was $0.2 million and $0.5 million for the three months ended September 30, 2022 and 2021, respectively, and $1.3 million for each of the nine months ended September 30, 2022 and 2021.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents property and equipment, net by geographic territory (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,014 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,621 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,389 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1 0.14 0.08 0.14 0.12 600000 700000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by geographic territory for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,874 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,390 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,406 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,033 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,960 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,780 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by line of business for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.230%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerate Pheno revenue</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,933 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,084 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,669 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,960 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,780 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents total net sales by products and services for the three and nine months ended September 30, 2022 and 2021 (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,532 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,773 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,554 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,474 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">965 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,960 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,122 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,780 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,439 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2551000 2874000 8390000 7406000 409000 248000 1390000 1033000 2960000 3122000 9780000 8439000 2933000 3084000 9669000 8324000 27000 38000 111000 115000 2960000 3122000 9780000 8439000 2532000 2773000 8554000 7474000 428000 349000 1226000 965000 2960000 3122000 9780000 8439000 200000 500000 1300000 1300000 <div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following presents property and equipment, net by geographic territory (in thousands):</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,014 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,621 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,389 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3383000 5014000 238000 375000 3621000 5389000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 18. STOCKHOLDERS' EQUITY</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">December 2020 Securities Purchase Agreement</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2020, the Company entered into a securities purchase agreement (the “December 2020 Securities Purchase Agreement”) with Jack W. Schuler, John Patience, Matthew Strobeck, Mark C. Miller, Thomas D. Brown and Jack Phillips, or entities affiliated with such persons (collectively, the “Original Purchasers”), for the issuance and sale by the Company of an aggregate of 4,166,663 shares of the Company’s common stock. Each of Jack W. Schuler, John Patience, Matthew Strobeck, Mark C. Miller, Thomas D. Brown and Jack Phillips is a member of the Company’s board of directors. Mr. Phillips also serves as the Company’s President and Chief Executive Officer.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Schuler Trust, which was the entity affiliated with Jack W. Schuler that originally entered into the December 2020 Securities Purchase Agreement for the purchase of 3,964,843 shares for an aggregate purchase price of approximately $30.5 million, subsequently entered into an assignment and assumption agreement whereby it assigned all of its rights and obligations as an Original Purchaser to three other entities under the December 2020 Securities Purchase Agreement (collectively, the “Schuler Purchasers”). These three entities are related to Jack W. Schuler but are not affiliates of his.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the December 2020 Securities Purchase Agreement, the Original Purchasers agreed to purchase the shares at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the Company’s common stock) of $7.68 per share, for an aggregate purchase price of approximately $32 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2020 Securities Purchase Agreement contemplated that the closing of the purchase and sale of the shares would occur in three tranches, with the first and second tranches having closed on February 19, 2021 and April 9, 2021, respectively, whereby the Company received total proceeds of approximately $21.3 million which were recorded to contributed capital.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2021, the Company entered into a rescission agreement (the “Rescission Agreement”) with the Schuler Purchasers and the Schuler Trust pursuant to which, effective as of January 29, 2021, the Company and the Schuler Purchasers agreed to rescind and unwind the December 2020 Securities Purchase Agreement for all legal, tax and financial purposes ab initio as if the related transactions, including the issuance and sale of an aggregate of 2,643,228 shares in the first two tranche closings and the third tranche (as discussed below) under the December 2020 Purchase Agreement, had never occurred with respect to the Schuler Purchasers and the Company. The 2,643,228 Shares re-acquired by the Company from the Schuler Purchasers as a result of the Rescission Agreement were treated as a reduction to contributed capital and were not outstanding for purposes of the calculation of basic and diluted earnings per share.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2021, the Company closed the final third tranche in connection with the December 2020 Securities Purchase Agreement and received total proceeds of approximately $0.5 million. In accordance with the Rescission Agreement, the Schuler Purchasers did not participate in the third tranche. During the nine months ended September 30, 2021, the Company issued 201,820 shares and received total proceeds of approximately $1.5 million under the December 2020 Securities Purchase Agreement, which were recorded to contributed capital, after giving effect to the Rescission Agreement.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">September 2021 Securities Purchase Agreement</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During September 2021, the Company entered into a new securities purchase agreement (the “September 2021 Securities Purchase Agreement”) with the Schuler Purchasers for the issuance and sale by the Company of an aggregate of 3,954,546 shares of the Company’s newly designated Series A Preferred Stock, par value $0.001 per share (the “Series A Preferred Shares”). Each share of Series A Preferred Stock is convertible, at the option of the holder, at any time into one share of the Company’s common stock.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the September 2021 Securities Purchase Agreement, the Schuler Purchasers agreed to purchase the Series A Preferred Shares at a purchase price of $7.70 per share for an aggregate purchase price of approximately $30.5 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The September 2021 Securities Purchase Agreement contemplated the closing of the purchase and sale of the Series A Preferred Shares would occur in two tranches. The first tranche closed on the date of the execution of the September 2021 Securities Purchase Agreement whereby an aggregate of 2,636,364 Series A Preferred Shares were issued and sold to the Schuler Purchasers. The Company received total proceeds of approximately $20.3 million, which was recorded to contributed capital during the three months ended September 30, 2021.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second tranche (the “Tranche Right”) had not closed by September 30, 2021 and was concluded to be an obligation of the Schuler Purchasers to acquire, and the Company to sell an additional 1,318,182 Series A Preferred Shares at a purchase price of $7.70 per share for proceeds of $10.2 million, subsequent to the September 30, 2021 balance sheet date. The Company concluded the Tranche Right met the definition of a freestanding financial instrument which was recorded within stockholder’s equity. The value of this Tranche Right as September 30, 2021 was $2.5 million. The estimated fair value of the Tranche Right represented a Level 3 measurement as this financial instrument has no market activity. The estimated fair value of the Tranche Right was determined as the excess value of the forward contract when compared to the underlying asset. The fair value of this forward contract can be represented by the difference between the contractual forward price of $7.70 and the prevailing exchange-traded common stock price ($5.81 at September 22, 2021 and $5.83 at September 30, 2021), multiplied by 1,318,182 Series A Preferred Shares. On October 29, 2021, the Company closed the final second tranche in connection with the September 2021 Securities Purchase Agreement whereby the Company issued and sold an aggregate of 1,318,182 Series A Preferred Shares to the Schuler Purchasers and received total proceeds of approximately $10.2 million. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Exchange Transactions</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the none months ended September 30, 2021, certain holders of the Notes exchanged $46.0 million in aggregate principal amount of Notes held by them for 5,945,718 shares of the Company’s common stock pursuant to their respective exchange agreement. Using the closing stock price on September 22, 2021 of $5.81, the 5,945,718 shares of the Company’s common stock were determined to have a value of $34.5 million, which was recorded to contributed capital during the nine months ended September 30, 2021. See Note 10, Convertible Notes, for additional information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">March 2022 Exchange Transaction</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, a holder of the Notes exchanged $14.0 million in aggregate principal amount of Notes held by it for 10,798,482 shares of the Company's common stock pursuant to the March 2022 Exchange Agreement. The 10,798,482 shares of the Company’s common stock were determined to have a value of $10.2 million, which was recorded to contributed capital during the nine months ended September 30, 2022. See Note 10, Convertible Notes for additional information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">March 2022 Securities Purchase Agreement</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2022, the Company entered into a securities purchase agreement (the “March 2022 Securities Purchase Agreement”) with the Schuler Trust for the issuance and sale by the Company of an aggregate of 2,439,024 shares of the Company’s common stock to the Schuler Trust in an offering (the “Private Placement”) exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. </span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the March 2022 Securities Purchase Agreement, the Schuler Trust agreed to purchase the shares at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the Company’s common stock) of $1.64 per share, for an aggregate purchase price of $4.0 million.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2022, the Company and the Schuler Trust agreed to extend the closing date of the Private Placement (the “Closing Date”) from June 30, 2022 to September 26, 2022, subject to the satisfaction of customary closing conditions. On September 29, 2022, the parties agreed to further extend the Closing Date to December 30, 2022, effective as of September 26, 2022. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">August 2022 Exchange Transaction</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for (a) the Secured Note in an aggregate principal amount of $34.9 million and (b) the Warrant to acquire the Company’s common stock. The gain from the extinguishment of the Notes was treated as a capital transaction. The net gain on extinguishment was $29.8 million during the three months ended months ended September 30, 2022, and was recorded to contributed capital. See Note 10, Convertible Notes and Note 11, Long-Term Debt Related-Party for additional information. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Warrant meets the criteria for classification in stockholders’ equity and was recorded in contributed capital at fair value of $3.8 million on August 15, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">August 2022 Public Offering</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 23, 2022, the Company completed a public offering 17,500,000 shares of its common stock at a public offering price of $2.00 per share. The Company received net proceeds of approximately $32.9 million from the offering after deducting underwriting discounts and commissions and offering expenses paid by the Company.</span></div> 4166663 3964843 30500000 3 3 7.68 32000000 3 21300000 2643228 2 2643228 500000 201820 1500000 3954546 0.001 1 7.70 30500000 2 2636364 20300000 1318182 7.70 10200000 2500000 7.70 5.81 5.83 1318182 1318182 10200000 46000000 5945718 5.81 5945718 34500000 14000000 10798482 10200000 2439024 1.64 4000000 49900000 34900000 29800000 3800000 17500000 2.00 32900000 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 19. RELATED-PARTY TRANSACTIONS</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Exchange Transactions</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 10, Convertible Notes, the Company carries Notes. The Schuler Family Foundation (the “Foundation”) previously held an aggregate of $42.0 million of the Notes. Jack W. Schuler, a member of the Company’s board of directors, is the President of the Foundation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, the Foundation transferred by gift the $42.0 million aggregate principal amount of Notes held by the Foundation to the Schuler Initiative Supporting Charitable Trust (the “Supporting Organization”), a tax-exempt organization that is not an affiliate of Jack W. Schuler.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2021 Exchange Transactions the Supporting Organization exchanged $42.0 million in aggregate principal amount of Notes held by it for 5,428,699 shares of the Company's common stock. Using the closing stock price on September 22, 2021 of $5.81, the 5,428,699 shares of the Company's common stock were determined to have a value of $31.5 million which was recorded to contributed capital for the three months ended September 30, 2021. The Supporting Organization had the same or similar terms as the other counter parties. The Company determined the 2021 Exchange Transactions did not meet the criteria of a capital transaction and was recorded as a gain on extinguishment of debt. See Note 10, Convertible Notes and Note 18, Stockholders' Equity, for additional information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">December 2020 Securities Purchase Agreement</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 24, 2020, the Company entered into the December 2020 Securities Purchase Agreement with the Original Purchasers for the issuance and sale by the Company of 4,166,663 shares of the Company’s common stock. The Original Purchasers are comprised of certain directors and officers of the Company, or entities affiliated or related to such persons. See Note 18, Stockholders' Equity, for further information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2021, the Company entered into the Rescission Agreement with the Schuler Purchasers and the Schuler Trust, an entity affiliated with Jack W. Schuler, pursuant to which, effective as of January 29, 2021, the Company and the Schuler Purchasers agreed to rescind and unwind the December 2020 Securities Purchase </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement for all legal, tax and financial purposes ab initio as if the related transactions, including the issuance and sale of an aggregate of 2,643,228 Shares in the first two tranche closings and the third tranche under the December 2020 Purchase Agreement, had never occurred with respect to the Schuler Purchasers and the Company. The Schuler Purchasers are related to Jack W. Schuler but are not affiliates of his. See Note 18, Stockholders' Equity, for further information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, the Company issued 201,820 shares and received total proceeds of approximately $1.5 million under the December 2020 Securities Purchase Agreement after giving effect to the Rescission Agreement.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">September 2021 Securities Purchase Agreement</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the Company entered into the September 2021 Securities Purchase Agreement with the Schuler Purchasers for the issuance and sale by the Company of 3,954,546 Series A Preferred Shares. The Schuler Purchasers are related to Jack W. Schuler but are not affiliates of his. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, the Company issued 2,636,364 Series A Preferred Shares and received total proceeds of approximately $20.3 million under the September 2021 Securities Purchase Agreement. See Note 18, Stockholders' Equity, for further information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">March 2022 Securities Purchase Agreement</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 24, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company entered into the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2022 Securities Purchase Agreement</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schuler Trust</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the issuance and sale by the Company of 2,439,024 shares of the Company’s common stock. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jack Schuler serves as a member of the Company’s board of directors and is the sole trustee of the Schuler Trust. See Note 18, Stockholders’ Equity, for further information. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">August 2022 Exchange Transaction</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2022, the Company entered into the August 2022 Exchange Agreement with the Schuler Trust. Under the terms of the August 2022 Exchange Agreement, the Schuler Trust agreed to exchange with the Company $49.9 million in aggregate principal amount of Notes held by it for the Secured Note in an aggregate principal amount of $34.9 million and a warrant to acquire the Company’s common stock. The net gain on extinguishment was $29.8 million during the nine months ended September 30, 2022, and was recorded as contributed capital. See Note 10, Convertible Notes and Note 11, Long-Term Debt Related-Party for additional information.</span></div> 42000000 42000000 42000000 5428699 5.81 5428699 31500000 4166663 2643228 201820 1500000 3954546 2636364 20300000 2439024 49900000 34900000 29800000 EXCEL 94 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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end XML 95 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 96 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 97 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 324 402 1 false 94 0 false 11 false false R1.htm 0000001 - Document - Cover Page Sheet http://acceleratediagnostics.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Sheet http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) Sheet http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) Statements 6 false false R7.htm 0000007 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPolicies Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies Notes 7 false false R8.htm 0000008 - Disclosure - Recently Issued Accounting Pronouncements Sheet http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncements Recently Issued Accounting Pronouncements Notes 8 false false R9.htm 0000009 - Disclosure - Concentration of Credit Risk Sheet http://acceleratediagnostics.com/role/ConcentrationofCreditRisk Concentration of Credit Risk Notes 9 false false R10.htm 0000010 - Disclosure - Fair Value of Financial Instruments Sheet http://acceleratediagnostics.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 10 false false R11.htm 0000011 - Disclosure - Investments Sheet http://acceleratediagnostics.com/role/Investments Investments Notes 11 false false R12.htm 0000012 - Disclosure - Inventory Sheet http://acceleratediagnostics.com/role/Inventory Inventory Notes 12 false false R13.htm 0000013 - Disclosure - Property and Equipment Sheet http://acceleratediagnostics.com/role/PropertyandEquipment Property and Equipment Notes 13 false false R14.htm 0000014 - Disclosure - Deferred Revenue and Remaining Performance Obligations Sheet http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligations Deferred Revenue and Remaining Performance Obligations Notes 14 false false R15.htm 0000015 - Disclosure - Long-Term Debt Sheet http://acceleratediagnostics.com/role/LongTermDebt Long-Term Debt Notes 15 false false R16.htm 0000016 - Disclosure - Convertible Notes Notes http://acceleratediagnostics.com/role/ConvertibleNotes Convertible Notes Notes 16 false false R17.htm 0000017 - Disclosure - Long-Term Debt Related-Party Sheet http://acceleratediagnostics.com/role/LongTermDebtRelatedParty Long-Term Debt Related-Party Notes 17 false false R18.htm 0000018 - Disclosure - Loss Per Share Sheet http://acceleratediagnostics.com/role/LossPerShare Loss Per Share Notes 18 false false R19.htm 0000019 - Disclosure - Employee Equity-Based Compensation Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensation Employee Equity-Based Compensation Notes 19 false false R20.htm 0000020 - Disclosure - Income Taxes Sheet http://acceleratediagnostics.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 0000021 - Disclosure - Commitments Sheet http://acceleratediagnostics.com/role/Commitments Commitments Notes 21 false false R22.htm 0000022 - Disclosure - Leases Sheet http://acceleratediagnostics.com/role/Leases Leases Notes 22 false false R23.htm 0000023 - Disclosure - Geographic and Revenue Disaggregation Sheet http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregation Geographic and Revenue Disaggregation Notes 23 false false R24.htm 0000024 - Disclosure - Stockholders' Equity Sheet http://acceleratediagnostics.com/role/StockholdersEquity Stockholders' Equity Notes 24 false false R25.htm 0000025 - Disclosure - Related-Party Transactions Sheet http://acceleratediagnostics.com/role/RelatedPartyTransactions Related-Party Transactions Notes 25 false false R26.htm 0000026 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies) Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies) Policies http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPolicies 26 false false R27.htm 0000027 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables) Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesTables Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables) Tables http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPolicies 27 false false R28.htm 0000028 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://acceleratediagnostics.com/role/FairValueofFinancialInstruments 28 false false R29.htm 0000029 - Disclosure - Investments (Tables) Sheet http://acceleratediagnostics.com/role/InvestmentsTables Investments (Tables) Tables http://acceleratediagnostics.com/role/Investments 29 false false R30.htm 0000030 - Disclosure - Inventory (Tables) Sheet http://acceleratediagnostics.com/role/InventoryTables Inventory (Tables) Tables http://acceleratediagnostics.com/role/Inventory 30 false false R31.htm 0000031 - Disclosure - Property and Equipment (Tables) Sheet http://acceleratediagnostics.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://acceleratediagnostics.com/role/PropertyandEquipment 31 false false R32.htm 0000032 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Tables) Sheet http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsTables Deferred Revenue and Remaining Performance Obligations (Tables) Tables http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligations 32 false false R33.htm 0000033 - Disclosure - Long-Term Debt (Tables) Sheet http://acceleratediagnostics.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://acceleratediagnostics.com/role/LongTermDebt 33 false false R34.htm 0000034 - Disclosure - Convertible Notes (Tables) Notes http://acceleratediagnostics.com/role/ConvertibleNotesTables Convertible Notes (Tables) Tables http://acceleratediagnostics.com/role/ConvertibleNotes 34 false false R35.htm 0000035 - Disclosure - Long-Term Debt Related-Party (Tables) Sheet http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyTables Long-Term Debt Related-Party (Tables) Tables http://acceleratediagnostics.com/role/LongTermDebtRelatedParty 35 false false R36.htm 0000036 - Disclosure - Loss Per Share (Tables) Sheet http://acceleratediagnostics.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://acceleratediagnostics.com/role/LossPerShare 36 false false R37.htm 0000037 - Disclosure - Employee Equity-Based Compensation (Tables) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables Employee Equity-Based Compensation (Tables) Tables http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensation 37 false false R38.htm 0000038 - Disclosure - Leases (Tables) Sheet http://acceleratediagnostics.com/role/LeasesTables Leases (Tables) Tables http://acceleratediagnostics.com/role/Leases 38 false false R39.htm 0000039 - Disclosure - Geographic and Revenue Disaggregation (Tables) Sheet http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationTables Geographic and Revenue Disaggregation (Tables) Tables http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregation 39 false false R40.htm 0000040 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details) Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details) Details http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesTables 40 false false R41.htm 0000041 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Allowance For Doubtful Accounts (Details) Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesAllowanceForDoubtfulAccountsDetails Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Allowance For Doubtful Accounts (Details) Details 41 false false R42.htm 0000042 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details) Sheet http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details) Details 42 false false R43.htm 0000043 - Disclosure - Recently Issued Accounting Pronouncements (Details) Sheet http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails Recently Issued Accounting Pronouncements (Details) Details http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncements 43 false false R44.htm 0000044 - Disclosure - Concentration of Credit Risk (Details) Sheet http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails Concentration of Credit Risk (Details) Details http://acceleratediagnostics.com/role/ConcentrationofCreditRisk 44 false false R45.htm 0000045 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details) Sheet http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details) Details 45 false false R46.htm 0000046 - Disclosure - Fair Value of Financial Instruments - Narrative (Details) Sheet http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails Fair Value of Financial Instruments - Narrative (Details) Details 46 false false R47.htm 0000047 - Disclosure - Investments - Schedule of Available-for-sale Securities (Details) Sheet http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails Investments - Schedule of Available-for-sale Securities (Details) Details 47 false false R48.htm 0000048 - Disclosure - Investments - Schedule of Available-for-Sale Investment Maturities (Details) Sheet http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails Investments - Schedule of Available-for-Sale Investment Maturities (Details) Details 48 false false R49.htm 0000049 - Disclosure - Investments - Narrative (Details) Sheet http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails Investments - Narrative (Details) Details 49 false false R50.htm 0000050 - Disclosure - Investments - Unrealized Losses or Gains on Equity Securities (Details) Sheet http://acceleratediagnostics.com/role/InvestmentsUnrealizedLossesorGainsonEquitySecuritiesDetails Investments - Unrealized Losses or Gains on Equity Securities (Details) Details 50 false false R51.htm 0000051 - Disclosure - Inventory (Details) Sheet http://acceleratediagnostics.com/role/InventoryDetails Inventory (Details) Details http://acceleratediagnostics.com/role/InventoryTables 51 false false R52.htm 0000052 - Disclosure - Property and Equipment - Property and Equipment at Cost (Details) Sheet http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails Property and Equipment - Property and Equipment at Cost (Details) Details 52 false false R53.htm 0000053 - Disclosure - Property and Equipment - Instruments at Cost and Accumulated Depreciation, Lessor (Details) Sheet http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails Property and Equipment - Instruments at Cost and Accumulated Depreciation, Lessor (Details) Details 53 false false R54.htm 0000054 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Details) Sheet http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails Deferred Revenue and Remaining Performance Obligations (Details) Details http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsTables 54 false false R55.htm 0000055 - Disclosure - Long-Term Debt - Narrative (Details) Sheet http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails Long-Term Debt - Narrative (Details) Details 55 false false R56.htm 0000056 - Disclosure - Long-Term Debt - Schedule of Long-term Debt (Details) Sheet http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails Long-Term Debt - Schedule of Long-term Debt (Details) Details 56 false false R57.htm 0000057 - Disclosure - Long-Term Debt - Schedule of Maturities of Future Principal Obligations (Details) Sheet http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails Long-Term Debt - Schedule of Maturities of Future Principal Obligations (Details) Details 57 false false R58.htm 0000058 - Disclosure - Convertible Notes - Narrative (Details) Notes http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails Convertible Notes - Narrative (Details) Details 58 false false R59.htm 0000059 - Disclosure - Convertible Notes - Schedule of Interest Expense (Details) Notes http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails Convertible Notes - Schedule of Interest Expense (Details) Details 59 false false R60.htm 0000060 - Disclosure - Convertible Notes - Gain on Extinguishment (Details) Notes http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails Convertible Notes - Gain on Extinguishment (Details) Details 60 false false R61.htm 0000061 - Disclosure - Convertible Notes - Schedule of Notes and New Notes (Details) Notes http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails Convertible Notes - Schedule of Notes and New Notes (Details) Details 61 false false R62.htm 0000062 - Disclosure - Long-Term Debt Related-Party - Narrative (Details) Sheet http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails Long-Term Debt Related-Party - Narrative (Details) Details 62 false false R63.htm 0000063 - Disclosure - Long-Term Debt Related-Party - Carrying Value of the Secured Notes (Details) Notes http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails Long-Term Debt Related-Party - Carrying Value of the Secured Notes (Details) Details 63 false false R64.htm 0000064 - Disclosure - Long-Term Debt Related-Party - Interest Expense in Connection with the Secured Note (Details) Sheet http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails Long-Term Debt Related-Party - Interest Expense in Connection with the Secured Note (Details) Details 64 false false R65.htm 0000065 - Disclosure - Long-Term Debt Related-Party - Summary of Inputs Used to Calculate Estimated Fair Value (Details) Sheet http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails Long-Term Debt Related-Party - Summary of Inputs Used to Calculate Estimated Fair Value (Details) Details 65 false false R66.htm 0000066 - Disclosure - Loss Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details) Sheet http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails Loss Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details) Details 66 false false R67.htm 0000067 - Disclosure - Loss Per Share - Narrative (Details) Sheet http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails Loss Per Share - Narrative (Details) Details 67 false false R68.htm 0000068 - Disclosure - Employee Equity-Based Compensation - Option Activity under the Company's Equity-Based Compensation (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails Employee Equity-Based Compensation - Option Activity under the Company's Equity-Based Compensation (Details) Details 68 false false R69.htm 0000069 - Disclosure - Employee Equity-Based Compensation - Narrative (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails Employee Equity-Based Compensation - Narrative (Details) Details 69 false false R70.htm 0000070 - Disclosure - Employee Equity-Based Compensation - Outstanding Options and Options that are Exercisable (Vested) (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails Employee Equity-Based Compensation - Outstanding Options and Options that are Exercisable (Vested) (Details) Details 70 false false R71.htm 0000071 - Disclosure - Employee Equity-Based Compensation - Restricted Stock Activity (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails Employee Equity-Based Compensation - Restricted Stock Activity (Details) Details 71 false false R72.htm 0000072 - Disclosure - Employee Equity-Based Compensation - Equity-Based Compensation Expense (Details) Sheet http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails Employee Equity-Based Compensation - Equity-Based Compensation Expense (Details) Details 72 false false R73.htm 0000073 - Disclosure - Income Taxes (Details) Sheet http://acceleratediagnostics.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://acceleratediagnostics.com/role/IncomeTaxes 73 false false R74.htm 0000074 - Disclosure - Commitments (Details) Sheet http://acceleratediagnostics.com/role/CommitmentsDetails Commitments (Details) Details http://acceleratediagnostics.com/role/Commitments 74 false false R75.htm 0000075 - Disclosure - Leases - Assets and Liabilities (Details) Sheet http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails Leases - Assets and Liabilities (Details) Details 75 false false R76.htm 0000076 - Disclosure - Leases - Maturities of Lease Liabilities (Details) Sheet http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails Leases - Maturities of Lease Liabilities (Details) Details 76 false false R77.htm 0000077 - Disclosure - Leases - Sales-type Lease Receivable Maturity (Details) Sheet http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails Leases - Sales-type Lease Receivable Maturity (Details) Details 77 false false R78.htm 0000078 - Disclosure - Geographic and Revenue Disaggregation - Narrative (Details) Sheet http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails Geographic and Revenue Disaggregation - Narrative (Details) Details 78 false false R79.htm 0000079 - Disclosure - Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details) Sheet http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details) Details 79 false false R80.htm 0000080 - Disclosure - Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details) Sheet http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details) Details 80 false false R81.htm 0000081 - Disclosure - Stockholders' Equity (Details) Sheet http://acceleratediagnostics.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://acceleratediagnostics.com/role/StockholdersEquity 81 false false R82.htm 0000082 - Disclosure - Related-Party Transactions (Details) Sheet http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails Related-Party Transactions (Details) Details http://acceleratediagnostics.com/role/RelatedPartyTransactions 82 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentConvertibleConversionRatio1, us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:PropertyPlantAndEquipmentUsefulLife - axdx-20220930.htm 4 axdx-20220930.htm a09302022-exh105.htm a09302022-exh311.htm a09302022-exh312.htm a09302022-exh32.htm axdx-20220930.xsd axdx-20220930_cal.xml axdx-20220930_def.xml axdx-20220930_lab.xml axdx-20220930_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 100 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "axdx-20220930.htm": { "axisCustom": 0, "axisStandard": 30, "contextCount": 324, "dts": { "calculationLink": { "local": [ "axdx-20220930_cal.xml" ] }, "definitionLink": { "local": [ "axdx-20220930_def.xml" ] }, "inline": { "local": [ "axdx-20220930.htm" ] }, "labelLink": { "local": [ "axdx-20220930_lab.xml" ] }, "presentationLink": { "local": [ "axdx-20220930_pre.xml" ] }, "schema": { "local": [ "axdx-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 639, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 5, "http://xbrl.sec.gov/dei/2022": 5, "total": 10 }, "keyCustom": 38, "keyStandard": 364, "memberCustom": 33, "memberStandard": 58, "nsprefix": "axdx", "nsuri": "http://acceleratediagnostics.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "role": "http://acceleratediagnostics.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Fair Value of Financial Instruments", "role": "http://acceleratediagnostics.com/role/FairValueofFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Investments", "role": "http://acceleratediagnostics.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Inventory", "role": "http://acceleratediagnostics.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Property and Equipment", "role": "http://acceleratediagnostics.com/role/PropertyandEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Deferred Revenue and Remaining Performance Obligations", "role": "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligations", "shortName": "Deferred Revenue and Remaining Performance Obligations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Long-Term Debt", "role": "http://acceleratediagnostics.com/role/LongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Convertible Notes", "role": "http://acceleratediagnostics.com/role/ConvertibleNotes", "shortName": "Convertible Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "axdx:LongTermDebtRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Long-Term Debt Related-Party", "role": "http://acceleratediagnostics.com/role/LongTermDebtRelatedParty", "shortName": "Long-Term Debt Related-Party", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "axdx:LongTermDebtRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Loss Per Share", "role": "http://acceleratediagnostics.com/role/LossPerShare", "shortName": "Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Employee Equity-Based Compensation", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensation", "shortName": "Employee Equity-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Income Taxes", "role": "http://acceleratediagnostics.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Commitments", "role": "http://acceleratediagnostics.com/role/Commitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorSalesTypeLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Leases", "role": "http://acceleratediagnostics.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LessorSalesTypeLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Geographic and Revenue Disaggregation", "role": "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregation", "shortName": "Geographic and Revenue Disaggregation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Stockholders' Equity", "role": "http://acceleratediagnostics.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Related-Party Transactions", "role": "http://acceleratediagnostics.com/role/RelatedPartyTransactions", "shortName": "Related-Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies)", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables)", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesTables", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Fair Value of Financial Instruments (Tables)", "role": "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Investments (Tables)", "role": "http://acceleratediagnostics.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Inventory (Tables)", "role": "http://acceleratediagnostics.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Property and Equipment (Tables)", "role": "http://acceleratediagnostics.com/role/PropertyandEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Tables)", "role": "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsTables", "shortName": "Deferred Revenue and Remaining Performance Obligations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Long-Term Debt (Tables)", "role": "http://acceleratediagnostics.com/role/LongTermDebtTables", "shortName": "Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Convertible Notes (Tables)", "role": "http://acceleratediagnostics.com/role/ConvertibleNotesTables", "shortName": "Convertible Notes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleOfExtinguishmentOfDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Long-Term Debt Related-Party (Tables)", "role": "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyTables", "shortName": "Long-Term Debt Related-Party (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Loss Per Share (Tables)", "role": "http://acceleratediagnostics.com/role/LossPerShareTables", "shortName": "Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Employee Equity-Based Compensation (Tables)", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables", "shortName": "Employee Equity-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "axdx:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Leases (Tables)", "role": "http://acceleratediagnostics.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "axdx:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Geographic and Revenue Disaggregation (Tables)", "role": "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationTables", "shortName": "Geographic and Revenue Disaggregation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)", "role": "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "axdx:NumberOfConvertibleDebtOfferings", "reportCount": 1, "unique": true, "unitRef": "instrument", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "axdx:NumberOfConvertibleDebtOfferings", "reportCount": 1, "unique": true, "unitRef": "instrument", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i320928da7ad14bd893777cc143c9e52c_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Allowance For Doubtful Accounts (Details)", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesAllowanceForDoubtfulAccountsDetails", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Allowance For Doubtful Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i320928da7ad14bd893777cc143c9e52c_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i320928da7ad14bd893777cc143c9e52c_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details)", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies - Schedule of Product Warranty Reserve Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i320928da7ad14bd893777cc143c9e52c_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StandardProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Recently Issued Accounting Pronouncements (Details)", "role": "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails", "shortName": "Recently Issued Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i36234338a60a41a0a8e78eb30e206381_I20220101", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ConvertibleDebt", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i9fc24b7a3db24edcbbe4a93e845ea4fb_D20220101-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Concentration of Credit Risk (Details)", "role": "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "shortName": "Concentration of Credit Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i9fc24b7a3db24edcbbe4a93e845ea4fb_D20220101-20220930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "us-gaap:EquitySecuritiesFvNi", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesFvNi", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details)", "role": "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "shortName": "Fair Value of Financial Instruments - Schedule of Fair Value Measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iab223cd71c164c469f89f133046bbcb8_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i4c4444526e344213a1418df40697a3de_I20220815", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstanding", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Fair Value of Financial Instruments - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "shortName": "Fair Value of Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i9df842db997849c298546c74dc941938_I20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Investments - Schedule of Available-for-sale Securities (Details)", "role": "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails", "shortName": "Investments - Schedule of Available-for-sale Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Investments - Schedule of Available-for-Sale Investment Maturities (Details)", "role": "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails", "shortName": "Investments - Schedule of Available-for-Sale Investment Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Investments - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails", "shortName": "Investments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "role": "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Investments - Unrealized Losses or Gains on Equity Securities (Details)", "role": "http://acceleratediagnostics.com/role/InvestmentsUnrealizedLossesorGainsonEquitySecuritiesDetails", "shortName": "Investments - Unrealized Losses or Gains on Equity Securities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Inventory (Details)", "role": "http://acceleratediagnostics.com/role/InventoryDetails", "shortName": "Inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Property and Equipment - Property and Equipment at Cost (Details)", "role": "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails", "shortName": "Property and Equipment - Property and Equipment at Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ib8ec5388cbe4455e9eaec7b7590fe74d_I20211231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Property and Equipment - Instruments at Cost and Accumulated Depreciation, Lessor (Details)", "role": "http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails", "shortName": "Property and Equipment - Instruments at Cost and Accumulated Depreciation, Lessor (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Deferred Revenue and Remaining Performance Obligations (Details)", "role": "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails", "shortName": "Deferred Revenue and Remaining Performance Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Long-Term Debt - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "shortName": "Long-Term Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i2d429f210e5d4088a520331a629f759d_D20200101-20201231", "decimals": "INF", "lang": "en-US", "name": "axdx:NumberOfDebtInstruments", "reportCount": 1, "unique": true, "unitRef": "loan", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Long-Term Debt - Schedule of Long-term Debt (Details)", "role": "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "shortName": "Long-Term Debt - Schedule of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:LongTermDebtNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Long-Term Debt - Schedule of Maturities of Future Principal Obligations (Details)", "role": "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails", "shortName": "Long-Term Debt - Schedule of Maturities of Future Principal Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Convertible Notes - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "shortName": "Convertible Notes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "if17d0c0e38de40ba9f2e1ed23496b41b_D20220101-20220930", "decimals": "-5", "lang": "en-US", "name": "axdx:PaymentsToFundPrepaidForwardStockRepurchase", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i07f5d20729a94341948bd566b4c9e325_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Convertible Notes - Schedule of Interest Expense (Details)", "role": "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "shortName": "Convertible Notes - Schedule of Interest Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i07f5d20729a94341948bd566b4c9e325_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iced5f6bea4f24c3387c8600323813d88_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited)", "role": "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iced5f6bea4f24c3387c8600323813d88_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Convertible Notes - Gain on Extinguishment (Details)", "role": "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "shortName": "Convertible Notes - Gain on Extinguishment (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Convertible Notes - Schedule of Notes and New Notes (Details)", "role": "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "shortName": "Convertible Notes - Schedule of Notes and New Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ief376f6d404242a888c0ca2d81c5d738_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Long-Term Debt Related-Party - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "shortName": "Long-Term Debt Related-Party - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i5cc5a281af98407b898cdc3be5e72a9e_D20220815-20220815", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Long-Term Debt Related-Party - Carrying Value of the Secured Notes (Details)", "role": "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "shortName": "Long-Term Debt Related-Party - Carrying Value of the Secured Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ib543785b855b4d4abff0970192e1125c_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i64399cdab6a14c398a6bf9437469e47e_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Long-Term Debt Related-Party - Interest Expense in Connection with the Secured Note (Details)", "role": "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "shortName": "Long-Term Debt Related-Party - Interest Expense in Connection with the Secured Note (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i64399cdab6a14c398a6bf9437469e47e_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i03ca9d32493d4712bf42547574c408ad_I20220930", "decimals": "1", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "year", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Long-Term Debt Related-Party - Summary of Inputs Used to Calculate Estimated Fair Value (Details)", "role": "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails", "shortName": "Long-Term Debt Related-Party - Summary of Inputs Used to Calculate Estimated Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i03ca9d32493d4712bf42547574c408ad_I20220930", "decimals": "1", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "year", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Loss Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details)", "role": "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails", "shortName": "Loss Per Share - Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Loss Per Share - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "shortName": "Loss Per Share - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ib8ec5388cbe4455e9eaec7b7590fe74d_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Employee Equity-Based Compensation - Option Activity under the Company's Equity-Based Compensation (Details)", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails", "shortName": "Employee Equity-Based Compensation - Option Activity under the Company's Equity-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "span", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Employee Equity-Based Compensation - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "shortName": "Employee Equity-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i26b6c3b4ea0c428d8fc30e0bdd582112_D20200101-20201231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies", "role": "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPolicies", "shortName": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Employee Equity-Based Compensation - Outstanding Options and Options that are Exercisable (Vested) (Details)", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails", "shortName": "Employee Equity-Based Compensation - Outstanding Options and Options that are Exercisable (Vested) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iafcdc816c4284bdf960edaa53a9e13f4_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Employee Equity-Based Compensation - Restricted Stock Activity (Details)", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails", "shortName": "Employee Equity-Based Compensation - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "iafcdc816c4284bdf960edaa53a9e13f4_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Employee Equity-Based Compensation - Equity-Based Compensation Expense (Details)", "role": "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails", "shortName": "Employee Equity-Based Compensation - Equity-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Income Taxes (Details)", "role": "http://acceleratediagnostics.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R74": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - Commitments (Details)", "role": "http://acceleratediagnostics.com/role/CommitmentsDetails", "shortName": "Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "axdx:AssetsAndLiabilitiesLesseeTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - Leases - Assets and Liabilities (Details)", "role": "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails", "shortName": "Leases - Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "axdx:AssetsAndLiabilitiesLesseeTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - Leases - Maturities of Lease Liabilities (Details)", "role": "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails", "shortName": "Leases - Maturities of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "us-gaap:LessorSalesTypeLeasesTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetInvestmentInLease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - Leases - Sales-type Lease Receivable Maturity (Details)", "role": "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails", "shortName": "Leases - Sales-type Lease Receivable Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetInvestmentInLease", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - Geographic and Revenue Disaggregation - Narrative (Details)", "role": "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails", "shortName": "Geographic and Revenue Disaggregation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i0ae9955abf9841c9bbde1c634f367b67_D20220701-20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000079 - Disclosure - Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details)", "role": "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails", "shortName": "Geographic and Revenue Disaggregation - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i5596637a9509418a9a7bf6c848b85096_D20220701-20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Recently Issued Accounting Pronouncements", "role": "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncements", "shortName": "Recently Issued Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i74c761f125ee443cab3fd47e6a02043e_I20220930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000080 - Disclosure - Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details)", "role": "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "shortName": "Geographic and Revenue Disaggregation - Long-lived Assets by Geographic Territory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i845c7047ec7d4239aeb773675274efb2_I20220930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie5f1165a5a4148b1bbcf54138376c358_I20210930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000081 - Disclosure - Stockholders' Equity (Details)", "role": "http://acceleratediagnostics.com/role/StockholdersEquityDetails", "shortName": "Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie9876d47135549138f29350d936fae04_I20220822", "decimals": "2", "lang": "en-US", "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "ie5f1165a5a4148b1bbcf54138376c358_I20210930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000082 - Disclosure - Related-Party Transactions (Details)", "role": "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "shortName": "Related-Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i22b5fec406f548b7a3a3cb3f66f90a91_D20210922-20210922", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Concentration of Credit Risk", "role": "http://acceleratediagnostics.com/role/ConcentrationofCreditRisk", "shortName": "Concentration of Credit Risk", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "axdx-20220930.htm", "contextRef": "i823d195923ed4151a42bbc5d9913ce90_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 94, "tag": { "axdx_A2021ExchangeTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Exchange Transaction [Member]", "label": "2021 Exchange Transaction [Member]", "terseLabel": "2021 Exchange Transaction" } } }, "localname": "A2021ExchangeTransactionMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_AcceleratePhenoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerate Pheno [Member]", "label": "Accelerate Pheno [Member]", "terseLabel": "Accelerate Pheno revenue" } } }, "localname": "AcceleratePhenoMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "axdx_AmortizationOfDebtIssuanceCostsRelatedParty": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortization of Debt Issuance Costs, Related Party", "label": "Amortization of Debt Issuance Costs, Related Party", "terseLabel": "Amortization of debt discount related-party" } } }, "localname": "AmortizationOfDebtIssuanceCostsRelatedParty", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "axdx_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Schedule of Supplemental Lease Information" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "axdx_August2022ExchangeTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "August 2022 Exchange With Related Party [Member]", "label": "August 2022 Exchange Transaction [Member]", "terseLabel": "August 2022 Exchange Transaction" } } }, "localname": "August2022ExchangeTransactionMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_August2022PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "August 2022 Public Offering", "label": "August 2022 Public Offering [Member]", "terseLabel": "August 2022 Public Offering" } } }, "localname": "August2022PublicOfferingMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_CertainDirectorsAndOfficersOrAffiliatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Certain Directors And Officers Or Affiliates [Member]", "label": "Certain Directors And Officers Or Affiliates [Member]", "terseLabel": "Original Purchasers" } } }, "localname": "CertainDirectorsAndOfficersOrAffiliatesMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_ConvertibleNotePurchasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Note Purchases [Member]", "label": "Convertible Note Purchases [Member]", "terseLabel": "Convertible Note Purchases" } } }, "localname": "ConvertibleNotePurchasesMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "axdx_ConvertibleNotesExchangeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Notes Exchange Agreement", "label": "Convertible Notes Exchange Agreement [Member]", "terseLabel": "Exchange Agreement" } } }, "localname": "ConvertibleNotesExchangeAgreementMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "axdx_ConvertiblePreferredStockSaleOrMergerTriggerSharesIssuedUponConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Preferred Stock, Sale or Merger Trigger, Shares Issued upon Conversion", "label": "Convertible Preferred Stock, Sale or Merger Trigger, Shares Issued upon Conversion", "terseLabel": "Sale or merger trigger conversion ratio (in shares)" } } }, "localname": "ConvertiblePreferredStockSaleOrMergerTriggerSharesIssuedUponConversion", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "pureItemType" }, "axdx_DebtConversionConversionNumerator": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Conversion, Conversion Numerator", "label": "Debt Conversion, Conversion Numerator", "terseLabel": "Conversion numerator (in usd per share)" } } }, "localname": "DebtConversionConversionNumerator", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "axdx_DebtConversionConvertedInstrumentRelatedPartyContributedCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Conversion, Converted Instrument, Related Party Contributed Capital", "label": "Debt Conversion, Converted Instrument, Related Party Contributed Capital", "terseLabel": "Capital contribution from related-party in connection with the exchange transaction" } } }, "localname": "DebtConversionConvertedInstrumentRelatedPartyContributedCapital", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "axdx_DebtConversionCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Conversion, Cost", "label": "Debt Conversion, Cost", "terseLabel": "Reacquisition costs" } } }, "localname": "DebtConversionCost", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "axdx_DebtConversionNumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Conversion, Number Of Tranches", "label": "Debt Conversion, Number Of Tranches", "terseLabel": "Number of tranches" } } }, "localname": "DebtConversionNumberOfTranches", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "integerItemType" }, "axdx_DebtInstrumentConvertibleNumberOfEquityInstrumentAccruedInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Convertible, Number Of Equity Instrument, Accrued Interest", "label": "Debt Instrument, Convertible, Number Of Equity Instrument, Accrued Interest", "terseLabel": "Debt instrument, convertible, number of accrued interest" } } }, "localname": "DebtInstrumentConvertibleNumberOfEquityInstrumentAccruedInterest", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "integerItemType" }, "axdx_DebtInstrumentConvertibleThresholdPercentageofNotesTradingPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Convertible, Threshold Percentage of Notes Trading Price Trigger", "label": "Debt Instrument, Convertible, Threshold Percentage of Notes Trading Price Trigger", "terseLabel": "Trading price threshold, percentage" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageofNotesTradingPriceTrigger", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "axdx_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year One Through Three", "label": "Debt Securities, Available-For-Sale, Amortized Cost, Maturity, Allocated And Single Maturity Date, After Year One Through Three", "terseLabel": "Due in 1-3 years" } } }, "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "axdx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Three", "label": "Debt Securities, Available-For-Sale, Fair Value, Maturity, Allocated And Single Maturity Date, After Year One Through Three", "terseLabel": "Due in 1-3 years" } } }, "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "axdx_December2020SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December 2020 Securities Purchase Agreement [Member]", "label": "December 2020 Securities Purchase Agreement [Member]", "terseLabel": "December 2020 Securities Purchase Agreement" } } }, "localname": "December2020SecuritiesPurchaseAgreementMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_EmbededWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Embeded Warrant [Member]", "label": "Embeded Warrant [Member]", "terseLabel": "Embeded Warrant" } } }, "localname": "EmbededWarrantMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_ExerciseOfOptionsAndRestrictedStockAwardsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Of Options And Restricted Stock Awards Issued", "label": "Exercise Of Options And Restricted Stock Awards Issued", "terseLabel": "Restricted stock awards released and exercise of options (in shares)" } } }, "localname": "ExerciseOfOptionsAndRestrictedStockAwardsIssued", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "sharesItemType" }, "axdx_ExtinguishedNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extinguished Notes", "label": "Extinguished Notes [Member]", "terseLabel": "Extinguished Notes" } } }, "localname": "ExtinguishedNotesMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_FinanceLeaseCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Cost", "label": "Finance Lease, Cost", "terseLabel": "Finance leases" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "axdx_FinanceLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Lease, Liability, to be Paid, after Year Four", "label": "Finance Lease, Liability, to be Paid, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "axdx_FinancialInstitutionsOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Institutions One", "label": "Financial Institutions One [Member]", "terseLabel": "Financial Institutions One" } } }, "localname": "FinancialInstitutionsOneMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "axdx_FinancialInstitutionsThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Institutions Three", "label": "Financial Institutions Three [Member]", "terseLabel": "Financial Institutions Three" } } }, "localname": "FinancialInstitutionsThreeMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "axdx_FinancialInstitutionsTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Institutions Two", "label": "Financial Institutions Two [Member]", "terseLabel": "Financial Institutions Two" } } }, "localname": "FinancialInstitutionsTwoMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "axdx_FivePointZeroPercentSecuredPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five Point Zero Percent Secured Promissory Note", "label": "Five Point Zero Percent Secured Promissory Note [Member]", "terseLabel": "5.0% Secured promissory note" } } }, "localname": "FivePointZeroPercentSecuredPromissoryNoteMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_GrossMarginPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross Margin Percentage", "label": "Gross Margin Percentage", "terseLabel": "Gross margin" } } }, "localname": "GrossMarginPercentage", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "pureItemType" }, "axdx_IncreaseDecreaseRelatedPartyAccruedInterest": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) Related Party Accrued Interest", "label": "Increase (Decrease) Related Party Accrued Interest", "terseLabel": "Accrued interest from related-party" } } }, "localname": "IncreaseDecreaseRelatedPartyAccruedInterest", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "axdx_InstrumentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Instruments [Member]", "label": "Instruments [Member]", "terseLabel": "Instruments" } } }, "localname": "InstrumentsMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "domainItemType" }, "axdx_InterestPayableRelatedPartyNoncurrent": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest Payable, Related Party, Noncurrent", "label": "Interest Payable, Related Party, Noncurrent", "terseLabel": "Accrued interest related-party" } } }, "localname": "InterestPayableRelatedPartyNoncurrent", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "axdx_InventoryTransferredtoFixedAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory Transferred to Fixed Assets", "label": "Inventory Transferred to Fixed Assets", "terseLabel": "Net transfer of instruments (to) from inventory to property and equipment" } } }, "localname": "InventoryTransferredtoFixedAssets", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "axdx_IssuanceOfCommonStockNumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of Common Stock, Number of Tranches", "label": "Issuance of Common Stock, Number of Tranches", "terseLabel": "Number of tranches" } } }, "localname": "IssuanceOfCommonStockNumberOfTranches", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "integerItemType" }, "axdx_JackWSchulerLivingTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jack W. Schuler Living Trust", "label": "Jack W. Schuler Living Trust [Member]", "terseLabel": "Schuler Trust" } } }, "localname": "JackWSchulerLivingTrustMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "axdx_LongTermDebtMaturityAfterYearFour": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-Term Debt, Maturity, after Year Four", "label": "Long-Term Debt, Maturity, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "LongTermDebtMaturityAfterYearFour", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "axdx_LongTermDebtRelatedPartyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Debt Related Party [Text Block]", "label": "Long Term Debt Related Party [Text Block]", "terseLabel": "Long-Term Debt Related-Party" } } }, "localname": "LongTermDebtRelatedPartyTextBlock", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedParty" ], "xbrltype": "textBlockItemType" }, "axdx_March2022ExchangeTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2022 Exchange Transaction [Member]", "label": "March 2022 Exchange Transaction [Member]", "terseLabel": "March 2022 Exchange Transaction" } } }, "localname": "March2022ExchangeTransactionMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_March2022SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2022 Securities Purchase Agreement", "label": "March 2022 Securities Purchase Agreement [Member]", "terseLabel": "March 2022 Securities Purchase Agreement" } } }, "localname": "March2022SecuritiesPurchaseAgreementMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_NumberOfCapitalAssetFinancingCompanies": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Capital Asset Financing Companies", "label": "Number of Capital Asset Financing Companies", "terseLabel": "Number of capital asset financing companies" } } }, "localname": "NumberOfCapitalAssetFinancingCompanies", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "axdx_NumberOfConvertibleDebtOfferings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Convertible Debt Offerings", "label": "Number Of Convertible Debt Offerings", "terseLabel": "Convertible debt offerings" } } }, "localname": "NumberOfConvertibleDebtOfferings", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "axdx_NumberOfDebtInstruments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Debt Instruments", "label": "Number of Debt Instruments", "terseLabel": "Number of loan agreements" } } }, "localname": "NumberOfDebtInstruments", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "axdx_OneCustomerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Customer", "label": "One Customer [Member]", "terseLabel": "One customer" } } }, "localname": "OneCustomerMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "axdx_OtherLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Loans", "label": "Other Loans [Member]", "terseLabel": "Loans - various interest", "verboseLabel": "Other loans" } } }, "localname": "OtherLoansMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "axdx_OtherRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Revenue [Member]", "label": "Other Revenue [Member]", "terseLabel": "Other revenue" } } }, "localname": "OtherRevenueMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "axdx_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paycheck Protection Program", "label": "Paycheck Protection Program [Member]", "terseLabel": "Paycheck Protection Program" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "axdx_PaymentsOfDebtConversionCosts": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments Of Debt Conversion Costs", "label": "Payments Of Debt Conversion Costs", "negatedTerseLabel": "Transaction costs related to debt exchange" } } }, "localname": "PaymentsOfDebtConversionCosts", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "axdx_PaymentsToFundPrepaidForwardStockRepurchase": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payments To Fund Prepaid Forward Stock Repurchase", "label": "Payments To Fund Prepaid Forward Stock Repurchase", "terseLabel": "Funded prepaid forward" } } }, "localname": "PaymentsToFundPrepaidForwardStockRepurchase", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "axdx_PerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance-based Restricted Stock Units", "label": "Performance-based Restricted Stock Units [Member]", "terseLabel": "Performance-based RSU expense" } } }, "localname": "PerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "axdx_PrepaidForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prepaid Forward", "label": "Prepaid Forward [Member]", "terseLabel": "Prepaid Forward" } } }, "localname": "PrepaidForwardMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "axdx_ProductsandServicesnotYetDeliveredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Products and Services not Yet Delivered [Member]", "label": "Products and Services not Yet Delivered [Member]", "terseLabel": "Products and services not yet delivered" } } }, "localname": "ProductsandServicesnotYetDeliveredMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails" ], "xbrltype": "domainItemType" }, "axdx_RelatedPartyNumberOfRelatedEntities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party, Number of Related Entities", "label": "Related Party, Number of Related Entities", "terseLabel": "Non-affiliate related entities" } } }, "localname": "RelatedPartyNumberOfRelatedEntities", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "integerItemType" }, "axdx_RestrictedStockUnitsAndRestrictedStockAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units And Restricted Stock Awards [Member]", "label": "Restricted Stock Units And Restricted Stock Awards [Member]", "terseLabel": "RSUs and RSAs" } } }, "localname": "RestrictedStockUnitsAndRestrictedStockAwardsMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "axdx_SalesTypeAndDirectFinancingLeasesLeaseReceivableToBeReceivedAfterYearFour": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 6.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableToBeReceivedAfterYearFour", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "axdx_SchulerFamilyFoundationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schuler Family Foundation [Member]", "label": "Schuler Family Foundation [Member]", "terseLabel": "Schuler Family Foundation" } } }, "localname": "SchulerFamilyFoundationMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "axdx_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreement", "label": "Securities Purchase Agreement [Member]", "terseLabel": "Securities Purchase Agreement" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "axdx_September2021RescissionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "September 2021 Rescission Agreement", "label": "September 2021 Rescission Agreement [Member]", "terseLabel": "September 2021 Rescission Agreement" } } }, "localname": "September2021RescissionAgreementMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_September2021SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "September 2021 Securities Purchase Agreement", "label": "September 2021 Securities Purchase Agreement [Member]", "terseLabel": "September 2021 Securities Purchase Agreement" } } }, "localname": "September2021SecuritiesPurchaseAgreementMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_September2021SecuritiesPurchaseAgreementSecondTrancheRightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "September 2021 Securities Purchase Agreement, Second Tranche Right", "label": "September 2021 Securities Purchase Agreement, Second Tranche Right [Member]", "terseLabel": "Tranche Right" } } }, "localname": "September2021SecuritiesPurchaseAgreementSecondTrancheRightMember", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedTermOfAward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Expected Term of Award", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expected Term of Award", "terseLabel": "Expected term of award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedTermOfAward", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value (in usd per share)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "perShareItemType" }, "axdx_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Fair Value", "terseLabel": "Weighted average fair value (in usd per shares)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageFairValue", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "perShareItemType" }, "axdx_StandardProductWarrantyAccrualIncreaseDecreaseForWarrantiesIssuedAndAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Standard Product Warranty Accrual, Increase (Decrease) for Warranties Issued and Adjustments", "label": "Standard Product Warranty Accrual, Increase (Decrease) for Warranties Issued and Adjustments", "terseLabel": "Provisions (reversals), net" } } }, "localname": "StandardProductWarrantyAccrualIncreaseDecreaseForWarrantiesIssuedAndAdjustments", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "axdx_StandardProductWarrantyInstrumentsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Product Warranty, Instruments, Term", "label": "Standard Product Warranty, Instruments, Term", "terseLabel": "Instrument warranty term" } } }, "localname": "StandardProductWarrantyInstrumentsTerm", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "axdx_StandardProductWarrantyKitsAndAccessoriesTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Standard Product Warranty, Kits And Accessories, Term", "label": "Standard Product Warranty, Kits And Accessories, Term", "terseLabel": "Kits and accessories warranty term" } } }, "localname": "StandardProductWarrantyKitsAndAccessoriesTerm", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "axdx_StockholdersEquityTrancheRight": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stockholders' Equity, Tranche Right", "label": "Stockholders' Equity, Tranche Right", "terseLabel": "Tranche right value" } } }, "localname": "StockholdersEquityTrancheRight", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "axdx_TreasuryStockAcquiredNumberOfSharesPrepaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Treasury Stock Acquired, Number Of Shares Prepaid", "label": "Treasury Stock Acquired, Number Of Shares Prepaid", "terseLabel": "Stock underlying the prepaid forward (in shares)" } } }, "localname": "TreasuryStockAcquiredNumberOfSharesPrepaid", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "axdx_TwoPointFiveZeroConvertibleNotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Five Zero Convertible Notes Due 2023 [Member]", "label": "Two Point Five Zero Convertible Notes Due 2023 [Member]", "terseLabel": "2.50% Convertible notes due 2023" } } }, "localname": "TwoPointFiveZeroConvertibleNotesDue2023Member", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_TwoPointFiveZeroNewConvertibleNotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Point Five Zero New Convertible Notes Due 2023", "label": "Two Point Five Zero New Convertible Notes Due 2023 [Member]", "terseLabel": "New Notes" } } }, "localname": "TwoPointFiveZeroNewConvertibleNotesDue2023Member", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "axdx_WarrantsIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants Issued", "label": "Warrants Issued", "terseLabel": "Fair value of common stock warrant issued to related-party in connection with exchange transaction" } } }, "localname": "WarrantsIssued", "nsuri": "http://acceleratediagnostics.com/20220930", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r783" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r784" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r781" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r781" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r781" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r804" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r781" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r781" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r781" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r781" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r780" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r782" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://acceleratediagnostics.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r440", "r650", "r651", "r653", "r776" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r58", "r60", "r126", "r127", "r330", "r374" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r133", "r144", "r150", "r254", "r495", "r496", "r497", "r516", "r517", "r545", "r548", "r551", "r552", "r644" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative effect of accounting changes" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r133", "r144", "r150", "r254", "r495", "r496", "r497", "r516", "r517", "r545", "r548", "r551", "r552", "r644" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r133", "r144", "r150", "r254", "r495", "r496", "r497", "r516", "r517", "r545", "r548", "r551", "r552", "r644" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r217", "r420", "r426", "r753" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r299", "r300", "r301", "r302", "r329", "r373", "r444", "r445", "r665", "r666", "r667", "r668", "r669", "r670", "r689", "r751", "r754", "r777", "r778" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r299", "r300", "r301", "r302", "r329", "r373", "r444", "r445", "r665", "r666", "r667", "r668", "r669", "r670", "r689", "r751", "r754", "r777", "r778" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r217", "r420", "r426", "r753" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r213", "r300", "r301", "r420", "r424", "r693", "r750", "r752" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r213", "r300", "r301", "r420", "r424", "r693", "r750", "r752" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r293", "r299", "r300", "r301", "r302", "r329", "r373", "r432", "r444", "r445", "r482", "r483", "r484", "r665", "r666", "r667", "r668", "r669", "r670", "r689", "r751", "r754", "r777", "r778" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r293", "r299", "r300", "r301", "r302", "r329", "r373", "r432", "r444", "r445", "r482", "r483", "r484", "r665", "r666", "r667", "r668", "r669", "r670", "r689", "r751", "r754", "r777", "r778" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r59", "r60", "r126", "r127", "r330", "r374" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]", "terseLabel": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r550", "r551", "r552", "r553" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "Accounting Standards Update 2020-06" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r43", "r658" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Schedule of Allowance For Credit Losses" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r771" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Net accounts receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r62", "r63", "r64", "r68", "r75", "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "terseLabel": "Reclassified debt securities available-for-sale balances" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r28", "r66", "r67", "r68", "r736", "r762", "r766" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r65", "r68", "r75", "r76", "r77", "r130", "r131", "r132", "r537", "r646", "r757", "r758" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r26", "r658" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Decrease in additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r26" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Contributed capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r130", "r131", "r132", "r495", "r496", "r497", "r551" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Contributed capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium": { "auth_ref": [ "r339" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid-in capital (APIC) from recognition of substantial premium at which convertible debt instrument is issued.", "label": "Adjustment to Additional Paid-in Capital, Convertible Debt Instrument Issued at Substantial Premium", "negatedTerseLabel": "Capital contribution from related-party in connection with exchange transaction", "terseLabel": "Capital contribution from related-party in connection with exchange transaction" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r136", "r137", "r138", "r140", "r150", "r228", "r229", "r251", "r252", "r253", "r254", "r257", "r258", "r495", "r496", "r497", "r514", "r515", "r516", "r517", "r528", "r529", "r530", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r550", "r551", "r552", "r553", "r554", "r573", "r574", "r575", "r576", "r577", "r578", "r582", "r583", "r596", "r597", "r605", "r606", "r607", "r608", "r640", "r642", "r643", "r644", "r645", "r646", "r694", "r695", "r696", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r448", "r500", "r501" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Equity-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r325", "r387", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Warrant issued to related-party" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r487" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Equity-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r32", "r223", "r259", "r261", "r264" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r263" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedTerseLabel": "Write-offs" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r91", "r106", "r349", "r598" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of the debt discount", "verboseLabel": "Amortization of the debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r84", "r106", "r349", "r600" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r106", "r349", "r361", "r362", "r600" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount and issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive common stock instruments outstanding (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r106", "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairment charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r18", "r122", "r197", "r202", "r209", "r250", "r311", "r312", "r313", "r315", "r316", "r317", "r318", "r319", "r320", "r322", "r323", "r534", "r538", "r572", "r656", "r658", "r714", "r734" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r12", "r42", "r122", "r250", "r311", "r312", "r313", "r315", "r316", "r317", "r318", "r319", "r320", "r322", "r323", "r534", "r538", "r572", "r656", "r658" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r558" ], "calculation": { "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r236" ], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r237" ], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r234", "r272" ], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r239" ], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Due in less than 1 year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r238", "r239", "r727" ], "calculation": { "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Due in less than 1 year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r232", "r235", "r272", "r718" ], "calculation": { "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair Value", "totalLabel": "Fair Value", "verboseLabel": "Debt securities available-for-sale:" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforSaleInvestmentMaturitiesDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r453", "r454", "r455", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r474", "r475", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r7", "r129", "r188" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r15", "r108" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents:" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r102", "r108", "r114" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r102", "r588" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Cash paid for amounts included in lease liabilities:" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r730" ], "lang": { "en-us": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of deposit", "verboseLabel": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r23", "r24", "r25", "r119", "r122", "r155", "r156", "r159", "r161", "r163", "r172", "r173", "r174", "r250", "r311", "r316", "r317", "r318", "r322", "r323", "r370", "r371", "r376", "r380", "r387", "r572", "r785" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r398", "r450" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r398", "r450" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]", "terseLabel": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r433", "r564" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper", "verboseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r54", "r719", "r741" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (see Note 14)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r295", "r297", "r298", "r303", "r772" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/Commitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r130", "r131", "r551" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r25", "r387" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Common Stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscribedButUnissued": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common Stock, Shares Subscribed but Unissued", "terseLabel": "Agreement to purchase shares (in shares)" } } }, "localname": "CommonStockSharesSubscribedButUnissued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscriptions": { "auth_ref": [ "r25", "r368" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common Stock, Value, Subscriptions", "terseLabel": "Purchase price" } } }, "localname": "CommonStockSharesSubscriptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockValueOutstanding": { "auth_ref": [ "r25" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.", "label": "Common Stock, Value, Outstanding", "terseLabel": "Common stock, $0.001 par value; 200,000,000 common shares authorized with 97,240,983 shares issued and outstanding on September\u00a030, 2022 and 100,000,000 common shares authorized with 67,649,018 shares issued and outstanding on December\u00a031, 2021" } } }, "localname": "CommonStockValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r70", "r72", "r73", "r81", "r722", "r744" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r182", "r183", "r217", "r569", "r570", "r771" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r182", "r183", "r217", "r569", "r570", "r768", "r771" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r182", "r183", "r217", "r569", "r570", "r768", "r771" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRisk" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r182", "r183", "r217", "r569", "r570" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Risk concentration" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r179", "r182", "r183", "r184", "r569", "r571", "r771" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r182", "r183", "r217", "r569", "r570", "r771" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r115", "r536" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Capital projects in progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of Deferred Revenue and Income Summary" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r400", "r401", "r421" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue", "verboseLabel": "Products and services not yet delivered" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "verboseLabel": "Revenues recognized included in contract liabilities balances" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r22", "r716", "r735" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "terseLabel": "Carrying amount of convertible notes" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r324", "r326", "r327", "r329", "r339", "r340", "r341", "r345", "r346", "r347", "r348", "r349", "r359", "r360", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible notes" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtNoncurrent": { "auth_ref": [ "r51" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.", "label": "Convertible Debt, Noncurrent", "terseLabel": "Convertible notes" } } }, "localname": "ConvertibleDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r433", "r441", "r767" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate notes and bonds", "verboseLabel": "Corporate notes and bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r87", "r693" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r85" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit Concentration Risk [Member]", "terseLabel": "Concentration of credit risk" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r180", "r217" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer concentration" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "auth_ref": [ "r111", "r113" ], "lang": { "en-us": { "role": { "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.", "label": "Debt Conversion Description [Axis]", "terseLabel": "Debt Conversion Description [Axis]" } } }, "localname": "DebtConversionByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r111", "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Convertible notes due from related-party extinguished in connection with the exchange transaction, net of deferred issuance costs", "verboseLabel": "Convertible notes value" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r111", "r113" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Shares issued (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": { "auth_ref": [ "r111", "r113" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued", "terseLabel": "Warrants issued (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtConversionNameDomain": { "auth_ref": [ "r111", "r113" ], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Name [Domain]", "terseLabel": "Debt Conversion, Name [Domain]" } } }, "localname": "DebtConversionNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionOriginalDebtAmount1": { "auth_ref": [ "r111", "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Original Debt, Amount", "terseLabel": "Notes exchanged" } } }, "localname": "DebtConversionOriginalDebtAmount1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r118", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r343", "r350", "r351", "r353", "r366" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Convertible Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r19", "r21", "r22", "r121", "r128", "r326", "r327", "r328", "r329", "r330", "r331", "r333", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r359", "r360", "r361", "r362", "r601", "r715", "r716", "r733" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r22", "r354", "r716", "r733" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Outstanding principal at par", "verboseLabel": "Outstanding principal" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r328", "r356" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Initial conversion price (in usd per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r50", "r328", "r388", "r391", "r393" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": { "auth_ref": [ "r50", "r328", "r388", "r391", "r393" ], "lang": { "en-us": { "role": { "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.", "label": "Debt Instrument, Convertible, Number of Equity Instruments", "terseLabel": "Debt instrument, convertible, number of equity instruments" } } }, "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Consecutive trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Stock price conversion threshold, percentage" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Threshold trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r121" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Debt Instrument, Decrease, Forgiveness", "terseLabel": "Debt forgiveness" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r326", "r359", "r360", "r599", "r601", "r602" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r49", "r357", "r599", "r601" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r49", "r327" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r51", "r121", "r128", "r326", "r327", "r328", "r329", "r330", "r331", "r333", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r359", "r360", "r361", "r362", "r601" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Option two to convert" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "Option one to convert" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Repurchase principal balance" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentRepurchaseAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value amount of debt instrument that was repurchased.", "label": "Debt Instrument, Repurchase Amount", "terseLabel": "Repurchase of exchanged amount" } } }, "localname": "DebtInstrumentRepurchaseAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r51", "r121", "r128", "r326", "r327", "r328", "r329", "r330", "r331", "r333", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r352", "r359", "r360", "r361", "r362", "r388", "r392", "r393", "r394", "r598", "r599", "r601", "r602", "r732" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Contractual term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r339", "r598", "r602" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Unamortized debt issuance" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtPolicyTextBlock": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.", "label": "Debt, Policy [Policy Text Block]", "terseLabel": "Convertible Notes" } } }, "localname": "DebtPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "auth_ref": [ "r243" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "terseLabel": "Realized gain (loss) from debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Schedule of Maturities of Available-for-Sale Investments" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r242", "r273", "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "terseLabel": "Unrealized loss position of debt securities" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualContributionsByEmployer": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of contributions made by employer into fund established for purposes of making future disbursement to individual in accordance with deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Contributions by Employer", "negatedTerseLabel": "Contributions to deferred compensation plan" } } }, "localname": "DeferredCompensationArrangementWithIndividualContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r339", "r600" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Unamortized debt issuance discount" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r106", "r287" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r106", "r195" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r420", "r424", "r425", "r426", "r427", "r428", "r429", "r430" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r452", "r453", "r489", "r490", "r492", "r503" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Employee Equity-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r451", "r493" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "terseLabel": "Schedule of Equity-Based Compensation Expense" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r52", "r125", "r314", "r316", "r317", "r321", "r322", "r323", "r651" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Due to Related Parties, Noncurrent", "terseLabel": "Long-term debt related-party" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r82", "r142", "r143", "r144", "r145", "r146", "r153", "r155", "r161", "r162", "r163", "r167", "r168", "r552", "r553", "r723", "r745" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per share (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r82", "r142", "r143", "r144", "r145", "r146", "r155", "r161", "r162", "r163", "r167", "r168", "r552", "r553", "r723", "r745" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per share (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r164", "r165" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r164", "r165", "r166", "r169" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r588" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Amount Capitalized", "terseLabel": "Cost capitalized to inventory" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r491" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized equity-based compensation cost, restricted stock units" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r491" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized equity-based compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Shares issuable upon exercise of stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r75", "r76", "r77", "r130", "r131", "r132", "r137", "r147", "r149", "r171", "r254", "r387", "r395", "r495", "r496", "r497", "r516", "r517", "r551", "r589", "r590", "r591", "r592", "r593", "r594", "r646", "r757", "r758", "r759" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r10", "r20", "r568" ], "calculation": { "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Equity investments:", "verboseLabel": "Fair value of equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r248", "r747" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "terseLabel": "Realized gains or losses from equity securities" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r558", "r559", "r566" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r558", "r559", "r560", "r565", "r566" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Schedule of Fair Value Measurement" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Summary of Inputs Used to Calculate Estimated Fair Value" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r341", "r359", "r360", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r559", "r662", "r663", "r664" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r558", "r559", "r562", "r563", "r567" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r341", "r433", "r434", "r439", "r441", "r559", "r662" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r341", "r359", "r360", "r433", "r434", "r439", "r441", "r559", "r663" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "verboseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r341", "r359", "r360", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r559", "r664" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "verboseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Estimated Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r341", "r359", "r360", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r662", "r663", "r664" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r564", "r567" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value on a Recurring Basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid [Abstract]", "terseLabel": "Finance" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r612", "r626" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Finance lease obligation" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r612" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease, current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r612" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease, non-current" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r626" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r626" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r626" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r626" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r626" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r626" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r626" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r614", "r621" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payments on finance leases", "terseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r611" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance lease assets, net" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r624", "r627" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate finance leases (%)" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r623", "r627" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term finance leases (years)" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r240", "r241", "r245", "r246", "r247", "r260", "r265", "r266", "r267", "r268", "r274", "r275", "r276", "r277", "r352", "r385", "r540", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r785", "r786", "r787", "r788", "r793", "r794", "r795" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r584", "r585", "r586", "r587" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Foreign currency exchange loss" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation and Foreign Currency Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r106" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Loss (gain) on disposal of property and equipment" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r106", "r363", "r364" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Gain on extinguishment of debt", "terseLabel": "Gain on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r181", "r771" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic concentration" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionAxis": { "auth_ref": [ "r269", "r724", "r725", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r798", "r799", "r800", "r801", "r802", "r803" ], "lang": { "en-us": { "role": { "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Axis]", "terseLabel": "Geographic Distribution [Axis]" } } }, "localname": "GeographicDistributionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicDistributionDomain": { "auth_ref": [ "r724", "r725", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r798", "r799", "r800", "r801", "r802", "r803" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities.", "label": "Geographic Distribution [Domain]", "terseLabel": "Geographic Distribution [Domain]" } } }, "localname": "GeographicDistributionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionDomesticMember": { "auth_ref": [ "r270", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r798", "r799", "r800", "r801", "r802", "r803" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic.", "label": "Geographic Distribution, Domestic [Member]", "terseLabel": "Domestic" } } }, "localname": "GeographicDistributionDomesticMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeographicDistributionForeignMember": { "auth_ref": [ "r271", "r724", "r725", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r798", "r799", "r800", "r801", "r802", "r803" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as foreign.", "label": "Geographic Distribution, Foreign [Member]", "terseLabel": "Foreign", "verboseLabel": "Outside the U.S." } } }, "localname": "GeographicDistributionForeignMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Long-lived Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r86", "r122", "r197", "r201", "r205", "r208", "r211", "r250", "r311", "r312", "r313", "r316", "r317", "r318", "r319", "r320", "r322", "r323", "r572" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r79", "r197", "r201", "r205", "r208", "r211", "r712", "r720", "r725", "r748" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Pre-tax loss", "totalLabel": "Net loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r291", "r294" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r123", "r508", "r509", "r512", "r521", "r523", "r525", "r526", "r527" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r124", "r148", "r149", "r196", "r507", "r522", "r524", "r749" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Provision for income taxes", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r74", "r505", "r506", "r509", "r510", "r511", "r513" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Deferred Tax" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r105" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r105" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r105" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities and other" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities [Abstract]", "terseLabel": "Increase (decrease) in liabilities:" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r105", "r690" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue and income" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r105" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Deferred compensation" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r105" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Accrued interest" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r105" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Assets [Abstract]", "terseLabel": "(Increase) decrease in assets:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r105" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expense and other" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r157", "r158", "r163" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "terseLabel": "Issuable upon conversion of the notes (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "auth_ref": [ "r157", "r158", "r163" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock", "terseLabel": "Common stock issuable upon conversion of the Series A Preferred Stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestAndDividendsPayableCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity). Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest and Dividends Payable, Current", "terseLabel": "Accrued interest" } } }, "localname": "InterestAndDividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r91", "r347", "r358", "r361", "r362" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "totalLabel": "Total interest expense on convertible notes" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r93", "r348", "r361", "r362" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Contractual coupon interest", "verboseLabel": "Contractual interest" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseOther": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense classified as other.", "label": "Interest Expense, Other", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest Expense, Related Party", "negatedTerseLabel": "Interest expense related-party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "terseLabel": "Schedule of Interest Expense", "verboseLabel": "Schedule of Interest Expense in Connection with the Secured Note" } } }, "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesTables", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r101", "r103", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r33", "r280" ], "calculation": { "http://acceleratediagnostics.com/role/InventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r9", "r39", "r658" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://acceleratediagnostics.com/role/InventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r14", "r37", "r116", "r170", "r278", "r279", "r281", "r691" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r35", "r280" ], "calculation": { "http://acceleratediagnostics.com/role/InventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r34", "r280" ], "calculation": { "http://acceleratediagnostics.com/role/InventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r89" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r91" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "Investment Income, Net, Amortization of Discount and Premium", "negatedTerseLabel": "Amortization of investment discount" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r249", "r746" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Investments": { "auth_ref": [ "r742" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r244", "r713", "r728", "r770", "r797" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "verboseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease Cost:" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r625" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease Costs" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseIncome": { "auth_ref": [ "r637" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lease income from operating, direct financing, and sales-type leases. Includes, but is not limited to, variable lease payments, interest income, profit (loss) recognized at commencement, and lease payments paid and payable to lessor.", "label": "Lease Income", "terseLabel": "Lease income" } } }, "localname": "LeaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement.", "label": "Leaseholds and Leasehold Improvements [Member]", "terseLabel": "Facilities" } } }, "localname": "LeaseholdsAndLeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases as Lessee" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Description [Abstract]", "terseLabel": "ROU assets obtained in exchange for lease obligations:" } } }, "localname": "LesseeOperatingLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r626" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r626" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r626" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r626" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r626" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r626" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r626" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r626" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease extension" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r628" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorLeasesPolicyTextBlock": { "auth_ref": [ "r630", "r633", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.", "label": "Lessor, Leases [Policy Text Block]", "terseLabel": "Leases as Lessor" } } }, "localname": "LessorLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r634" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Term of Contract", "terseLabel": "Lessor lease term" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LessorSalesTypeLeasesTextBlock": { "auth_ref": [ "r639" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of lessor's sales-type leases.", "label": "Lessor, Sales-type Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LessorSalesTypeLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r46", "r122", "r203", "r250", "r311", "r312", "r313", "r316", "r317", "r318", "r319", "r320", "r322", "r323", "r535", "r538", "r539", "r572", "r656", "r657" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r31", "r122", "r250", "r572", "r658", "r717", "r738" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r13", "r48", "r122", "r250", "r311", "r312", "r313", "r316", "r317", "r318", "r319", "r320", "r322", "r323", "r535", "r538", "r539", "r572", "r656", "r657", "r658" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r44", "r121" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r44", "r121" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConcentrationofCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long-Lived Assets by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of Long-lived Assets by Geographic Territory" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r22", "r340", "r355", "r359", "r360", "r716", "r735" ], "calculation": { "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "totalLabel": "Long-term debt, Total" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt", "verboseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-Term Debt, Fair Value", "terseLabel": "Fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r128", "r309", "r345" ], "calculation": { "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r128", "r309", "r345" ], "calculation": { "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r128", "r309", "r345" ], "calculation": { "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r128", "r309", "r345" ], "calculation": { "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 6.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r128" ], "calculation": { "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtScheduleofMaturitiesofFuturePrincipalObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r22" ], "calculation": { "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-Term Debt [Text Block]", "terseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r51", "r310" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesGainonExtinguishmentDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofInterestExpenseDetails", "http://acceleratediagnostics.com/role/ConvertibleNotesScheduleofNotesandNewNotesDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Expected dividends" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Contractual term (in years)" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk free interest rates" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]", "terseLabel": "Movement in Standard Product Warranty Accrual [Roll Forward]" } } }, "localname": "MovementInStandardProductWarrantyAccrualRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MutualFundMember": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.", "label": "Mutual Fund [Member]", "terseLabel": "Mutual funds" } } }, "localname": "MutualFundMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r102" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r102" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r102", "r104", "r107" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r6", "r69", "r71", "r77", "r80", "r107", "r122", "r136", "r142", "r143", "r144", "r145", "r148", "r149", "r160", "r197", "r201", "r205", "r208", "r211", "r250", "r311", "r312", "r313", "r316", "r317", "r318", "r319", "r320", "r322", "r323", "r553", "r572", "r721", "r743" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentInLease": { "auth_ref": [ "r225", "r259", "r266", "r629" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of net investment in sales-type and direct financing leases.", "label": "Net Investment in Lease, before Allowance for Credit Loss", "terseLabel": "Net investment in leases" } } }, "localname": "NetInvestmentInLease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r5", "r134", "r135", "r138", "r139", "r150", "r151", "r152", "r230", "r231", "r255", "r256", "r518", "r519", "r520", "r549", "r555", "r556", "r557", "r579", "r580", "r581", "r609", "r610", "r641", "r647", "r697", "r698", "r699", "r761", "r762", "r763", "r764", "r766" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r133", "r136", "r137", "r138", "r140", "r141", "r144", "r150", "r167", "r228", "r229", "r251", "r252", "r253", "r254", "r257", "r258", "r495", "r496", "r497", "r514", "r515", "r516", "r517", "r528", "r529", "r530", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r550", "r551", "r552", "r553", "r554", "r573", "r574", "r575", "r576", "r577", "r578", "r582", "r583", "r596", "r597", "r605", "r606", "r607", "r608", "r640", "r642", "r643", "r644", "r645", "r646", "r694", "r695", "r696", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Standards that were recently adopted and standards not yet adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r90" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other (expense) income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock Activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesIssued1": { "auth_ref": [ "r111", "r112", "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of notes issued in noncash investing and financing activities.", "label": "Notes Issued", "terseLabel": "Fair value of new note from related-party issued in connection with the exchange transaction" } } }, "localname": "NotesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Loans - various interest", "verboseLabel": "Notes payable, other payables" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r197", "r201", "r205", "r208", "r211" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r619", "r627" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "terseLabel": "Operating" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r612" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lessee lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r612" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r612" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r615", "r621" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "verboseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r611" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right of use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r624", "r627" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate (%)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r623", "r627" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r41", "r658" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r17" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r62", "r63", "r66" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Net unrealized gain (loss) on debt securities available-for-sale", "verboseLabel": "Net unrealized gain (loss) on debt securities available-for-sale" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r61" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash financing activities:" } } }, "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r92" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other (expense) income:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r94", "r96", "r233" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r97", "r531", "r532", "r533" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedTerseLabel": "Purchases of equipment" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy": { "auth_ref": [ "r442", "r443", "r446" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for plans, other than pension plans, that provide postretirement benefits (including both defined benefit and defined contribution plans). This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.", "label": "Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block]", "terseLabel": "Nonqualified Cash Deferral Plan" } } }, "localname": "PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance-based stock option expense", "verboseLabel": "Performance-based stock options" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConvertibleConversionRatio": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.", "label": "Preferred Stock, Convertible, Conversion Ratio", "terseLabel": "Conversion ratio (in shares)" } } }, "localname": "PreferredStockConvertibleConversionRatio", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "pureItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r24", "r370" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, par value (in usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockShareSubscriptions": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The number of nonredeemable preferred stock (shares) (or preferred stock redeemable solely at the option of the issuer) allocated to investors to buy shares of a new issue of preferred stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Preferred Stock, Shares Subscribed but Unissued", "terseLabel": "Agreement to purchase preferred shares (in shares)" } } }, "localname": "PreferredStockShareSubscriptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Preferred Stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesSubscribedButUnissuedValue": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of subscription received from investors who have been allocated nonredeemable preferred stock or preferred stock redeemable solely at the option of the issuer.", "label": "Preferred Stock, Value, Subscriptions", "terseLabel": "Aggregate purchase price" } } }, "localname": "PreferredStockSharesSubscribedButUnissuedValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r24", "r658" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred shares, $0.001 par value; 5,000,000 preferred shares authorized and 3,954,546 outstanding as of September\u00a030, 2022 and December\u00a031, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r11", "r40", "r282", "r283" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r98" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r99" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from Issuance of Preferred Stock and Preference Stock", "terseLabel": "Proceeds from issuance of preferred stock" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r94", "r95", "r233" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from sales of debt securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r98", "r494" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r98" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from issuance of common stocks under employee purchase plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Products" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r289", "r613", "r618" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "negatedTerseLabel": "Accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r290", "r618" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r18", "r288", "r611" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "totalLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r292", "r773", "r774", "r775" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation": { "auth_ref": [ "r289", "r632" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of accumulated amortization, depreciation, depletion for physical asset used in normal conduct of business to create and distribute product and service.", "label": "Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, Accumulated Depreciation", "negatedTerseLabel": "Accumulated depreciation under operating leases" } } }, "localname": "PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation": { "auth_ref": [ "r290", "r632" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of physical asset used in normal conduct of business to create and distribute product and service.", "label": "Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, after Accumulated Depreciation", "totalLabel": "Net property and equipment under operating leases" } } }, "localname": "PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r16", "r288" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r290", "r658", "r729", "r740" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "verboseLabel": "Long-lived assets (excluding intangible assets)" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r290", "r773", "r774" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life of assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross": { "auth_ref": [ "r288", "r603", "r604", "r632" ], "calculation": { "http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation, of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.", "label": "Property, Plant, and Equipment, Lessor Asset under Operating Lease, before Accumulated Depreciation", "terseLabel": "Instruments at cost under operating leases" } } }, "localname": "PropertySubjectToOrAvailableForOperatingLeaseGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentInstrumentsatCostandAccumulatedDepreciationLessorDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r83", "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "verboseLabel": "(Reversals) provisions, net" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesAllowanceForDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r658", "r739", "r769" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "terseLabel": "Trade accounts receivable, net" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r68", "r75", "r76", "r78", "r589", "r593", "r594" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "terseLabel": "Reclassified from out of accumulated other comprehensive income (loss)" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r440", "r650", "r651" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r440", "r650", "r651", "r653" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r440", "r650", "r653", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r648", "r649", "r651", "r654", "r655" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r100" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "negatedTerseLabel": "Payment of debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r504", "r692", "r779" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Shares issuable upon the release of RSUs", "verboseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r27", "r395", "r658", "r737", "r761", "r766" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "verboseLabel": "Decrease in accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r130", "r131", "r132", "r137", "r147", "r149", "r254", "r495", "r496", "r497", "r516", "r517", "r551", "r757", "r759" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r193", "r194", "r200", "r206", "r207", "r213", "r214", "r217", "r419", "r420", "r693" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r117", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r431" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r402", "r403", "r404", "r405", "r406", "r407", "r409", "r410", "r423", "r431" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Deferred Revenue and Remaining Performance Obligations" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligations" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.", "label": "Revenue, Performance Obligation, Description of Timing", "terseLabel": "Contact period" } } }, "localname": "RevenuePerformanceObligationDescriptionOfTiming", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r408" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue expected to be recognized from remaining performance obligations" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/DeferredRevenueandRemainingPerformanceObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r622", "r627" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Finance leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r622", "r627" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]", "terseLabel": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of stock (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Share price (in usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r182", "r217" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Total revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable": { "auth_ref": [ "r631", "r638" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails_1": { "order": 1.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type and direct financing leases.", "label": "Sales-type and Direct Financing Leases, Lease Receivable", "terseLabel": "Present value of lease payments" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position.", "label": "Sales-type and Direct Financing Leases, Lease Receivable, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Sales-type Lease Receivables" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived": { "auth_ref": [ "r631" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases.", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, Payments to be Received", "totalLabel": "Total undiscounted cash flows" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears": { "auth_ref": [ "r631" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 5.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Four", "terseLabel": "2026" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r631" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year One", "terseLabel": "2023" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear": { "auth_ref": [ "r631" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Remainder of Fiscal Year", "terseLabel": "Remainder of 2022" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r631" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Three", "terseLabel": "2025" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r631" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two", "terseLabel": "2024" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount": { "auth_ref": [ "r631" ], "calculation": { "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails_1": { "order": 2.0, "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of undiscounted lease receivable in excess of discounted receivable for sales-type and direct financing leases.", "label": "Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest" } } }, "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesSalestypeLeaseReceivableMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potentially Issuable Common Shares not Included in Computation of Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of Available-for-Sale Investments" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r51", "r128", "r359", "r361", "r388", "r392", "r393", "r394", "r598", "r599", "r602", "r732" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Carrying Value of the Notes", "verboseLabel": "Schedule of Carrying Value of the Secured Notes" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesTables", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r486", "r499" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfExtinguishmentOfDebtTextBlock": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of debt extinguished which may include, amount of gain (loss), the income tax effect and the per share amount of the aggregate gain (loss), net of the related income tax.", "label": "Schedule of Extinguishment of Debt [Table Text Block]", "terseLabel": "Schedule of Gain on Extinguishment" } } }, "localname": "ScheduleOfExtinguishmentOfDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r14", "r36", "r37", "r38" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Components of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Schedule of Warranty Reserve" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesNarrativeDetails", "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock": { "auth_ref": [ "r290", "r604", "r632" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.", "label": "Property, Plant, and Equipment, Lessor Asset under Operating Lease [Table Text Block]", "terseLabel": "Schedule of Instruments at Cost and Accumulated Depreciation, Lessor" } } }, "localname": "ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r652", "r653" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r197", "r198", "r204", "r284" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r447", "r449", "r453", "r454", "r455", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r474", "r475", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r458", "r473", "r476" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Option Activity under the Company's Equity-Based Compensation" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year.", "label": "Share-Based Payment Arrangement, Option and Stock Appreciation Rights, Activity [Table Text Block]", "terseLabel": "Schedule of Outstanding Options and Options that are Exercisable (Vested)" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r23", "r24", "r25", "r119", "r172", "r173", "r367", "r368", "r369", "r370", "r371", "r373", "r374", "r376", "r380", "r385", "r387", "r388", "r389", "r390", "r392", "r393", "r394", "r395" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt and Equity Securities, FV-NI [Line Items]", "terseLabel": "Debt and Equity Securities, FV-NI [Line Items]" } } }, "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured Debt" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r189", "r191", "r192", "r197", "r199", "r205", "r209", "r210", "r211", "r212", "r213", "r216", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Geographic and Revenue Disaggregation" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationLonglivedAssetsbyGeographicTerritoryDetails", "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r88" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Sales, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Sales, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyCarryingValueoftheSecuredNotesDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyInterestExpenseinConnectionwiththeSecuredNoteDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [ "r23", "r24", "r387" ], "lang": { "en-us": { "role": { "documentation": "Series A preferred stock.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Services" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/GeographicandRevenueDisaggregationDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r105" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Equity-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]", "terseLabel": "Options Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of\u00a0Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance (in usd per share)", "periodStartLabel": "Beginning balance (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Released (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Released (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (in shares)", "terseLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r493" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value (in thousands)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)", "terseLabel": "Number of options (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of\u00a0Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, ending balance (in usd per share)", "periodStartLabel": "Outstanding, beginning balance (in usd per share)", "terseLabel": "Weighted average exercise price (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r453", "r454", "r455", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r474", "r475", "r477", "r478", "r481", "r482", "r483", "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationEquityBasedCompensationExpenseDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails", "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r464" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Exercised (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Forfeited (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted (in usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r456", "r479", "r480", "r481", "r482", "r485", "r498", "r503" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Equity-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in usd per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r493" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "verboseLabel": "Aggregate intrinsic value (in thousands)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOutstandingOptionsandOptionsthatareExercisableVestedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Exercisable (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r620", "r627" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term leases" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrual": { "auth_ref": [ "r306" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability.", "label": "Standard Product Warranty Accrual", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "StandardProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyAccrualPayments": { "auth_ref": [ "r304" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Decrease for Payments", "negatedTerseLabel": "Warranty cost incurred" } } }, "localname": "StandardProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesScheduleofProductWarrantyReserveActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty, Policy [Policy Text Block]", "terseLabel": "Warranty Reserve" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r23", "r24", "r25", "r119", "r122", "r155", "r156", "r159", "r161", "r163", "r172", "r173", "r174", "r250", "r311", "r316", "r317", "r318", "r322", "r323", "r370", "r371", "r376", "r380", "r387", "r572", "r785" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareNarrativeDetails", "http://acceleratediagnostics.com/role/RelatedPartyTransactionsDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r56", "r75", "r76", "r77", "r130", "r131", "r132", "r137", "r147", "r149", "r171", "r254", "r387", "r395", "r495", "r496", "r497", "r516", "r517", "r551", "r589", "r590", "r591", "r592", "r593", "r594", "r646", "r757", "r758", "r759" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited", "http://acceleratediagnostics.com/role/InvestmentsNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r130", "r131", "r132", "r171", "r693" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r111", "r112", "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Extinguishment of convertible senior notes through issuance of common stock" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r55", "r344", "r387", "r388", "r395" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Issuance of shares to retire Convertible Senior Notes (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": { "auth_ref": [ "r24", "r25", "r387", "r395", "r502" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.", "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan", "terseLabel": "Issuance of common stock under employee purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r24", "r25", "r387", "r395" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r24", "r25", "r387", "r395", "r464" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/EmployeeEquityBasedCompensationOptionActivityundertheCompanysEquityBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r56", "r387", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of shares to retire convertible notes" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": { "auth_ref": [ "r24", "r25", "r387", "r395", "r502" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan", "terseLabel": "Issuance of common stock under employee purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r24", "r25", "r387", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Proceeds from issuance of stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r56", "r387", "r395" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Restricted stock awards released and exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock Redeemed or Called During Period, Shares", "negatedTerseLabel": "Rescission of common stock (in shares)" } } }, "localname": "StockRedeemedOrCalledDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r24", "r25", "r387", "r395" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Rescission of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r25", "r29", "r30", "r122", "r226", "r250", "r572", "r658" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance, amount", "periodStartLabel": "Beginning Balance, amount", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r120", "r371", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r386", "r395", "r399", "r541" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used in the creation, maintenance and utilization of information systems which include computers and peripherals.", "label": "Technology Equipment [Member]", "terseLabel": "Technical equipment" } } }, "localname": "TechnologyEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/PropertyandEquipmentPropertyandEquipmentatCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r219", "r220", "r221", "r222", "r224", "r227" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r240", "r241", "r245", "r246", "r247", "r352", "r385", "r540", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r785", "r786", "r787", "r788", "r793", "r794", "r795" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury stock" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r57", "r396", "r397" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "negatedTerseLabel": "Treasury stock" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r136", "r137", "r138", "r140", "r150", "r228", "r229", "r251", "r252", "r253", "r254", "r257", "r258", "r495", "r496", "r497", "r514", "r515", "r516", "r517", "r528", "r529", "r530", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r550", "r551", "r552", "r553", "r554", "r573", "r574", "r575", "r576", "r577", "r578", "r582", "r583", "r596", "r597", "r605", "r606", "r607", "r608", "r640", "r642", "r643", "r644", "r645", "r646", "r694", "r695", "r696", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/RecentlyIssuedAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r433", "r726", "r767" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "U.S. Treasury securities", "verboseLabel": "U.S. Treasury securities" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsScheduleofFairValueMeasurementDetails", "http://acceleratediagnostics.com/role/InvestmentsScheduleofAvailableforsaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r106" ], "calculation": { "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedTerseLabel": "Unrealized loss (gain) on equity investments", "verboseLabel": "Unrealized (loss) gain on equity investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://acceleratediagnostics.com/role/InvestmentsUnrealizedLossesorGainsonEquitySecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of unrealized gains and losses on investments.", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "terseLabel": "Schedule of Unrealized Losses or Gains on Equity Securities" } } }, "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": { "auth_ref": [ "r296" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Unrecorded Unconditional Purchase Obligation", "terseLabel": "Total commitments" } } }, "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]", "terseLabel": "Unsecured obligations" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r175", "r176", "r177", "r178", "r185", "r186", "r187" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/OrganizationandNatureofBusinessBasisofPresentationPrinciplesofConsolidationSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Shares issuable upon the exercise of the Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LossPerShareScheduleofPotentiallyIssuableCommonSharesnotIncludedinComputationofDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrants fair value" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/ConvertibleNotesNarrativeDetails", "http://acceleratediagnostics.com/role/FairValueofFinancialInstrumentsNarrativeDetails", "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartyNarrativeDetails", "http://acceleratediagnostics.com/role/StockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants issued, measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/LongTermDebtRelatedPartySummaryofInputsUsedtoCalculateEstimatedFairValueDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r154", "r163" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r153", "r163" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://acceleratediagnostics.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r152": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r218": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1),(c)(5)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631" }, "r366": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r399": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r431": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r442": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/subtopic&trid=2235172" }, "r443": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/subtopic&trid=2235116" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r446": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/subtopic&trid=2235144" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "40", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920" }, "r503": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r527": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r595": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123422147&loc=d3e41457-112716" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r628": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123420820&loc=SL77919306-209978" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919391-209981" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919398-209981" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919379-209981" }, "r639": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888252" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r655": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r7": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r713": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803" }, "r728": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r770": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r780": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r781": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r782": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r783": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r784": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r785": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r786": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r787": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r788": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r789": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(4)" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r790": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(5)" }, "r791": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(i)" }, "r792": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)(ii)" }, "r793": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r794": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r795": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r796": { "Name": "Regulation S-K (SK)", "Number": "229", "Publisher": "SEC", "Section": "1402", "Subsection": "Instruction 5" }, "r797": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r798": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(1)" }, "r799": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(2)" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r800": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(3)" }, "r801": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(4)" }, "r802": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1406", "Subparagraph": "(5)" }, "r803": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1406" }, "r804": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" } }, "version": "2.1" } ZIP 101 0001628280-22-029903-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-22-029903-xbrl.zip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�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�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end

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ⅅ2:PSY)++)8)S!#1+ N"**,R?MD MR2+_PK?'TG=>@?;-^LX$5I.GR%#@!K1/>84',I%S2R)?H]V+1;PW KPQOK@#\9L.; MP5'AL;"(8<_ ",0!:<$8,D%3:7A*(OJ1BZQ>-(W\^-5JPS;HCY___2EHYL<* MR.E;E4GA"TY8F-8_>A'V_.;W>,T%GQ5TZL+QU.'K2ZR#61H.;K]DG@_XEC&O M!FZF^,%'TS_U[W'OFA?\*"('1L\IL@G&_(=MG=N+_IO_N_%J[68'S4SE'6;A M 4LW^A<$(\-ALS.T!5(6J"-B#,YP&Y-,G$CBE&&2^)@4YC&H= 6P8X&ZB:B: MLD",,)3%P(D@EE/GO C&$.:CP8<[16,.@@FZ[M!Q$TQG+,<9:*WGG^OPO#]; M77^ZF4C9BO_O\\7!MW &3JH\V*D=5R_?-VOUOUO5G8.3VDYH5MM[(J/?0?W@ MN+K3 .0[.#TX>9\ -4EM^Q +Q1G,(2+1.<1%T,CR)%!DFG&BA8;I?5.)L)V< M94GI#>-#96=%YR#'$3;&5JM[#G!8&;>G&+;;M@#RI=X-BB8 M_D?@SW!!]T^+W,5)$X#Q1^-. )7?FAUX>'<(;QOZO_]QE[8;9?^.#>J(L5FW M75'_#KE1[3NNM+HR4>A;4Y WZ\7*OB1E7Y+[MZ1XH6];KO&K:CNR,\S66Z45 M^]D2RD6T<[0,):GLJR:574U7R.J5*_*M.3AN=O8[L0&R>",AYG4$^JKM MQD6M<%'_.U M/!X*/]<_'Q]\V+LXV*E>U+[!^]#:HD8D-F!/L5H MKN!%OTAIED54L4:G&25XE>"U=/#*AD5A5Y3 M43@FDU3T9GIW%F-HO,&<84S M:8!U*%(GH^<6''K[-(UN2^ J@6NS#U%+JVO%X#7'"2HQ#IQFLA-.$#F26[B_9'^/&+5(L;MM48PBZV M6ZUN[OXUI *74H S MQ8U'W(N$',<&$<.,XRX:IDRIO&NIO(]U&U:]^Y:*>A]%G0U]8*X5=Q2V52\U MXI);9*,B*(7(-."WELJ"!\$>W=VP5-(-4]*E[;"E@MY'06==?&V4UY9%I$+@ M8 ;[B)S/7?]2P%+Z!!^%K* OL(G*G5WW(K/XN;AM1D4'RZBJN3VV\N*CL8^; MD T'\Z$!"Y_ %YLAA^(<13;SWQC'FGB:3YU&Z M]%PERR7VE=CW=*E!KZU,>468-QOU(2D16"F,L-0"<1H\TDPZI(B16BF"$Y-/ MDP148EZ)>1N#>26+X0O OME 6G"!:!$9HM0%Q!6SR$I'D!2686*Y5%RNDL6P MQ+X2^UX1]I7VW@HP;RXVZ9GGSA-DM96($\60XTFBR)+A*21N4EPE+F"=A72@M>K%RGO^Y3_-V8JQ0C(E(-1@?!$QNUMLX9+XD0-/(HQNNM MRO5^EO56TAL6&=BGFEO$/?SDE*>Y>9!D3%D;&+O7>C^(':E<[U6MM^:&1ZD] MHL*#>Q)$S*W0\ZFBM5Y91[A-]UIO;*,Q0@ ^&,V)-X /D7C)>&)2.:G&ZZW* M]7Z>];8R89_I4H-P.7LR(N.U1IJ"(^JYUL[1-^\ZW3FS[ %_J)R-5ZZ28.DJ MF8^JH+*Z VW5;\V.;PVS908W@9^;9[95.;,7H7O>Z?^>5[8@Q!KD3(*"O*H# MYDBE#8)XW*]$,(#"3ZFN\L[RME*I7W-JP: &L=>&N_0K1[;9&;7S;'7[_=&8 MV[9W&LF!XD"VRO_-**7&Q-W35T"MF<8/7HMC*6? MYWI\GF)TSZS%I4[-Z%2M_O7RD$KK0R[.9T$SQ&.4R& :80ME1":+J?/\F??, M4R/WZ9#>AN\(PC381' MW-B(=)0,"4IAB0A3L($^L\=3+O/CESD0I8*2%'DE)1B^A".G94">RF2H8(Q+ MO#1#"&8_Y@!+9=("8&QC@!DS-C$*"^D.AM&2+)][B*_0.>XJ!54A<=B"+*%, M"MB( DY@2++[;T:?HV_9?O_*2LJ&_52WA'UXOUXVRWKQ.';ZS>]QK^.[[?C7 ML-<#X^HCS&0WU.)@/]VEO&N,1$XOC^&%8*P5,+@8E@EUIL$?@*L)'! MD@/"P:^"6P^&#%8L%\K=0PC RR 4_C\(+KD'ST,QR27%7#/OA'+W]SY*(7AJ M(7 A!$E2T0<)!N<8K7&.KP &7#JQ7Y7-I$Q$(_&X'6Q@1B;D< M; MW@RM8^"N/:Q++[=S%S3JV #\NQD[&K>Y1I[A#LS-!I&5 T5;%COH\-/O] M8>P54>;^T!]/C^PXMD+%752&8Q"%KQPWCXXKOA=#;7#Q=J4]&=8B MUV"[F*Y;IG@K3^LDNM[I5HZ[K7R2<->SA[PQ=2Y 4"9+LS7>G H6YKQB7]]^ M>5LYZGZ/O4[NK+&5)0,^LNWNL#.H'('(#29?)_A?Y?+,:,!@^MBE";K3'52\ M[?4N*J.#F%^N$,SL8+2Z+K:ZY],W_-]^I=WL--O#]D1)>F!4=HY@X]]NM>ZF M^J%B;UZ<7V8;Y6B-BX.\M/9G[_<*UWOWOT/ H1L3"XM3&'/-XH0LW6A$ ^K2 M'@X O"IIV G]\4E5_%[B]I;/-.2SC M_SQ]CJ*8M11&LW5M*[S_7FO>+1]1OC)SH%K_>EX[/^0Z!,X]15&#O<>M4,C0 M8!#8 M08Q[C);>Z>OKJH7,G'KJ0,-#K. [(#V:3N^W>R6GGV"_<[>-426+=^.#I726EALD :/#/&$ M<\LW+5",SN1D%4!>OTDMW[[.^R*]R3E09\%^ESV/7KCA=P3X++>+>Z3K,;*= M;'_<@:Y?]GB[5Q\R9MXRHS:I:]H#;_OSS_0=>[&MR1R\KLYQ^D[-E0HFGDIU MA!V[-[$C]Y*[0X.IES4AM8RE=YR/Y;6?VX0^7#_M*KAQKT*6(=D;]]8O=@%7 M32SU+$;C^!@L6XQ3!N-47*5L#??R>?Y_6UU^:2ZN[<-KPD_W]%Y?1OUL>^]' M[7+[1^/;/ZU:?5M4=^ >[2IOG!PW]S_LXAI]?WS0_MQJ?/N[.5L_VSC99=4= M^/S;5U+=.3VO[=2:C2?FJ?U^7SO6_A*&7CT,/3+_N82A5<'0'&V3-IRFQ &! ME$<\2H<<5@D9*2*.AB3X!6!H,U#H(6;AK.5?(MGK1K)'UF652+8J))OKAR24 MYIAK)!5V");.(A,"1HP*0Z2,G.2J=HKE9F!9B4,O#X=65P4\3YI4HL]2T8?, MVE%,"145.'$!@SO'/,T=BR(RRGO!LU\T-,?1 ,+ X:J$#<.HLL%@P)C2E7"9MDGIL8H%S>AR]O83E& MPY$6)N8\=8>LI %9$SSWFA'R[-PYY?(^?'G!O@+H=!JYF%D,,>&P;1MP&AP) ME%KFA;U?Z=SRV5O*Y7WX\BJ?"R E18H26%[))-*),Q05YD%RIZ242R, ^'G= M_Z]SG1]5\S;3D@;&EL6RV1G:T6B7:JP5H@3;D56!XQA(X@"#6ON8<*+*&K"E MK#S,G,O%G-S7_7DF=]W?J;6K[4^L]J%VVOBV MQZH4QM6&:TX\:] J ;U(^SO50TFC-F *HAAAH^)>);!(B$(.=AEP4HP)!"_* MJ5SEZ7YMO[Y;D6 "[]7^V:W5]S\W-C+#]XL_CF'8BOOI2@;')BG< M/I3:&V6%0=(:EYL+.F2XY2@Z[:V-F(F@-BFS=[+ &;E!C/K-_F!4])*A>Y1C MF]-V[> A52IE;NY],CVE>2OE[1^O8U[JW?)OGS';<- ]6VEZUT-34-?VA2:: M70&E7I<4TE7/P5.E'S[#>[R6W,//]OR*S:-,+BS/H)9003EW]'1E&X.P52>R M5K#Y?([P%M\WI5/' \WH\='4YR:8RG#-^Y/JCL>-2QCCARJOTNIYX_+H?/_; MGJB>P#V_?6[/'DT=?-B[/ #3N_JM>IZ?5=OY\Q2NN6Q<_GD"IK9HG)Q>%-T_ M/APLRC1T)B2N<4 Y%HUXQ Y9ISQ*8*)KK"D//+UY1[:4W)C3J1*;7CLV+:N7 M4(E-*\6FV?3#%(V07B>DJ,ZM";Q%QCB.K%)2)P N%4+&)L;9IF#3O6W%Q ,A:>GF4I[OO<['T6R7F/0TF'0Q M9R]Q3:606"(+JX4X51P9I1(2CG!!;#[V4. C;A'V:$Q:K/J/3G]^I0JX=)N@ M5,"5*."L48"C"T$)A2AA$110$F0]$XAIY;P@+"5&LU$@Z7Q=PO,IX,N-$;UO M=IK]XWRPW>V&AVW["][UI:#.TK?]R71_R+-=HLZ3H$[MK[EMGZ@80TP629?+ MH0@..=/+(!58])KPI$5N8+_%S7Q-YL-^[9<*N!(%G"M%#$FG M:"W"RMC<13TBRZQ'@*;>$2JQS=L^W<)F67'*=7#W[UQ_.+[NITV0\<_Z(+_, MP.?RIV7#X7#I]@@@8(E[2\.]+_-,$#I&$9A$7@HP/%Q.4C6<(AJP)M*+9"-_ M\TYL,4.7Y.XL3UF>X@"G!+H2Z)[%[BN!;KE -VO@.1&XD=2CF)1&L&0>&2X% MPI([H@$&"2F #DOU8H#N#G64"^HJ[Y3#.=8;3M^JG'%Y-NXW\D M)UK^ZV9J[7@Z\/4EUL&;#P>W7S*?HO6LR;A3:6:C*9WZ]QX%"N:J0.&X=YV< M=A21ZT5[BFR"%_W#ML[M1?_-_]V8CW:S@V;F_PY3]X"+H+%>%KU\]Q?Z7"?+M_@"4:]5.JOB@O@OH][E5W0G'U9-C^%O( M:'39 !0[.-GELYGLC?HNJ]*OM'H)U]1K[=J'K^J.R7=NI['[ZNO>QNENKSX'(639"GH33G#^,7_^5M:5DV M499-O/A%+WO[-'&M_QL^#L] M:![43R]@/#\:=(_N[\#SO_US.ANVJNZTP-3VO'IR -?\&,$Q^'K69UPBFFP*+BVI=F*-#<9Z],>=/(3;+<;7 MGL9MA&;>:!NXHEQ%8G *A 1+,%6<<5^:3&L&3?,E%((:J30F*&C/$+?1(JU, M0A)S8H33R46;H8F*1Z=RE244R]0]J3UU@2J?L.91!".Q- $,!16^LTMJ9--:]1V_X:U0WL?X;_EZG/^@- M%W;M?.UN1G(,:R]I\";R('1V]B-L_-YJ1Q)AY8Z_9J@S7[40K+,L$HVB( YQ MHS0R%+;]"*8;]M)'2U1&'6$>O>.7+OY2ZX.",D($KZ)@''9ZZZ@DL(<(\!G! M#K#ECK]VNC>72*]48%H(9+U7B%,>D1/0]F27K#CX8+G.D2L#/%%K^6;MC2 'P^R\$8[#!7%L6F*&$MU>)KHMBU:A1+?-0K=9\Q0,3P RP1".DF=J;H-L4A$%)IR0 M!!Q"E_GPY!;1CW;_5H5N+S\$-:4XH)W7FO,JPD^_;8X15P+<:@%N?SYGQ>OD M+-8$6<8\XL9J9'ARB 0;I5 X"FD!X/"6IO.,G[^7H:WGT=MG-D]*O5VYWLX: M)C;)8$DFRY RU^,IAPRA!"D?0W F!=#K0F_5 J+09]';EQLU6TSTL57IQ(<& MS4J^OY+O;STMMLP&5L+_BN%_/O'(6ZQP, I)9R/B5GD$5EP"-]53SB6#3T61 M[DB7''0KZ5*?'RY*^-S4N%X)G\\#GW.Y8U: 8\L-PKC(Z #75ROXU3(AJ";1 M:&*+W#&]K-+,YX?/!22L3TP.MQ8L?-,J5HD_SF*GGRGW>@7UWN"X%V-AMG?@ MPDH;[G;>W!M?\S?UW^-/'P$X[=X1/9Z7R(^9MXR\S1$ M?,2LTVU__IFF;)T&^ZO;WG&TC^6MDP_G>UNF_:'OQ/A6+T"D.L*.W9O8<4^& MPI,EX8E(YJ<:L[NH&J_O/(@33,@<_M^)"'_\EN/'M MKWD\X'8W:./DS].#^N>36OV4'YPT2.WR%-SP!JO5_VSO[YR*N5XJ]??M6A[# MR4&S^N%SJ_:A2O;KQ^W:R5>V7S^BM1-/JA\:?+_>6D1*R9Q)4OJ$K(\*\1@\ MLEH[)&'-HF5>"YK)WS:'^JW$H=>.0XX+YDF4Q-/ B8U:6^>,ET0(&GD4!0Z1 M"0Z1$H>> X?F#N,]]5@EC%C,S>NXQ CV$H-8/IOCV":K8RX0>W1'IQ7BT$,L MP#NW\2RQ[#5@V8,ZY3P>RU[\NNI"86*L4(R)"&(K4C+84D:4D2X-8@SBY%++"%AK/0X*>IBR# E^'Q.\YK"U!U::"[M MB/%IF]]]\<]O?;;.57_)]M[J#:6(2J=1=S9G.UK$@*_$$LA+!;2;U)KO"E6N-STSG?[@^)_O$Z'G#?[2#_%35F*[OMO31OOK>;7^=RM;\+7V MY[D%'?E" M$([;R!"#!46.U8MNSZCQ*IGP:JY M U(*2,6E0-Q0C'B0 1D9.=+6&&)L\HJ,NO21S0K(O%;PU"@5PY^%95E7_/:W(2U6^K,2J!;&M#-L^$QJF#/<@ZI3$7.>8C( MY;YC&&L3#>,T&II/'@A^#"M#V0M@L]A42H5=&X6=M4RT,ER "(&N)HNX912Y M9"B*27O#HQ.<\$)AY7S?H&=1V)<;X*K%P2W4P\N-+.: MG+W/\7OL#./[7K?]%]PZK^NWYN#X+WBY+CQQ37+S2&VB6B='9'^G^@/$NP6B MS4%-VHWZD3AH[XG:AP:IUO\\@7%<'GQX?SR;F[>_\Y57+W?Q_H=_0!V/0$T. MX'FM=N/D%!^EV.O%4.F-Y'^23]C/Z82V#9@%/\+V$YO? MX4N95 C\US#,3>_@9WCH]Z:/_4JG.ZA<@',;8@N^F.\'GT;;Z\0 $[R7*N>9 M@PC J'D&6]K5P\Z;K59QK8OC;\.?!L=%!N)T)N/@/+:^3\B+MHH/1V/+.9*] M>-;MY4B^A3'!1SVX8P?Y(;P6?*'5M*[9:@Z:L0\C>6(0680<(U:T3OC/>" 7 M]0RYKQA/<'4;8#WBW'$.<44T_,,2J\%"9*-XLGVY7^L-VVO8M)9JRSK+%@ M#.,)&YUE%7+URTDK4VW+5-LRU;9,M2U3;5]5JNW'B167=[O;S;@RS[;,79NN M(V5>P7^,C$F#T68-8\'R1#!-5F)F[WJ2L,A.OK*/_QI9[NL2S7JHB3PF #YE M8!:WX5FTT=[[43WY=-&XW.8PGLM<-5H]\9>-]C]POR,Z&\W:KWL.XX'W.F@V M3G8O:CM_GX!Y+6H[,/:3QD7MLM8\^/9/:W_G8&'R+"4I2*Z0#Y&!B2TE,D)2 MY"GCUGN'E59OW@E:EK&7\+,A\!.#M4E(K1TFW"KKF%#,4^\!C!*UYJX1^A)^ ME@\_L\%T3'P(3DMD0\KM&V) 5B8/;K[$6 22B"1OWG&Q,<1E-^/E,\[V:NMC MGS=D^"W'[WSWJ /7A,K_K)"!4-Q+D<<1_<]78[W;X9G<3'U_>$3NLGIQB)VG M@*X>66 M1AC$8= JZ9@XBAP FT>ONQ3$JE,#R),'AZ".C$J'8*!4;!WV4T(!.T0(8;$T4B1'J?A6$^Q6T=48O< M1*VWE5JW NL>L_DV.?N\'NZT03;UV#/X>C=4SG,'EUZWG7\OQ >&5^DZL"@+ MV[5?Z\ZC'X4D>M% M>XIL3A7[P[;.[47_S?_=>+5VLX-FIO(.L_" I;M*SID_?/QE!LAS^SG%??YH M#N"I_@[G _4>W&Z\1WP$!8B5[5:KZXLRPD&W\CFV;;, AH]3BK9_K6C/P:7T MO!*]_;.3]JU[[;P/S&*?VW"O]M3Q8DVMU?52E?OLHGUV?V?[_#!DHQ>[@'!4 M G&O$S(I8!1AMW64<4VE?O/.O)TOE5;=L M7V\KE?IQ\VKCS1M8V_9 @BO%EI'W\NXD:ZG2/Q[EXO:+7"8 T:/B%]@GBN?[ ML076']?C]&&=^VAP<19'!3D5>P0[>7&#I\\F&DOJ0@'=B7W?:Y[E'_=3O0EH M?_3*A+'()#HZ#!$L?L$#4M(2Q(54R,%6@SS7RL)>!S9ZR@VLXHW%JQS;[]F2 M&YS'"%;=>;2.V4K,8?T0^S0HS/9:_LS+%56AB@ M>0CGM@<[TN!B8JUE56KVXN@9\+X+KK\:( S_>S.,^@3F]T9W>N];7^M94Z#6 M8JNK3S$WQE;,LYV/TV$]0[/O6]W^B-SQNVW!K ("#CO79O=MAGE>G-^:OT\M M8$Z/A/6Y!LU6[!S!G^"&75B,8A'AHLP962SC;\T;E^<;GA\W_7%.R+Q:UZO% M!N&:RJV$H5]]M]"7_%D1*<\?-3O?NUFXTG0>Z/A%8EC@.-R,ES]'+KE>42[Y M?[J=HSIHTDYT@W5)]-S_:P+/U?/]S#UL4/K+",\162L@YOK]%JD@1O S/_LUSZ@^N[G:F5G M]\_Z*P>P[ P7\0#0]%N-]%;7=F;C8X%3DRB!/1E446LK*&:,6 E_5<*$0GOP M1'OP[%GM7NW]1)GLC_#C#]!02T&4M)6"0)M?K1H8.=*5KMD(I<(XX#13IJ#SZL8D[+ M)*WF;]Z!S3 O"6DRR["^8R;J3G;8<0;)+"5@._H8P=XLXJ/W"I\_3D;FO?F/ MXZ'DNJV]?G]8>$EI>@/>#%=^Y6 !GMEA<,;DVG"4F/"9N$PCIUUN>&*P#)A+ M*?G/3WVW1C#1++:+_J#2*WP8<$J.LO@4_ONMTM$I%'Q&0)*E5!BE"<&.VR < MC8YH:5CRFOE BRC/S[#CND/%](ZQ-Q[@9QC?ET$.V(%7G4.^X/]?R0"BKTX( M/I%#[J27U"64(!^G,PR)'U02.J!)%1*6?S ML1BA"T[S_U5XD "=P][X: L,>?F* M?39^Z 78B-PI9#$-N30O(N=T1%S;:*UP$INY4KMU=FM^>@3QDV*_+;"(.T$S:@*U>L MK-PK2V>FS&5O@F(F.2\]Y02#VQ5\TE;C*"S&4=VU:">/2V0: MXF"G\:-1][1VTN#5RT_\X$.#'^QL7]3JU?-&_1.MGL"]Z$%KMD2F=M(ZK9V\ M/ZY=-N#:H\O:SO'IP5 MG$5:6XF<%DQ+RS')F11Z8_CB2Y1Y[2@#^.&PX)9B3+F@S#$G;&":>D*H3^RN M!7HERCP<968+\?+9MP&D00)'C7C,K'9@ZB(6E1%)&Q*PW"24>;E=*<:5IY5, M9S5.D[L9@GA,'XI'D)IN(! MB_)X&HC6K3!X(_!HOG\$T92RR PBW.=&.=@C M1X5#FD81+"=J62OAH)9PU"ISQD9N$48K,(ZX" M14YHB@3@9B 6"Z/QQBCA2P[N_&S[?[ I]@H]K1?E9CV%=5/K=OP$6Z<39E+S M1PSH,O:Z)>;> W,7=&%P8-Z E#H4* 7,]3(@C8E C, ::DT)YO0- "S\1/_] MU-[8LP=\2@S:; QZ"N.NQ*!E8]"LW>>5"H%ZA2C5X'Q%ZI#ASB-)"5=*,.RP MW2P,ND,;@XU+1ZI>I5S=3&5=*^;P9TA.$H?6Q*0,MRCI&!%WCB&8](B484F! MS#JIY"8E)]5OI!&=]6*_R+V?RKGKIDH:PF]%76LG\^>W;I2(S04)?\%N_IRI M2E=4Y1N3J:3Y6P#*ITDINMMM7ZYS.ZK +[H>ILJBS)/[O.*+LB!?DIWX%+[J M]?[X.9[9BR)G=S]]G.#CE6#MI_?-;"\VHNV]#,NQO7N^_PTLQ?;?I_L[!^WJ MY>?V_K<]L"#W+O;K?Y]6ZU_/#]J?+AN7C8M9R[%1WQ9@*;8;[4^\UFY:]AY\W[+G<[-L91%+I%$ M!7':*KK$8\0U.BDLGJW6$EE ==AC#@5?XJG#,P#.7J<&CZ\738JJ!;?7R_9? M5X5"7^:;SSL9M$D416$4XAPSI#D/B+C@+54AD_$MS7]=OY;6ZPU%_$%0=%=C MKH2BNT%1-G;JY]T2@9:!0/-)FYXH+#$U*%?3 P(EAAR@#S(X8FFT\]+(94?0 M2F/HC@@D2F-H71 H,YZ6&+0,#)I/H0I,&"M8! RR.8J?%'(1?F+&24Z-=$J5 M5M!S89 LK: UP:#WW6&OA* E0-"B9(:@%'N(--V!;95UQF4%X!,;>R5RW@2[/\\G?AN2_E:5P[6_OUZ3GRT%_XX^M/*QUYW M$">])[I'/=NN_/;QX\??"TK&U\=6N]^I;)_UFJT*X45F$]XJ.)D6$MC:S%C9 M;O;[W=Y%)N6.E=_R=[.M0/&_81(K-?AC\2OY]^^5F(G11P28-H-=/_IAOE?! MD#IN G3=@N<^])<<#!B2%-86P#!0:7TP41OJO.0&$SZBO\.<\)^S7M[D*WMO M?=PNQE-R72ZD0SW9QK7+ZH_JY2FI70)D;A]B37&4GB%A#4-]V._=[L#?N5[6;8JGR.K69,HT9VNR!?(-J^\B4+*?@BE6T_>"HZOO6& M@[^'K8L*$1/VMCQU7T#L6Y4_AWWX?A]F+[2;G69N7U LQ60)OORY?;4$S< 1$ M!2_/UH13W_;OUX50@\OCB=3*>.Z"LR&'8()16 C%-)]T(20"37ZX#X;L1-_+ M#4[>7[]>"2:_!I.JJ!T=$F,PN*,:*2; ,TU"(FN)0AY39H4$R/?D+F R2MS- M A7LH.@1,25LX\8A8UDEZM]]6-V<]-OLV&NV %"W:0$-W3CJ0G'6BT43.Y#A M'CR@E[LW@#".LX@K[F*D+G]N9WD%^ZWH(-NJY\ZWHA/% M6>XCDE.2T[3&_&\_?P(&SNCVHQXCU\.:UJWUL,X/E# MP,$LF9-;WZ)D]]R!EZY&'V#0_?]T^_W8W^_LWACYB%>T5*-?J]'7"U CK%+D M.#$D@Z.(VX21]88BIIS#/$4=D[F+&CVN[V+9\7"EYV5\9KJG_KU[8Y?<27YC MVB0^8051AIN=4;,A<%C6I%"(5J\:@]6:C9,C7BT^V^.-DT_\H-T0M?;>1>WD MSV:U7;TX.#DE^Q\:= Y:Z-_-_9VC'\4X3HZ;M9WC-GR7-D[V:/7#WD7C\N_V M?OTK/S@Y2$5)W?:A2#H(P1P2.DC$N>+(*:T0EHQRHRAQ$8\VAV8'#+3M#-"! M"$9M",DRQHDAVBKM"-R)!R/ *5B+7C4D]V'X:[_VS^[G^MZ?_]FMY+]^>7TF M?S:'LB4 MD8O3ML45P92/W9R+]MK#WZZ<.J*VSQFFZ-J>V"4C[T'=B,^,#GE MJ>S8ZR#!%MRU:+(5;0^\L=Q*\&P(MP 3.N0&7"!7.88UB4#TCV&,A7GGNVW8 MAF"&0#''3IZ'+V;3QS=[?M@&'W#4/KCH\.?@#BZVNN>PYE_/X,+1C?MCBV\P MF8.;T8]SV HK9_8BCR2 MPA7;&7S,G_'YS:&;?C,Q:W\R_'6U.@6S>+TB+?R M'6W^DYNR._-=BOE<_)I;D[YBLW>.H5>V-#^.H]66U#^=]@$*S:.FIX549ZYH9P5 M#5_A!H7-^Z.9NS&#P_E3X_-C['W)@YSM@I"8DDG"EL8II["?:8^]I4$3P'NP M0A<'R>G//;B_1A+7=*WXU]6HBRZU9%T:X3S#5K!'#F.01$B=>R)E CP>%#(F M::0QIE%H164 ^X'AMV9!GY,L3(64 MO!EGK@6Y']M-9#N=8=&.,3=T[(&QTNM/HU&A5-=,V_ '&$6T\%EN]/=V^E%7 M2C6Z>]&OSU:*XV<8]_!L2IGNV;+C0<+Z,EIVK%Q@]W>J^)"Y0(FD"3$:$^*! M&Z0I5LB1"#:(I-KFCBSTK5C0L2/+:Q:J]D389B'P%<8&IQ6R.6*8@&UYW"P* MA+V?HQQ%^]4PB>5>?7IC[[G:+V J 6F+AJC?QU':GYGVWFLIM&02EI53RBV3 M(HF8I/2<@8U_1]/^6GGRR>A\YS-P?*\ZG[TJK2DL_D^'EB9FO!0HNX:(.P5Z MDY1&3#)!+3=28//F70)KJ&AV.^O;7[5)!40N&N'>7/P<1!Y%%6)*V6[Y'J^1 MO1T'Q]TP!O\%GX^@MS-M?( DMH9%H"V'B.-@UJ(KNE;;7A$H7@5BSQW!WX[7 MNY,7+"'[(&6VE=K1H94J C;[W'0Q!X&M129Y@:+4DD1I!><)K(P%O=3^]4HA M>6S/=T:!Z5'G==N[F.I![0%=.[8SN*$M$V\IMRP>%-9_B,D.6X-*8>2,,/I: MBT:>3M&Q*M\2#+*">Z+9;L?0+$QXT-K_UVV%W/3]JLMQM^BL7G2$'YG5TQY( MI]*&QS7/6B/GXS9? YR>O.,,FNUB%\YG1=VK7D,35Y-N5=PP6X8C&_!F6Z$; M#N$*J#K&R1DH9UG](?C-U*M%MT9$KUAP"O];7N6DK.K!_[XQ-82_%?F]FXL= MYK$;6OB+\<>H4^;]$)S0%!.G@1&%N28A1Z*,8LER!DZ,I L-AGL8WU.^8B[4 MZ1^#_%]C^7[ZDM^@\!WKO>;14>R]9GC_Q/<_'0JF _?!@#%!7,9X\!]9(@@S M*74"ZX)8_>8=8?-)5/^:[.ISL81\+':K7 1[L09" 7_+L;.\U]=[-FO #GBT MKS>@4*U_O,)8%EH6C,(U M7_NI!7_-ZWU9^W3(X?]4XB'WS\2PWI@B8XP'[;>1$V>5TS*'D.;7>S":Q$K( M@: ,\5Y XZJ3W"FG,&.(11^0" M.&N1>9 ACQFLQYMW\U$UL-#'"62PO#G"UNR&LQB6B@ _EJAIA%](@O-.;=S[ MP?(DIZABNX\[T$W%*XWEJ/0*1@+E+ZI'A]Y1'VRBB&L&_P0:D.,N MH. (+)2WRE#[YIU9U#I]; B>];IAZ ?7/L+T068A-#E^T)]U('(\\=^5;J^T M$M;-2BBB1WY$8STZ/[@ZWN_VSKI%('@4NLHGB( 9MI\/U $1CL9GC)U!K]O: MJK1C[RAS8_8JK>9_A\U0G+:_PE#A]E08+8?()^;R@DB:K1P7@;PBZ#<)W.4< MUGL%[J;B@3.G/S>B@]6WASYUQ?O]YD18+(SB-"*YHY91;,/8SS.9\@M$Z M_V9S?D>"=PV3J-]>,;T%S^^PEP^?BH/EV6CF>>R-#J=B^#VGO6S]+(5DJ\B9 M';1&QUI%5L,HR7ORS!E @1??ZU2R4.XT0OAK@^X&G(R5![2IV1D?$\F M1 XTP L:J?$3 M5ZVDLBJIK*:\5*R2"!0K:JSAN1R0:Q>$E [\I\CH)(ZC;HGCS'-:S;JHT<&/ MXXC ]BBCO CRK@O?U4.]U7&30\]JET>B]NW3>>/;UQ^U^N=V;:?5A&?RQK=/ M%[5O7W'C6^/'0;U!YIH<7GJVOW-*#F ^A03DV_>*;,I?%L):,8(BLDPHN@MY18E3=\*IN6:LL&E@ M:0T2WF<2*A.0)EPB13!-7FJ3HVSOR%;1665CH.HA9N.L9U#"W:N&NT>>H)5P MMQ9PAV%G'>&NA*I7#568 M:TN4XSJD7!_"C;%*)Q)MH. NBCBVS$AIF:TS5)$9J").?N.+:>T892.YP4R9?]D1XXE#7--KD+LO=VS! MH_Q7GOP2E.X#2O-=OV!Q? K@) K%L />B8GJ\160\= MN\>&?NMI["O5TZ4''4H]79Z>SL82: Q>D,!0DM@C3K5"-@:-#';8L9"XR@78 M3,LUU=-7JF-+]Y9+'5N>CLTYP3P*,%X(\E::3'+@" M/?H<=?V:K6V0EUNT"\B>;FCV?:Y8*-O/KM3'G7!NYZG_V(OMYK"][AT@-P*0 M%O2$;RROH DYG/%Q'7F".;/$762 DN6$A6AM*T*9%D M0P,SI6GSM' R&[K1#-, R)$-&C!MC,]'A?D?BX/ (3B=F<[TEB*//BQ<(I@L M*45A#;&EWLV,*%7+S].'!E7;#.8^M =YKOE=[D] MK>0%PO(R)V33X7P%I4LE1M\'H[_,1;-22)[$9%'0!# Z;ZU&PD\Z7X9>/(696.)8B6//6?=4&J)+!+G9&%L@&!L2&0)1\(A;7KBT M!'D)R^=U8 GK-^_X%C'+.JE_9IA;1B9."94E5#Y_++"$RJ>%RKD0H"5$1^(0 MBR8BSIU"%@N'<'+*!(N]$+G#R)8ACZX&70^H+&&NA+GG#U26,/>T,#<;FO0B MRMR5$%&?,ZQ=;L(@N$2P<5G.*7?[8K^^?5&]W(-Q MGN;NCHQ1$WC2R)G,]H])0E;3A)+/Q8'),ASP)A&B?LA,VX"T\<:R%]VE?XR( MO<.83WAI3*F9Y[XD2BV)4DNBU)(HM21*+8E2[T).^6)Y-LL%W+A7>1*BU#4, M2RPV#9?&9[&&X9G%2[X\SIMU"L L?M?[',EA081BSB?CN-!8XQ@ELR:?Y$3_ M@-2"+&_]_W3[_=C?[RQR0U]XSNG>976G=E)M?SZM[NR>U^J?+AKU/5'[L,MJ MWSZQZLD>J>Z<@L_ZS^EL)*9Z4CVO4KCG!QA[?9O4=OX^KIZ_=C:M\_3-*EPOZ\7M4^'B7')@L/(2ADRR0U#CBJ!5"(J4!RB,>SVG--5 M=UM[LVQBG6&>2/@R ],K@\.+&3BTA&IIM48X*9;+G24R40B$G>:,PEHK7Z0J&//DQ-&; M5"A4PML+A3>!J0:HX];- 6 M'!86/ -_5$MR[R2 $II6"4UD%IJHHESCA%SB%'&:%++*2!0)-=;M%VV5_^C%EATTO\?K8\E_W3RL'A]JXNM+ MK(,I&@YNOV0^9ONLQ]M4W)R5Z7^/>]>!YZ.(7"_:4U2T%/_#ML[M1?_-_]UX MM7:S@V:F\@ZS\("ENTKX&/=A'5'\C "%"'!!0DB6Y6H>HJW2CHBD>3#"JSC; MNY498:76AAG,N?'<8ITXX*,2& <5\9O5)984B22ON07O7#;)^2$FCD6%/0*C MFB,>"(BA#1Y)$XT0PDFBY%P[7@\&G+ NJ !K&BR (=CCPH(19RV79).R3^JY M][SM]2YR9LEWVQK&N7;LM^63P*3TF_U!#),K1@DE^49E2LE]$A0T?TOU[1\_ M*N_A;K=]QM-LV/A7>KZRED?ZJYZ$N>/@59^A3JGN^!8H?_^/5-&-B2B89..8Y=5IK[;&W-&@"5IEB M^G#O;A&X;(OM=?I@(&3/]J_Q#KS=SK0<]FH?Z4']8-6-8]MQ_-: M>_>\>EEK5>M[/VHGGPAXK>?S2>^?X)U@G'!=K0U>:_:0+X]HH[Y]6:5??X"1 M1VL[_QS7+O^<.6H%O_CHT"62?5R&F!,2<6? ]*/"("]=X [,ZVC!)A=R2Y@G MC[XMU:";R*MJ(_/8L )5BKQ?#B,@Y%C3.M?ABJ"96 M S\7<_ 3M7$FH'GOMUW(2LAJ@ MGF*X)M6Z%[7S0\F42)((Q)7AB!/BD<%4(RR" +!.%$M?V(F,+ME.7(*V/&V) MY%-&[]8B*+I7D,%UXDBKSYN#XZF(Z,3RW"K^]E>W#<.ZJ!1A'3!.FYU!MV(K M9[UX9F%Q0$'/;2\O?=>?5N"/PYX_MOU8&?1@?&/8^"TG=E+\[X_CB]Z/+BK^ M2O[]^V@ MI)&+34*]CJ8I,'PQL7CBV! PSR4,]L;7$SN\+92^3CLY6$/*C"\ M/.Z99]U\F6$?WL2>G?6Z/P!*!K%U4?F?>V!=3EK%'D>F0^3869-H)#%0QHUT MG+A?I:N(">C9'^'''Q_M17:1^_7N>U"9\;C'P_Z2I_7SU:S>#1#E9@+B@T\] M:B?;N'99_5&]/&7[.WL750 WS17C1"+EBWXBS" P2A62!.0E*&^< B>8B[?S MG)05T++65,.+#IA0("B 8*%?2;UNN](<7"O)S<,$D+T$:[A( $%$\U&$/3KJ MQ2,0N0JL7@[2PO7]8]N#B\=W&LMHD0NM_MT'R6NWNYVQ@L'-8Z]U,:F2G7G& MJ/#UAEC?*M6CA\XFW#,;B,%&>$*X2LQ18Y,W%E.BM;AU$ZB[8_[%T4 MLKOM_SML F[4BK?=3U^*QX['?3=QQJ]:G#_]V-\^5$X1$55 4>1\46TT%MB 8O?6/CBC[-F;W34&[((PNPO%*-FOU*U@#@5(HJC M,+95L:U\W'5T#,)?:=N+BHN5?AP,6H"CT?9:39#D)NPDQUW8S;O%SQF@X;E? MS[+P%E^=E'TOA&<[F!X>W&*8+RQV'KC_Q=0M1E"^:#N C:35 L%L-<$(F&P$ M$\PO='F!SMU'O\;S=98C-=U\ @A;(MS"Q7S!]'Q&[X( MFV:T^;P1U'@PUJ+QP(I*^"Y,WU0\/R\?W/FLV[]&#U 9/VQ==>QQMM_TQ<6A MF9,JBM%UX&(8$XRC&-Y6Q0T'HZGKQ791D37S$-^%A_2RQ+3L^=4CMV"5Q\VB MYX:2)SP-!\->'(T?Y +>NS\&M *_&[( M_X+;;57Z0]A_)O8]KPI/[N!L^:0$F;*)>*RZ3UCP)XJ5VCGA'M/E5"JI8=#;W M5T$&WL^4^> W U:T\E]'YW.D]#-^89CQZN57GK.K9.#*>#OBO>)**2H"!3]#OKV-67GB;(#27+L&4P?UQ7ID<;Y%WN]GWS]2DO9J[W\N2J.? MP,RX/OD=&?Q[X"[%<$>Y>L4&/\A5X[)Z=$B(E$Y3CU06*?!8:L$W8%#[E'4'K6JRN8R+W22EXW8AU=%G[=!B8<(P#8A%#=:[$!L0* M)"#&372")>,$N)(-O;SLMF(JKW<2?&RX/+&W@FDF18H&:8" M9P$["I*"W][&N3DE*+UH?(^U(L^GQ@5 1.;+TC]6)P M'-W*.9B3:\8B=ZO1#_?M#UN#PN\!?SKOC:,;IGL)))%!8I"/1"+C/"4G@L58 M6J(HYEZ&7Q7MSV':DDK'7K>(?CVO;A]*YB+G8%!);AWBF!MD/,D%^(8(^)OT M+MZ/$GW9^U>YUDM;:Q\$26!&ZT1AXXJ4("U%0I%$2ATG7&868+' 1?L%/O5B M:D4_AHEN#@;GC:O;CI7?QEVW?M\JP&,29[\_J2D!J/H21T9XA>BMRI>I:.K_ M5G8!&P<7Q?WSX7@>8Q'O&TE&&>\;Q;A&9QE%2<\BM'^14_3SHH#.^'PG!ZCR MO/SBJ+_Y?728V(E'W4&S.*&8C]G=B*9T^G,B4<%%41]O#@Q/]G[]V;VDB6O.&OHN#=?7=.!,76 M_3(G'D